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2 Chemical Tools to Study Sphingolipid Metabolism  
 
1.1 Introduction 
Sphingolipids are, together with sterols and glycerophospholipids, the major lipids present 
in mammalian cell membranes. Sphingolipids are composed of ceramide that is 
functionalized at the primary alcohol with a hydrophilic head group which can be neutral 
or charged carbohydrates, phosphates or phosphodiesters.[1] Ceramide in turn is 
  5 
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composed of sphingosine, the secondary amine of which is condensed with a fatty acid to 
give the corresponding amide. Sphingolipids are found in the outer cell membrane layer, 
with the hydrophobic part embedded within the membrane and the hydrophilic part 
pointing towards the extracellular matrix. Sphingolipids are key players in many 
physiological processes and malfunctioning of sphingolipid metabolism is at the basis of 
many human pathologies. For these reasons, many studies have been directed towards 
understanding of sphingolipid biochemistry and biology: how are they (dis)assembled and 
what is the molecular basis of their physiological activity? In these studies, synthetic 
sphingolipid analogues and derivatives have been used. The main body of the work in this 
Thesis focuses on such sphingolipid analogues, and specifically on the design and synthesis 
of stable-isotope-encoded sphingolipids. This chapter provides a brief overview of the 
various classes of synthetic, labeled sphingolipids, including stable-isotope-encoded 
derivatives but also analogues bearing other chemical reporter groups (such as 
fluorophores and radio-isotopes). 
1.2 Radioisotope labeled sphingolipids 
In the past decades, several strategies for the preparation of radio-isotopic sphingolipids 
have been reported. Carbon-14[2-6] and tritium (hydrogen-3)[7-17] are obvious choices with 
respect to the nature of the radioisotope employed and examples of both have appeared 
in the literature. The most commonly applied method for introducing carbon/hydrogen 
isotopes comprises N-acylation of sphingosine with an appropriately labeled fatty acid.[2-4, 
7,20] Other commonly used methods to introduce radioisotopes are reductive tritiation of 
the alkene bond in sphingosine (catalytic palladium on charcoal, 3H2 (g)[8,9], or by reducing 
the ketone of 3-ketosphingosine to sphingosine using sodium borotritide (NaB3H4).[10-13] 
Radioisotopes can also be introduced to the carbohydrate moiety in glycosphingolipids. 
For instance, introduction of tritium (3H) in the glucose moiety of glucosylceramide can be 
accomplished by selective manipulation of the C6-hydroxyl of glucosylceramide 1 as 
described in Scheme 1.1. Selective 6-O-tritylation, followed by global O-acetylation and 
removal of the trityl group using acidic conditions resulted in partially protected resulted 
glucosylceramide 2. The free primary hydroxyl in 2 was oxidized to aldehyde 3 and next 
reduced with NaB3H4 (3 to 4) followed by global deprotection, yielding tritium-labeled 
glucosylceramide 5.[14] A similar strategy (selective oxidation followed by tritide reduction) 
has been developed for galactosyl/GM2/GalNAc[15,16] sphingolipids, although here the 
primary alcohol-to-aldehyde transformation was effected by the use of galactose oxidase. 
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Scheme 1.1 Synthesis of tritium-labeled glucosylceramide 5. 
Reagents and conditions: (a) (i) TrCl, pyridine, 40 oC, 18 h; (ii) Ac2O, pyridine, r.t., 20 h; (iii) HBr (33% 
in HOAc), HOAc/DCM (1:1), -10 oC, 5 min; (b) (i) N,N-dicyclohexylcarbodiimide, H3PO4, DMSO; (ii) 
HOAc; (c) (i) NaB3H4, 1 mM NaOH (aq), THF, r.t., 20 h; (ii) 1 M HOAc (aq); (d) NaOMe, MeOH, r.t., 20 
h. 
An alternative strategy for the introduction of radio-isotopic labels in the glycan part 
comprises glycosylating the primarily hydroxyl of the ceramide with a radio-isotope 
labeled glycan donor.[5,6] This strategy is exemplified in the use of carbon-14 labeled 
glucosyl donor 5 (Scheme 1.2). Donor 5 was condensed with partially protected ceramide 
6 producing glucosylceramide 7, followed by global deprotection (sodium methoxide in 
methanol) resulting in 14C-glucosylceramide 8.[6]  
  Scheme 1.2 Synthesis of 14C-glucosylceramide.  
Reagents and conditions: (a) BF3OEt2, DCM, -10 oC to r.t., 10 h, 55%; (b) NaOMe, MeOH, r.t., 24 h, 
95%. 
1.3 Stable isotope-labeled sphingolipids 
Both carbon-13[6,18,19] and deuterium (hydrogen-2)[20,21] have been used for isotopic 
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has been N-acylation of sphingosine with a deuterium labeled fatty acid.[20] In the example 
depicted in Scheme 1.3, phosphocholinyl sphingosine 9 was N-acylated using deuterated 
nitrophenyl ester 10 with K2CO3 as the base, resulting in deuterated sphingomeylin 11. 
This compound was used in NMR-experiments aimed to establish the conformation and 
interaction of sphingolipids with other lipids in membranes.[20] 
Scheme 1.3. Synthesis of deuterium labeled sphingomyelin 11. 
Reagents and conditions: (a) K2CO3, DMF/DCM, r.t., 24 h. 
Glycosphingolipids in which the carbohydrate moiety contains carbon-13 atoms have been 
synthesized as well. 13C6-Glucosylsphingosine 15[6] was for instance prepared (Scheme 1.4) 
by condensation of carbon-13 labeled glucosyl-donor 12 with N-trifluoracetamide 
protected sphingosine 13 using BF3OEt2 as the activator for the glycosylation reaction. The 
resulting fully protected and carbon-13-labeled glucosylsphingosine 14 was transformed 
into 15 by treatment with sodium methoxide. 
Scheme 1.4. Synthesis of 13C6-labeled glucosylsphingosine 15. 
Reagents and conditions: (a) BF3OEt2, DCM, -10 oC to r.t., 10 h, 27%; (b) NaOMe, MeOH, r.t., 24 h, 
78%. 
1.4 Fluorescent sphingolipids 
Sphingolipids containing a fluorescent reporter group have been used over the past 
decades to follow the trafficking and localization of sphingolipids in living cells as well as to 
measure activities of several sphingolipid-processing enzymes. The most common 
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Alternative fluorophores are borondipyrromethene (BODIPY),[26-31] pyrene,[32-35] 
diphenylhexatrientyl,[36] lissamine rhodamine,[37] Nile red[38] and dansyl.[39] Again, N-
acylation of sphingosine with an appropriately modified fatty acid to give the 
corresponding ceramide has been the method of choice. As an example (Scheme 1.5), the 
synthesis of NBD-glucosylceramide 18 by N-acylation of glucosylsphingosine 16 with NBD-
hexanoic acid 17 under the agency of PPh3 and 2,2-dipyridyldisulfide has been 
accomplished.[22] 
Scheme 1.5 N-acylation of glucosylsphingosine 16 with NBD-hexanoic acid 17. 
Reagents and conditions: (a) PPh3, 2,2 dipyridyldisulfide, DCM. 
A related strategy had been applied by Bittman[26], who prepared the three stereoisomeric 
(2R,3R), (2S,3S) and (2R,3S) lactosylceramides to study the influence of the 
stereochemistry of the sphingosine base on endocytosis (Scheme 1.6). In the first instance 
the stereoisomeric sphingosines 20 were synthesized, after which glycosylation of primary 
hydroxyl with donor lactoside 19 produced the fully protected lactosylsphingosines 21. 
Removal of the ester protecting groups (sodium methoxide in methanol) gave the set of 
stereoisomers of azido-lactosylsphingosine 22. Staudinger reduction of the azide in 21 and 
ensuing condensation of the in situ formed amine with BODIPY-C5-NHS provided target 
compounds 23. 
Scheme 1.6 Synthesis of BODIPY-labeled stereoisomers of lactosylceramide 23. 
Reagents and conditions: (a) BF3OEt2, DCM, 20 h, (2R,3R) 66%, (2R,3S) 54%; (b) NaOMe, MeOH, 6 h, 
(2R,3R) 68%, (2R,3S) 62%; (c) BODIPY-C5-NHS, PPh3, THF/H2O (9:1), (2R,3R) 38%, (2R,3S) 36%,  (2S,3S) 






















































































In the above examples, the fluorophores were all located on the fatty acid of the 
ceramide. In case however lysosphingolipids (that is, compounds featuring sphingosine, 
not ceramide) are the subject of study, the fluorescent label has to be introduced in the 
sphingosine backbone. One such strategy entails addition of lithium-alkyne 25 to ester 24 
to form alkyne 26 (Scheme 1.7). Stereoselective reduction of the ketone in 26, followed by 
Birch reduction of the triple bond to the trans-alkene, removal of the cyclic carbamate and 
N-benzyl and N-Boc protection of the thus liberated amine gave sphingosine 27.[25] Next, 
the hydroxyls of the N-Boc protected sphingosine 27 were silylated followed by removal of 
the  THP protective group. The primary hydroxyl was converted to an azide, by mesylation 
followed by azide substitution to produce azido-sphingosine 28. This azido-sphingosine 28, 
after removal of all protecting groups, can be used as bioorthogonal handle (see part 1.6) 
for metabolic studies of sphingolipids. The azide in 28 was reduced to the amine, which 
was then reacted with NBD-Cl in a nucleophilic aromatic substitution reaction to give 29. 
The silyl-groups of the protected NBD-sphingosine were removed using 2 M aqueous 
hydrochloric acid. The resulting NBD-sphingosine 29 was next phosphorylated to produce 
NBD-sphingosine-1-phosphate 30. 
Scheme 1.7 Synthesis of NBD-labeled sphingosine-1-phospate 30. 
Reagents and conditions: (a) n-BuLi, THF, -100 oC, 93% (b) (i) diisobutylaluminum hydride, 2,6-di-tert-
butyl-4-methylphenoxide, toluene, 0 oC, 99%; (ii) Li, NH3, THF, reflux, 96%; (iii) KOH, EtOH, reflux; (iv) 
Boc2O, K2CO3, THF, H2O, 0 oC, 84%; (c) (i) TBSCl, imidazole, DMF; (ii) MgBr2, Et2O, 82% (over the two 
steps); (iii) MsCl, Et3N, THF; (iv) NaN3, DMF, 50 oC, 89% (for two steps); (d) (i) PPh3, 10% aq THF, 60 
oC; (ii) NBDCl, Et3N, THF; (iii) 2 M HCl, MeOH, 82% (over the three steps); (e) (i) CBr4, P(OMe)3, 
pyridine, -10 oC, 82%; (ii) TMSBr, CH3CN, 71%. 
Cross-metathesis has often been used as a versatile strategy to create chemically modified 
sphingosines.[40,41] For instance, alkenes 31 and 32 undergo efficient cross-metathesis 
using Grubbs’ 2nd catalyst to give, after deprotection, fluorescent sphingosine derivative 
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Scheme 1.8 Synthesis of BODIPY-sphingosine 34 featuring cross-metathesis as the key step. 
Reagents and  conditions:   (a)  Grubbs’  2nd catalyst, DCM, reflux, 31a: 67%, 31b: 79%, 31c: 57%;  (b) 
HCl, dioxane, 31a: 48%, 31b: 68%, 31c: 54%. 
1.5 Fluorogenic ceramides 
Bedia and co-workers have developed compound 37 as a fluorogenic substrate to 
measure ceramidase activities.[42] After ceramidase-mediated deacylation, the sphingosine 
is subjected to oxidation and subsequent beta-elimination releasing umbelliferone, which 
becomes fluorescent in alkaline conditions. The amount of fluorescent signal produced is 
proportional to the activity of ceramidase. The synthesis of 37 is depicted in Scheme 1.9 
and comprises hydroboration and subsequent oxidation of the alkene in 31 followed by 
mesylation of the primary alcohol in 35, nucleophilic substitution of the resulting 
mesylate, acid-mediated cleavage of the Boc- and isopropylidene protective groups and 
final N-acylation (36 to 37). 
 
Scheme 1.9 Synthesis of umbelliferone-ceramide 37. 
Reagents and conditions: (a) (i) BH3, THF, 0 oC to r.t., 4 h; (ii) H2O2, 80%; (b) (i) MsCl, Et3N, DCM, 0 oC, 
30 min; (ii) umbelliferone, CsCO3, acetone, 65 oC, 6 h; (c) (i) TFA, H2O, DCM, 0 oC, 10 min; (ii) 
palmitoyl chloride, NaOAc, H2O, DCM, 0 oC to r.t., 16 h. 
1.6 Bioorthogonal sphingolipids. 
Sphingolipid derivatives containing an azide or terminal alkyne have been applied in 
bioorthogonal chemistry based studies.[43-46] The main advantages of bioorthogonal 
groups is that they are small and therefore are less likely to interfere with, or prohibit, 
sphingolipid metabolic steps. Fluorophores, biotin or mass tags can be introduced in a 
later stage by means of click chemistry. Scheme 1.10 provides representative examples of 
bioorthogonal sphingolipids by depicting the syntheses of azido-sphingosine 41 and azido-
sphinganine 45.[43] Delgado and co-workers reacted alkene 38 and bromo-alkene 39 in a 
cross-metathesis event to produce bromo-sphingosine 40. Substitution of the bromide for 
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different strategy, Garner aldehyde 37 was reacted with the lithium anion of undec-10-yn-
1-ol to give alkyne 42. Full reduction of the alkyne in 42 followed by introduction of the 
azide (tosylation of the primary free alcohol followed by nucleophilic displacement of the 
resulting tosylate) and removal of the acid-labile groups gave azidosphinganine 44. 
Scheme 1.10 Synthesis of azido-sphingosine 41 and azido-sphinganine 44. 
Reagents and conditions: (a) (i) Tetravinyl tin, THF, n-BuLi, -78 oC to r.t, 1h; (ii) 37, THF, -78 oC to r.t., 
20  h,  49%;  (b)  Grubbs’  2nd generation catalyst, DCM, reflux, 59%; (c) (i) NaN3, DMF, 80 oC, 93%; (ii) 
HCl, MeOH, r.t., 1 h, 84%; (d), undec-10-yn-1-ol, BuLi, HMPA, THF, -78 oC, 50%, (e) (i) H2 (g), Rh 
catalyst, MeOH, 89%; (ii) TsCl, DMAP, Et3N, DCM, r.t., 58%; (f) (i) NaN3, DMF, 80 oC, 76%; (ii) HCl, 
MeOH, r.t., 1 h, 85%. 
Besides introduction of a bioorthogonal tag in the sphingosine/sphinganine base, such 
moieties can also be introduced in the fatty acid moiety of the corresponding ceramide, or 
alternatively in the carbohydrate moiety of glycosphingolipids. Scheme 1.11[44] represents 
an example of the former in the synthesis of alkyne-terminating glucosylceramide 48 
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Scheme 1.11 Synthesis of N-alkyne glucosylceramide 48. 
Reagents and conditions: (a) 7-heptynoic acid N,O-succinate ester, Et3N, DCM, r.t., 16 h; (b) (i) 
TBDMSCl, imidazole, DCM, r.t., 20 h, 60% (two steps); (ii) BzCl, pyridine, r.t., 2 h, 95%, (iii) 
HF.pyridine, THF, r.t., 16 h, 50%; (c) (i) BF3OEt2, DCM, r.t., 2.5 h, 44%; (ii) NaOMe, MeOH, r.t. 16 h; 
71%. 
Scheme 1.12 depicts an illustrative example of a synthesis of bioorthogonal 
glucosylceramide 50,[44] with the bioorthogonal tag now on the sugar moiety, and again by 
following standard transformations related to those described earlier in this Chapter. 
Scheme 1.12. Synthesis of 6-deoxy-6-azido glucosylceramide. 
Reagents and conditions: (a) BF3OEt2, DCM, r.t., 2.5 h, 20%; (ii) NaOMe, MeOH, r.t. 16 h, 48%. 
Finally, with respect to bioorthogonal sphingosines, alkyne-modified sphingomyelin 55 has 
been synthesized[45] from partially protected sphingosine 51 as shown in Scheme 1.13. 
Treatment of 51 with cyclic chlorophosphate and base resulted in the formation of 
phosphate triester 52. Treatment of triester 52 with propargyldimethylamine and Lewis 
acid led to the quaternary ammonium salt 53. Reduction of the azide in 53, ensuing N-



































































Scheme 1.13 Synthesis of alkyne-sphingomeylin 55. 
Reagents and conditions: (a) Et3N, DMAP, toluene, 12 h; (b) TMSOTf, DCM, 12 h, 70% (for two steps); 
(c) (i) Zn, HOAc, 24 h; (ii) NHS-palmitate, DMAP (cat), DCM, 12 h; (d) TFA, DCM, 0 oC, 1 h, 76% (for 
two steps). 
1.7 Photo-reactive sphingolipids 
The previous parts described chemical tools that mainly focused on trafficking, localization 
and quantification of sphingolipids and their metabolic pathways. However, these tools do 
not allow the identification of proteins or other biomolecules that may interact with 
specific sphingolipids. With the aim to enable the study of protein-sphingolipid 
interactions, diazirine sphingolipids have been developed.[47-52] Under influence of UV-
light, diazirines collapse under expulsion of dinitrogen to yield a carbene that will insert in 
any X-H bond available. When the diazirine is in close proximity to a sphingolipid-
interacting protein a covalent linkage will be the result. For the purpose to identify such 
sphingolipid-interacting proteins, the development of diazirine-sphingolipids further 
functionalized with radio-isotopes[47-49,52] or bioorthogonal handles,[50] have been 
described. 
 
Scheme 1.14 depicts the synthesis of 35S-tagged diazirine-containing sphingosine 
derivative 58, as a relevant example of the former class.[46] N-Bromoacetylation of 
sphingosine 45 yielded alkylating agent 56, which was reacted with diazirine reagent 57 
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Scheme 1.14 Synthesis of N-acyl-[35S]-diazirine ceramide 58. 
Reagents and conditions: (a) 2-bromoacetyl chloride, Et3N, MeOH, -40 oC to r.t., 1 h, 91%; (b) 57, 
K2CO3, MeOH, 55-70 oC; 39%. 
An alternative sphingosine-based photo-cross linker, now with the diazirine embedded 
within the sphingosine backbone, rather than the fatty acid moiety, and bearing a tritium 
atom, is represented by compound 63, the synthesis of which is depicted in Scheme 1.15. 
Ester 59 was reacted with dimethoxymethyl phosphonate forming ketophosphonate 
60.[48] Horner-Wadsworth-Emmons olefination of aldehyde 61 with ketophosphonate 60 
provided protected 3-keto-sphingosine 62, which was reduced with NaB3H4, followed by 
acidic removal of the isopropylidene and N-Boc protective groups yielding 63. More 
recently, variation of this synthesis strategy enabled the synthesis of compound 66 
(Scheme 1.15), now bearing a bioorthogonal alkyne instead of a radioisotope as a reporter 
entity. 
Scheme 1.15 Synthesis of tritium-diazirine-sphingosine 63 and alkyne-diazirine-sphingosine 66. 
Reagents and conditions: (a) (i) CH3PO(OMe)2, BuLi, THF, -78 oC, 30 min; (ii) 59, -78 oC, 30 min; (iii) 
10% citric acid (aq); (b) (i) K2CO3, H2O, CH3CN, 5 min; (ii) 61 or 64, DCM, 45 oC, 6 h; (c) (i) 
NaBH4/NaB3H4, CeCl3. H2O, MeOH, 4 oC, 3 h; (ii) 6 M HCl, MeOH, 50 oC, 6 h. 
1.8 Fluorine-containing sphingolipids 
In a recent article, Saito and co-workers describe the synthesis and use of fluorine 
containing sphingolipids for metabolic studies.[53] Fluorine is considered to be an attractive 
hydrogen isostere at least  when regarding steric bulk: fluorine and hydrogen substituents 
on carbon have about the same size. In case, numerous fluorines are installed, as in the 
described study, fluorous phase extraction should enable enrichment of fluorine-















































































lipid fractions. The synthese of fluorous sphingolipids 68 and 69 and fluorous ceramide 69 
are depicted in Scheme 1.16 and followed a synthetic strategy closely related to that 
described above for the synthesis of photo-reactive diazirine sphingolipids (see part 1.7), 
featuring a Horner-Wadsworth-Emmons (HWE) reaction as the key step. 
 
Scheme 1.16 Synthesis of fluorine-containing sphingolipids. 
Reagent and conditions: (a) (i) K2CO3, H2O, THF, 0 oC to r.t., 72 h, 79%; (ii) Zn(BH4), Et2O, -78 to 0 oC, 
88%; (b) 1 M HCl, THF, 70 oC, 18 h, 85%; (c) hexanoyl chloride, NaOAc, THF/H2O, r.t., 12 h. 90%; (d) (i) 
Pd/C, H2 (g), MeOH, r.t., 3 h;  (ii) 1 M HCl, THF, reflux, 2 h, 63%. 
1.9 Contents of this thesis 
This first Chapter provides an overview of the chemical tools that have been developed for 
studying sphingolipids, with as main focus the routes of synthesis. The described research 
tools and the routes of synthesis are complementary to the reagents and chemistry 
described in this Thesis, which, as mentioned before, focused on the design and 
development of carbon-13-enriched sphingolipid derivatives. Chapter 2 describes the 
synthesis of a panel of carbon-13-labeled (glyco)sphingolipids containing five carbon-13 
isotopes in the sphingosine backbone. Chapter 3 discusses optimization of the 
glycosylation reaction between glycosyl donors and protected sphingosines. Chapter 4 
describes the synthesis of a panel of carbon-13-labeled phosphosphingolipids. Chapter 5 
describes the synthesis of another sphingosine backbone, namely 6-hydroxysphingosine, 
which was assembled using a cross-metathesis strategy. Chapter 6 discusses the synthesis 
of modified sphingolipids, containing an aziridine for activity based protein profiling.  
Chapter 7 provides a summary of the results describes in this Thesis and projects some 
directions for future research. 
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2.1 Introduction 
Sphingolipids and their derivatives (glycosphingolipids, phosphosphingolipids, 
sphingomyelins) are important structural components of mammalian cell membranes. The 
biosynthesis of sphingolipids is a tightly controlled process, and disruption of a specific 
metabolic step can lead to disease. A variety of genetic disorders linked to sphingolipid 
metabolism occur in man. Often, these diseases are characterized by mutations in genes 
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that encode for enzymes or chaperones involved in a specific metabolic step in the 
lysosomal degradation of sphingolipids. Prominent examples of such lysosomal storage 
disorders are Gaucher disease (inherited defect in acid glucocerebrosidase, GBA1, the 
enzyme responsible for the hydrolysis of glucosylceramide to glucose and ceramide) and 
Fabry disease (inherited defect in   lysosomal  α-galactosidase, the enzyme responsible for 
the hydrolysis of globotriaosylceramide to galactose and lactosylceramide).[1] 
Studies on Gaucher and Fabry diseases revealed that both are characterized by storage of 
the substrate of the genetically impaired enzyme (i.e., glucosylceramide in Gaucher and 
globotriaosylceramide in Fabry), but also the occurrence of alternative metabolic 
pathways.[1–3] There is also evidence that metabolites produced by these alternative 
pathways, lysoglycosphingolipids in both cases, may be involved in, or are perhaps even 
causative in, the onset and development of the disease.[5] Those discoveries were made 
thanks in part to stable-isotope-labeled (13C5) sphingolipids, which were synthesized for 
this purpose. These studies led to the realization that a comprehensive set of sphingolipids 
differing both in structure and in the number of 13C-atoms embedded in both the 
sphingosine and the N-acyl (palmitate) moieties, as represented by the general structure 
in the insert of Figure 2.1, would be a very useful set of research tools.  
Some relevant sphingolipid biosynthesis pathways are shown in Figure 2.1.[4] At the basis 
of the biosynthesis of all sphingolipids is sphinganine 1, itself the condensation product of 
serine and palmitate. In a reaction catalyzed by sphinganine acyl transferase (SAT), the 
free amine in 1 is condensed with a fatty acid, here shown as palmitate but in reality one 
of a number of saturated or partially unsaturated fatty acids of varying size. In the next 
step, the resulting dihydroceramide (2) is dehydrogenated through the action of 
dihydroceramide dehydrogenase (DCD) to produce ceramide 3. At this stage, a number of 
different pathways can take place, giving rise to a wide variety of sphingolipids featuring 
different polar head groups. Glucosylceramide (4) is the product of the glucosylceramide 
synthase (GCS) catalyzed condensation of 3 with UDP-glucose. Glucosylceramide (4) in 
turn is the starting point for the synthesis of a wide variety of glycosphingolipids and 
gangliosides featuring oligosaccharides of different sizes and natures, and including 
branched   oligosaccharides.   After   it’s synthesis, glucosylceramide is modified to more 
complex glycosphingolipids by the sequential action of glycosyltransferases. As a 
representative example, globotriaosylceramide (5)   emerges   after   sequential   β-
galactosylation  and  α-galactosylation of glucosylceramide (4) effected by two independent 
glycosyltransferases.[4] In time, sphingolipids are internalized by endocytosis, and 
transported to the lysosomal compartments, where they are degraded. The degradation 
of glycosphingolipids is commonly viewed to take place in a stepwise manner, with the 
product of one enzyme acting as the substrate of the next enzyme of the disassembly line. 
In this fashion, globotriaosylceramide (5)   is   transformed   by   the   action   of   lysosomal   α-
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galactosidase   into   lactosylceramide.   Lysosomal   β-galactosidase   next   removes   the   β-
galactose residue to deliver glucosylceramide, which in turn is deglucosylated by GBA1 to 
give ceramide as the penultimate degradation product. Finally, acid ceramidase (ACase) 
hydrolyses the amide bond to produce sphingosine (6; Figure 2.1) and palmitate for 
reuptake into the cytoplasm as new building blocks for catabolism. 
 
Figure 2.1 Partial overview of sphingolipid metabolism in man, and the target structures (insert) of the synthetic 
studies presented here. ACase: acid ceramidase; DCD: dihydroceramide dehydrogenase; GBA: 
glucocerebrosidase; GCS; glucosyceramide synthase; SAT: sphinganine acyl transferase.  
In contrast to common belief, it was found a few years ago that in tissue from Fabry 
patients, as well as in animal models, which are characterized by elevated levels of 
globotriaosylceramide due to genetically and partially disabled lysosomal  α-galactosidase, 
the N-acyl chain of a portion of the accumulated globotriaosylsphingosine is removed, 









































































































related alternative metabolic pathway also appeared to occur in Gaucher patients: 
accumulated glucosylceramide, caused by partially dysfunctional GBA1, is partially 
deacylated to produce glucosylsphingosine (7).[3] These alternative pathways are probably 
occurring through the action of acid ceramidase (ACase), although this needs to be 
confirmed. The generation of stable-isotope-labeled [13C5]-globotriaosylsphingosine (8) 
and glucosylsphingosine (7) allows the detailed study of such alternative metabolic 
pathways. Stable-isotope analogues are also very useful for the diagnosis of both diseases 
and for monitoring their treatment, with corrections for glycolipid metabolism being 
reflected by lowered levels of lysolipids in tissue samples.[5–7] With this reasoning in mind, 
the idea came to construct a focused library of stable-isotope (glyco)sphingosine and 
(glyco)sphingolipid derivatives. In the design, it was decided to incorporate five 13C-atoms 
into the sphingosine base, and three into the palmitate, to obtain compounds that would 
be easily detected, together with their unlabeled counterparts, from complex biological 
lipid fractions. The details of their synthesis, relying on a cross-metathesis reaction to give 
stable-isotope-labeled sphingosine for further elaboration into a library of 24 compounds, 
are reported here. 
3.1 Results and discussion 
Ready access to [13C5]-sphingosine, the common backbone of all target structures, is 
crucial to the synthesis of the panel of [13Cn]-sphingolipids. Based on literature 
precedence,[8,9] cross-metathesis of [13C5]-pentadeca-1-ene (20) with aminodiol 21 was 
selected as the key step towards this common intermediate.[10–16] Introduction of carbon-
13 isotopes into 20 was achieved using [13C]-potassium cyanide and [13C2]-acetic acid, the 
latter of which was converted into Horner–Wadsworth–Emmons (HWE) reagent 12 in a 
four-step procedure as shown in Scheme 2.1. Transformation of acetic acid 9 into 
bromoacetic acid 10 by a Hell-Volhard-Zelinsky reaction[8] was followed by treatment of 10 
with oxalyl chloride and addition of N,O-dimethylhydroxylamine in an one-pot fashion to 
give a mixture of bromo- and chloro-N-methoxy-N-methylacetamides (11). Subjection of 
this mixture of Weinreb amides to Arbuzov reaction conditions gave the target HWE 
reagent (12) in 74% yield over four steps. 
Scheme 1. Synthesis of the 13C2-Horner-Wadsworth-Emmons reagent 12. 
 
Reagents and conditions: (a) (i) TFAA (trifluoroacetic acid anhydride), Br2, r.t., 20 h; (ii) water, 88 %; (b) (i) oxalyl 
chloride, DMF, CH2Cl2, 0 °C to r.t., 2 h; (ii) N,O-dimethylhydroxylamine, -78 °C to r.t., 2 h, 97 %; (c) 
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Next, 1-bromononane (13) was treated with [13C]-potassium cyanide to give nitrile 14, 
which was partially reduced to aldehyde 15 using DIBAL-H (diisobutylaluminium hydride) 
(87% over two steps; Scheme 2.2). This aldehyde was treated with reagent 12 and n-BuLi 
to give unsaturated [13C3]-Weinreb amide 16, the C=C double bond in which was reduced 
to give 17 in 82% yield. A similar sequence of events, reduction of the Weinreb amide in 
17 to the aldehyde, followed by HWE olefination with 12, and C=C reduction, provided the 
corresponding Weinreb amide (19), which was transformed in two steps (reduction to the 
aldehyde, followed by Wittig reaction with in situ generated Ph3P=CH2) into [13C5]-
pentadeca-1-ene (20) in 93% yield. 
With [13C5]-pentadeca-1-ene (20) in hand, its cross-metathesis with alkene 21 under the 
conditions advocated in the literature (Grubbs 2nd generation catalyst, dichloromethane, 
20:21 = 1:2) was investigated.[9] Close examination of the metathesis product revealed 
partial elimination of one or two methylene units, leading to truncated cross-metathesis 
products. This came as a surprise, since there are several literature reports that describe 
the synthesis of unlabeled sphingosine using essentially the same procedure as described 
here, and none of these report the formation of truncated (C17 or C16) sphingosines.[11–16] 
Methylene eliminations have been reported as side-reactions in (cross)-metathesis studies 
unrelated to the synthesis of sphingosine. These events are thought to be the result of 
alkene isomerization of terminal alkenes while bound to the ruthenium metal center.[17–19] 
This isomerization can be prevented by the addition of acetic acid to the cross-metathesis 
reaction mixture.[20] Indeed, the addition of acetic acid (20 mol% relative to 21) to an 
otherwise unchanged reaction mixture led to a clean cross-metathesis reaction to give 22 
as the major product in 81% yield. Sphingosine 22 was transformed into a suitable 
substrate for the ensuing glycosylation by protecting group manipulations. Benzoylation of 
the secondary alcohol in 22 and removal of the isopropylidene with a catalytic amount of 
p-TsOH in methanol/ethanol to suppress unwanted Boc (tert-butyloxycarbonyl) cleavage 









Scheme 2.2 Synthesis of the protected 13C5-sphingosine 23.  
 
Reagents and conditions: (a) K13CN, EtOH/H2O, 80 °C, 20 h, 95%; (b) DIBAL-H, THF, 0 °C to r.t., 2.5 h, acidic work 
up, 92%; (c) (i) 12, n-BuLi, THF, 0 °C, 10 min; (ii) [13C1]-decanal (15), THF, 0 °C to r.t., 20 h, 87%; (d) Pd/C, H2 (g), 
EtOAc, r.t., 20 h, 82%; (e) LiAlH4, THF, 0 °C, 45 min, to give crude [13C3]-dodecanal, which was added to a solution 
of (12, n-BuLi, THF, 0 °C, 10 min), 0 °C to r.t., 20 h, 77%; (f) Pd/C, H2 (g), EtOAc, 93%; (g) LiAlH4, THF, 0 °C, 45 min, 
then transfer to a solution of (MePh3PBr, n-BuLi, THF, 0 °C, 10 min), 0 °C to r.t., 20 h, 93%; (h) 21, Grubbs 2nd 
catalyst, AcOH, CH2Cl2, reflux, 48 h, 81%; (j) (i) BzCl, DMAP, CH2Cl2/pyridine, r.t., 20 h, 92%; (ii) MeOH/EtOH, p-
TsOH, r.t., 20 h, 63%. 
 [13C3]-Palmitoyl chloride 30 was obtained starting from commercially available [13C3]-
myristic acid (24; Scheme 2.3). Labeled acid 24 was converted into the corresponding 
Weinreb amide (25) by treatment with oxalyl chloride, and subsequent addition of N,O-
dimethylhydroxylamine. The two-carbon elongation of 25 to give 27 was realized by 
reduction with DIBAL-H, and subsequent subjection of the resulting aldehyde to HWE-
olefination with reagent 26. Reduction of the double bond in 27, saponification, and 
treatment with oxalyl chloride gave [13C3]-palmitoyl chloride 30. 
Scheme 2.3 Synthesis of 13C3-palmitoyl chloride 30. 
Reagents and conditions: (a) (i) oxalyl chloride, DMF, CH2Cl2, 0 °C to r.t., 2 h; (ii) N,O-dimethylhydroxylamine, -78 
°C to r.t., 2 h, 98%; (b) DIBAL-H, THF, -78 °C, 30 min, to give crude [13C3]-tetradecanal, which was added to a 
solution of (26, n-BuLi, THF, 0 °C, 10 min), 0 °C to r.t., 20 h, 81%; (c) Pd-C, H2 (g), EtOAc, 20 h, 95%; (d) LiOH, 
THF/EtOH/H2O, 20 h, 95%; (e) oxalyl chloride, DMF, CH2Cl2, 0 °C to r.t., 2 h, 100%. 
The synthesis of sphingolipids and glycosphingolipids in various 13C-enriched forms based 
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followed by TFA (trifluoroacetic acid) mediated removal of the Boc group provided [13C5]-
sphingosine (31b; 59% yield). Both [13C0]-31a and [13C5]-31b were condensed with either 
[13C0]-palmitoyl chloride or [13C3]-palmitoyl chloride 30 to give the panel of labeled 
ceramides 32a–32d. Alternatively, debenzoylation of 23a/b, reduction of the alkene 
moiety with Adams catalyst, and TFA-mediated Boc removal gave stable-isotope 
sphinganine pair 33a and 33b, which were used as starting materials to produce dihydro- 
ceramides 34a–34d. 
The glycosylated sphingolipids were assembled by reacting the labeled sphingosine 
alcohols with the appropriate glycosyl donors. Thus, N-phenyltrifluoroacetimidate glucose 
35 (see Experimental Section for its synthesis; Scheme 2.5) and sphingosine 23a/b were 
condensed in a reaction promoted by boron trifluoride diethyl etherate to give fully 
protected glucosylsphingosines 36a/b. The moderate yield of the glycosylation reaction 
can be explained by the concomitant cleavage of the Boc group, which took place under 
the Lewis acidic reaction conditions. Glucosylation of 23a/b using the corresponding 
perbenzoylated N-phenyltrifluoroacetimidate donor and boron trifluoride diethyl etherate 
was unproductive, and led only to the isolation of the product of Boc removal from 23a/b. 
Global deprotection of 36 by successive treatment with HF/pyridine, sodium methoxide, 
and trifluoroacetic acid provided stable-isotope glucosylsphingosine pair 37a/b. Both 
[13C0]-glucosylsphingosine (37a) and [13C5]-glucosylsphingosine (37b) were condensed with 
either [13C0]-palmitoyl chloride or [13C3]-palmitoyl chloride 30 to give the panel of labeled 












Scheme 2.4 Synthesis of panel of 13C-labeled (glyco)sphingolipids. 
Reagents and conditions: (a) (i) NaOMe, MeOH, r.t., 20 h; (ii) KOH, H2O, r.t., 20 h; (iii) TFA, H2O, 0 °C, 30 min, 31a: 
54%, 31b: 59 %; (b) palmitoyl chloride, satd. aq. NaOAc, THF, r.t., 3 h; (c) (i) NaOMe, MeOH, r.t., 20 h; (ii) KOH, 
H2O, r.t., 20 h; (iii) PtO2, H2 (g), EtOAc, r.t., 20 h; (iv) TFA, H2O, 0 °C, 30 min, 33a: 47%, 33b: 52 %; (d) 35/39, 
BF3·OEt2, CH2Cl2, 0 °C, 1 h, 36a: 49%, 36b: 54%, 40a: 60%, 44b: 55%; (e) (i) HF/pyridine, THF/pyridine, r.t., 2 h; (ii) 
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Scheme 2.5 Synthesis of donor glucoside 35. 
Reagents and conditions: (a) tBu2SiOTf2, pyridine, DMF, –40 °C, 30 min, 77 %; (b) BzCl, pyridine, r.t., 3 h, 98%; 
(c) NIS, TFA, CH2Cl2, 0 °C, 3 h, 98%; (d) ClC(NPh)CF3, CsCO3, acetone, 0 °C, 2 h, 80 %. 
Finally, the syntheses of globotriaosylsphingosines 41a/b and globotriaosylceramides 42a–
42d were preformed. To this end, sphingosine 23 was condensed with trisaccharide donor 
39[21] in a reaction promoted by boron trifluoride diethyl etherate to give fully protected 
globotriaosylsphingosines 40a/b. Subsequent global deprotection by the same procedure 
as described above gave 41a/b. Standard palmitoylation with either [13C0]-palmitoyl 
chloride or [13C3]-palmitoyl chloride gave the panel of globotriaosylceramides 42a–42d to 
complete the library of labeled (glyco)sphingolipids. 
The physical properties of all the labeled compounds matched those of their 12C-
counterparts, apart from their mass spectra and their 1H and 13C NMR spectra. As a 
representative example, Figure 2 shows the 1H and 13C NMR spectra of 13C5- 
globotriasylsphingosine 41b (Figure 2a, b and d), and the 13C NMR spectrum of its non-
enriched counterpart 41a (Figure 2c). In Figure 2b, the 13C-decoupled 1H NMR spectrum of 
13C-labeled 41b is shown, which is identical in all respects to the spectrum of unlabeled 



































Figure 2.2 1H- and 13C NMR spectra of globotriaosylsphingsosine both in 13C-enriched (41b) and unenriched 
(41a) form. (a) 400 MHz 1H NMR spectrum ([D4]methanol) of 41b, in which the 13C, 1H coupling of the double-
bond proton is apparent. (b) 400 MHz 13C-decoupled 1H NMR spectrum ([D4]methanol) of 41b. (c) 151.1 MHz 13C 
NMR spectrum ([D4]methanol) of 41a. (d) 151.1 MHz 13C NMR spectrum ([D4]methanol) of 41b, with integration 
of the 13C labels. 
2.4 Conclusion 
In conclusion, a comprehensive library of stable-isotope-enriched sphingolipids has been 
constructed by straightforward synthetic routes taking into consideration that the 
synthesis of 13C-enriched lipids with the carbons introduced at specific predetermined 
sites can be executed with only a limited number of reagents available from commercial 
sources. The key step in the assembly of the sphingosine backbone, the cross-metathesis 
reaction between the sphingosine head-group alkene and the long-chain alkene, was 
optimized to minimize truncation of the long-chain alkene before the cross-metathesis 
event. Elimination of one or two methylene units, leading to the loss of 13C-labels, was 
observed during this reaction under conditions previously described. The addition of 
acetic acid to the reaction mixture effectively prevented the truncation of the alkene 
chain. With this work we believe we have obtained a valuable set of molecular probes to 
study sphingolipid metabolism in healthy and disease states in a chemical metabolomics 
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setting. The route is also flexible, and is thus amenable for the production of other 
sphingolipid metabolites, with respect to both the polar head group, such as for instance 
phosphate and phosphate diesters, and also the N-acyl-substituted fatty acid moiety. 
2.3 Experimental section 
General Remarks: [13C2]-acetic acid (99.95% isotopically pure, product code CLM-105), potassium [13C]-cyanide 
(99% isotopically pure, product code CLM-297), and [1,2,3-13C3]-myristic acid (99% isotopically pure, product 
code CLM-3665) were purchased from Cambridge Isotope Laboratories, Inc., and were used as received. 
Commercially available reagents and solvents (Acros, Fluka, or Merck) were used as received, unless otherwise 
stated. CH2Cl2 and THF were freshly distilled before use, over P2O5 and Na/benzophenone, respectively. 
Triethylamine was distilled from calcium hydride and stored over potassium hydroxide. Traces of water were 
removed from starting compounds by coevaporation with toluene. All moisture-sensitive reactions were carried 
out under an argon atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column chromatography 
was carried out using forced flow of the indicated solvent systems on Screening Devices silica gel 60 (40–63  μm  
mesh). Size-exclusion chromatography was carried out on Sephadex LH20 (MeOH/CH2Cl2, 1:1). Analytical TLC 
 was carried out on aluminium sheets (Merck, silica gel 60, F254). Compounds were visualized by UV absorption 
(254 nm), or by spraying with ammonium molybdate/cerium sulphate solution [(NH4)6Mo7O24· 4 H2O (25 g/L), 
(NH4)4Ce(SO4)6· 2 H2O (10 g/L), 10 % sulphuric acid in ethanol] or phosphomolybdic acid in EtOH (150 g/L), 
followed by charring (ca. 150 °C). IR spectra were recorded with a Shimadzu FTIR-8300 instrument and are 
reported in cm–1. Optical rotations were measured with a Propol automatic polarimeter (sodium D-line, λ  = 589 
nm). 1H and 13C NMR spectra were recorded with a Bruker AV 400 MHz spectrometer at 400.2 (1H) and 100.6 
(13C) MHz, or with a Bruker AV 600 MHz spectrometer at 600.0 (1H) and 151.1 (13C) MHz. Chemical shifts are 
reported as δ  values (ppm), and were referenced to tetramethylsilane (δ  =  0.00  ppm)  directly in CDCl3, or using 
the residual solvent peak (D2O). Coupling constants (J) are given in Hz, and all 13C spectra were proton decoupled. 
NMR assignments were made using COSY and HSQC, and in some cases TOCSY experiments. LC–MS analysis was 
carried out with an LCQ Advantage Max (Thermo Finnigan) instrument equipped with a Gemini C18 column 
(Phenomenex, 50  4.6 mm, 3 μm), using the following buffers: A: H2O, B: acetonitrile, and C: aq. TFA (1.0 %). 
HPLC–MS purifications were carried out with an Agilent Technologies 1200 Series automated HPLC system with a 
Quadrupole MS 6130, equipped with a semi-preparative Gemini C18 column (Phe-nomenex, 250 10.00, 5μm). 
Products were eluted using the following buffers: A: aq. TFA (0.2 %), B: acetonitrile (HPLC-grade), 5 mL/min. 
Purified products were lyophilized with a CHRIST ALPHA 2–4 LDPLUS apparatus to remove water and traces of 
buffer salts. 
General producere for the synthesis of ceramides from the sphingosines. Sphingosine (0.1 mmol) was dissolved 
in THF (12 mL) and sat. aq. NaOAc (10 mL) was added. Palmitoyl chloride (0.13 mmol, 1.3 eq) was added and the 
reaction was stirred vigorously at room temperature for 3 hours. The mixture was diluted with THF (20 mL) and 
washed with water (10 mL). The water layer was extracted with THF (3x 20 mL) and the combined organics were 
dried (Na2SO4), filtered and concentrated in vacuo. The ceramides were purified by column chromatography 
(chloroform/MeOH) and HPLC–MS, using a C4 column. Products were eluted using the following buffers: A: 25 
nM NH4OAc in MeOH/H2O (3:1), B: acetonitrile (HPLC-grade). Purified products were lyophilised to remove water 
and traces of buffer salts. The symbol * in the NMR analysis stands for the palmitate group of the ceramide. 
[13C2]-2-Bromoacetic acid (10). Trifluoroacetic anhydride (67.3 mL, 484 mmol, 3.0 eq) was slowly added to [1,2-
13C2]-acetic acid 9 (10 g, 161 mmol, 1.0 eq), under stirring. Bromine (8.30 mL, 161 mmol, 1.0 eq) 
was added and the reaction was stirred at room temperature for 20 h. The reaction mixture was 
cooled to 0 °C followed by addition of water (10.2 mL, 564 mmol, 3.5 eq). Excess bromine was 






in vacuo. This procedure was repeated twice giving [13C2]-2-bromoacetic acid 10 as an off-white solid without 
further purification (23.2 g, 142 mmol, 88%). Analytical data are in agreement with the literature.[8] 
 [1,2-13C2]-2-Bromo-N-methoxy-N-methylacetamide and [1,2-13C2]-2-Chloro-N-methoxy-N-methylacetamide 
(11).   [13C2]-2-Bromoacetic acid 10 (8.46 g, 60 mmol, 1.0 eq) was then dissolved in anhydrous 
DCM (100 mL), put under an atmosphere of argon, and cooled to 0 °C. Oxalyl chloride (10.5 
mL, 120 mmol, 2.0 eq) was added followed by a drop of DMF. The reaction was then kept 
under a flow of argon and continuous stirring at room temperature. When gas evolution 
stopped (~ 2 h), the reaction was concentrated in vacuo (10–15 °C, 180 mbar). The residue was dissolved in 
anhydrous DCM (40 mL) and cooled to -70 °C. N,O-Dimethylhydroxylamine (12.3 mL, 168 mmol, 2.8 eq), 
dissolved in anhydrous DCM (30 mL), was slowly added to the acylchloride at -70 °C and then left stirring, 
reaching room temperature over 2 h. The reaction mixture was then stirred at room temperature for 30 min. The 
solids were filtered over a Whatmann paper and washed with DCM. The eluent was concentrated in vacuo and 
purified by column chromatography (10–40% EtOAc in petroleum ether), giving [1,2-13C2]-2-Bromo-N-methoxy-N-
methylacetamide and  [1,2-13C2]-2-Chloro-N-methoxy-N-methylacetamide in a 4:1 ratio (as determined by 1H- 
and 13C-NMR) as a clear oil (10.25 g, 58.3 mmol, 97%). Rf = 0.35 (30% EtOAc in petroleum ether); [1,2-13C2]-2-
Bromo-N-methoxy-N-methyl-acetamide: 1H NMR (400 MHz, CDCl3) δ 4.01 (dd, 2 H, J = 154.0, 3.6 Hz, H-2), 3.80 (s, 
3 H, CH3-OMe), 3.24 (s, 3 H, CH3-NMe); 13C NMR (101 MHz, CDCl3) δ 167.5 (d, J = 58.5 Hz, C=O), 61.6 (CH3-OMe), 32.5 
(CH3-NMe), 25.1 (d, J = 58.4 Hz, CH2); HRMS calculated for [C213C2H8NO2Br + H]+: 183.9878, found 183.9877. [1,2-
13C2]-2-Chloro-N-methoxy-N-methylacetamide: 1H NMR (400 MHz, CDCl3) δ 4.25 (dd, 2 H, J = 152.3, 4.4 Hz, H-2), 
3.76 (s, 3 H, CH3-OMe), 3.24 (s, 3 H, CH3-NMe); 13C NMR (101 MHz, CDCl3) δ 167.5 (d, J = 57.2 Hz, C=O), 61.6 (CH3-OMe), 
40.7 (d, J = 57.7 Hz, CH2), 32.5 (CH3-NMe); HRMS calculated for [C213C2H8NO2Cl + H]+: 140,0383 found 140.0381.  
Diethyl-([1,2-13C2]-N-methoxy-N-methylcarbamoylmethyl) phosphonate (12). [1,2-13C2]-2-Bromo/chloro-N-
methoxy-N-methylacetamide 11 (10.25 g, 58.3 mmol, 1.0 eq) and triethylphosphite (10.5 
mL, 60 mmol, 1.05 eq) were put in a round bottom flask equipped with an 15 cm air cooled 
condenser and heated for 3 h at 150 °C. The crude mixture was cooled down and directly 
purified by column chromatography (30–50% acetone in petroleum ether), giving the title compound 12 as a 
clear oil (13.7 g, 56.8 mmol, 95%). Rf = 0.20 (40% acetone in petroleum ether); 1H NMR (400 MHz, CDCl3) δ 4.24 – 
4.13 (m, 4 H, CH2-OEt x2), 3.79 (s, 3 H, CH3-OMe), 3.22 (s, 3 H, CH3-NMe), 3.16 (ddd, 2 H, J = 129.8, 21.9, 6.6 Hz, H-2), 
1.35 (t, 6 H, J = 7.1 Hz, CH3-OEt x 2); 13C NMR (101 MHz, CDCl3) δ 165.5 (dd, J = 53.1, 4.5 Hz, C=O), 62.0, 61.9 (CH2-OEt 
x 2), 60.9 (CH3-OMe), 31.57 (CH3-NMe), 30.9 (dd, J = 136.1, 53.1 Hz, H-2), 15.82, 15.76 (CH3-OEt x2); IR (neat): 2984, 
1658, 1423, 1381, 1253, 1018, 961, 789 cm-1; HRMS calculated for [C613C2H18NO5P + H]+: 242.1063, found 
242.1064. 
 [1-13C1]-Decanitrile (14). [13C1]-Potassium cyanide (5.00 g, 76.0 mmol, 1.0 eq) was added to a solution of 1-
bromononane 13 (16.5 g, 79.0 mmol, 1.05 eq) in a mixture of ethanol/water (9:1, 140 mL) and 
heated over night at 80 °C. The reaction was cooled to room temperature and diluted with 
ether (500 mL) and washed with water (2 x 500 mL) and brine (400 mL). The waterlayers were extracted with 
ether (400 mL) and the combined organics were dried (Na2SO4), filtered and concentrated in vacuo. Purification 
by column chromatography (0–2% EtOAc in petroleum ether) gave the title compound as a clear oil (11.1 g, 72.0 
mmol, 95%). Rf = 0.23 (3% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ 2.33 (dt, 2 H, J = 9.6, 7.1 Hz, H-
2), 1.65 (m, 2 H, H-3), 1.44, (m, 2 H, H-4), 1.35 – 1.22 (m, 10 H, H-5 to H-9), 0.88 (t, 3 H, J = 6.9 Hz, H-10); 13C NMR 
(101 MHz, CDCl3) δ 119.8  (C≡N),  31.7,  29.2,  29.1,  28.7  (CH2 x4), 28.5 (d, J = 3.3 Hz, C-4), 25.3 (d, J = 0.4 Hz, C-3), 
22.5 (CH2), 17.0 (d, J = 55.8 Hz, C-2), 14.0 (C-10); IR (neat): 2925, 2856, 2194, 1467, 1425, 1378, 721 cm-1; HRMS 
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[1-13C1]-Decanal (15). [1-13C1]-Decanitrile 14 (11.1 g, 72.0 mmol, 1.0 eq) was dissolved in anhydrous THF (250 mL) 
and cooled to 0 °C before addition of DIBAL-H (1.5 M in hexanes, 52.9 mL, 79.0 mmol, 1.1 eq). 
The reaction mixture was stirred at room temperature for 2.5 h. The mixture was then 
transferred to an extraction funnel, diluted with ether (200 mL), and washed with 1 M HCl (2 
x 400 mL), sat. aq. NaHCO3 (400 mL). The water layers were extracted with ether (2 x 400 mL) and the combined 
organics were dried (MgSO4), filtered over Celite, and concentrated in vacuo. Purification by column 
chromatography (0–10% DCM in petroleum ether) produced the title compound as a clear oil (10.4 g, 66.1 mmol, 
92%). Rf = 0.22 (20% DCM in petroleum ether); 1H NMR (400 MHz, CDCl3) δ 9.76 (dt, 1 H, J = 169.8, 1.9 Hz), 2.42 
(dtd, 2 H, J = 7.4, 6.2, 1.8 Hz), 1.62 (m, 2 H), 1.36 – 1.23 (m, 12 H), 0.88 (t, 3H, J = 6.9 Hz); 13C NMR (101 MHz, 
CDCl3) δ 203.0 (C=O), 43.9 (d, J = 38.8, C-2), 31.8, 29.35, 29.32, 29.2 (CH2 x4), 29.1 (d, J = 3.4 Hz, C-4), 22.6 (CH2), 
22.0 (d, J = 1.6 Hz, C-3), 14.0 (C-10); IR (neat): 2922, 2855, 1728, 1466, 719 cm-1.  
 [1,2,3-13C3]-(E/Z)-N-Methoxy-N-methyl-dodec-2-en-amide (16). Diethyl-([1,2-13C2]-N-methoxy-N-
methylcarbamoylmethyl)phosphonate 12 (10.4 g, 43.1 mmol, 1.1 eq) was dissolved in 
dry THF (200 mL) and cooled to 0 °C before addition of n-butyllithium 1.6 M in 
hexanes (26.5 mL, 42.3 mmol, 1.08 eq). The reaction mixture was stirred for 10 min at 
0 °C. [1-13C1]-Decanal 15 (6.16 g, 39.2 mmol, 1.0 eq) dissolved in anhydrous THF (40 
mL) was added to the phosphonate carbanion and the reaction mixture was stirred at room temperature over 
night. The mixture was then transferred to an extraction funnel with diethyl ether (50 mL), washed with water 
(250 mL) and brine (200 mL). The water layers were extracted with ether (2 x 250 mL) and the combined organics 
were dried (Na2SO4), filtered and concentrated in vacuo.  Purification by column chromatography (0–15% EtOAc 
in petroleum ether), giving [1,2,3-13C3]-(E)-N-Methoxy-N-methyl-dodec-2-en-amide (7.52 g, 30.8 mmol, 79%) and 
[1,2,3-13C3]-(Z)-N-Methoxy-N-methyl-dodec-2-en-amide (0.75 mg, 3.07 mmol, 8%) in a combined yield of 87% as 
clear oil. Rf 16E = 0.42; 16Z = 0.64 (20% EtOAc in petroleum ether); (E-isomer, 16E)  1H NMR (400 MHz, CDCl3) δ 
6.98 (dm, 1 H, J = 153.8 Hz, H-3), 6.38 (ddd, 1 H, J = 160.8, 15.4, 4.1 Hz, H-2), 3.70 (s, 3 H, CH3-OMe), 3.24 (s, 3 H, 
CH3-NMe), 2.23 (m, 2 H, H-4), 1.46 (m, 2 H, H-5), 1.35 –1.23 (m, 12 H, H-6 to H-11), 0.88 (t, 3 H, J = 6.8 Hz, H-12); 13C 
NMR (101 MHz, CDCl3) δ 167.1 (d, J = 67.1 Hz, C=O), 148.0 (d, J = 71.6 Hz, C-3), 118.5 (dd, J = 71.6, 67.1 Hz, C-2), 
61.6 (CH3-OMe), 32.5 (m, C-4), 32.3 (m, CH3-NMe), 31.9, 29.5, 29.4, 29.3 (CH2 x4), 29.2 (d, J = 3.6 Hz, C-6), 28.3 (m, C-
5), 22.7 (CH2), 14.1 (C-12); IR (neat): 2926, 5856, 1622, 1584, 1462, 1368, 1175, 993 cm-1; HRMS calculated for 
[C1113C3H27NO2H]+: 245.2215, found 245.2216; (Z-isomer, 16Z). 1H NMR (400 MHz, CDCl3) δ 6.22 (dd, 1 H, J = 
161.8, 11.5 Hz, H-2), 6.11 (dm, 1 H, J = 152.0 Hz, H-3), 3.68 (s, 3 H, CH3-OMe), 3.21 (s, 3 H, CH3-NMe), 2.61 (m, 2 H, H-
4), 1.43 (m, 2 H, H-5), 1.35 – 1.22 (m, 12 H, H-6 to H-11), 0.88 (t, 3H, J = 6.9 Hz, H-12); 13C NMR (101 MHz, CDCl3) δ 
167.6 (d, J = 63.6, C=O), 147.8 (d, J = 67.1 Hz, C-3), 117. 9 (dd, J = 67.1, 63.6 Hz, C-2), 61.5 (CH3-OMe), 31.9, 31.6 
(CH3-NMe)‡, 29.6, 29.5 (CH2 x3), 29.38 (d, J = 4.0 Hz, C-6), 29.35 – 29.29 (m, CH2 x2), 29.1 (m, C-3), 22.7 (CH2), 14.1 
(C-12); IR (neat): 2925, 2855, 1618, 1459, 1334, 1178, 996, 776 cm-1; HRMS calculated for [C1113C3H27NO2 + H]+: 
245.2215, found 245.2216. 
 [1,2,3-13C3]-N-methoxy-N-methyl-dodecanamide (17). [1,2,3-13C3]-(E/Z)-N-Methoxy-N-methyl-dodec-2-en-amide 
16E and 16Z (8.25 g, 33.8 mmol, 1.0 eq) was dissolved in EtOAc (200 mL). The solution 
was bubbled with argon under stirring and palladium 10% on charcoal (0.72 g, 0.67 
mmol, 0.02 eq), was added. The reaction mixture was then stirred under a flow of 
hydrogen gas for 30 min and left over night under a hydrogen atmosphere. The palladium was removed by 
filtration over a Whatmann paper and rinsed with EtOAc (100 mL) followed by removal of the solvents in vacuo. 
Purification by column chromatography (5–20% EtOAc in petroleum ether) afforded [1,2,3-13C3]-N-methoxy-N-
methyl-dodecanamide as a clear oil (6.85 g, 27.8 mmol, 82%). Rf = 0.38 (20% EtOAc in petroleum ether); 1H NMR 
(400 MHz, CDCl3) δ 3.68 (s, 3 H, CH3-OMe), 3.18 (s, 3 H, CH3-NMe), 2.41 (dm, 2 H, J = 127.3 Hz, H-2), 1.62 (dm, 2 H, J = 
127.9 Hz, H-3), 1.35 – 1.23 (m, 16 H, H-4 to H-11), 0.88 (t, 3 H, J = 6.8 Hz, H-12); 13C NMR (101 MHz, CDCl3) δ 174.6 












(dd, J = 34.9, 1.3 Hz, C-3) , 22.6 (CH2), 14.1 (C-12); IR (neat): 2923, 2854, 1627, 1464, 1369, 1174, 1119, 998, 722, 
436 cm-1; HRMS calculated for [C1113C3H29NO2 + H]+: 247.2372, found 247.2373. 
 [1,2,3,4,5-13C5]-(E/Z)-N-Methoxy-N-methyl-tetradec-2-enamide  (18). [1,2,3-13C3]-N-Methoxy-N-methyl-
dodecanamide 17 (3.91 g, 15.9 mmol, 1.0 eq) was dissolved in anhydrous THF 
(120 mL) and cooled to 0 °C before addition of lithium aluminium hydride (4.0 M 
in THF) (2.38 mL, 9.52 mmol, 0.6 eq). The reaction mixture was stirred for 45 min 
and was then cooled to -15 °C, before addition of sat. aq. KHSO4 (100 mL) and 
diethylether (300 mL). The two-phase system was stirred vigorously for 30 min and was then dried with MgSO4 
followed by Na2SO4. The solids were filtered and washed with diethylether (200 mL). The eluate was 
concentrated in vacuo, giving crude [1,2,3-13C3]-dodecanal (2.96 g, 15.8 mmol) as a clear oil which was used 
without further purification.  
Diethyl (N-Methoxy-N-methyl-carbamoylmethyl)phosphonate 12 (4.20 g, 17.4 mmol, 1.1 eq) was dissolved in 
anhydrous THF (80 mL) and cooled to 0 °C before addition of n-butyllithium (1.6 M in hexanes) (10.4 mL, 16.6 
mmol, 1.05 eq). The reaction mixture was stirred for 10 minutes at 0 °C. The crude [1,2,3-13C3]-dodecanal was 
dissolved in anhydrous THF (20 mL) and added to the Horner-Wadsworth-Emmons reagent at 0 °C. The reaction 
mixture was then stirred at room temperature over night. The mixture was transferred to an extraction funnel 
with ether (50 mL) and washed with water (100 mL) and brine (100 mL). The water layers were extracted with 
ether (2 x 100 mL) and the combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by column chromatography (5–15% EtOAc in petroleum ether) giving [1,2,3,4,5-13C5]-(E)-N-Methoxy-
N-methyl-tetradec-2-enamide (3.05 g, 11.1 mmol, 70%) and [1,2,3,4,5-13C5]-(Z)-N-Methoxy-N-methyl-tetradec-2-
enamide (310 mg, 1.13 mmol, 7%) in a combined yield of 77% as clear oils. Rf 18E = 0.39; 18Z = 0.58 (15% EtOAc 
in petroleum ether). (E-isomer, 18E) 1H NMR (600 MHz, CDCl3) δ 6.98 (dm, 1 H, J = 153.8 Hz, H-3), 6.39 (ddm, 1 H, 
J = 161.1, 15.4 Hz, H-2), 3.70 (s, 3 H, CH3-OMe), 3.24 (s, 3 H, CH3-NMe), 2.23 (ddt, 2 H, J = 126.2, 7.0, 6.1 Hz, H-4), 1.60 
– 1.20 (m, 18 H, H-5 to H-13), 0.88 (t, 3 H, J = 7.0 Hz, H-14); 13C NMR (151 MHz, CDCl3) δ 167.1 (dd, J = 67.1, 6.1 
Hz,  C=O), 148.0 (ddd, J = 71.6, 41.8, 2.1  Hz, C-3), 118.6 (dddd, J = 71.6, 67.1, 3.6, 1.5 Hz, C-2), 61.6 (CH3-OMe), 32.5 
(dddd, J = 41.8, 33.7, 6.1, 1.5 Hz, C-4), 32.3 (CH3-NMe), 31.9 (CH2), 29.6 – 29.0 (m, CH2 x6), 28.3 (ddd, J = 33.7, 3.6, 
2.1 Hz, C-5), 22.7 (CH2), 14.1 (C-12); IR (neat): 2924, 2854, 1618, 1583, 1464, 1368, 991 cm-1; HRMS Calculated for 
[C1113C5H31NO2 + H]+: 275.2595, found 275.2595; (Z-isomer, 18Z) 1H NMR (600 MHz, CDCl3) δ 6.23 (dm, 1 H, J = 
160.7 Hz, H-2), 6.12 (dm, 1 H, J = 152.0 Hz, H-3), 3.68 (s, 3 H, CH3-OMe), 3.21 (s, 3 H, CH3-NMe), 2.62 (dm, 2 H, J = 
125.3 Hz, H-4), 1.59 – 1.20 (m, 18 H, H-5 to H-13), 0.88 (t, 3 H, J = 7.1 Hz, H-14); 13C NMR (151 MHz, CDCl3) δ 167.6 
(dm, J = 67.1 Hz, C=O), 147.8 (dd, J = 69.9, 35.2 Hz, C-3), 117. 9 (dd, J = 69.9, 67.1 Hz, C-2), 61.4 (CH3-OMe), 32.0 
(CH3-NMe)‡, 31.9 (CH2), 30.2 – 28.4 (m, CH2 x8), 22.7 (CH2), 14.1 (C-12); IR (neat): 2923, 2854, 1618, 1464, 1331, 
1176, 1086, 999, 775 cm-1; HRMS calculated for [C1113C5H31NO2 + H]+: 275.2595, found 275.2595. 
 [1,2,3,4,5-13C5]-N-methoxy-N-methyl-tetradecanamide (19). [1,2,3,4,5-13C5]-(E/Z)-N-Methoxy-N-methyl-
tetradec-2-enamide 18E/Z (3.20 g, 11.66 mmol, 1.0 eq) was dissolved in EtOAc 
(100 mL). The solution was bubbled with argon under stirring, before addition of 
palladium (10% on charcoal) (0.62 g, 0.58 mmol, 0.05 eq). The reaction mixture 
was then stirred under a flow of hydrogen gas for 30 min and was then left over night under a hydrogen 
atmosphere. The palladium residue was removed by filtration over a Whatmann paper and rinsed with EtOAc 
(100 mL) followed by removal of the solvents in vacuo. Purification by column chromatography (5–15% EtOAc in 
petroleum ether) yielded [1,2,3,4,5-13C5]-N-methoxy-N-methyl-tetradecanamide as a clear oil (3.00 g, 10.85 
mmol, 93%). Rf = 0.38 (15% EtOAc in petroleum ether); 1H NMR (600 MHz, CDCl3) δ 3.68 (s, 3 H, CH3-OMe), 3.18 (s, 
3 H, CH3-NMe), 2.41 (dm, 2 H, J = 128.4 Hz, H-2), 1.62 (dm, 2 H, J = 127.1 Hz, H-3), 1.46 – 1.12 (m, 20 H, H-4 to H-
13), 0.88 (t, 3 H, J = 7.1 Hz, H-14); 13C NMR (151 MHz, CDCl3) δ 174.8 (dm, J = 51.5 Hz, C=O), 61.1 (CH3-OMe), 32.1 
(CH3-NMe)‡, 31.9 (dd, J = 51.5, 35.6 Hz, C-2), 29.7 – 29.1 (m, CH2 x9), 24.6 (m, C-3), 22.6 (CH2), 14.1 (C-14).; IR 
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 [2,3,4,5,6-13C5]-Pentadec-1-ene (20). [1,2,3,4,5-13C5]-N-Methoxy-N-methyl-tetradecanamide 19 (1.57 g, 5.72 
mmol, 1.0 eq) was dissolved in anhydrous THF (55 mL) and LiAlH4 (4 M in THF) (0.86 
mL, 3.43 mmol, 0.6 eq) was added at 0 °C. The reaction mixture was stirred for 45 
minutes and then cooled to ca -15 °C before addition of sat. aq. KHSO4 (40 mL) and diethylether (100 mL). The 
resulting two phase mixture was stirred vigorously for 30 min and then dried with MgSO4, and then Na2SO4. The 
solids were filtered and washed with diethylether (100 mL). The eluate was concentrated in vacuo giving crude 
[1,2,3,4,5-13C5]-tetradecanal (1.24 g, 5.72 mmol) as a clear oil which was used without further purification.  
Methyltriphenylphosphonium bromide (3.06 g, 8.58 mmol, 1.5 eq) was suspended in anhydrous THF (150 mL) 
and n-butyllithium (1.6 M in hexanes) (4.65 mL, 7.44 mmol, 1.3 eq) was added at 0 °C. The reaction was then 
stirred for 10 min at 0 °C. The crude [1,2,3,4,5-13C5]-tetradecanal was dissolved in 20 mL anhydrous THF and then 
added to the phosphorylide at 0 °C. The reaction mixture was stirred over night at room temperature and 
transferred to an extraction funnel using ether (100 mL). The reaction mixture was washed with water (200 mL x 
2) and brine (200 mL). The water phases were extracted with ether (200 mL) and the combined organics were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography (100% petroleum 
ether) produced the title compound 20 as a clear oil (1.15 g, 5.34 mmol, 93%). Rf = 0.98 (100% petroleum ether); 
1H NMR (400 MHz, CDCl3)  δ  5.81  (dm,  1  H,  J = 150.3 Hz, H-2), 4.99 (dd, 1 H, J = 17.1, 6.5 Hz, H-1Z), 4.92 (t, 1 H, J = 
10.8 Hz, H-1E), 2.03 (dm, 2 H, J = 125.4 Hz, H-3), 1.57 – 1.11 (m, 22 H, H-4 to H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 
13C NMR (101 MHz, CDCl3)  δ  139.2  (dm,  J = 42.1 Hz, C-2), 114.0 (dd, J = 69.1, 3.1 Hz, C-1), 33.9 (m, C-3), 32.0 (CH2), 
29.9 – 28.6 (m, CH2 x9), 22.7 (CH2), 14.1 (C-15); IR (neat): 2922, 2853, 1628, 1458, 1370, 1175, 1117, 996, 721 cm-
1. 
 (E)-1,2-O,N-Isopropyliden-N-(tert-butoxycarbonyl)-D-erythro-sphingosine (22a). (2S,3R)-2-Amino-N-(tert-
butyloxycarbonyl)-1,3-dihydroxy-1,2-O,N-isopropylidene-4-pentene 21 (1 g, 
4.0 mmol, 1.0 eq) and pentadec-1-ene (1.70 g, 8.0 mmol, 2.0 eq) were 
dissolved in anhydrous DCM (4 mL) and flushed with argon before addition 
of Grubbs catalyst 2nd generation (67 mg, 79 µmol, 0.02 eq) and acetic acid 
(45 µL, 0.79 mmol, 0.2 eq). The reaction was refluxed under a flow of argon for 36 h. The reaction mixture was 
concentrated in vacuo and purified by column chromatography (0–10% EtOAc in petroleum ether). The title 
compound was isolated as a viscous oil in a (1.30 g, 2.96 mmol, 74%). Rf = 0.19 (10% EtOAc in petroleum ether); 
[α]D22:  −26  (c  =  0.25  CHCl3); 1H NMR (400 MHz, DMSO-d6,  363  °K)  δ  5.56  (dt,  1  H,  J = 15.8, 6.5 Hz, H-5), 5.45 (ddd, 1 
H, J =15.8, 6.6, 1.1 Hz, H-4), 4.61 (bs, 1 H, OH), 4.03 (m, 1 H, H-3), 3.93 (bd, 1 H, J = 8.5 Hz, H-1a), 3.83 (bt, 1 H, J = 
7.3 Hz, H-1b), 3.75 (m, 1 H, H-2), 1.98 (m, 2 H, H-6)m 1.48 (s, 3 H, CH3-acetonide), 1.43 (m, 12 H, CH3-acetonide and CH3-
tBu-Boc), 1.39-1.20 (m, 22 H, H-7 to H-17), 0.87 (t, 3 H, J = 6.6 Hz, H-18); 13C NMR (100 MHz, DMSO-d6, 363 °K)  δ  
151.3 (C=OBoc), 130.8 (C-5) 130.4 (C-4), 92.8 (Cq-acetonide), 78.7 (Cq-Boc), 71.4 (C-3), 63.7 (C-1), 61.0 (C-2), 31.2 (C-6), 
30.8, 28.5 (x4), 28.4, 28.2, 28.12, 28.06, 27.7 (x3), 26.2, 21.5, (C-7 to C-17, CH3-tBu-Boc and CH3-acetonide x2), 13.2 (C-
18). IR (neat): 3436, 2924, 2854, 1702, 1381, 1365, 1255, 1173, 1097, 848, 766 cm-1; HRMS calculated for 
[C26H49NO4 + H]+: 440.3734, found 440.3733.  
 (E)-[5,6,7,8,9-13C5]-1,2-O,N-Isopropylidene-N-(tert-butoxycarbonyl)-D-erythro-sphingosine (22b) (2S,3R)-2-
Amino-N-(tert-butyloxycarbonyl)-1,3-dihydroxy-1,2-O,N-isopropylidene-4-
pentene 21 (3.58 g, 13.9 mmol, 3.0 eq) and [2,3,4,5,6-13C5]-pentadec-1-ene 
20 (1.00 g, 4.64 mmol, 1.0 eq) were dissolved in anhydrous DCM (4 mL) and 
flushed with argon before addition of Grubbs catalyst 2nd generation (79 mg, 
93 µmol, 0.02 eq) and acetic acid (53 µL, 0.93 mmol, 0.2 eq). The reaction was refluxed under a flow of argon for 
36 h. The reaction mixture was concentrated in vacuo and purified by column chromatography (0–10% EtOAc in 
petroleum ether). The title compound was isolated as a viscous oil in a (1.68 g, 3.29 mmol, 81%). Rf = 0.19 (10% 
EtOAc in petroleum ether); [α]D22:  −19  (c  =  0.5  CHCl3); 1H NMR (400 MHz, DMSO-d6,  363  °K)  δ  5.55  (dm,  1  H,  J = 










1a), 3.82 (dd, 1 H, J = 8.6, 6.1 Hz, H-1b), 3.75 (td, 1 H, J = 6.1, 2.0 Hz, H-2), 1.98 (dm, 2 H, J = 124.2 Hz, H-6), 1.56 – 
1.06 (m, 37 H, CH3-tBu-Boc, CH3-acetonide and H-7 to H-17), 0.87 (t, 3 H, J = 6.9 Hz, H-18); 1H NMR (400 MHz, CDCl3)  δ  
5.74 (dm, 1 H, J = 149.4 Hz, H-5), 5.45 (dd, 1 H, J = 15.4, 6.0 Hz, H-4), 4.39 – 3.74 (m, 5 H, H-3, H-2, H-1 and OH), 
2.04 (dm, 2 H, J = 125.2 Hz, H-6), 1.72 – 1.01 (m, 37 H, CH3-tBu-Boc, CH3-acetonide and H-7 to H-17), 0.88 (t, 3 H, J = 6.8 
Hz, H-18); 1H NMR (400 MHz, CDCl3, 13C-decoupled)  δ  5.74  (dt,  1  H, J = 15.4, 6.6 Hz, H-5), 5.45 (dd, 1 H, J = 15.4, 
6.4 Hz, H-4), 4.39 – 3.74 (m, 5 H, H-3, H-2, H-1 and OH), 2.04 (q, 2 H, J = 7.0 Hz, H-6), 1.71 – 1.16 (m, 37 H, CH3-tBu-
Boc, CH3-acetonide and H-7 to H-17), 0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (100 MHz, DMSO-d6,   363   °K)  δ  151.3  
(C=OBoc), 130.8 (d, J = 42.3 Hz, C-5), 130.4 (d, J = 73.4 Hz, C-4), 92.8 (Cq-acetonide), 78.4 (Cq-Boc), 71.4 (d, J = 5.2 Hz, C-
3), 63.7 (C-1), 61.0 (d, J = 2.7 Hz, C-2), 31.9 – 30.5 (m, C-6Sp and CH2-Sp), 29.7 – 26.1  (CH2-Sp x10, CH3-tBu-Boc and CH3-
acetonide x2), 21.5 (CH2-Sp), 13.2 (C-18Sp); IR (neat): 3436, 2922, 2853, 1698, 1458, 1386, 1365, 1256, 1173, 1098, 
965, 848, 766 cm-1; HRMS calculated for [C2113C5H49NO4 + H]+: 445.3902, found 445.3902.  
3-O-Benzoyl-N-(tert-butoxycarbonyl)-D-erythro-sphingosine (23a).  (E)-1,2-O,N-Isopropyliden-N-(tert-
butoxycarbonyl)-D-erythro-sphingosine 22a (0.59 g, 1.3 mmol, 1.0 eq) was 
dissolved in a mixture of 2:1 pyridine and DCM (10 mL). DMAP (16 mg, 0.13 
mmol, 0.1 eq) was added followed by benzoyl chloride (0.23 mL, 2.0 mmol, 
1.5 eq). The reaction was stirred over night and was then quenched with 
methanol (0.5 mL). The reaction was concentrated in vacuo and dissolved in EtOAc (50 mL). The organics was 
washed with 1 M HCl (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL). The aqueous layers were extracted 
with EtOAc (50 mL) and the combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by column chromatography (1.5% EtOAc in petroleum ether) 1,2-O,N-Isopropylidene-3-O-benzoyl-N-
(tert-butyloxycarbonyl)-D-erythro-sphingosine as a clear oil. (0.61 g, 1.1 mmol, 84%). Rf = 0.82 (10% EtOAc in 
petroleum ether); [α]D22: -29 (c = 0.66 CHCl3); 1H NMR (400 MHz, DMSO-d6,  363  °K)  δ  8.00  (dm,  1  H,  J = 7.9 Hz, 
Harom), 7.63 (m, 1 H, Harom), 7.55-7.47 (m, 2 H, Harom), 5.82 (bs, 1 H, H-3), 5.75 (dt, 1 H, J = 15.4, 6.5 Hz, H-5), 5.53 
(ddd, 1 H, J = 15.4, 6.2, 1.4 Hz, H-4), 4.09 (m, 1 H, H-2), 4.06-3.97 (m, 2 H, H-1a and H-1b), 2.01 (m, 2 H, H-6), 1.43 
(s, 9 H, CH3-tBu-Boc), 1.40 (s, 3 H, CH3-acetonide), 1.36-1.17 (m, 25 H, CH3-acetonide and H-7 to H-17), 0.86 (t, 3 H, H-18); 13C 
NMR (100 MHz, DMSO-d6,  363  °K)  δ  164.5  (C=OBz), 134.4 (C-5), 132.7 (CHarom), 129.7 (Cq-arom), 128.9, 128.1 (CHarom 
x2), 125.4 (C-4), 93.2 (Cq-acetonide), 79.1 (Cq-Boc), 73.4 (C-3), 62.9 (C-1), 59.1 (C-2), 31.1, 30.8, 28.5 (x2), 28.4 (x2), 
28.4, 28.2, 27.8 (x2), 27.6 (x2), 21.5 (C-7 to C-17, CH3-tBu-Boc and CH3-acetonide x2), 13.3 (C-18); IR (neat): 2924, 2854, 
1724, 1701, 1365, 1268, 1097, 1070, 855, 709 cm-1; HRMS calculated for [C33H53NO5 + Na]+; 566.3816, found 
566.3814. 
1,2-O,N-Isopropylidene-3-O-benzoyl-N-(tert-butyloxycarbonyl)-D-erythro-sphingosine (0.5 g, 0.92 mmol, 1.0 eq) 
was dissolved in methanol:ethanol (1:1, 15 mL) and p-toluenesulfonic acid (mono hydrate) (87 mg, 0.46 mmol, 
0.5 eq) was added. The reaction was stirred at room temperature over night and was the quenched with 
triethylamine (0.32 mL, 2.3 mmol, 2.5 eq). The mixture was diluted with toluene (10 mL) and then concentrated 
in vacuo. The residue was dissolved in EtOAc (60 mL), washed with sat. aq NaHCO3 (60 mL) and brine (50 mL). 
The water layers were back extracted with EtOAc (60 mL). The combined organics were dried (Na2SO4), filtered 
and concentrated in vacuo. Purification by column chromatography (10% EtOAc in petroleum ether) produced 
the title compound as a clear waxy solid (0.25 g, 0.50 mmol, 54%; 88% based on recovering starting material). Rf 
= 0.07 (10% EtOAc in petroleum ether); [α]D22: +15 (c = 1.0 CHCl3); 1H NMR (400 MHz, CDCl3) δ  8.04  (dm,  2  H,  J = 
7.5 Hz, Harom), 7.57 (t, 1 H, J = 7.4 Hz, Harom), 7.44 (t, 2 H, J = 7.7 Hz, Harom), 5.87 (dt, 1 H, J = 14.9, 6.6 Hz, H-5), 5.60 
(dd, 1 H, J = 14.9, 7.7 Hz,H-4), 5.53 (t, 1 H, J = 7.3 Hz, H-3), 5.12 (d, 1 H, J = 8.9 Hz, NHBoc), 3.95 (m, 1 H, H-2), 3.76-
3.67 (m, 2 H, H-1a and H-1b). 2.82 (bs, 1 H, OH), 2.05 (m, 2 H, H-6), 1.43 (s, 9 H, CH3-tBu-Boc), 1.40-1.20 (m, 22 H, H-7 
to H-17), 0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (100 MHz, CDCl3)  δ  166.2  (C=OBz), 155.8 (C=OBoc), 137.3 (C-5), 
133.2 (CHarom), 129.8 (Cq-arom), 129.7, 128.4 (CHarom x2), 124.6 (C-4), 79.6 (Cq-Boc), 74.8 (C-3), 61.7 (C-1), 54.5 (C-2), 
32.2 (C-6), 31.9, 29.62 (x3), 29.60, 29.5, 29.4, 29.3, 29.2, 28.9, (Csp x10), 28.3 (CH3-tBu-Boc), 22.6 (Csp), 14.1 (C-18); IR 
(neat): 3372, 2924, 2854, 1715, 1268, 1171, 1111, 1070, 969, 710 cm-1; HRMS calculated for [C30H49NO5 + Na]+: 
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 [5,6,7,8,9-13C5]-3-O-Benzoyl-N-(tert-butoxycarbonyl)-D-erythro-sphingosine (23b). [5,6,7,8,9-13C5]-1,2-O,N-
Isopropylidene-N-(tert-butyloxycarbonyl)-D-erythro-sphingosine 22b (1.14 
g, 2.56 mmol, 1.0 eq) was dissolved in a 2:1 mixture of pyridine and DCM 
(20 mL). DMAP (16 mg, 0.13 mmol, 0.05 eq) was added followed by 
benzoyl chloride (0.45 mL, 3.85 mmol, 1.5 eq). The reaction mixture was 
stirred over night and was then quenched with methanol (0.5 mL). The reaction solvent was removed in vacuo 
and the resulting residue was dissolved in EtOAc (50 mL), washed with 1M HCl (50 mL), sat. aq. NaHCO3 (50 mL) 
and brine (40 mL). The aqueous layers were extracted with EtOAc (50 mL) and the combined organics were dried 
(Na2SO4), filtered, and concentrated in vacuo. Purification by column chromatography (1.5% EtOAc in petroleum 
ether) giving [5,6,7,8,9-13C5]-1,2-O,N-isopropylidene-3-O-benzoyl-N-(tert-butoxycarbonyl)-D-erythro-sphingosine 
as a clear oil (1.13 g, 2.37 mmol, 92%). Rf = 0.29 (5% EtOAc in petroleum ether); [α]D22:   −30   (c   =   0.5   CHCl3); 
1H NMR (400 MHz, DMSO-d6,  363  °K)  δ  8.00  (d,  2  H,  J = 7.6 Hz, Harom), 7.64 (t, 1 H, J = 7.4 Hz, Harom), 7.52 (t, 2 H, J = 
7.6 Hz, Harom), 5.82 (bs, 1 H, H-3), 5.75 (dm, 1 H, J = 149.2 Hz, H-5), 5.53 (m, 1 H, H-4), 4.15 – 3.97 (m, 3 H, H-2, H-
1a and H-1b), 2.04 (dm, 2 H, J = 126.1 Hz, H-6), 1.54 – 1.01 (m, 37 H, CH3-tBu-Boc, CH3-acetonide x2 and H-7 to H-17), 
0.86 (t, 3 H, J = 6.3 Hz, H-18); 13C NMR (101 MHz, DMSO-d6,  363  °K)  δ  164.5  (C=OBz), 151.1 (C=OBoc), 134.4 (d, J = 
42.6 Hz, C-5), 132.8 (CHarom), 129.7 (Cq-arom), 128.9, 128.2 (CHarom x2), 125.2 (d, J = 72.2 Hz, C-4), 93.2 (Cq-acetonide), 
79.2 (Cq-Boc), 73.4 (d, J = 5.6 Hz, C-3), 62.9 (C-1), 59.1 (C-2), 31.8 – 30.4 (m, C-6 and CH2), 28.8 – 27.3 (m, CH2 x9, 
CH3-tBu-Boc and CH3-acetonide x2), 21.6 (CH2), 13.4 (C-18); The same sample in CDCl3 at room temperature shows two 
rotamers:  1H NMR (400 MHz, CDCl3)  δ  8.10  (d,  2  H,  J = 7.4 Hz, Harom), 7.55 (t, 1 H, J = 7.4 Hz, Harom), 7.44 (t, 2 H, J = 
7.6 Hz, Harom), 5.93 – 5.82 (m, 1 H, H-3), 5.82 (dm, 1 H, J = 149.8 Hz, H-5), 5.46 (m, 1 H, H-4), 4.25 – 4.10 (m, 1.5 H, 
H-2, H-1a), 4.07 – 3.96 (m, 1.5 H, H-2, H-1b), 2.03 (dm, 2 H, J = 125.7 Hz, H-6), 1.58 – 1.00 (m, 37 H, CH3-tBu-Boc, CH3-
acetonide x2 and H-7 to H-17), 0.88 (t, 3 H, J = 6.9 Hz, H-18); 13C NMR (100 MHz, CDCl3)  δ  165.5,  165.4  (C=OBz x2), 
152.5, 151.7 (C=OBoc x2), 135.8 (d, J = 42.6 Hz, C-5) 135.7 (d, J = 42.6 Hz, C-5), 132.9, 132.8 (CHarom x2), 130.5, 
130.3 (Cq-arom x2), 129.8 (CHarom), 128.3 (CHarom), 125.0 (d, J = 72.8 Hz, C-4), 94.6, 94.0 (Cq-acetonide x2), 80.4, 80.2 (Cq-
Boc x2), 74.4 (d, J = 5.6 Hz, C-3), 74.2 (d, J = 5.6 Hz, C-3), 63.70, 63.66 (C-1 x2), 60.00, 59.97 (C-2 x2), 32.8 – 31.7 (m, 
C-6 and CH2), 29.8 – 28.2 (m, CH2 x9, CH3-tBu-Boc and CH3-acetonide x2), 22.7 (CH2), 14.1 (C-18); HRMS calculated for 
[C2813C5H53NO5 + Na]+: 571.3984, found 571.3982.  
[5,6,7,8,9-13C5]-1,2-O,N-isopropylidene-3-O-benzoyl-N-(tert-butoxycarbonyl)-D-erythro-sphingosine (120 mg, 0.22 
mmol, 1.0 eq) was dissolved in methanol:ethanol (1:1 10 mL) and p-toluenesulphonic acid (mono hydrate) (8.3 
mg, 44 µmol, 0.2 eq) was added. The reaction mixture was stirred over night at room temperature. The reaction 
mixture was transferred to an extraction funnel using EtOAc (60 mL) and washed with sat. aq. NaHCO3:water 2:1 
(60 mL) and brine (50 mL). The water layer was extracted with EtOAc (60 mL). The combined organics were dried 
(Na2SO4), filtered, and concentrated in vacuo. Purification by column chromatography (5-10% EtOAc in 
petroleum ether) produced the title compound 23b as an amorphous solid (70 mg, 0.14 mmol, 63%; 83% based 
on recovered starting material). Rf = 0.07 (10% EtOAc in petroleum ether); [α]D22: +16 (c = 0.5 CHCl3); 1H NMR (400 
MHz, CDCl3)  δ  8.03  (dm,  2  H,  J = 7.8 Hz, Harom), 7.57 (tt, 1 H, J = 7.0, 1.5 Hz, Harom), 7.45 (t, 2 H, J = 7.8 Hz, Harom), 
5.88 (dm, 1 H, J = 149.8 Hz, H-5), 5.60 (m, 1 H, H-4), 5.52 (m, 1 H, H-3), 5.08 (d, 1 H, J = 8.9 Hz, NHBoc), 3.93 (m, 1 
H, H-2), 3.76 – 3.67 (m, 2 H, H-1a and H-1b), 2.66 (bs, 1 H, OH), 2.08 (dm, 2 H, J = 125.5 Hz, H-6), 1.58 – 1.01 (m, 31 
H, CH3-tBu-Boc and H-7 to H-17), 0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, CDCl3)  δ  166.3  (C=OBz), 155.8 
(C=OBoc), 137.4 (d, J = 42.5 Hz, C-5), 133.3 (CHarom), 129.80 (Cq-arom), 129.75, 128.4 (CHarom x2), 124.6 (d, J = 71.5 Hz, 
C-4), 79.7 (Cq-Boc), 74.9 (d, J = 5.4 Hz, C-3), 61.9 (C-1), 54.6 (C-2), 33.0 – 31.6  (C-6 and CH2), 29.8 – 28.1  (CH2 x9 
and CH3-tBu-Boc), 22.7 (CH2), 14.1 (C-18); IR (neat): 3372, 2922, 2853, 1696, 1505, 1452, 1267, 1169, 1111, 1070, 
1026, 966, 710 cm-1; HRMS calculated for [C2513C5H49NO5 + Na]+: 531,3671, found 531,3667. 
 [1,2,3-13C3]-N-Methoxy-N-(methyl)-tetradecanamide (25). [1,2,3-13C3]-myristic acid 24 (3.00 g, 13.0 mmol, 1.0 
eq) was dissolved in anhydrous DCM (26 mL), put under an atmosphere of argon and 
cooled to 0 °C. Oxalyl chloride (2.28 mL, 26.0 mmol, 2.0 eq) was added followed by a 
drop of DMF. The reaction was then left stirring under a flow of argon at room 










dissolved in anhydrous DCM (13 mL) and cooled to -78 °C. N,O-Dimethylhydroxylamine (2.30 mL, 32.5 mmol, 2.5 
eq), dissolved in anhydrous DCM (13 mL), was slowly added to the myristoyl chloride at -78 °C. Then the reaction 
was lift stirring, reaching room temperature over 2 h. The reaction was stirred at room temperature for 30 min. 
The solids were filtered over a Whatmann paper and washed with DCM. The mother liquor was concentrated in 
vacuo and purified by column chromatography (5-20% EtOAc in Pentane), giving the title product as a clear oil 
(3.45 g, 12.7 mmol, 98%). Rf = 0.42 (20% EtOAc in pentane); 1H NMR (400 MHz, CDCl3) δ  3.68  (s,  3  H,  CH3-OMe), 
3.13 (d, J = 2.0 Hz, 3 H, CH3-NMe), 2.41 (dm, 2 H, J = 127.2 Hz, H-2), 1.62 (dm, 2 H, J = 128.8 Hz, H-3), 1.35-1.22 (m, 
20 H, H-4 to H-13), 0.88 (t, 3 H, J = 6.8 Hz, H-14); 13C NMR (101 MHz, CDCl3)  δ  175.0  (d,  J = 51.0 Hz, C=O), 61.4 
(CH3-OMe), 32.04 (CH3-NMe), 31.99 (dd, J = 51.0, 34.0 Hz, C-2), 29.8-29.3 (m, CH2 x9), 24.77 (dd, J = 35.0, 2.0 Hz, C-3), 
22.8 (CH2), 14.2 (C-16); IR (neat): 2924, 2855, 1616, 1462, 1375, 1176, 908, 729 cm-1; HRMS calculated for 
[C1313C3H33NO2 +H]+: 275.2612, found 275.2683.  
Ethyl (E)-[3,4,5-13C3]-hexadec-2-enoate (27). [1,2,3-13C3]-N-(Methoxy)-N-Methyl-tetradecanamide 25 (2.74 g, 
10.0 mmol, 1.0 eq) was dissolved in dry THF (20 mL) and cooled to -78 °C, before 
addition of DIBAL-H (1.5 M in toluene) (8.0 ml, 12.0 mmol, 1.2 eq). The reaction 
was stirred for 30 min before being quenched with sat. aq. Rochelle salt (12 mL). 
The mixture was then transferred to an extraction funnel with EtOAc (50 mL) and washed with water (40 mL) and 
brine (40 mL). The aqueous layers were extracted with EtOAc (50 mL). The combined organics were dried 
(Na2SO2), filtered and concentrated in vacuo giving crude [1,2,3-13C3]-tetradecanal (2.15 g, 10.0 mmol) as a clear 
oil which was used without further purification. Triethyl phosphonoacetate 26 (3.14 g, 14.0 mmol, 1.4 eq) was 
dissolved in dry THF (50 mL) and cooled to 0 °C before addition of n-butyllithium (1.6 M in hexanes, 7.8 mL, 12.5 
mL, 1.25 eq). The reaction was stirred for 10 min at 0 °C. The crude [1,2,3-13C3]-tetradecanal was dissolved in 
anhydrous in THF (10 mL) and added to the Horner-Wadsworth-Emmons reagent at 0 °C. The mixture was then 
stirred over night at room temperature. The mixture was transferred to an extraction funnel with ether (50 mL) 
and washed with water (50 mL) and brine (50 mL). The water layers were extracted with ether (50 mL) and the 
combined organics were dried with (Na2SO4), filtered and concentrated in vacuo. Purification by column 
chromatography (0-2% EtOAc in pentane) gave the title compound (2.3 g, 8.1 mmol, 81%) as a clear oil. Rf = 0.58 
(2% EtOAc in Pentane); 1H NMR (400 MHz, CDCl3) δ  6.96  (dm,  1  H,  J = 152.0 Hz, H-3), 5.81 (dd, 1 H, J = 15.6, 5.2 
Hz, H-2), 4.18 (q, 2 H, J = 7.2 Hz, CH2-Ethyl), 2.19 (dm, 2 H, J = 126.0 Hz), 1.62-1.22 (m, 25 H, CH3-Ethyl and C-5 to C-
15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C NMR (101 MHz, CDCl3)  δ  166.9  (d,  J = 6.0 Hz, C=O), 150.84 (dt, J = 39.0, 17.0 
Hz, C-2), 149.65 (dd, J = 41.0, 2.0 Hz), 60.24 (CH2-Ethyl), 32.33 (dd, J = 41.0, 34.0 Hz, C-4), 29.8-29.0 (m, CH2 x9), 28.1 
(dd, J = 34.0, 2.0 Hz, C-5), 22.8 (CH2), 14.4 (CH3-Ethyl), 14.3 (C-16); IR (neat): 2922, 2852, 1720, 1626, 1466, 1365, 
1301, 1263, 1175, 1034, 977, 721 cm-1; HRMS calculated for [C1513C3H34O2 +H]+: 286.2738, found 286.2733. 
Ethyl-[3,4,5-13C3]-hexadecanoate (28). Ethyl (E)-[3,4,5-13C3]-hexadec-2-enoate 27 (2.20 g, 7.71 mmol, 1.0 eq) was 
dissolved in EtOAc (40 mL). The solution was purged with argon under stirring, 
before addition of palladium (10% on charcoal, 0.41 g, 0.38 mmol, 0.05 eq). The 
reaction mixture was then stirred under a flow of hydrogen gas for 30 min and 
was then left under a hydrogen atmosphere over night. The palladium residue was removed by filtration over a 
Whatmann paper and rinsed with EtOAc (50 mL) followed by removal of the solvents in vacuo. Purification by 
colomn chromatography (1% EtOAc in pentane) afforded the title compound as a clear oil (2.21 g, 7.32 mmol, 
95%). Rf = 0.58 (2% EtOAc in pentane); 1H NMR (400 MHz, CDCl3) δ 4.12 (q, 2 H, J = 7.2 Hz, CH2-Ethyl), 2.28 (m, 2 H, 
H-2), 1.61 (dm, 2 H, J = 130.8 Hz, H-3), 1.46-1.08 (m, 27 H, CH3-Ethyl and C-4 to C-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 
13C NMR (101 MHz, CDCl3) δ 174.0 (C=O), 62.0 (CH2-Ethyl), 32.1 (C-2), 29.8-28.8 (m, C-4, C-5 and CH2 x10), 25.4-24.7 
(m, C-3), 22.8 (CH2), 14.3 (CH3-Ethyl), 14.2 (C-16); IR (neat): 2920, 2851, 1738, 1463, 1238, 1174, 1035, 733 cm-1; 
HRMS calculated for [C1513C3H36O2 +H]+: 288.2894, found 288.2889. 
 [3,4,5-13C3]-palmitic acid (29). Ethyl-[3,4,5-13C3]-hexadecanoate 28 (2.10 g, 7.30 mmol, 1.0 eq) was dissolved in 
THF:EtOH:H2O (1:1:1) (35 mL) and lithium hydroxide (0.52 g, 21.9 mmol, 3.0 eq) was 
added. The reaction was stirred at room temperature over night. The reaction 







Synthesis of a Panel of Carbon-13-Labeled (Glyco)Sphingolipids 
 37 
washed with 1 M HCl (50 mL), water (50 mL) and brine (50 mL). The aqueous layers were extracted with EtOAc 
(50 mL) and the combined organics dried (Na2SO4), filtered and concentrated in vacuo. Purification by column 
chromatography (5% EtOAc, 1% AcOH in pentane) gave 29 as a white solid (1.89 g, 6.94 mmol, 95%). Rf = 0.6 
(10% EtOAc, 1 % AcOH in pentane); 1H NMR (400 MHz, CDCl3)  δ  11.40  (bs,  1  H,  COOH),  2.35  (m,  2  H,  H-2), 1.61 
(dm, 2 H, J = 130.0 Hz, H-3), 1.52-1.06 (m, 24 H, C-4 to C-15), 0.88 (t, 3 H, J = 6.8 Hz, C-16); 13C NMR (100 MHz, 
CDCl3)  δ  180.1  (COOH),  32.1  (C-2), 29.9-28.7 (m, C-4, C-5 and CH2 x10), 25.2-24.4 (m, C-3), 22.8 (CH2), 14.3 (C-16); 
IR (neat); 2912, 2847, 1694, 1470, 1430, 1308, 1288, 941, 718, 679 cm-1. 
 [3,4,5-13C3]-palmitoyl chloride (30). [3,4,5-13C3]-Palmatic acid (1.80 g, 6.93 mmol, 1.0 eq) was dissolved in dry 
DCM  (72 mL), put under an atmosphere of argon, and cooled to 0 °C. Oxalyl chloride 
(1.2 mL, 14 mmol, 2 eq) was added followed by a drop of DMF. The reaction was 
then keept under a flow of argon and at room temperature. When gas evolution 
stopped (~ 2 h), the reaction was concentrated in vacuo giving the title product (1.90 g, 6.93 mmol, 100%). 1H 
NMR (400 MHz, CDCl3) δ 2.88 (m, 2 H, H-2), 1.70 (dm, 2 H, J = 130.5 Hz,  H-3), 1.56-1.05 (m, 24 H, H-4 to H-15), 
0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (100 MHz, CDCl3) δ  166.4  (C=O),  32.0  (CH2), 29.8-28.0 (m, C-4, C-5 and 8x 
CH2), 25.15 (C-2), 24.14 (dd, J = 32.0, 1.5 Hz, C-3), 22.8 (CH2), 14.2 (C-16); IR (neat); 2918, 2848, 2747, 1800, 1660, 
1384, 1305, 1161, 1033, 908, 802 cm-1. 
 
D-erythro-sphingosine (31a). 3-O-Benzoyl-N-(tert-butyloxycarbonyl)-D-erythro-sphingosine 23a (90 mg, 0.18 
mmol, 1.0 eq), was dissolved in methanol (6 mL), and sodium methoxide 
(30% in methanol) (12 µL, 0.09 mmol, 0.5 eq) was added. The reaction was 
stirred at room temperature until TLC showed full conversion to a lower 
running spot. Potassium hydroxide (0.5 M in water) (0.72 mL, 0.36 mmol, 
2.0 eq), was added and the reaction was stirred over night at room temperature. The reaction was quenched 
with acetic acid (0.05 mL, 0.9 mmol), before concentration in vacuo. The residue was cooled to 0 °C before 
addition of water (0.66 mL) and TFA (2 mL). The reaction was stirred for 2 minutes at 0 °C and was then diluted 
with toluene (40 mL)  and concentrated in vacuo. Purification by HPLC-MS (52-62% B, following general 
producere for HPLS-MS purifications) produced the title compound (41 mg, 0.1 mmol, 54%) as a TFA adduct. 
[α]D22: -2.0 (c = 0.5 MeOH); 1H NMR (600 MHz, MeOD-d4)  δ  5.85  (m,  1  H,  H-5), 5.47 (m, 1 H, H-4), 4.28 (m, 1 H, H-
2), 3.79 (dd, 1 H, J = 11.6, 4.0 Hz, H-1a), 3.66 (dd, 1 H, J = 11.6, 8.4 Hz, H-1b), 3.19 (dt, 1 H, J = 8.6, 4.4 Hz, H-2), 
2.10 (q, 2 H, J = 7.1 Hz, H-6), 1.45-1.32 (m, 2 H, H-7), 1.35-1.26 (m, 20 H, H-8 to H-17), 0.90 (t, 3 H, J = 7.0 Hz, H-
18); 13C NMR (151 MHz, MeOD-d4)  δ  136.6  (C-5), 128.5 (C-4), 71.0 (C-3), 59.4 (C-1), 58.5 (C-2), 33.4 (C-4), 33.1, 
30.81, 30.80 (2x CH2), 30.77, 30.75, 30.65, 30.5, 30.4 (9x CH2), 30.2 (C-7), 23.8 (CH2), 14.4 (C-18); IR (neat): 3289, 
2918, 2850, 1668, 1520, 1470, 1192, 1134, 986, 720 cm-1; HRMS calculated for [C18H37NO2 + H]+: 300.2897, found 
300.2899. 
 
 [5,6,7,8,9-13C5]-D-erythro-sphingosine (31b). [5,6,7,8,9-13C5]-3-O-Benzoyl-N-(tert-butoxycarbonyl)-D-erythro-
sphingosine 23b (90 mg, 0.29 mmol, 1 eq.) was dissolved in methanol (10 
mL) and sodium  methoxide (30% in methanol) (19 µL, 0.14 mmol, 0.5 eq) 
was added. The reaction was stirred at room temperature until TLC showed 
full conversion to a lower running spot. Potassium hydroxide (0.5 M in 
water) (1.2 mL, 0.59 mmol, 2 eq) was added and the reaction was stirred over night at room temperature. The 
reaction was quenched with acetic acid (0.08 mL, 1.45 mmol, 5 eq), before concentration in vacuo. The residue 
was cooled to 0 °C before the addition of water (1 mL) and TFA (3 mL). The reaction was stirred for 2 minutes at 0 
°C and was then diluted with toluene (40 mL) and concentrated in vacuo. Purification by HPLC-MS (52-62% B, 
following the general procedure for HPLC-MS purifications) produced the title compound (52 mg, 0.17 mmol, 
59%) as a TFA adduct. [α]D22: -2.0 (c = 0.5 MeOH); 1H NMR (600 MHz, MeOD-d4) δ  5,85  (dm,  1  H,  J = 150 Hz, H-5), 
5.47 (dt, 1 H, J = 15.6, 6.0 Hz, H-4), 4.28 (dd, 1 H, J = 11.4, 4.8 Hz, H-3), 3.79 (dd, 1 H, J = 11.6, 4.0 Hz, H-1a), 3.66 
(dd, 1 H, J = 11.6, 8.3 Hz, H-1b), 3.19 (dt, 1 H, J = 8.5, 4.3 Hz, H-2), 2.1 (dm, 2 H, J = 126.0 Hz, H-6), 1.56-1.20 (m, 22 











128.5 (dd, J = 72.0, 3.0 Hz), 71.0 (dd, J = 5.5, 1.3 Hz, C-3), 59.5 (C-1), 58.5 (d, J = 3.0 Hz, C-2), 33.8-32.9 (m, C-6 and 
CH2), 30.9-29.8 (m, CH2 x10), 23.7 (CH2), 14.5 (C-18); IR (neat): 3287, 2914, 2847, 1661, 1526, 1470, 1198, 1136, 
966, 721 cm-1; HRMS calculated for [C1313C5H37NO2 + H]+: 305.2897, found 305.3065. 
Ceramide (32a). See general procedure for the synthesis of the ceramides from sphingosine. Yield (20 mg, 37 
µmol, 79%).  Rf = 0.48 (EtOAc:pentane 1:1); [α]D22: -7.6 (c = 1.0 MeO:CHCl3 
1:1); 1H NMR (600 MHz, CDCl3)  δ  6.26  (d,  1  H,  J  = 7.8 Hz, NH), 5.78 (dt, 1 H, 
J = 15.4, 7.0 Hz, H-5), 5.53 (dd, 1 H, J = 15.4, 6.5 Hz, H-4), 4.31 (t, 1 H, J = 4.7 
Hz, H-3), 3.95 (dd, 1 H, J = 11.2, 3.8 Hz, H-1a), 3.90 (m, 1 H, H-2), 3.70 (dd, 1 
H, J = 11.4, 3.6 Hz, H-1b), 3.00-2.60 (bs, 2 H, 2x OH), 2.23 (t, 2 H, J = 7.7 Hz, 
H-2*), 2.05 (q, 2 H, J = 7.2 Hz, H-6), 1.63 (m, 2 H, H-3*), 140-1.21 (m, 46 H, H-7 to H-17 and H-4* to H-15*), 0.88 
(t, 6 H, J = 7.0 Hz, H-18 and H-16*); 13C NMR (150 MHz, CDCl3)  δ  174.1  (C=O*),  134.4  (C-5), 128.9 (C-4), 74.5 (C-3), 
62.4 (C-1), 54.7 (C-2), 37.0 (C-2*), 32.4 (C-6), 32.08, 29.86 x4, 29.85 x4, 29.82 x3, 29.80, 29.78, 29.67, 29.65, 
29.53, 29.52 x2, 29.45, 29.39, 29.28, 25.92, 22.84 (CH2 x24 C-7 to C-17 and C-3* to C-15*), 14.3 x2 (C-18 and C-
16*); IR (neat): 3308, 2914, 2865, 1645, 1548, 1464, 1049, 959, 719 cm-1; HRMS calculated for [C34H67NO3 + H]+: 
538.5121, found 538.5192. 
2-N-([3,4,5-13C3]-hexadecanoyl)-sphingosine (32b). See general procedure for the synthesis of the ceramides 
from sphingosine. Yield (14 mg, 25 µmmol, 71%). Rf = 0.48 (EtOAc:pentane 
1:1); [α]D22: -8.0 (c = 0.1 MeOH:CHCl3 1:1) ; 1H NMR (600 MHz, 
CDCl3/MeOD-d4)  δ  6.26  (d,  1  H,  J  = 7.8 Hz, NH), 5.78 (dt, 1 H, J = 15.4, 7.0 
Hz, H-5), 5.53 (dd, 1 H, J = 15.4, 6.5 Hz, H-4), 4.31 (t, 1 H, J = 4.7 Hz, H-3), 
3.95 (dd, 1 H, J = 11.2, 3.8 Hz, H-1a), 3.90 (m, 1 H, H-2), 3.70 (dd, 1 H, J = 11.4, 3.6 Hz, H-1b), 3.00-2.60 (bs, 2 H, 2x 
OH), 2.23 (m, 2 H, H-2*), 2.05 (q, 2 H, J = 7.2 Hz, H-6), 1.63 (dm, 2 H, J = 130 Hz, H-3*), 1.45-1.15 (m, 46 H, H-7 to 
H-17 and H-4* to H-15*), 0.88 (t, 6 H, J = 7.0 Hz, H-18 and H-16*); 13C NMR (151 MHz, CDCl3/MeOD-d4)  δ  174.1  
(C=O*), 134.4 (C-5), 128.9 (C-4), 74.8 (C-3), 62.6 (C-1), 54.7 (C-2), 37.0 (d, J = 35.0 Hz, C-2*), 32.4 (C-6), 32.0, 
29.91, 29.85-29.38 (m), 26.15-25.79 (m), 22.84 (CH2 x24 C-7 to C-17 and C-3* to C-15*), 14.3x2 (C-18 and C-16*); 
IR (neat): 3293, 2914, 2847, 1636, 1547, 1465, 1038, 972, 721 cm-1; HRMS calculated for [C3113C3H67NO3 + H]+: 
541.5121, found 541.5293.  
2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (32c). See general procedure for the synthesis of the ceramides 
from sphingosine. Yield (12 mg, 22 µmol, 73%). Rf = 0.48 (EtOAc:pentane 
1:1); [α]D22: -7.2 (c = 0.25 MeOH:CHCl3 1:1); 1H NMR (600 MHz, CDCl3)   δ  
6.31 (d, 1 H, J  = 7.8 Hz, NH), 5.76 (dm, 1 H, J = 150.0 Hz, H-5), 5.53 (m, 1 H, 
H-4), 4.30 (m, 1H, H-3), 3.95 (m, 1 H, H-1a), 3.90 (m, 1 H, H-2), 3.70 (m, 1 H, 
H-1a), 3.00-2.60 (bs, 2 H, 2x OH), 2.22 (t, 2 H, J = 7.9 Hz, H-2*), 2.05 (dm, 2 
H, J = 124.0 Hz, H-6), 1.63 (m, 2 H, H-3*), 1.52-1.13 (m, 46 H, H-7 to H-17 and H-4* to H-15*), 0.88 (t, 6 H, J = 7.0 
Hz, H-18 and H-16*); 13C NMR (151 Hz, CDCl3)  δ  174.2  (C=O*),  133.0  (d,  J = 43.0 Hz, C-5), 129.1 (d, J = 72.0 Hz, C-
4), 74.7 (d, J = 20.8 Hz, C-3), 62.6 (C-1), 54.6 (d, J = 2.6 Hz, C-2), 37.0 (C-2*), 32.8-32.0 (m, C-6 and CH2), 29.9-29.0 
(m), 28.25-27.74 (m), 25.92 (m), 22.84 (CH2 x24 C-7 to C-17 and C-3* to C-15*), 14.3 x2 (C-18 and C-16*); IR 
(neat): 3300, 2914, 2847, 1701, 1635, 1547, 1464, 1124, 970, 719 cm-1; HRMS calculated for [C2913C5H67NO3 + H]+: 
543.5121, found 543.5358. 
2-N-([3,4,5-13C3]-hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (32d). See general procedure for the synthesis of 
the ceramides from sphingosine. Yield (18 mg, 33 µmol, 81%). Rf = 0.48 
(EtOAc:pentane 1:1); [α]D22: -7.0 (c = 0.33 MeOH:CHCl3 1:1); 1H NMR (600 
MHz, CDCl3)  δ  6.26  (d,  1  H,  J  = 7.8 Hz, NH), 5.76 (dm, 1 H, J = 150.0 Hz, H-
5), 5.53 (m, 1 H, H-4), 4.31 (m, 1H, H-3), 3.95 (dd, 1 H, J = 11.2, 4.0 Hz, H-
1a), 3.90 (m, 2 H, H-2), 3.70 (dd, 1 H, J = 11.4, 3.2 Hz, H-1b), 3.00-2.60 (bs, 2 
H, 2x OH), 2.23 (m, 2 H, H-2*), 2.05 (dm, 2 H, J = 124.0 Hz, H-6), 1.63 (dm, 2 H, J = 130 Hz, H-3*), 1.50-1.15 (m, 46 
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(C=O*), 134.4 (d, J = 43.0 Hz, C-5), 128.8 (d, J = 72.0 Hz, C-4), 74.5 (d, J = 20.8 Hz, C-3), 62.6 (C-1), 54.6 (d, J = 2.6 
Hz C-2), 37.0 (d, J = 35.0 Hz, C-2*), 32.8-32.0 (m, C-6 and CH2), 29.9-29.0 (m), 28.2-27.7 (m), 26.2-25.6 (m), 21.7 
(CH2 x24 C-7 to C-17 and C-3* to C-15*), 14.3 x2 (C-18 and C-16*); IR (neat): 3294, 2914, 2847, 1699, 1636, 1547, 
1464, 1040, 970, 719 cm-1; HRMS calculated for [C2613C8H67NO3 + H]+: 546.5121, found 546.5461. 
Sphinganine (33a). 3-O-Benzoyl-N-(tert-butyloxycarbonyl)-D-erythro-sphingosine 23a (36.8 mg, 0.07 mmol, 1.0 
eq), was dissolved in methanol (2.4 mL), and sodium methoxide (30% in 
methanol) (4.6 µL, 0.035 mmol, 0.5 eq) was added. The reaction was 
stirred at room temperature until TLC showed full conversion to a lower 
running spot. Potassium hydroxide (0.5 M in water) (0.28 mL, 0.14 mmol, 2.0 eq), was added and the reaction 
was stirred over night at room  temperature. The reaction was quenched with acetic acid (0.019 mL, 0.35 mmol, 
5.0 eq), before concentration in vacuo. The residue was co-evaporated once with toluene (4.0 mL) and then 
dissolved in EtOAc (1 mL). The solution was purged with argon, before addition of platinum dioxide (1.5 mg, 
0.007 mmol, 0.1 eq). The reaction mixture was then stirred under a flow of hydrogen gas for 30 min and then left 
under a hydrogen atmosphere over night. The platinum dioxide residue was removed by filtration over a plug of 
Celite and then rinsed with EtOAc followed by concentration in vacuo. The residue was cooled to 0 °C before the 
addition of water (1 mL) and TFA (2 mL). The reaction was stirred for 2 minutes at 0 °C and then diluted with 
toluene (4 mL) and concentrated in vacuo. Purification by HPLC-MS (52-62% B, following the general procedure 
for HPLC-MS purifications) produced the title compound (10 mg, 33 µmol, 47%) as a TFA adduct. [α]D22: -7.0 (c = 
0.1 MeOH); 1H NMR (600 MHz, MeOD-d4) δ 3.83 (dd, 1 H, J = 11.6, 4.0 Hz, H-1a), 3.77 (dt, 1 H, J = 8.4, 4.2 Hz, H-3), 
3.70 (dd, 1 H, J = 11.5, 8.7 Hz, H-1b), 3.19 (dt, 1 H, J = 8.3, 3.9 Hz, H-2), 1.55-1.22 (m, H 28, H-4 to H-17), 0.90 (t, 3 
H, J = 7.0 Hz, H-18); 13C NMR (151 MHz, MeOD-d4) δ  70.3  (C-3), 58.8 (C-1), 58.4 (C-2), 34.2 (C-4), 33.1, 30.84 (x4), 
30.78, 30.77, 30.74, 30.70, 30.57, 30.49, 27.0, 23.8 (CH2 x13, C-5 to C-17), 14.5 (C-18); IR (neat): 3150, 2914, 
2849, 1676, 1207, 1186, 1153, 1126, 1053, 840, 800, 721 cm-1; HRMS calculated for [C18H39NO2 + H]+: 302,2981, 
found 302.3054. 
 [5,6,7,8,9-13C5]-Sphinganine (33b). [5,6,7,8,9-13C5]-3-O-Benzoyl-N-(tert-butoxycarbonyl)-D-erythro-sphingosine 
23b ( 81.4 mg, 0.16 mmol, 1.0 eq), was dissolved in methanol (5.5 mL), and 
sodium methoxide (30% in methanol)  (10 µL, 0.08 mmol, 0.5 eq) was 
added. The reaction was stirred at room temperature until TLC showed full 
conversion to a lower running spot. Potassium hydroxide (0.5 M in water) 
(0.64 mL, 0.32 mmol, 2.0 eq), was added and the reaction was stirred over night at room temperature. The 
reaction was quenched with acetic acid (4.4 µL, 0.8 mmol, 5.0 eq), before concentration in vacuo. The residue 
was co-evaporated once with toluene (10 mL) and then dissolved in EtOAc (2 mL). The solution was purged with 
argon, before addition of platinum dioxide (3.6 mg, 0.016 mmol, 0.1 eq). The reaction mixture was then stirred 
under a flow of hydrogen gas for 30 min and then left under a hydrogen atmosphere over night. The platinum 
dioxide residue was removed by filtration over a plug of Celite and then rinsed with EtOAc followed by 
concentration in vacuo. The residue was cooled to 0 °C before the addition of water (0.5 mL) and TFA (1.5 mL). 
The reaction was stirred for 2 minutes at 0 °C and was then diluted with toluene (10 mL) and concentrated in 
vacuo. Purification by HPLC-MS (52-62% B, following the general procedure for HPLC-MS purifications) produced 
the title compound (25 mg, 83 µmol, 52%) as a TFA adduct. [α]D22: -7.5 (c= 0.1 MeOH); 1H NMR (600 MHz, MeOD-
d4) δ  3.83 (dd, 1 H, J = 11.5, 4.0 Hz, H-1a), 3.76 (dt, 1 H, J = 8.3, 4.3 Hz, H-3), 3.69 (dd, 1 H, J = 11.5, 8.8 Hz, H-1b), 
3.18 (dt, 1 H, J = 8.9, 40 Hz, H-2), 1.65-1.15 (m, 28 H, H-4 to H-17), 0.90 (t, 3 H, J = 7.0 Hz, H-18); 13C NMR (151 
MHz, MeOD-d4)  δ  70.3  (C-3), 58.6 (C-1), 58.4 (C-2), 34.1 (d, J = 34.7 Hz, C-4), 33.1 (CH2), 31.1-30.2 (m, CH2 x10), 
27.3-26.7 (m, CH2), 23.8 (CH2), 14.5 (C-18); IR (neat): 3120, 2914, 2847, 1676, 1206, 1186, 1153, 1130, 840, 800, 











Dihydroceramide (34a). See general procedure for the synthesis of the ceramides from the sphingosine. Yield (12 
mg, 22 µmol, 68%); Rf = 0.50 (EtOAc:pentane 1:1); [α]D22: +4.5 (c = 0.15 
MeOH:CHCl3 1:1); 1H NMR (600 MHz, CDCl3, 318 oK)  δ  6.36  (d,  1  H,   J = 7.6 
Hz, NH), 4.01 (d, 1 H, J = 11.3 Hz, H-1a), 3.83 (m, 1 H, H-2), 3.80-3.72 (m, 2 
H, H-1b and H-3), 2.90-2.50 (bs, 2 H, 2x OH), 2.23 (t, 2 H, J = 7.4 Hz, H-2*), 
1.68-1.59 (m, 4 H, H-4 and H-3*), 1.59-1.45 (m, 2 H, H-5 and H-4*), 1.38-1.19 (m, 46 H, H-6 to H-17 and H-5* to 
H15*), 0.88 (t, 6 H, J = 7.2 Hz, H-18 and H-16*); 13C NMR (151 MHz, CDCl3, 318 oK) δ  173.7  (C=O*),  74.4  (C-3), 62.7 
(C-1), 54.2 (C-2), 37.1 (C-2*), 34.7 (C-4), 32.10, 29.86 x4, 29.84 x3, 29.82 x3, 29.79 x2, 29.75 x3, 29.72, 29.71, 
29.67, 29.66, 29.52, 29.51 x2, 29.48, 22.84 (CH2 x26 C-4 to C-17 and C-4* to C-15*), 14.2 x2 (C-18 and C-16*); IR 
(neat): 3395, 2914, 2849, 1738, 1630, 1570, 1470, 1047, 719 cm-1; HRMS calculated for [C34H67NO3 + H]+: 
540.5121, found 540.5347. 
2-N-([3,4,5-13C3]-hexadecanoyl)-sphinganine (34b). See general procedure for the synthesis of the ceramides 
from the sphingosine (15 mg, 27 µmol, 74%); Rf = 0.50 (EtOAc:pentane 1:1); 
[α]D22: +4.8 (c = 0.1 MeOH:CHCl3 1:1) ; 1H NMR (600 MHz, CDCl3, 318 oK)  δ  
6.26 (d, 1 H, J = 7.6 Hz, NH), 4.01 (d, 1 H, J = 11.3 Hz, H-1a), 3.83 (m, 1 H, H-
2), 3.80-3.72 (m, 2 H, H-1b and H-3), 2.80-2.40 (bs, 2 H, 2x OH), 2.23 (m, 2 
H, H-2*), 1.80-1.10 (m, 54 H, H-4 to H-17 and H-3* to H-15*), 0.88 (t, 6 H, J 
= 7.2 Hz, H-18 and H-16*); 13C NMR (151 MHz, CDCl3, 318 oK)  δ  173.7  (C=O*),  74.5  (C-3), 62.7 (C-1), 54.1 (C-2), 
37.1 (d, J = 34.0 Hz, C-2*),  34.8 (C-4), 32.09, 29.9-29.3 (m), 29.18, , 26.2-25.8 (m), 25.67, 22.83 (CH2 x26 C-4 to C-
17 and C-4* to C-15*), 14.2 x2 (C-18 and C-16*); IR (neat): 3394, 2914, 2849, 1738, 1630, 1570, 1470, 1049, 719 
cm-1; HRMS calculated for [C3113C3H67NO3 + H]+: 543.5121, found 543.5442. 
2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphinganine (34c). See general procedure for the synthesis of the ceramides 
from the sphingosine. Yield (14 mg, 25 µmol, 65%); Rf = 0.50 
(EtOAc:pentane 1:1); [α]D22: +5.2 (c = 0.25 MeOH:CHCl3 1:1); 1H NMR (600 
MHz, CDCl3, 318 oK)  δ    6.26  (d,  1  H,  J = 7.6 Hz, NH), 4.01 (d, 1 H, J = 11.3 Hz, 
H-1a), 3.83 (m, 1 H, H-2), 3.80-3.72 (m, 2 H, H-1b and H-3), 2.70-2.40 (bs, 2 
H, 2x OH) 2.22 (t, 2 H, J = 7.9 Hz, H-2*), 1.65-1.15 (m, 54 H, H-4 to H-17 and 
H-3* to H-15*), 0.89 (t, 6 H, J = 7.2 Hz, H-18 and H-16*); 13C NMR (151 MHz, CDCl3, 318 oK)  δ  173.7  (C=O*),  74.4  
(C-3), 62.7 (C-1), 54.1 (d, J = 2.6 Hz, C-2), 37.1 (C-2*), 34.8 (d, J = 35.0 Hz, C-4), 34.0, 32.10, 29.9-29.5 (m), 26.4-
25.8 (m), 22.8 (CH2 x26 C-4 to C-17 and C-4* to C-15*), 14.2 x2 (C-18 and C-16*); IR (neat): 3399, 2914, 2849, 
1630, 1568, 1470, 1047, 717 cm-1; HRMS calculated for [C2913C5H67NO3 + H]+: 545.5121, found 545.5515. 
2-N-([3,4,5-13C3]-hexadecanoyl)-[5,6,7,8,9-13C5]-sphinganine (34d). See general procedure for the synthesis of 
the ceramides from the sphingosine. Yield (18 mg, 33 µmol, 66%); Rf = 0.50 
(EtOAc:pentane 1:1); [α]D22: +5.0 (c = 0.25 MeOH:CHCl3 1:1); 1H NMR (600 
MHz, CDCl3, 318 oK)  δ  6.26  (d,  1  H,  J = 7.6 Hz, NH), 4.01 (d, 1 H, J = 11.3 Hz, 
H-1a), 3.83 (m, 1 H, H-2), 3.80-3.72 (m, 2 H, H-1b and H-3), 2.55 (bs, 1 H, 
OH), 2.45 (bs, 1 H, OH), 2.23 (m, 2 H, H-2*), 1.72-1.12 (m, 54 H, H-4 to H-17 
and H-3* to H-15*), 0.88 (t, 6 H, J = 7.2 Hz, H-18 and H-16*); 13C NMR (151 MHz, CDCl3, 318 oK)  δ  δ  173.7  (C=O*),  
74.4 (C-3), 62.7 (C-1), 54.1 (d, J = 2.6 Hz, C-2), 37.1 (d, J = 35.0 Hz, C-2*), 34.8 (d, J = 35.0 Hz, C-4), 34.0 (m), 32.1, 
30.0-29.3 (m), 29.18, 26.4-25.7 (m), 25.67, 22.8 (CH2 x26 C-4 to C-17 and C-4* to C-15*), 14.2 (C-18 and C-16*); IR 
(neat): 3390, 2914, 2849, 1726, 1630, 1572, 1470, 1047, 716 cm-1; HRMS calculated for [C2613C8H67NO3 + H]+: 
548.5121, found 548.5611. 
Phenyl-4,6-O-(di-tert-butylsilanediyl)-1-thio-β-D-glucosylpyranoside (35b). Phenyl-1-thio-β-D-glucoside (35a) 
(1.85 g, 6.8 mmol, 1.05 eq) was dissolved in dry DMF (27 mmol) under an Argon 
atmosphere. This solution was cooled down to -40 0C before drop wise addition of di-
tert-butylsilylbis(trifluoromethanesulfonate) (2.1 mL, 6.5 mmol, 1 eq). The resulting 
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19.5 mmol, 3 eq).  The reaction was stirred for an additional 15 minutes and then transferred to an extraction 
funnel with diethyl ether (50 mL). The organics were washed with water (2x 100 mL) and brine (100 mL). The 
aqueous layers were extracted with diethyl ether (50 mL) and the combined organics were dried (Na2SO4) filtered 
and concentrated in vacuo. Purification by silica column chromatography (10% Et2O in petroleum ether) yielded 
the title compound (2.16 g, 5.2 mmol, 77%). Rf  = 0.8 (50% EtOAc in petroleum ether); [α]D22: -37 (C = 1.0 CHCl3); 
1H NMR (400 MHz, CDCl3) δ  7.53-7.50 (m, 2 H, Harom),  7.33-7.28 (m, 3 H, Harom), 4.61 (d, 1 H, J = 10.0 Hz, H-1), 4.21 
(dd, 1 H, J = 10.3, 5.2 Hz, H-6a),  3.90 (t, 1 H, J = 10.2 Hz, H-6b), 3.69 (t, 1 H, J = 9.2 Hz, H-3), 3.61 (t, 1 H, J = 8.7 Hz, 
H-4), 3.49 (m, 2 H, H-2 and H-5), 3.25 (bs, 2 H, OH), 1.05 (s, 3 H, H-tBu-Si), 0.98 (s, 3 H, H-tBu-Si); 13C NMR (101 MHz, 
CDCl3)  δ  132.9 (Cq-arom), 131.9 (Cq-arom), 129.1 (CHarom x2), 128.3 (CHarom x2) , 88.6 (C-1), 77.9 (C-3), 76.5 (C-4), 74.6 
(C-5), 71.9 (C-2), 66.2 (C-6), 27.5 (CH3-tBu-Si), 27.1 (CH3-tBu-Si), 22.8 (Cq-tBu-Si), 20.0 (Cq-tBu-Si); IR (neat): 3380, 2931, 
2858, 1472, 1055, 823, 731, 651 cm-1; HRMS: calculated. For [C20H32O5SSi + H]+ 413.1740, found 413.1801. 
Phenyl 2,3-di-O-benzoyl-4,6-O-(di-tert-butylsilanediyl)-1-thio-β-D-glucopyranoside (35c). Phenyl-   4,6-O-(di-
tert-butylsilanediyl)-1-thio-β-D-glucosylpyranoside (35b) (2.16 g, 5.2 mmol, 1.0 eq) was 
dissolved in dry pyridine (13 mL) and benzoyl chloride (3.25 mL, 28.0 mmol, 2.4 eq) was 
added. The reaction was stirred until TLC showed full conversion to a higher running 
product and was then quenched with methanol (1 mL) and concentrated in vacuo. The 
residue was dissolved in EtOAc (50 mL) and washed with 1 N HCl (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 
mL). The aqueous layers were extracted with EtOAc (50 mL), and the combined organics were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by silica gelcolumn chromatography (10% Et2O in petroleum 
ether) afforded the title compound (3.18 g, 5.12 mmol, 98%). [α]D22: +47.2 (C = 1.0 CHCl3); Rf = 0.7 (15% EtOAc in 
petroleum ether); 1H NMR (400 MHz, CDCl3) δ  8.00-7.92 (m, 4 H, Harom), 7.55-7.26 (m, 11 H, Harom), 5.59 (t, 1 H, J = 
9.5 Hz H-3), 5.39 (t, 1 H, J = 9.8 Hz, H-2), 4.99 (d, 1 H, J = 10.0 Hz, H-1), 4.31 (dd, 1 H, J = 10.0, 5.1 Hz, H-6a), 4.10 (t, 
1 H, J = 9.2 Hz, H-4), 4.01 (t, 1 H, J = 10.0 Hz, H-6b), 3.69 (td, 1 H, J = 10.0, 5.2 Hz. H-5), 0.973 (s, 9 H, CH3-tBu-Si), 
0.967 (s, 9H, CH3-tBu-Si); 13C NMR (101 MHz, CDCl3)   δ   165.8 (C=OBz), 165.1 (C=OBz) , 134.5, 133.2, 132.9, 132.1, 
130.5, 129.8, 129.7, 129.6, 128.3, 129.0, 128.8, 128.3, 128.2 (CHarom), 87.0 (C-1), 76.2 (C-3), 75.1 (C-5), 74.9 (C-4), 
70.6 (C-2), 66.1 (C-6), 27.3 (CH3-tBu-Si), 26.9 (CH3-tBu-Si), 22.5 (Cq-tBu-Si), 19.9 (Cq-tBu-Si); IR (neat): 2959, 2932, 2883, 
2858, 1732, 1271, 1177, 1126, 827, 708 cm-1; HRMS: calculated for [C34H40O7SSi + H]+  621.2344; found 621.2337. 
2,3-di-O-benzoyl-4,6-O-(di-tert-butylsilaanediyl)-α/β-D-glucopyranose (35d). Phenyl 2,3-di-O- benzoyl-4,6-O-(di-
tert-butylsilanediyl)-1-thio-β-D-glucopyranoside (35c) (6.27 g, 10.7 mmol, 1.0 eq) was 
dissolved in DCM (100 mL). N-iodosuccamide (4.81 g, 21.4 mmol, 2.0 eq) was added at 0 
oC, before addition of trifluoroacetic acid (0.82 mL, 10.7 mmol, 1.0 eq). The reaction was 
left stirring under exposure to the atmosphere until TLC showed full conversion. The 
mixture was transferred to an extraction funnel with EtOAc (200 mL) and washed with 
sodium thiosulfate (20% aq., 200 mL), sat. aq. NaHCO3 (200 mL), and brine (200 mL). The aqueous layers were 
extracted with EtOAc (100 mL), and the combined organics were dried (Na2SO4), filtered and concentrated in 
vacuo. Purification by silica gel column chromatography (5% EtOAc in petroleum ether) afford the title 
compound  (6.63  g,  10.5  mmol,  98%,  5:3  α:β).  Rf = 0.1 (10% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) 
δ  8.10  (m,  1  H, Harom), 8.03-7.94 (m, 6 H, Harom), 7.60 (m, 0.6 H, Harom), 7.55-7.43 (m, 4.5 H, Harom), 7.41-7.32 (m, 6.3 
H, Harom), 5.92 (t, 1 H, J = 9.1 Hz, H-3), 5.66-5.61 (m, 1.6 H,H-2), 5.22 (dd, 0.6 H, J = 9.5, 7.8 Hz), 5.18 (dd, 1 H, J = 
10.3, 3.9 Hz), 4.97 (d, 0.6 H, J = 8.1 Hz), 4.31-4.13 (m, 3.2 H), 4.12-4.06 (m, 2 H), 4.03-3.91 (m, 2 H), 3.67 (td, 0.6 
H, J = 10.4, 5.2 Hz), 1.00-0.97 (m, 25.2 H); 13C NMR (101 MHz, CDCl3)  δ  167.1,  166.2,  166.15,  166.0 (C=Obz, 133.73, 
133.69, 133.50, 133.20, 133.00, 130.27, 130.11, 130.09, 130.02, 129.72, 129.69, 129.16, 128.95, 128.54, 128.46, 
128.40 (CHarom), 96.4, 90.9, 75.6, 75.3, 74.51, 74.47, 72.4, 74.3, 71.2, 66.73, 66.52, 66.32, 27.44 (CH3-tBu-Si), 27.41 
(CH3-tBu-Si), 27.00 (CH3-tBu-Si), 26.96 (CH3-tBu-Si), 22.75 (Cq-tBu-Si), 22.72 (Cq-tBu-Si), 20.08 (Cq-tBu-Si), 20.05(Cq-tBu-Si); IR (neat): 














2,3-di-O- benzoyl-4,6-O-(di-tert- butylsilanediyl)-1-O-(N-[phenyl]-trifluoroacetimidoyl)-α/β-D-  glucopyranose 
(35). 2,3-di-O-benzoyl-4,6-O-(di-tert-butylsilaanediyl)-α/β-D-glucopyranose (35d) 
(1.71 g, 3.45 mmol, 1.0 eq) was dissolved in acetone (20 mL) and cooled down to 0 
oC. Cesium carbonate (1.69 g, 5.18 mmol, 1.5 eq) was added followed by chloro N-
phenyl-trifluoroimidiate (0.78 mL, 5.18 mmol, 1.5 eq), and the reaction was stirred 
at 0 0C for 2 hours. The reaction mixture was filtered and concentrated in vacuo. Purifiaction by silica gel column 
chromatography, using silica gel that was neutralized by running an eluent of 3% Et3N in petroleum ether (100 
mL) through the column (0-5% EtOAc, 20% DCM in petroleum ether) produced the title compound (1.93 g, 2.76 
mmol, 80%, ). Rf = 0.1 (10% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ  8.05-8.00 (m, 4 H, Harom), 7.54-
7.44 (m, 2 H, Harom), 7.41-7.31 (m, 4 H, Harom), 7.28 (m, 1 H, Harom), 7.11 (t, 2 H, J = 8.0 Hz, Harom), 7.00 (t, 1 H, J = 8.0 
Hz, Harom), 6.74 (m, 1 H, H-1), 6.45 (m, 1 H, H-3), 5.98 (m, 1 H, H-4), 5.50 (m, 1 H, H-2), 4.32-4.20 (m, 2 H, H-5 and 
H-6a), 4.00 (m, 1 H, H-6b), 1.05-0.97 (m, 18 H, HtBu-Si); 13C NMR (101 MHz, CDCl3)  δ  165.55,  165.49 C=OBz), 142.96 
(C=N), 133.68, 133.10, 130.00, 129.86, 129.70, 129.65, 128.82, 128.67, 128.63, 128.49, 128.40 (Carom), 119.21 (C-
1), 75.00 (C-2), 72.08 (C-4), 70.53 (C-3), 69.27 (C-5), 66.29 (C-6), 27.31 (Cq-tBu-Si), 26.83 (Cq-tBu-Si), 22.65 (Cq-tBu-Si), 
20.00 (Cq-tBu-Si); IR (neat): 2959, 2936, 2860, 1728, 1273, 1211, 995, 766, 710 cm-1; HRMS: calculated for 
[C36H40F3NO8Si + H]+ 700.2555, found 700.2549. 
Glucosyl sphingosine (36a). 2,3-di-O-Benzoyl-4,6-O-(di-tert-butylsilanediyl)-1-O-(N-[phenyl]-trifluoracetimidoyl) -
α/β-D-glucopyranose 35 (0.325 g, 0.465 mmol, 1.3 eq) and 
sphingosine acceptor 23a (180 mg, 0.357 mmol, 1.0 eq) 
were co-evaporated twice with toluene (10 mL) and then 
dissolved in anhydrous DCM (4 mL). Activated molsieves (3 
Å) were added and the mixture was stirred for 1 h at room 
temperature, cooled to 0 oC before  the addition of BF3.OEt2 (44 µL, 0.36 mmol, 1.0 eq). The reaction was stirred 
until TLC showed a lower running spot (debocylation of the sphingosine acceptor) (~ 1 h). The reaction mixture 
was transferred to an extraction funnel with EtOAc (50 mL), and washed with sat. aq. NaHCO3 (50 mL) and brine 
(50 mL). The aqueous layers were extracted with EtOAc (50 mL) and the combined organics were dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by column chromatography (2-5% Et2O, 20% DCM in petroleum 
ether) produced the title compound as an amorphous solid (177 mg, 0.17 mmol, 49%); Rf = 0.45 (10% Et2O, 20% 
DMC in petroleum ether); [α]D22: +6.8 (c = 0.1 CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.03-7.95 (m, 6H, Harom), 7.56-
7.48 (m, 3 H, Harom) 7.45-7.35 (m, 6 H, Harom), 5.79 (m, 1 H, H-5sp), 5.56 (t, 1 H, J = 9.4 Hz, H-3), 5.50-5.41 (m, 2 H, 
H-3sp and H-4sp), 5.35 (dd, 1 H, J = 10.4, 7.8 Hz, H-2), 4.80 (d, 1 H, J = 9.5 Hz, NH), 4.68 (d, 1 H, J = 7.8 Hz, H-1), 
4.11-4.02 (m, 3 H, H-4, H-1a-Sp and H-2Sp), 3.97 (dd, 1 H, J = 10.2, 4.5 Hz, H-6a), 3.74 (t, 1 H, J = 10.2 Hz, H-6b), 3.62 
(m, 1 H, H-1b-Sp), 3.55 (m, 1 H, H-5), 1.96 (q, 2 H, J = 6.8 Hz, H-6sp), 1.34 (s, 9 H, CH3-tBu-Boc), 1.32-1.18 (m, 22 H, H-7sp 
to H-17Sp), 0.95 (s, 18 H, CH3-tBu-Si), 0.88 (t, 3 H, J = 6.8 Hz, H-18sp); 13C NMR (101 MHz, CDCl3) δ  165.9,  165.4,  165.1  
(C=OBz x3), 155.4 (C=OBoc), 137.6 (C-5Sp), 133.3, 133.1, 133.0 (CHarom x3), 130.6 (Cq-arom), 129.9 (CHarom x2), 129.8 (Cq-
arom), 129.7 (CHarom x4), 129.5 (Cq-arom), 128.5 (CHarom  x2), 128.4 (CHarom x4), 124.7 (C-4sp), 101.4 (C-1), 79.5 (Cq-Boc), 
75.1 (C-3), 74.8 (C-4), 74.4 (C-3sp), 72.1 (C-2), 70.8 (C-5), 67.9 (C-6), 66.0 (C-1Sp), 52.4 (C-2Sp), 32.4 (C-6Sp), 32.0, 
29.80 (x4), 29.71, 29.59, 29.48, 29.35, 28.92 (CH2-Sp x10), 28.4 (CH3-tBu-Boc), 27.4, 26.9 (CH3-tBu-Si x2), 22.8 (Cq-tBu-Si), 
22.6 (CH2-Sp), 20.0 (Cq-tBu-Si), 14.3 (C-18Sp); IR (neat): 3070, 2958, 2924, 2854, 1728, 1271, 1174, 1103, 1070, 709 
cm-1; HRMS calculated for [C58H83NO12Si + Na]+: 1036.5685, found 1036.5584. 
 [5,6,7,8,9-13C5]-glucosyl sphingosine (36b). 2,3-di-O-Benzoyl-4,6-O-(di-tert-butylsilanediyl)-1-O-(N-[phenyl]- 
trifluoracetimidoyl)-α/β-D-glucopyranose 35 (0.27 g, 0.4 
mmol, 1.5 eq) and sphingosine acceptor 23b (137 mg, 0.27 
mmol, 1.0 eq) were co-evaporated twice with toluene (10 
mL) and then dissolved in anhydrous DCM (3 mL). 
Activated molsievies  (3 Å) were added and the mixture 





















Synthesis of a Panel of Carbon-13-Labeled (Glyco)Sphingolipids 
 43 
1.0 eq). The reaction was stirred until TLC showed a lower running spot (debocylation of sphingosine acceptor) (~ 
1 h). The reaction mixture was transferred to an extraction funnel with EtOAc (40 mL), and washed with sat. aq. 
NaHCO3 (40 mL) and brine (40 mL). The aqueous layers were extracted with EtOAc (40 mL) and the combined 
organics were dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography (2-5% 
Et2O, 20% DCM in petroleum ether) produced the title compound as an amorphous solid (147 mg, 0.145 mmol, 
54%). Rf = 0.45 (10% Et2O, 20% DMC in petroleum ether); [α]D22: +6.0 (c = 0.1 CHCl3); 1H NMR (400 MHz, CDCl3) δ 
8.03-7.95 (m, 6H, Harom), 7.57-7.48 (m, 3 H, Harom) 7.45-7.34 (m, 6 H, Harom), 5.79 (dm, 1 H, J = 151.2 Hz, H-5Sp), 5.55 
(t, 1 H, J = 9.4 Hz, H-3), 5.50-5.41 (m, 2 H, H-3Sp and H-4Sp), 5.35 (dd, 1 H, J = 10.4, 7.8 Hz, H-2), 4.79 (d, 1 H, J = 8.9 
Hz, NH), 4.67 (d, 1 H, J = 7.8 Hz, H-1), 4.11-4.02 (m, 3 H, H-4, H-1a-Sp and H-2Sp), 3.98 (dd, 1 H, J = 10.2, 4.5 Hz, H-
6a), 3.74 (t, 1 H, J = 10.2 Hz, H-6b), 3.62 (m, 1 H, H-1b-Sp), 3.55 (m, 1 H, H-5), 1.96 (dm, 2 H, J = 126.2, H-6Sp), 1.34-
1.10 (m, 31 H, CH3-tBu-Boc and H-7sp to H-17Sp), 0.95 (s, 18 H, CH3-tBu-Si), 0.88 (t, 3 H, J = 6.8 Hz, H-18Sp); 13C NMR (101 
MHz, CDCl3) δ  166.0,   165.4,  165.1   (C=OBz x3), 155.4 (C=OBoc), 137.6 (d, J = 42.6 Hz, C-5Sp), 133.3, 133.1, 133.0 
(CHarom x3), 130.6 (Cq-arom), 129.9 (CHarom x2), 129.8 (Cq-arom), 129.7 (CHarom x4), 129.5 (Cq-arom), 128.5 (CHarom  x2), 
128.4 (CHarom x4), 124.7 (d, J = 71.2 Hz, C-4sp), 101.4 (C-1), 79.5 (Cq-Boc), 75.1 (C-3), 74.8 (C-4), 74.4 (d, J = 5.2 Hz, C-
3Sp ), 72.1 (C-2), 70.8 (C-5), 67.9 (C-6), 66.0 (C-1Sp), 52.4 (C-2Sp), 32.4 (m, C-6Sp), 32.0 (CH2-Sp), 29.80-28.4 (m, CH2-Sp 
x9 and CH3-tBu-Boc), 27.4, 26.9 (CH3-tBu-Si x2), 22.8 (Cq-tBu-Si), 22.6 (CH2-Sp), 20.0 (Cq-tBu-Si), 14.3 (C-18Sp); IR (neat): 3070, 
2922, 2854, 1724, 1267, 1172, 1069, 827, 708 cm-1; HRMS calculated for [C5313C5H83NO12Si + H]+: 1041.5748, 
found 1041.5748.  
Glucosylsphingosine (37a). Protected glucosylsphingosine 36a (130 mg, 0.128 mmol, 1.0 eq) was dissolved in 
THF:pyridine (15 mL) and hydrogen fluoride (70% HF in 
pyridine) (53 µL, 0.256 mmol, 2.0 eq) was added. The reaction 
was stirred at room temperature until TLC showed full 
conversion (~ 2 hours) (Rf(product) = 0.75 (40% EtOAc in DCM). The 
reaction was concentrated in vacuo, re-dissolved in EtOAc (30 mL) and washed with 1 M HCl (30 mL), sat. aq. 
NaHCO3 (30 mL), and brine (30 mL). The aqueous layers were extracted with EtOAc (30 mL) and the combined 
organics were dried (Na2SO4), filtered and concentrated in vacuo. The crude mixture was dissolved in MeOH (13 
mL) and sodium methoxide (30% in methanol) (18 µL, 0.128 mmol, 1.0 eq) was added. The reaction was stirred 
over night at room temperature and the progress of the reaction was followed by HPLC-MS. Aqueous potassium 
hydroxide (0.5 M) (3.8 mL, 1.9 mmol, 15 eq) was added and the reaction was left stirring over night at room 
temperature. The reactio was then quenched with AcOH (0.73 mL, 13 mmol, 100 eq) and concentrated in vacuo. 
The crude reaction mixture was coevaporated in tolune and put on ice-bath before addition water (1 mL) and 
TFA (3 mL). The reaction was stirred for 2 minutes at 0 °C and was then diluted with toluene (20 mL) and 
concentrated in vacuo. Purification by HPLC-MS (52-62% B, following the general procedure for HPLC-MS 
purifications) produced the title compound (31 mg, 0.067 mmol, 53%) as a TFA adduct. [α]D22: -5.0 (c = 0.1 
MeOH); 1H NMR (600 MHz, MeOD-d4) δ  5.87  (dtd,  1  H,  J = 15.0, 6.8, 1.2 Hz, H-5Sp), 5.48 (ddt, 1 H, J = 15.4, 6.9, 1.5 
Hz, H-4Sp), 4.33-4.29 (m, 2 H, H-1 and H-3Sp), 3.97-3.88 (m, 3 H, H-6 and H-1a-Sp), 3.66 (m, 1 H, H-1b-Sp), 3.40-3.32 
(m, 2 H, H-5 and H-2sp), 3.29-2.21 (m 3 H, H-2, H-3 and H-4), 2.1 (q, 2 H, J = 7.2 Hz, H-6sp), 1.42 (m, 2 H, H-7sp), 
1.36-1.22 (m, 20 H, H-8sp to H-17sp), 0.9 (t, 3 H, J = 7.0 Hz, H-18Sp); 13C NMR: (151 MHz, MeOD-d4) δ 136.8 (C-5Sp), 
128.4 (C-4Sp), 104.1 (C-1), 78.1 (C-4), 77.9 (C-5), 74.8 (C-3), 71.5 (C-2), 70.9 (C-3Sp), 67.3 (C-6), 62.5 (C-1Sp), 56.8 (C-
2Sp), 33.4 (C-6Sp), 33.1, 30.82, 30.81 (2x), 30.78, 30.77, 30.66, 30.50, 30.41, 30.18, 23.6 (11x CH2-Sp), 14.2 (C-18Sp); 
IR (neat): 3300, 2918, 2850, 1668, 1435, 1202, 1134, 1074, 1026, 800, 721 cm-1; HRMS calculated for [C24H47NO7 + 
H]+: 462.3431, found 462.3424. 
Glucosyl-[5,6,7,8,9-13C5]-Sphingosine (37b). Protected glucosyl-[5,6,7,8,9-13C5]-Sphingosine 36a (48 mg, 47 µmol, 
1.0 eq) was dissolved in THF:pyridine (10 mL) and hydrogen 
fluoride (70% HF in pyridine) (20 µL, 94 µmol, 2.0 eq) was 
added. The reaction was stirred at room temperature until TLC 
showed full conversion (~ 2 hours) (Rf(product) = 0.75 (40% EtOAc in DCM). The reaction was concentrated in vacuo, 



















aqueous layers were extracted with EtOAc (20 mL) and the combined organics were dried (Na2SO4), filtered and 
concentrated in vacuo. The crude mixture was dissolved in MeOH (8 mL) and sodium methoxide (30% in 
methanol) (6.5 µL, 47 µmol, 1.0 eq) was added. The reaction was stirred over night at room temperature and the 
progress of the reaction was monitored by HPLC-MS. Aqueous potassium hydroxide (0.5 M) (1.4 mL, 0.7 mmol, 
15 eq) was added and the reaction was left stirring over night at room temperature. The reaction was then 
quenched with AcOH (0.3 mL, 4.7 mmol, 100 eq) and concentrated in vacuo. The crude reaction mixture was 
coevaporated with toluene and put on an ice-bath before the addition of water (0.3 mL) and TFA (1 mL). The 
reaction was stirred for 2 minutes at 0°C and then diluted with toluene (20 mL) and was concentrated in vacuo. 
Purification by HPLC-MS (52-62% B, following the general procedure for HPLC-MS purifications) produced the 
title compound (10.7 mg, 23 µmol, 49%) as a TFA adduct. [α]D22: -5.1 (c = 0.1 MeOH); 1H NMR (600 MHz, MeOD-
d4) δ  5.85  (dm,  1  H,  J = 150.2 Hz, H-5Sp), 5.48 (dt, 1 H, J = 15.8, 6.4 Hz, H-4Sp), 4.34-4.29 (m, 2 H, H-1 and H-3Sp), 
3.97-3.88 (m, 3 H, H-6 and H-1a-Sp), 3.66 (dd, 1 H, J = 11.7, 6.1 Hz, H-1b-Sp), 3.40-3.31 (m, 2 H, H-5 and H-2Sp), 3.29-
2.21 (m 3 H, H-2, H-3 and H-4), 2.10 (dm, 2 H, J = 126.9 Hz, H-6Sp), 1.56-1.15 (m, 22 H, H-7Sp to H-17Sp), 0.90 (t, 3 
H, J = 7.0 Hz, H-18Sp); 13C NMR(151 MHz, MeOD-d4) δ  136.8  (d,  J = 43.0 Hz, C-5Sp), 128.2 (dd, J = 72.5, 3.5 Hz, C-
4Sp), 104.1 (C-1), 78.1 (C-4), 77.9 (C-5), 74.9 (C-3), 71.5 (C-2), 70.9 (m, C-3Sp), 67.3 (C-6), 62.5 (C-1Sp), 56.8 (d, J = 
3.4 Hz, C-2Sp), 33.6-32.9 (m, C-6Sp and CH2-Sp), 30.9-29.6 (m, CH2-Sp x10), 23.4 (CH2-Sp), 14.5 (C-18Sp); IR (neat): 3300, 
2918, 2851, 1670, 1433, 1200, 1134, 1074, 1024, 800, 721 cm-1; HRMS calculated for [C1913C5H47NO7 + H]+: 
467.3598, found 467.3591. 
Glucosylceramide (38a). See general procedure for the synthesis of the ceramides from the sphingosine. Yield  
(3.1 mg, 4.4 µmol, 57%); Rf = 0.25 (CHCl3:MeOH 9:1); [α]D22: 
+6.0 (c = 0.1 MeOH:CHCl3 1:1); 1H NMR (600 MHz, 
CDCl3/MeOD-d4)   δ   5.68   (dt,   1  H,   J = 13.8, 6.9 Hz, H-5Sp), 5.44 
(dd, 1 H, J = 15.3, 7.8 Hz, H-4Sp), 4.26 (d, 1 H, J = 7.9 Hz, H-1’),  
4.16 (dd, 1 H, J = 10.3, 4.8 Hz, H-1b-Sp), 4.06 (t, 1 H, J = 8.4 Hz, H-3Sp), 3.97 (dt, 1 H, J = 8.4, 4.0 Hz, H-2Sp), 3.86 (dd, 
1 H, J = 11.9, 1.8 Hz, H-6a’),  3.66  (m  1  H,  H-6b’),  3.59  (dd,  1  H,  J = 10.1, 3.3 Hz, H-1a-Sp), 3.36 (m, 1 H, H-3’),  3.29-
3.26 (m, 2 H, H-4’  and  H-5’),  3.21  (dd,  1  H,  J = 9.4, 7.8 Hz, H-2’),  2.17  (t,  2  H,  J = 7.2 Hz, H-2*), 2.02 (m, 2 H, H-6Sp), 
1.58 (m, 2 H, H-3*), 1.42-1.23 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 7.0 Hz, H-18Sp and H-
16*); 13C NMR (151 MHz, CDCl3/MeOD-d4)  δ  173.9  (C=O*),  133.0  (C-5Sp), 129.2 (C-4Sp), 102.5 (C-1’),  75.8  (C-4’),  
75.7 (C-3’),  73.0  (C-2’),  70.9 (C-3sp), 69.5 (C-5’),  67.8  (C-1sp), 60.5 (C-6’),  52.6  (C-2sp), 35.3 (C-2*), 31.4 (C-6Sp), 31.0, 
28.80, 28.77 x3, 28.76 x4, 28.74 x2, 28.73, 28.71, 28.70, 28.64, 28.57, 28.50, 28.43, 28.42, 28.38, 28.37, 28.34, 
25.10, 21.67 (CH2 x24, C-7Sp to C-17Sp and C-3* to C-15*), 14.4 x2 (C-18Sp and C-16*); IR (neat): 3300, 2916, 2848, 
1670, 1540, 1467, 1200, 1134, 1074, 1028, 721 cm-1; HRMS calculated for [C40H77NO8 + H+]: 700.5727, found 
700.5720. 
Glucosyl-2-N-([3,4,5-13C3]-hexadecanoyl)-sphingosine (38b) See general procedure for the synthesis of the 
ceramides from the sphingosine. Yield (3.2 mg, 4.5 µmol, 
59%); Rf = 0.25 (CHCl3:MeOH 9:1); [α]D22: +4.8 (c = 0.2  
MeOH:CHCl3 1:1); 1H NMR (600 MHz, MeOD-d4)  δ  5.68  (dt,  1  
H, J = 13.8, 6.9 Hz, H-5Sp), 5.44 (dd, 1 H, J = 15.3, 7.8 Hz, H-
4Sp), 4.26 (d, 1 H, J = 7.9 Hz, H-1’),  4.16  (dd,  1  H,  J = 10.3, 4.8 
Hz, H-1b-Sp), 4.06 (t, 1 H, J = 8.4 Hz, H-3Sp), 3.97 (dt, 1 H, J = 8.4, 4.0 Hz, H-2Sp), 3.86 (dd, 1 H, J = 11.9, 1.8 Hz, H-6a’),  
3.66 (m 1 H, H-6b’),  3.59  (dd,  1  H,  J = 10.1, 3.3 Hz, H-1a-Sp), 3.36 (m, 1 H, H-3’),  3.29-3.26 (m, 2 H, H-4’  and  H-5’),  
3.21 (dd, 1 H, J = 9.4, 7.8 Hz, H-2’),  2.17  (m,  2  H,  H-2*), 2.02 (m, 2 H, H-6Sp), 1.58 (dm, 2 H, J = 130 Hz, H-3*), 1.42-
1.16 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 7.0 Hz, H-18Sp and H-16*); 13C NMR (151 MHz, 
MeOD-d4)  δ  176.0  (C=O*),  135.1  (C-5Sp), 131.3 (C-4Sp), 104.7 (C-1’),  78.0 (C-4’),  77.9  (C-3’),  75.2  (C-2’),  73.0  (C-3Sp), 
71.6 (C-5’),  69.9  (C-1Sp), 62.6 (C-6’),  54.7  (C-2Sp), 34.8 (d, J = 35.0 Hz, C-2*), 33.1 (C-6Sp), 31.0-30.0 (m), 27.51, 27.4-
27.0 (m), 26.87, 23.77 (CH2 x24, C-7Sp to C-17Sp and C-3* to C-15*), 14.4 x2 (C-18Sp and C-16*); IR (neat): 3260, 
2914, 2847, 1643, 1541, 1468, 1205, 1134, 1076, 1030, 717 cm-1; HRMS calculated for [C3713C3H77NO8 + H+]: 
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Glucosyl-2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (38c). See general procedure for the synthesis of the 
ceramides from the sphingosine. Yield (2.8 mg, 3.9 µmol , 52%). 
Rf = 0.25 (CHCl3:MeOH 9:1); [α]D22: +5.4 (c = 0.1 MeOH:CHCl3); 
1H NMR (600 MHz, MeOD-d4)  δ  5.68  (dm,  1  H,  J = 154.0 Hz, H-
5Sp), 5.44 (m, 1 H, H-4Sp), 4.26 (d, 1 H, J = 7.9 Hz, H-1’),  4.16  (dd,  
1 H, J = 10.3, 4.8 Hz, H-1b-Sp), 4.06 (m, 1 H, H-3Sp), 3.97 (m, 1 H, H-2Sp), 3.86 (dd, 1 H, J = 11.9, 1.8 Hz, H-6a’),  3.66  
(m 1 H, H-6b’),  3.59  (dd,  1  H,  J = 10.1, 3.3 Hz, H-1a-Sp), 3.36 (m, 1 H, H-3’),  3.29-3.26 (m, 2 H, H-4’  and  H-5’),  3.21  
(dd, 1 H, J = 9.4, 7.8 Hz, H-2’),  2.17  (m,  2  H,  H-2*), 2.02 (dm, 2 H, J = 128.0 Hz, H-6Sp), 1.58 (dm, 2 H, J = 130.0 Hz, 
H-3*), 1.42-1.14 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 7.0 Hz, H-18Sp and H-16*); 13C NMR 
(151 MHz, MeOD-d4)  δ  176.0  (C=O*),  135.1  (d,  J = 44.0 Hz, C-5Sp), 131.3 (d, J = 72.5 Hz, C-4Sp), 104.6 (C-1’),  78.0  
(C-4’),  77.9  (C-3’),  75.2  (C-2’),  73.0  (C-3Sp), 71.6 (C-5’),  69.9  (C-1Sp), 62.6 (C-6’),  54.7  (C-2Sp), 37.4 (C-2*), 33.9-33.0 
(m), 31.1-30.1 (m), 27.20, 23.78 (CH2 x24, C-7Sp to C-17Sp and C-3* to C-15*), 14.5 (C-18Sp and C-16*); IR (neat): 
3300, 2913, 2847, 1643, 1544, 1468, 1260, 1085, 1030, 718 cm-1; HRMS calculated for [C3513C5H77NO8 + H+]: 
705.5895, found 705.5906.  
Glucosyl-2-N-([3,4,5-13C3]-hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (38d). See general procedure for the 
synthesis of the ceramides from the sphingosine. Yield (4.9 mg, 
6.9 µmol, 61%); Rf = 0.25 (CHCl3:MeOH 9:1); [α]D22: +5.0 (c = 0.2 
MeOH:CHCl3 1:1); 1H NMR (600 MHz, MeOD-d4)  δ  5.68   (dm,  1  
H, J = 154.0 Hz, H-5Sp), 5.44 (m, 1 H, H-4sp), 4.26 (d, 1 H, J = 7.9 
Hz, H-1’),  4.16  (dd,  1  H,  J = 10.3, 4.8 Hz, H-1b-Sp), 4.06 (m, 1 H, H-3Sp), 3.97 (m, 1 H, H-2Sp), 3.86 (dd, 1 H, J = 11.9, 
1.8 Hz, H-6a’),  3.66  (m  1  H,  H-6b’),  3.59  (dd,  1  H,  J = 10.1, 3.3 Hz, H-1a-Sp), 3.36 (m, 1 H, H-3’),  3.29-3.26 (m, 2 H, H-
4’  and  H-5’),  3.21  (dd,  1  H,  J = 9.4, 7.8 Hz, H-2’),  2.17  (m,  2  H,  H-2*), 2.02 (dm, 2 H, J = 128.0 Hz, H-6Sp), 1.58 (dm, 
2 H, J = 130.0 Hz, H-3*), 1.42-1.14 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 7.0 Hz, H-18Sp and 
H-16*); 13C NMR (151 MHz, MeOD-d4)  δ  176.0  (C=O*),  135.1  (d,  J = 44.0 Hz, C-5Sp), 131.3 (d, J = 72.5 Hz, C-4Sp), 
104.6 (C-1’),  78.0  (C-4’),  77.9  (C-3’),  75.2  (C-2’),  73.0  (C-3Sp), 71.6 (C-5’),  69.9  (C-1Sp), 62.6 (C-6’),  54.7  (C-2Sp), 37.4 
(d, J = 35.0 Hz, C-2*), 33.9-33.0 (m), 31.1-30.0 (m), 27.50, 27.4-27.0 (m), 26.87, 23.78 (CH2 x24, C-7Sp to C-17Sp and 
C-3* to C-15*), 14.4 (C-18Sp and C-16*); IR (neat): 3295, 2913, 2847, 1643, 1545, 1468, 1260, 1086, 1032, 718 cm-
1; HRMS calculated for [C3213C8H77NO8 + H+]: 708.5995, found 708.5989. 
Globotriaosyl sphingosine (40a). Globotriaosyl imidate donor 39 (0.54 g, 0.33 mmol, 1.2 eq) and sphingosine 
acceptor 23a (0.14 g, 0.27 mmol, 1.0 eq) 
were co-evaporated twice with toluene (5 
mL) and then dissolved in anhydrous DCM 
(3 mL). Activated molsieves (3 Å) were 
added and the mixture was stirred for one 
hour at room temperature and then cooled 
to 0 ºC, before addition of BF3·OEt2 (48% in 
Et2O) (38 µL, 0.3 mmol, 1.1 eq). The 
reaction was stirred until TLC showed complete conversion of the sphingosine acceptor (~2 h). The reaction 
mixture was then transferred to an extraction funnel with EtOAc (40 mL) and washed with sat. aq. NaHCO3 (40 
mL) and brine (40 mL). The aqueous layers were extracted with EtOAc (40 mL) and the combined organics were 
dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography (12% Et2O, 10% DCM 
in petroleum ether) produced the title compound as an amorphous solid (0.32 g, 0.16 mmol, 60%). Rf = 0.54 (30% 
Et2O, 20% DCM in petroleum ether); [α]D22: +31 (c = 1.0 CHCl3); 1H NMR (400 MHz, CDCl3)  δ  8.19  (m,  2  H,  Harom), 
7.92 (m, 2 H, Harom), 7.92-7.85 (m, 6 H, Harom), 7.68 (dm, 2 H, J = 7.2 Hz, Harom), 7.58-7.41 (m, 9 H, Harom), 7.40-7.18 
(m, 18 H, Harom), 7.11 (m, 2 H, Harom), 5.78 (t, 1 H, J = 9.3 Hz, H-3), 5.72 (dd, 1 H, J = 10.7, 3.7 Hz, H-2’’),  5.66  (m,  1  
H, H-5Sp), 5.60 (dd, 1 H, J = 10.8, 7.8 Hz, H-2’),  5.50  (dd,  1  H,  J = 10.7 Hz, 3.0 Hz, H-3’’),  5.47-5.32 (m, 4 H, H-3Sp, H-
2, H-4Sp and H-1’’),  5.25  (dd,  1  H,  J = 10.8, 2.1 Hz, H-3’),  5.10  (d,  1  H,  J = 2.9 Hz, H-4’’),  4.81-4.74 (m, 2 H, H-1’  and  
NHBoc), 4.66 (d, 1 H, J = 7.8 Hz, H-1), 4.55 (d, 1 H, J = 11.9 Hz, H-6a’’),  4.46  (d,  1  H,  J = 11.9 Hz, H-6b’’),  4.39-4.32 (m, 






































3.97 (dd, 1 H, J = 10.9, 5.3 Hz, H-6a’),  3.81-3.72 (m, 2 H, H-5 and H-6b’),  3.59  (m,  1  H,  H-1b-Sp), 3.53 (m, 1 H, H-5’),  
1.88 (m, 2 H, H-6Sp), 1.33 (s, 9 H, CH3-tBu-Boc), 1.30-1.11 (m, 22 H, H-7Sp to H-17Sp), 1.06 (s, 9 H, CH3-tBu-Si), 1.00 (s, 9 
H, CH3-tBu-Si), 0.87 (t, 3 H, J = 6.8 Hz, H-18Sp); 13C NMR (101 MHz, CDCl3)  δ  166.2,  165.9,  165.7,  165.6,  165.2,  164.98,  
164.95, 164.8, 164.7 (C=OBz x9), 155.2 (C=OBoc), 137.2 (C-5sp), 133.4, 133.13, 133.10, 132.97, 132.94, 132.87, 
132.7 (CHarom x7), 130.2 (Cq-arom), 130.1, 130.0 (CHarom x2), 129.9 (Cq-arom), 129.8, 129.64, 129.59, 129.58, 129.5 
(CHarom x5), 129.4 (Cq-arom), 129.3 (CHarom), 129.2, 129.0, 128.6, 128.50, 128.47 (Cq-arom x5), 128.45, 128.39, 128.35, 
128.29, 128.28, 128.16, 128.12, 128.07 (CHarom x8), 124.4 (C-4Sp), 101.3 (C-1’),  100.9  (C-1), 98.68 (C-1’’),  79.3  (Cq-
Boc), 76.6 (C-4), 76.3 (C-4’),  74.3 (C-3Sp), 73.02 (C-5), 72.94 (C-3), 72.8 (C-3’),  72.6   (C-5’),  71.9   (C-2), 71.2 (C-3’’),  
71.0 (C-4’’),  69.7  (C-2’),  69.5  (C-2’’),  68.3  (C-5’’),  67.8  (C-1Sp), 66.9 (C-6’),  62.3  (C-6), 60.5 (C-6’’),  52.3  (C-2Sp), 32.2 
(C-6Sp), 31.9, 29.62 (x3), 29.61, 29.5, 29.3, 29.2, 28.7 (CH2-Sp x10), 28.2 (CH3-tBu-Boc), 27.5, 27.2 (CH3-tBu-Si x2), 23.2 
(Cq-tBu-Boc), 22.6 (CH2-Sp), 20.7 (Cq-tBu-Si), 14.1 (C-18Sp); IR (neat): 3070, 2926, 2856, 1722, 1451, 1267, 1095, 1070, 
1028, 708 cm-1; HRMS calculated for [C112H127NO28Si + Na]+: 1984.8206, found 1984.8204.  
 [5,6,7,8,9-13C5]-Globotraiosyl sphingosine (40b).  Globotriaosyl imidate donor (39) (158 mg, 96 µmol, 1.2 eq) 
and 13C5-sphingosine acceptor 23b (40.7 
mg, 80 µmol, 1.0 eq) were co-evaporated 
twice with toluene (5 mL) and then 
dissolved in anhydrous DCM (2 mL). 
Activated molsieves (3 Å) were added and 
the mixture was stirred at room 
temperature for 1 hour and then cooled to 
0 ºC, before addition of BF3·OEt2 (48% in 
Et2O) (23 µL, 88 µmol, 1.1 eq). The reaction 
was stirred until TLC showed complete conversion of the 13C5-sphingosine acceptor (~2 h). The reaction mixture 
was then transferred to an extraction funnel with EtOAc (40 mL) and washed with sat. aq. NaHCO3 (40 mL) and 
brine (30 mL). The aqueous layers were then extracted with EtOAc (40 mL) and the combined organics were 
dried (Na2SO4), filtered, and concentrated in vacuo. Purification by column chromatography (12% ether, 10% 
DCM in petroleum ether) 40b as an amorphous solid (87 mg, 44 µmol, 55%). Rf = 0.54 (30% ether, 20% DCM in 
petroleum ether); [α]D22: +30 (c = 1.0 CHCl3); 1H NMR (400 MHz, CDCl3)  δ  8.17  (m,  2    H,  Harom), 8.06 – 8.00 (m, 4 H, 
Harom), 7.95 (m, 2 H, Harom), 7.92 – 7.84 (m, 6 H, Harom ), 7.67 (m, 2 H, Harom),  7.55 (m, 2 H, Harom), 7.53 – 7.42 (m, 7 
H, Harom), 7.40 – 7.27 (m, 16 H, Harom), 7.21 (m, 2 H, Harom ), 7.11 (m, 2 H, Harom ),  5.77 (t, 1 H, J = 9.3 Hz, H-3), 5.71 
(dd, 1 H, J = 10.7, 3.7 Hz, H-2’’),  5.67  (dm,  1  H,  J  =  151.2 Hz, H-5Sp), 5.59 (dd, 1 H, J = 10.8, 7.8 Hz, H-2’),  5.49  (dd,  1  
H, J = 10.7, 3.0 Hz, H-3’’),  5.47  – 5.31 (m, 4 H, H-3Sp, H-2, H-4Sp and H-1’’),  5.24  (dd,  1  H,  J  =  10.9,  2.1  Hz,  H-3’),  5.10  
(d, 1 H, J = 3.0 Hz, H-4’’),  4.80  – 4.73 (m, 2 H, H-1’  and  HNBoc), 4.65 (d, 1 H, J = 7.8 Hz, H-1), 4.54 (d, 1 H, J = 12.0 Hz, 
H-6a’’),  4.44  (d,  1  H,  J  =  12.0  Hz,  H-6b’’),  4.38  – 4.30 (m, 3 H, H-5’’,  H-6a and H-6b), 4.12 (t, 1 H, J = 9.4 Hz, H-4), 4.07 
(d, 1 H, J = 1.5 Hz, H-4’),  4.06  – 3.99 (m, 2 H, H-1a-Sp and H-2Sp), 3.97 (dd, 1 H, J = 10.9, 5.4 Hz, H-6a’),  3.81  – 3.71 
(m, 2 H, H-5 and H-6b’),  3.58  (m,  1  H,  H-1b-Sp), 3.51 (dd, 1 H, J = 13.9, 6.9 Hz, H-5’),    1.87  (dm,  2  H,  J  =  124.6  Hz,  H-
6Sp), 1.40 – 1.14 (m, 31 H, H-7Sp to H-17Sp, and CH3-tBu-Boc), 1.05 (s, 9 H, CH3-tBu-Si), 1.00 (s, 9 H, CH3-tBu-Si), 0.87 (t, 3 H, 
J = 6.8 Hz, H-18Sp); 13C NMR (101 MHz, CDCl3)  δ  166.2,  166.0,  165.7,  165.6,  165.2,  165.00,  164.98,  164.79,  164.75  
(C=OBz x9), 155.2 (C=OBoc), 137.2 (d, J = 42.4 Hz, C-5Sp), 133.4, 133.2, 133.1, 133.00, 132.99, 132.96, 132.89, 132.7, 
130.2, 130.1, 130.00, 129.95, 129.8, 129.67, 129.62, 129.60, 129.50, 129.48, 129.4, 129.2, 129.0, 128.6, 128.53, 
128.50, 128.48, 128.41, 128.37, 128.32, 128.30, 128.18, 128.14, 128.09 (CHarom and Cq-arom x32), 124.4 (d, J = 71.2 
Hz, C-4Sp), 101.3 (C-1’),  100.9  (C-1), 98.7 (C-1’’),  79.4  (Cq-Boc), 76.6 (C-4), 76.3 (C-4’),  74.3  (d,  J  =  5.4  Hz,  C-3Sp), 73.04 
(C-5), 72.97 (C-3), 72.8 (C-3’),  72.7  (C-5’),  71.9  (C-2), 71.2 (C-3’’),  71.0  (C-4’’),  69.7  (C-2’),  69.6  (C-2’’),  68.3  (C-5’’), 
67.8 (C-1Sp), 66.9 (C-6’),  62.3  (C-6), 60.5 (C-6’’),  52.3  (d,  J  =  2.4  Hz,  C-2Sp), 32.2 (m, C-6Sp), 31.9 (CH2-Sp), 29.8 – 28.1 
(m, CH2-Sp x9 and CH3-tBu-Boc), 27.5, 27.2 (CH3-tBu-Si x2), 23.2 (Cq-tBu-Si), 22.7 (CSp), 20.7 (Cq-tBu-Si), 14.1 (C-18Sp); IR (neat): 
3070, 2925, 2853, 1718, 1452, 1266, 1094, 1069, 706 cm-1; HRMS calculated for [C10713C5H127O28Si + Na]+: 
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Globotriaosylsphingosine (41a). Protected globotriaosylsphingosine 40a (200 mg, 0.10 mmol, 1.0 eq) was 
dissolved in THF:pyridine 4:1 (20 mL) and 
hydrogen fluoride (70% HF in pyridine) (53 µL, 
0.26 mmol, ca. 20 eq) was added. The reaction 
was stirred at room temperature until TLC 
showed full conversion to a lower running spot 
(~4 h). The reaction was then concentrated in 
vacuo, re-dissolved in EtOAc (50 mL) and 
washed with 1 M HCl (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL). The water phases were extracted with 
EtOAc (50 mL) and the combined organics were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
mixture was then dissolved in methanol (20 mL) and sodium methoxide (30% in methanol) (14 µL, 0.10 mmol, 
1.0 eq) was added. The reaction was stirred over night at room temperature and the progression of the reaction 
was followed by HPLC-MS. Aqueous potassium hydroxide (0.5 M, 4.1 mL, 2.0 mmol, 20 eq) was added and the 
reaction left stirring over night at room temperature. The reaction was then quenched with AcOH (0.58 mL, 100 
eq) and concentrated in vacuo. The crude reaction mixture was co-evaporated with toluene and put on an ice-
bath before the addition of trifluoracetic acid (5 mL). The reaction mixture was completely dissolved after one 
minute and was then stirred for another minute at 0 °C. The solution was then transferred to a round bottom 
flask containing toluene (50 mL) and concentrated to about 10 mL in vacuo. The co-evaporation was repeated 
two times with toluene (40 mL), before concentration to dryness. The completion of the reaction was confirmed 
by HPLC-MS. The residue was then purified over a short silica column and eluted with MeOH/DCM 1:9, followed 
by H2O/MeOH/DCM 3:27:70 (TLC visualised with ninhydrin spray). Purification by HPLC-MS (40-48% B, following 
the general procedure for HPLC-MS purifications) produced globotraiosylsphingosine 41a (43 mg, 54 µmol, 53%) 
as a TFA adduct. [α]D22: +34.0 (c = 0.5 MeOH); 1H NMR (600 MHz, MeOD-d4)  δ:  5.87  (m,  1  H,  H-5Sp), 5.49 (m, 1 H, 
H-4Sp), 4.94 (d, 1 H, J = 3.9 Hz, H-1’’),  4.40  (d,  1  H,  J = 6.9 Hz, H-1’),  4.37  (d,  1  H,  J = 7.8 Hz, H-1), 4.32 (ddd, 1 H, J = 
6.8, 4.7, 1.3 Hz, H-3Sp), 4.25 (ddd, 1 H, J = 7.1, 5.2, 1.3 Hz, H-5’’),  4.01-3.96 (m, 2 H, H-4’  and  H-1a-Sp), 3.94 (dd, 1 H, 
J = 11.9, 2.6 Hz, H-6a), 3.93-3.91 (m, 2 H, H-4’’  and  H-1b-Sp), 3.89 (dd, 1 H, J = 7.7, 4.1 Hz, H-6b), 3.88-3.81 (m, 3 H, 
H-6a’,H-6b’  and  H-2’’),  3.77  (dd,  1  H,  J = 10.2, 3.2 Hz, H-3’’),  3.74  (dd,  1  H,  J = 11.1, 7.1 Hz, H-5), 3.40 (ddd, 1 H, J = 
8.5, 4.7, 3.6 Hz, H-2Sp), 3.30 (t, 1 H, J = 7.7 Hz, H-2), 2.10 (q, 2 H, J =7.0 Hz, H-6Sp), 1,42 (m, 2 H, H-7Sp), 1.36-1.22 
(m, 20 H, H-8Sp to H-17Sp), 0.90 (t, 3 H, J = 7.0 Hz, H-18Sp); 13C NMR (151 MHz, MeOD-d4)  δ:  136.8  (C-5Sp), 128.3 (C-
4Sp), 105.4 (C-1’),  103.7  (C-1), 102.7 (C-1’’),  80.8  (C-4), 79.8 (C-4’),  76.6  (C-5’  and C-5), 76.3 (C-2’),  74.7  (C-3), 74.6 
(C-2), 72.8 (C-5’’),  72.6  (C-3’),  71.3  (C-4’’),  71.0  (C-3’’),  70.8  (C-3Sp), 70.5 (C-2’’),  67.1  (C-1Sp), 62.7 (C-6’’),  61.6  (C-6), 
61.5 (C-6’),  56.7  (C-2Sp), 33.4 (C-6Sp), 33.1, 30.79 (x3), 30.76, 30.74, 30.6, 30.5, 30.4, 30.2, 23.7 (CH2-Sp x11), 14.4 
(C-18Sp); IR (neat): 3345 bs, 2925, 2855, 1674, 1202, 1134, 1067, 1027, 974, 801, 721 cm-1; HRMS calculated for 
[C36H67NO17 + H]+: 786.4482, found 786.4485. 
Globotriaosyl-[5,6,7,8,9-13C5]-sphingosine (41b). Globally protected globotriaosyl-[5,6,7,8,9-13C5]-sphingosine 
40b   (87 mg, 0.45 µmol, 1.0 eq) was dissolved 
in THF:pyridine 4:1 (10 mL) and hydrogen 
fluoride (70% HF in pyridine) (24 µL, 0.11 
mmol, ca. 20 eq) was added. The reaction 
mixture was stirred at room temperature until 
TLC showed full conversion to a lower running 
spot (~4 h). The reaction was then concentrated in vacuo, re-dissolved in EtOAc (50 mL) and washed with 1N HCl 
(50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL). The water phases were extracted with EtOAc (50 mL) and the 
combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The crude mixture was then 
dissolved in methanol (8 mL) and sodium methoxide (30% in MeOH) (6.2 µL, 0.45 µmol, 1.0 eq) was added. The 
reaction mixture was stirred over night at room temperature. The progression of the reaction was monitored by 
HPLC–MS. Aqueous potassium hydroxide (0.5 M) (1.8 mL, 0.89 mmol, 20 eq) was added and the reaction mixture 
was left stirring over night at room temperature. The reaction was then quenched with AcOH (0.25 mL, 100 eq) 





























before the addition of trifluoroacetic acid (3 mL). The product was completely dissolved in about 1 min and the 
reaction was stirred for an additional minute at 0 °C. The solution was then transferred to a round bottom flask 
containing toluene (50 mL) and concentrated in vacuo to about 10 mL. The co-evaporation was repeated twice 
with toluene (40 mL), before concentration to dryness. The completion of the reaction was monitored by HPLC–
MS. The reaction mixture was filtered over a small silica column and eluted with MeOH/DCM 1:9 and 
H2O/MeOH/DCM 3:27:70 (TLC visualised with ninhydrin spray). Purification by HPLC–MS (40–48% B, following 
the general procedure for HPLC–MS purifications) produced globotriaosylsphingosine 41b (17 mg, 21 µmol, 48%) 
as a TFA adduct. [α]D22: +33.0 (c = 0.20 MeOH); 1H NMR (600 MHz, MeOD-d4)  δ  5.85  (dm,  1  H,  J = 150.2 Hz, H-5Sp), 
5.47 (m, 1 H, H-4Sp), 4.94 (d, 1 H, J = 3.8 Hz, H-1’’), 4.39 (d, 1 H, J = 7.1 Hz, H-1’), 4.36 (d, 1 H, J = 7.8 Hz, H-1), 4.31 
(ddd, 1 H, J = 6.4, 4.8 Hz, H-3Sp), 4.25 (ddd, 1 H, J = 6.8, 5.2, 1.3 Hz, H-5’’), 4.01 – 3.96 (m, 2 H, H-4’ and H-1a-Sp), 
3.94 (dd, 1 H, J = 12.0, 2.4 Hz, H-6a), 3.92 – 3.90 (m, 2 H, H-4’’ and H-1b-Sp), 3.89 (dd, 1 H, J = 7.7, 4.0 Hz, H-6b), 3.88 
– 3.79 (m, 3 H, H-6a’, H-6b’ and H-2’’), 3.77 (dd, 1 H, J = 10.1, 3.1 Hz, H-3’’), 3.74 (dd, 1 H, J =11.2, 7.3 Hz, H-6a’’), 
3.70 – 3.65 (m, 2 H, H-5’ and H-6b’’), 3.58 – 3.50 (m, 4 H, H-4, H-3, H-3’ and H-2’), 3.46 (m, 1 H, H-5), 3.40 (ddd, 1 
H, J = 8.5, 4.7, 3.6 Hz, H-2Sp), 3.30 (m, 1 H, H-2), 2.10 (dm, 2 H, J = 126.9 Hz, H-6Sp), 1.56 – 1.14 (m, 22 H, H-7Sp to 
H-17Sp), 0.89 (t, 3 H, J = 7.0 Hz, H-18Sp); 13C NMR (151 MHz, MeOD-d4)  δ  136.8  (d,  J = 42.8 Hz, C-5Sp), 128.3 (d, J = 
72.3 Hz, C-4Sp), 105.4 (C-1’), 103.7 (C-1), 102.7 (C-1’’), 80.8 (C-4), 79.8 (C-4’), 76.6 (C-5’ and C-5), 76.3 (C-2’), 74.65 
(C-3), 74.2 (C-2), 72.8 (C-5’’), 72.6 (C-3’), 71.3 (C-6’’), 71.0 (C-4’’), 70.8 (d, J = 5.1 Hz, C-3Sp), 70.5 (C-2’’), 67.1 (C-
1Sp), 62.7 (C-6’’), 61.6 (C-6), 61.5 (C-6’), 56.7 (d, J = 2.2 Hz, C-2Sp), 33.8 – 32.9 (m, C-6Sp and CH2-Sp), 30.9 – 29.8 (m, 
CH2-Sp x10), 23.7 (CH2-Sp), 14.4 (C-18Sp); HRMS calculated for [C3113C5H67NO17H]+: 791.4650, found 791.4654. 
Globotriaosylceramide (42a).  See general procedure for the synthesis of the ceramides from the sphingosine. 
Yield (6 mg, 5.8 µg, 49%); Rf = 0.35 
(CHCl3:MeOH:H2O 70:27:3);  [α]D22: +24 (c = 
0.75 MeOH:CHCl3 1:1); 1H NMR (600 MHz, 
CDCl3/MeOD-d4)  δ  5.69   (dt,  1  H,   J = 14.7, 6.9 
Hz, H-5Sp), 5.45 (dd, 1 H, J = 15.3, 7.8 Hz, H-
4Sp), 4.96 (d, 1 H, J = 3.8 Hz, H-1’’),  4,41  (d,  1  H,  
J =6.9 Hz, H-1’),  4.30  (d,  1  H,   J = 7.8 Hz, H-1), 
4.25 (ddd, 1 H, J = 6.8, 4.7, 1.3 Hz, H-3Sp), 4,19 (dd, 1 H, J = 10.1, 4.5 Hz, H-5’’),  4.07  (t,  1  H,  J = 8.8 Hz), 4.04-3.96 
(m, 4 H), 3.92 (d, 1 H, J = 3.0 Hz) 3.89 (d, 1 H, J = 3.2 Hz), 3.85-3.81 (m, 3 H), 3.79-3.73 (m, 2 H), 3.71-3.3.63 (m, 
3H), 3.60-3.51 (m, 4 H), 2.17 (t, 2 H, J = 7.2 Hz, H-2*), 2.03 (m, 2 H, H-6sp), 1.58 (dm, 1 H, J = 130.0 Hz, H-3*), 1.43-
1.20 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 6,9 Hz, H-18Sp and H-16*); 13C NMR (151 MHz, 
CDCl3/MeOD-d4)  δ  177.5   (C=O*),  133.1   (C-5Sp), 132.6 (C-4Sp), 103.3 (C-1’),   102.3   (C-1), 100.6 (C-1’’),  78.8   (C-4), 
77.7 (C-4’),  74.3  (C-5’  and  C-5), 74.1 (C-2’),  72.8  (C-3), 72.5 (C-2), 70.9 (C-5’’),  70.7  (C-3’),  70.5  (C-4’’),  69.2  (C-3’’),  
68.9 (C-3Sp), 68.4 (C-2’’),  67.8  (C-1Sp), 60.6 (C-6’’),  58.8  (C-6), 57.2 (C-6’),  52.5  (C-2Sp), 35.3 (C-2*), 31.4 (C-6Sp), 31.0 
28.78 x2, 28.77 x4, 28.74 x2, 28.72 x2, 28.71 x2, 28.64, 28.59, 28,54, 28,52, 28.44 x2, 28.41, 28.40, 28.38, 28.36, 
21.7 (CH2 x24, C-7sp to C-17sp and C-3* to C-15*), 12.5 (C-18Sp and C-16*); IR (neat): 3300, 2918, 2851, 1636, 1465, 
1379, 1205, 144, 1070, 1016, 719 cm-1; HRMS calculated for [C52H97NO18 + H]+: 1024.6784, found 1024.6783. 
Globotriaosyl-2-N-([3,4,5-13C3]-hexadecanoyl)-sphingosine (42b). See general procedure for the synthesis of the 
ceramides from the sphingosine. Yield (9 mg, 8.7 
µmol, 71%); Rf = 0.35 (CHCl3:MeOH:H2O 
70:27:3); [α]D22: +24 (c = 0.25 (MeOH:CHCl3 1:1); 
1H NMR (600 MHz, CDCl3/MeOD-d4)  δ  5.69  (dt,  1  
H, J = 14.7, 6.9 Hz, H-5Sp), 5.45 (dd, 1 H, J = 15.3, 
7.8 Hz, H-4Sp), 4.96 (d, 1 H, J = 3.8 Hz, H-1’’),  4,41  
(d, 1 H, J =6.9 Hz, H-1’),  4.30  (d,  1  H,  J = 7.8 Hz, H-1), 4.25 (ddd, 1 H, J = 6.8, 4.7, 1.3 Hz, H-3Sp), 4,19 (dd, 1 H, J = 
10.1, 4.5 Hz, H-5’’),  4.07  (t,  1  H,  J = 8.8 Hz), 4.04-3.96 (m, 4 H), 3.92 (d, 1 H, J = 3.0 Hz) 3.89 (d, 1 H, J = 3.2 Hz), 
3.85-3.81 (m, 3 H), 3.79-3.73 (m, 2 H), 3.71-3.3.63 (m, 3H), 3.60-3.51 (m, 4 H), 2.17 (m, 2 H, H-2*), 2.03 (m, 2 H, 
H-6sp), 1.58 (dm, 1 H, J = 130.0 Hz, H-3*), 1.43-1.14 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, J = 
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60.7, 52.6, 31.5, 31.3, 29.0-28.2 (m), 25.5-24.8 (m), 24.3-24.0 (m), 21.71, 21.60, 19.68 (CH2 x24, C-7Sp to C-17Sp 
and C-3* to C-15*), 12.6 (C-18Sp and C-16*); IR (neat): 3300, 2914, 2849, 1632, 1551, 1470, 1370, 1203, 1070, 
1024, 716 cm-1; HRMS calculated for [C4913C3H97NO18 + H]+: 1027.6884, found 1027.6881. 
Globotriaosyl-2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (42c). See general procedure for the synthesis of 
the ceramides from the sphingosine. Yield (5.5 
mg, 5.3 µmol, 51%); Rf = 0.35 
(CHCl3:MeOH:H2O 70:27:3); [α]D22: +26 (c = 
0.15 MeOH:CHCl3 1:1); 1H NMR (850 MHz, 
CDCl3/MeOD-d4)  δ  5.69  (dm,  1  H,  J = 150.0, H-
5Sp), 5.45 (m, 1 H, H-4Sp), 4.96 (d, 1 H, J = 3.8 
Hz, H-1’’),  4,41  (d,  1  H,  J =6.9 Hz, H-1’),  4.30  (d,  1  H,  J = 7.8 Hz, H-1), 4.25 (ddd, 1 H, J = 6.8, 4.7, 1.3 Hz, H-3Sp), 4,19 
(dd, 1 H, J = 10.1, 4.5 Hz, H-5’’),  4.07  (t,  1  H,  J = 8.8 Hz), 4.04-3.96 (m, 4 H), 3.92 (d, 1 H, J = 3.0 Hz) 3.89 (d, 1 H, J = 
3.2 Hz), 3.85-3.81 (m, 3 H), 3.79-3.73 (m, 2 H), 3.71-3.63 (m, 3H), 3.60-3.51 (m, 4 H), 2.17 (m, 2 H, H-2*), 2.03 (m, 
2 H, H-6Sp), 1.58 (dm, 1 H, J = 130.0 Hz, H-3*), 1.43-1.14 (m, 46 H, H-7Sp to H-17Sp and H-4* to H-15*), 0.90 (t, 6 H, 
J = 6,9 Hz, H-18Sp and H-16*); 13C NMR (213 MHz, CDCl3/MeOD-d4)  δ  174.0  (C=O*),  133.2  (d,  J = 42.0 Hz, C-5Sp), 
103.4 (C-1’),  102.4  (C-1), 100.7 (C-1’’),  74.4,  72.9,  72.6,  70.9,  70.5,  69.0,  68.4,  67.6, 66.1, 60.8, 38.6 35.6, 31.8-
31.0 (m), 29.1-28.1 (m), 25.2, 25.1, 21.8, 21.6, 19.7 (CH2 x24, C-7sp to C-17sp and C-3* to C-15*), 12.6 (C-18Sp and 
C-16*); IR (neat): 3300, 2914, 2849, 1633, 1549, 1468, 1204, 1069, 1026, 719 cm-1; HRMS calculated for 
[C4713C5H97NO18 + H]+: 1029.6951, found 1029.6949. 
Globotriaosyl-2-N-([3,4,5-13C3]-hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (42d). See general procedure for the 
synthesis of the ceramides from the 
sphingosine. Yield (8.6 mg, 8.3 µmol, 64%); Rf 
= 0.35 (CHCl3:MeOH:H2O 70:27:3); [α]D22: +25 
(c = 0.1 MeOH:CHCl3 1:1); 1H NMR (850 MHz, 
CDCl3/MeOD-d4)  δ  5.69  (dm,  1  H,  J = 150.0, H-
5Sp), 5.45 (m, 1 H, H-4Sp), 4.95 (d, 1 H, J = 3.8 
Hz, H-1’’),  4,41   (d,  1  H,   J = 6.9 Hz, H-1’),  4.30  
(d, 1 H, J = 7.8 Hz, H-1), 4.25 (m, 1 H, H-3Sp), 4,19 (dd, 1 H, J = 10.1, 4.5 Hz, H-5’’),  4.07  (m,  1  H),  4.04-3.96 (m, 4 H), 
3.92 (d, 1 H, J = 3.0 Hz) 3.89 (m, 1 H), 3.85-3.81 (m, 3 H), 3.79-3.73 (m, 2 H), 3.71-3.63 (m, 3H), 3.60-3.51 (m, 4 H), 
2.17 (m, 2 H, H-2*), 2.02 (dm, 2 H, J = 128.0 Hz, H-6Sp H-6Sp), 1.65-1.14 (m, 48 H, H-7Sp to H-17Sp and H-3* to H-
15*), 0.90 (t, 6 H, J = 6,9 Hz, H-18Sp and H-16*); 13C NMR (213 MHz, CDCl3/MeOD-d4)  δ δ  174.0  (C=O*), 133.1 (d, J 
= 44.6 Hz, C-5Sp), 31.8-30.8 (m), 29.8-28.0 (m), 25.95, 25.27-24.95 (m), 21.67, 21.52, 19.56 (CH2 x24, C-7Sp to C-
17Dp and C-3* to C-15*), 12.4 (C-18Sp and C-16*); IR (neat): 3300, 2955, 2849, 1634, 1549, 1466, 1070, 1028, 719 
cm-1; HRMS calculated for [C4413C8H97NO18 + H]+: 1032.7052, found 1032.7053. 
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4 N-Fmoc-Protected Sphingosine is a 
Suitable Starting Material in the 
Synthesis of Glycosylsphingosines  
3.1  Introduction 
In Chapter 2 the synthesis of carbon-13-labeled glucosylsphingosine 3 was described. Key 
step in this synthesis comprised glycosylation of N-Boc-protected sphingosine 1 using 
imidate 2 as the donor glucoside (Figure 3.1).[1] During the research that led to the 
identification of 4,6-silylidene donor 2, perbenzoylated glucopyranosyl imidates 4 and 5 
were assessed as well. In these studies it was found that the use of stoichiometric BF3.OEt2 
as the Lewis acid to activate these donors in the presence of N-Boc-sphingosine 1 did not 
    51 
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yield the desired, fully protected sphingosine 6. Instead, removal of the N-Boc protective 
group was observed to occur as the main event. Arguably the lower reactivity of donors 4 
and 5 when compared to donor 2 is behind this difference in glucosylation outcome. 
 
Figure 3.1. N-Boc-protected sphingosine 1 could be glucosylated with donor imidate 2, but not with the 
comparatively less reactive donor glucosides 4 and 5. Conditions: a) BF3OEt2, DCM, 0 oC, 1 h, 3: 49%; 6: no 
productive yield from either 4 or 5. 
 
When looking more closely at the outcome in the glycosylation reaction of silylidene-
protected glucosyl imidate 2 with N-Boc-protected sphingosine, the desired, fully 
protected glucosylsphingosine 3 was obtained in a rather moderate yield of 49%, and also 
this reaction was accompanied by partial loss of the N-Boc protective group. While the 
process proved effective enough to allow the synthesis of a panel of (carbon-13-labeled) 
glucosylsphingosine derivatives (see Chapter 2), there remained obvious room for 
improvement, especially when considering translation to functional analogues of 
compound 3. With these observations in mind, attention was focused on the use of 
alternative amine protective group strategies, specifically on the nature of the protective 
groups by means of which the amine and the secondary alcohol of the sphingosine 
acceptor are temporarily blocked. As is described in this Chapter, glucosylation of 
sphingosine 7, with the amine blocked with an Fmoc group and the secondary alcohol 
masked as the para-methoxybenzyl ether, proved to proceed more effectively when 
compared to the methodology described in Chapter 2. Moreover, besides glucosylation, 
also galactosylation could be accomplished, a transformation that could not be 
accomplished using acceptor 1. This results allows the construction of 
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3.2  Results and discussion 
The efficacy of acceptor 10,[2,3] featuring protection of the amine in the sphingosine 
acceptor as the azide, in combination with the benzoyl group as protecting group for the 
secondary alcohol, in glycosylation events was investigated. As can be seen (Scheme 3.1), 
perbenzoylated glucosyl imidate 5 can be coupled to acceptor 10 (itself prepared in three 
steps from known azide 8[4]) under the agency of triflic acid to give 11 in good yield. Thus, 
the comparatively stronger protic acid (TfOH versus the Lewis aicd BF3OEt2), which proved 
detrimental in the coupling of N-Boc-sphingosine 1 with donor 5, could be used effectively 
in combination with sphingosine 10 (which does not bear any acid-labile protective 
groups). 
Scheme 3.1. Glycosylation of azide-protected sphingosine. 
  
Reagents and conditions: (a) i) TBDPSCl, pyridine, 0 oC to r.t., 20 h; ii) BzCl, pyridine, r.t., 20 h, 91%; (b) TBAF, 
acetic acid , THF, 0 oC, 1 h, 62%. (c) TfOH, DCM, 0 oC, 1 h, 87%. 
However and as was shown previously, the azide in terminal alkene 12 prevented its 
effective cross-metathesis with terminal alkene 13 (Scheme 3.2).[5,6] Cross-metathesis of 
carbon-13-enriched alkene 13 to an appropriately protected form of alkene 12, which 
itself can be prepared in an enantiomerically pure form from serine, is the strategy of 
choice for the preparation of neutron-encoded sphingosine bases, as was described in 
Chapter 2.[1] On paper, one could produce 13C5-enriched, N-Boc protected sphingosine 1, 
remove both O-benzoyl protection and N-Boc protection (in this order to avoid acyl 
migration from O to N), perform a diazo transfer, and then install the secondary benzoyl 
following the scheme as depicted for sphingosine 10. Performing this, rather lengthy, 
protective group manipulation scheme on a (comparatively expensive) carbon-13-
enriched compound however is suboptimal. Therefore, an alternative, partially protected 
sphingosine acceptor, that could be prepared through the cross-metathesis scheme, and 
that at the same time would be able to withstand rather acidic glycosylation conditions, 
was required. Such a sphingosine derivative was found in compound 7, in which the amine 



































Scheme 3.2. Synthesis of partially protected sphingosine 10. 
  
Reagents and conditions: (a) Grubbs 2nd generation catalyst, AcOH, CH2Cl2, reflux, 48 h; (b) NaOMe, MeOH, r.t., 
20 h; (ii) KOH, H2O, r.t., 20 h; (iii) TFA, H2O, 0 °C, 30 min; (iv) imidazole-1-sulfonyl azide hydrochloride, K2CO3, 
CuSO4. 5 H2O, MeOH. r.t., 20 h. 
 
The synthesis of N-Fmoc protected sphingosine 7 was accomplished following the strategy 
published by Yamamoto and co-workers[7] with as adaptation that, while the Yamamoto 
group started from Boc-L-serine, here Fmoc-L-serine 14 was employed as the starting 
material (Scheme 3.3). The carboxylic acid in 14 was converted to the Weinreb amide 
(EDC.HCl, N,O-dimethylhydroxylamine hydrochloride), followed by silylation of the 
primary hydroxyl with TBS-Cl, giving 16 in 75% yield over the two steps. 
Scheme 3.3 Synthesis of N-Fmoc-protected aminodiol 
Reagents and conditions: (a) N,O-dimethylhydroxylamine hydrochloride, EDC.HCl, DIPEA, DCM, HOBt.H2O, 0 oC to 
r.t., 20 h;  (b) TBS-Cl, NMM, DMF, 0 oC to r.t., 20 h, 75% over two steps; (c) (i) vinylmagnesium bromide, THF, 0 0C, 
1 h, 67%; (d) LiAlH(OtBu)3, EtOH, -78 oC, 5 h, 73%; (e) PMB-N-phenyltrifluoroimidate, camphor-10-sufonic acid, 
toluene, 0 0C to r.t., 20 h, 58%; (f) TBAF, acetic acid, THF, r.t., 20 h, 94%. 
In the next step, Weinreb amide 16 was treated with vinylmagnesium bromide to give the 
,-unsaturated ketone 17. The stable tetrahedral intermediate that is formed upon 
addition of the Grignard reagent and that collapses only during work-up (addition of 2M 
HCl) ensures that a second Grignard addition is prevented.[8,9] Ketone 17 was then reduced 
in a stereoselective fashion to give allylic alcohol 18 using LiAlH(OtBu)3 as reducing 
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(PMB)[11] after which the primary alcohol was unmasked (19 to 20), both steps using 
standard protective group manipulation conditions. 
At this stage, three functionalized pentene derivatives were available for an ensuing cross-
metathesis: partially protected alkenes 18 and 20 and fully protected alkene 19. All three 
were subjected to a cross-metathesis reaction with 2 equivalents of linear, terminal alkene 
13 and Grubbs’ 2nd generation catalyst in the presence of acetic acid to prevent (see 
Chapter 2) alkene migration (Table 3.1).[1,12] As can be seen, the partially protected alkenes 
18 and 20 perform about equally well in this process, whereas the fully protected alkene 
19 delivers the desired product in low yield only. 
Table 3.1. Optimization of cross-metathesis mediated assembly of  N-Fmoc-protected sphingosine. 
 
entry pentene R1 R2 Product Yield (%) 
1 18 TBS H 21 62 
2 19 TBS PMB 22 18 
3 20 H PMB 7 65 
 
Both because of the (slightly) higher yield and because the partially protected sphingosine 
produced from 20 would allow modification of the primary alcohol directly, the process 
summarized in entry 3 is the most suitable for preparation of 13C5-enriched sphingosine 
derivatives. For this to become feasible, the compatibility of Fmoc-sphingosine 7 in 
glycosylation events needed to be established. In a first attempt, glycosylation of 7 with 
imidate 5 under the agency of BF3OEt2 (Scheme 3.4) proved abortive. Switching to the 
stronger Lewis acid, TMSOTf (10 mol%) led to the formation of the desired, fully protected 
glycosylated sphingosine 23 in good yield, thus revealing that switching from N-Boc-
protection to N-Fmoc-protection, as was hypothesized, pays off.[5,13] Removal of the para-
methoxybenzyl group (10% TFA in DCM), followed by global removal (sodium hydroxide in 
a mixture of methanol and methylene chloride) of the benzoyl and N-Fmoc protective 
groups yielded -glucosylsphingosine 25 in 80% yield based on 23. All spectroscopic and 
analytical data on 25 were in full agreement with the data obtained on the same 
compound as synthesized in Chapter 2.[1] In a similar vein, but now starting from 13C6-



















Scheme 3.4 Synthesis of 13C6-glucosylsphingosine 25a/b using N-Fmoc-protected sphingosine 7. 
 
Reagent and conditions: (a) (i) 10 mol% TMSOTf, DCM -20 oC, 1 h, (82%); (b) 10% TFA in DCM, 0 0C, 3 h; (c) (i) 
NaOH, DCM/MeOH (3:1), r.t., 20 h; (ii) acetic acid, r.t., 80% over the two steps. 
The usefulness of sphingosine 7 as acceptor in glycosphingolipid synthesis is finally 
demonstrated in the construction of 6-deoxy-6-azidoglucosylsphingosine 28 and 
galactosylsphingosine 31 (Scheme 3.5). As can be seen, TMSOTf-catalyzed glycosylation of 
7 with either donor imidate 26 or 29 proceeded uneventfully and the same holds true for 
the global deprotection of the resulting glycosylsphingosines 27 and 30, to produce 
compounds 28 and 31, respectively. 
Scheme 3.5 Synthesis of 6-azido-glucosylsphingosine 28 and galactosylsphingosine 31. 
Reagent and conditions: (a) (i) 10 mol% TMSOTf, DCM -20 oC, 1 h, (79% 27, 74% 30); (b) i) 10% TFA in DCM, 0 
0C, 3 h; (ii) NaOH, DCM/MeOH (3:1), r.t., 20 h.; (iii) acetic acid, r.t., 75% 28, 77% 31 over two steps. 
3.3 Conclusion 
In conclusion, this Chapter describes an improved strategy, hinging on the use of N-Fmoc-
protected sphingosine 7 as acceptor in glycosylation events, for the synthesis of 
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was employed in Chapter 2) are in improved yields, and in the potential use of strong 
Lewis acids. This in turn allows the synthesis of structural and functional 
glucosylsphingosine analogues, as is demonstrated by the construction of 6-deoxy-6-
azidoglucosylsphingosine 28 (with an azide installed for bioconjugation purposes) and 
galactosylsphingosine 31. The latter compound is thought to be the secondary storage 
material[14-16] in Krabbe disease (deficiency in galactocerebrosidase)[17] and the strategy 
presented here, in combination with the methodology developed in Chapter 2 for the 
construction of 13C-labeled sphingosine, allows for the construction of neutron-encoded 
galactosylsphingosine for quantitative lipidomics studies in the context of this lysosomal 
storage disorder. 
 
3.4 Experimental section 
General Remarks: Commercially available reagents and solvents (Acros, Fluka, or Merck) were used as received, 
unless otherwise stated. CH2Cl2 and THF were freshly distilled before use, over P2O5 and Na/benzophenone, 
respectively. Triethylamine was distilled from calcium hydride and stored over potassium hydroxide. Traces of 
water were removed from starting compounds by co-evaporation with toluene. All moisture-sensitive reactions 
were carried out under an argon atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column 
chromatography was carried out using forced flow of the indicated solvent systems on Screening Devices silica 
gel 60 (40–63  μm  mesh).  Size-exclusion chromatography was carried out on Sephadex LH20 (MeOH/CH2Cl2, 1:1). 
Analytical TLC  was carried out on aluminum sheets (Merck, silica gel 60, F254). Compounds were visualized by 
UV absorption (254 nm), or by spraying with ammonium molybdeen/cerium sulphate solution 
[(NH4)6Mo7O24·4H2O (25 g/L), (NH4)4Ce(SO4)6·2H2O (10 g/L), 10 % sulphuric acid in ethanol] or phosphormolybdic 
acid in EtOH (150 g/L), followed by charring (ca. 150 °C). IR spectra were re- corded with a Shimadzu FTIR-8300 
instrument and are reported in cm–1. Optical rotations were measured with a Propol automatic polarimeter 
(sodium D-line, λ  = 589 nm). 1H and 13C NMR spectra were recorded with a Bruker AV 400 MHz spectrometer at 
400.2 (1H) and 100.6 (13C) MHz, or with a Bruker AV 600 MHz spectrometer at 600.0 (1H) and 151.1 (13C) MHz. 
Chemical shifts are reported as δ  values (ppm), and were referenced to tetramethylsilane  (δ  =  0.00  ppm)  directly 
in CDCl3, or using the residual solvent peak (D2O). Coupling constants (J) are given in Hz, and all 13C spectra were 
proton decoupled. NMR assignments were made using COSY and HSQC, and in some cases TOCSY experiments. 
LC–MS analysis was carried out with an LCQ Advantage Max (Thermo Finnigan) instrument equipped with a 
Gemini C18 column (Phenomenex, 50, 4.6  mm,  3  μm),  using  the  following  buffers:  A:  H2O, B: acetonitrile, and C: 
aq. TFA (1.0 %).  
General procedure for the glycosylation of N-Fmoc-protected sphingosine 7 and trichloro-imidate donors. 
Protected sphingosine (1 eq) and imidate-donor (1.5 eq) were co-evaporated twice with toluene before it was 
dissolved in dry DCM (0.1 M) under protected atmosphere. To the solution was added activated 4 Å molsieves 
and was stirred for 30 minute. The reaction mixture was cooled to -20 oC, followed by activation with TMSOTf 
(10% mol, based on sphingosine). The reaction was stirred at -20 oC until, according TLC, all sphingosine acceptor 
was consumed (approximately 1 hour). When the reaction was complete, the reaction mixture was neutralized 
with triethylamine and filtered over Celite. The reaction was concentrated in vacuo followed by purification by 
silica gel chromatography or with size exclusion column giving  protected glycosylsphingosine. 
General procedure for deprotection of protected glycosylsphingosine. The protected sphingosine (1 eq) was 
dissolved in DCM (0.1 M) and was cooled to 0 oC. To the solution was added TFA (10 volume%) and stirred for 4 
hours allowing to reach room temperature. The mixture was diluted with toluene and concentrated in vacuo. 
The crude mixture was dissolved in DCM/MeOH (1:1, 0.1 M) and sodium hydroxide (6 eq) and stirred overnight 
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at room temperature. The reaction was according LC-MS finished and the reaction was neutralized with AcOH 
and concentrated in vacuo. The crude product was purified with silica column chromatography (10% MeOH in 
chloroform to 3:27:70 H2O:MeOH:CHCl3) giving fully deprotected sphingosine. 
9H-fluoren-9-yl)methyl (S)-(3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (15). To a 
solution of DIPEA (8.2 mL, 46.9 mmol, 0.9 eq) in DCM (300 mL) was added Fmoc-L-Serine 14 
(17.1 g, 52.2 mmol, 1 eq). The mixture was stirred under argon at 0 oC. EDC.HCl  (12 g, 62.6 
mmol, 1.2 eq) and HOBt.H2O (9.58 g, 62.6 mmol, 1.2 eq) were added and stirred for 10 
minutes, followed by addition of Weinreb salt (6.12 g, 62.6 mmol, 1.2 eq) and DIEA (4.5 mL, 26.1 mmol, 0.5 eq). 
The reaction was stirred over night, which was allowed to reach room temperature. The mixture was washed 2x 
2M HCl, 2x sat. aq. NaHCO3 and brine. All water layers were extracted with DCM and the combined organic layers 
were dried with MgSO4, filtered and concentrated in vacuo giving resulting oil 10, which was used in the next 
step without further purification. Rf = 0.39 (EtOAc); 1H NMR (400 MHz, CDCl3)  δ  7.76  (d,  2 H J = 7.5 Hz, CHFmoc), 
7.64–7.56 (m, 2 H, CHFmoc), 7.40 (t, 2 H, J = 7.5 Hz, CHFmoc), 7.31 (t, 2 H, CHFmoc), 5.92 (d, 1 H, J = 8.3 Hz, NH), 4.87 
(m, 1 H, H-2), 4.40 (d, 2 H, J = 7.1 Hz, CH2-Fmoc), 4.22 (t, 1 H, J = 7.0 Hz, CHFmoc), 3.86 (s, 2H, H-1), 3.78 (s, 3 H, CH3-
OMe), 3.25 (s, 3 H, CH3-NMe), 2.52 (bs, 1 H, OH); 13C NMR (101 MHz, CDCl3)  δ  156.0 (C=OFmoc) 143.93, 143.82, 2x 
141.39 (Cq-Fmoc), 141.46 (C-3), 127.84, 127.21, 125.25, 120.10 (4x CHFmoc), 67.35 (CH2-Fmoc), 63.70 (C-1), 61.79 (CH3-
OMe), 52.88 (C-2), 47.26 (CHFmoc) 31.91 (CH3-OMe); IR (neat): 3412, 3315, 2941, 1714, 1448, 1263, 1053 cm-1; HRMS 
calculated for [C20H22N2O5 +H]+: 371.1537, found 371.1531. 
 (9H-fluoren-9-yl)methyl (S)-(3,8,8,9,9-pentamethyl-4-oxo-2,7-dioxa-3-aza-8-siladecan-5- yl)carbamate (16). 
Crude product 15 was dissolved in dry DMF (500 mL)  under protected atmosphere and 
cooled to 0 oC. To the solution was added TBDMS-Cl (10.2 g, 67.6 mmol, 1.3 eq) followed by 
addition of NNM  (6.3 mL,  57.2  mmol,  1.1  eq). The mixture was stirred over night, which 
was allowed to reach room temperature. The reaction mixture was diluted with H2O was added and was 
extracted twice with diethyl ether. The organic layers were combined, washed with brine, dried with MgSO4, 
filtered and concentrated in vacuo. The resulting crude oil was purified with silica gel chromatography (0-10% 
EtOAc in pentane), which gave yellow oil 16 (18.9 g, 39.0 mmol, 75% over two steps). Rf = 0.95 (EtOAc); 1H NMR 
(400 MHz, CDCl3)  δ  7.76  (d, 2 H, J = 7.5 Hz, CHFmoc), 7.62 (t, 2 H, J = 8.2 Hz, CHFmoc), 7.40 (t, 2 H, J = 7.5 Hz, CHFmoc), 
7.32 (t, 2 H, J = 7.5 Hz, CHFmoc), 5.72 (d, 1 H, J = 8.7 Hz, NH), 4.85 (m, 1 H, H-2), 4.37 (d, 2H, J = 7.2 Hz, CH2-Fmoc), 
4.25 (t, 1 H, J = 7.3 Hz, CHFmoc), 3.96–3.83 (m, 2 H, H-1), 3.77 (s, 3 H, CH3-OMe), 3.25 (s, 3 H, CH3-NMe), 0.90 (s, 9 H, 
TBStBu ), 0.06 (s, 6 H, 2x TBSMe); 13C NMR (101 MHz CDCl3) δ 168.0 (C-3), 156.0 (C=OFmoc) 143.93, 143.82, 2x 141.39 
(Cq-Fmoc), 127.82, 127.20, 125.34, 120.09, (4x CHFmoc) 67.27 (CH2-Fmoc), 63.48 (C-1), 61.65 (CH3-OMe), 53.16 (C-2), 
47.28 (CHFmoc), 32.62 (CH3-NMe), 25.93 (TBStBu), 18.26 (TBStBu-q), -5.35 (TBSMe); IR (neat) 3305, 3057, 2924, 1712, 
1450, 1053 cm-1; HRMS calculated for [C26H36N2O5Si + H]+: 485.2401, found 485.2404. 
 (9H-fluoren-9-yl)methyl (S)-(1-((tert-butyldimethylsilyl)oxy)-3-oxopent-4-en-2-yl)carbamate (17). Silylated 
protected 16 (4.8 g, 10 mmol, 1 eq) was in dry THF (20 mL) under protected atmosphere and 
cooled to 0 0C. To the solution was added slowly vinyl MgBr  (1 M in THF, 40 mL, 40 mmol, 4 
eq) and the reaction was stirred for one hour at 0 oC. The reaction mixture was quenched by 
slowly adding it to cold 2M HCl (200 mL) and quickly extracted twice with EtOAc. The organic layers were 
combined, washed with brine, dried with MgSO4, filtered and concentrated in vacuo. The resulting residue was 
purified with silica gel chromatography (2.5-10% EtOAc in pentane), which gave a white solid 17 (3 g, 6.7 mmol, 
67%). Rf = 0.75 (15% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ  7.77  (d,  2 H, J = 7.5 Hz, HArom), 7.62 (t, 2 H, J = 
6.8 Hz, HArom), 7.41 (t, 2 H, J = 7.5 Hz, HArom), 7.32 (t, 2 H, J = 7.5, HArom), 6.57 (dd, 1 H, J = 17.2, 10.8 Hz, H-4), 6.39 
(d, 1 H, H-5a), 5.90–5.83 (m, 2 H, H-5b + NH), 4.70 (m, 1 H, H-2), 4.39 (d, 2 H, J = 7.2 Hz, CH2-Fmoc), 4.24 (t, 1 H, J = 
7.2 Hz, CHFmoc), 4.05 (d, 1 H, J = 10.2 H-1a), 3.90 (dd, 1 H, J = 10.4, 4.0 H-1b), 0.86 (s, 9 H, TBStBu), 0.02 (s, 3 H, 
TBSMe), 0.01 (s, 3 H, TBSMe); 13C NMR (101 MHz CDCl3) δ  196.9 (C-3) 155.96 (C=OFmoc), 144.05, 143.93, 2x 141.44 
(Cq-Fmoc), 133.14 (C-4), 129.9 (C-5), 127.85, 127.21, 125.30, 120.12 (4x CHFmoc), 67.26 (CH2-Fmoc), 63.47 (C-1), 60.05 
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1251, 1026 cm-1; HRMS calculated for [C26H33N1O4Si + H]+: 452.2799, found 452.2783. 
 (9H-fluoren-9-yl)methyl ((2S,3R)-1-((tert-butyldimethylsilyl)oxy)-3-hydroxypent-4-en-2- yl)carbamate (18). 
Allic ketone 17 (3.0 g, 6.7 mmol, 1 eq) was dissolved in EtOH (500 mL) under an protected 
atmosphere and cooled to -78 oC. To the solution was added LiAlH(OtBu)3 (3.7 g, 14.7 mmol, 
2.2 eq)  and for 5 hours at -78 oC and was quenched with 0.1 M HCl (175 mL) at the same 
temperature. The mixture was quickly extracted twice with EtOAc and the combined organic 
layers were washed with 0.1 M HCl and brine, dried with MgSO4, filtered and concentrated in vacuo. The crude 
oil was purified with silica gel chromatography (2.5-10% EtOAc in pentane) giving a white solid 18 (2.2 g, 4.9 
mmol, 73%) and starting material (0.7 g, 1.6 mmol, 23 %). Rf = 0.52 (15% EtOAc in pentane); 1H NMR (400 MHz, 
CDCl3)  δ  7.77  (d, 2 H, J = 7.5 Hz, HFmoc), 7.58 (m, 2 H, HFmoc), 7.40 (t, 2 H, J = 7.5 Hz, HFmoc), 7.31(m, 2 H, HFmoc), 5.94 
(m, 1 H, H-4), 5.56 (d, 1 H, J = 8.6 Hz, NH), 5.41 (d, 1 H, J = 17.1 Hz, H-5a), 5.27 (d, 1 H, J = 10.6 Hz, H-5b), 4.39 (d, 2 
H, J = 7.2, Hz, CH2-Fmoc), 4.31 (m, 1 H, H-3), 4.24 (t, 1 H, J = 7.0 Hz, CHFmoc), 3.97 (dd, 1 H, J = 10.4, 2.8 Hz, H-1a), 3.78 
(d, 1 H, J = 10.2, 3.2 Hz, H-1b), 3.37 (m, 1 H, H-2), 3.38 (d, 1 H, J = 8.4 Hz, OH), 0.91 (s, 9 H, TBStBu), 0.07 (s, 6 H, 2x 
TBSMe); 13C NMR (101 MHz CDCl3) δ 156.3 (C=OFmoc), 144.06, 143.97, 2x 141.44 (4x Cq-Fmoc) 137.34 (C-4), 127.83, 
127.18, 125.22, 120.14 (4x CHFmoc), 116.36 (C-5), 74.88 (C-3), 66.95 (CH2-Fmoc), 62.35 (C-1), 55.19 (C-2), 47.34 
(CHFmoc), 25.94 (TBStBu), 18.24 (TBStBu-q), -5.50 (TBSMe); IR (neat): 3439, 2927, 2854, 1705, 1251, 1080 cm-1; HRMS 
calculated for [C26H35NO4Si + H]+: 453.2343, found 453.2348. 
 (9H-fluoren-9-yl)methyl ((2S,3R)-1-((tert-butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)pent-4- en-2-
yl)carbamate (19). Allylic alcohol 18 was dissolved in dry DCM toluene (1 mL) under 
protected atmosphere, followed  by addition of activated 4 Å molsieves and PMB-fluoro 
imidate (0.11 g, 0.36 mmol, 1.5 eq) The mixture was stirred for 30 minutes, after which was 
cooled to 0 0C before addition of 10-Camphorsulphonic acid (7 g, 0.024 mmol, 0.1 eq). The 
mixture was stirred over night and was allowed reaching room temperature. The mixture was diluted with DCM 
and filtered over Celite, washed with sat. aq. NaHCO3 (aq) and brine. The water layers were extracted with DCM 
and the combined organic layers were dried with MgSO4, filtered and concentrated in vacuo. The product was 
purified with silica gel chromatography (2.5-10 % EtOAc in pentane) giving a slightly yellow solid 19 (0.08 g, 0.13 
mmol, 58%). Rf = 0.5 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ  7.75  (d,  2 H, J = 7.5 Hz, HFmoc), 7.57 (m, 
2 H, HFmoc), 7.39 (t, 2 H, J = 7.5 Hz, HFmoc), 7.29 (t, 2 H, J = 7.5 Hz, HFmoc), 7.23 (d, 2 H, J = 7.5 Hz, HPMB), 6.86 (d, 2 H, J 
= 8.0 Hz, HPMB), 5.83 (m, 1 H, H-4), 5.52 (d, 1 H, J  = 8.4, NH), 5.42-5.34 (m, 2 H, H-5a and NH), 5.06 (d, 1 H, J = 9.7 
Hz, H5b), 4.54 (d, 1 H, J = 11.3 Hz, CH2-PMB-a), 4.34-4.12 (m, 5 H, CH2-Fmoc, CHFmoc, CH2-PMB-b and H-3), 3.96 – 3.87 (m, 2 
H, H-1a and H-2), 3.78 (s, 3 H, OMePMB), 3.65 (dd, 1H, J = 10.0, 4.1 Hz, H-1b), 0.90 (d, 9 H, J = 2.9 Hz, TBStBu), 0.06 (s, 
3 H, TBSMe), 0.05 (s, 3 H, TBSMe); 13C NMR (101 MHz, CDCl3)  δ  156.32  (C=OFmoc), 144.02, 141.37 (4x Cq-Fmoc), 136.02 
(C-4), 130.3 (CHPMB), 129.4, 127.74, 127.48, 125.20, 120.12 (4x Cq-Fmoc), 116.33 (C-5), 113.8 (CHPMB), 74.81 (C-3), 
70.50 (CH2-PMB), 66.98 (CH2-Fmoc), 62.24 (C-1), 55.39 (OMePMB) 55.13 (C-2), 47.30 (CHFmoc), 25.92 (TBStBu), 18.22 
(TBStBu-q), -5.50 (TBSMe); IR (neat): 3444, 3317, 3070, 2950, 2854, , 1242 cm-1; HRMS calculated for [C34H43NO5Si + 
H]+: 573.2919, found 573.2923. 
 (9H-fluoren-9-yl)methyl ((2S,3R)-1-hydroxy-3-((4-methoxybenzyl)oxy)pent-4-en-2-yl)carbamate (20). To a 
solution of 19 (0.25 g, 0.43 mmol, 1 eq) in 2 mL THF was added acetic acid (0.1 mL, 1.7 mmol, 4 
eq) followed addition of TBAF (1 M in THF, 0.9 mL, 0.86 mmol, 2 eq). The reaction mixture was 
stirred over night at room temperature. The reaction was diluted with EtOAc, washed with sat. 
NaHCO3 (aq), 1 M HCl (aq), and brine. The water layers were extracted with EtOAc and the 
combined organic layers were dried with MgSO4, filtered and concentrated in vacuo. The crude mixture was 
purified with silica gel chromatography (10-40% EtOAc in pentane) giving a white solid 20 (0.19 g, 0.4 mmol, 94 
%). Rf = 0.05 (20% EtOAc in pentane); 1H
 
NMR (400 MHz, CDCl3)  δ  7.76  (d,  2 H, J = 7.6 Hz, HFmoc), 7.63 – 7.55 (m, 
2H, HFmoc), 7.40 (t, 2 H, J = 7.8 Hz,  HFmoc), 7.31 (t, 2 H, J 7.2 Hz, HFmoc), 7.22 (d, 2 H, J = 8.3 Hz, HPMB), 6.86 (d, 2 H, J = 
7.9 Hz, HPMB), 5.82 (m, 1-H, H-4), 5.52 (d, 1 H, J = 8.5 Hz, H-5a), 5.44 – 5.35 (m, 2 H, H-5b + NH), 4.59 (d, 1 H, J = 












H, J = 11.6 Hz, H-1b), 3.76 (s, 3 H, OMePMB), 3.68 (m, 1 H, H-2), 3.63 (dd, 1 H, J = 11.2, 2.4 Hz, H-1b); 13C NMR (101 
MHz, CDCl3)  δ 156.31 (C=OFmoc), 144.06, 141.41 (4x Cq-Fmoc), 136.09 (C-4), 129.92 (CHPMB), 127.83, 127.19, 125.23 
(C-4), 125.29, 120.08 (4x CHFmoc) 116.37, (C-5), 114.03 (CHPMB), 74.89 (C-3), 70.46 (CH2-PMB), 66.96 (CH2-Fmoc), 62.20 
(C-1), 55.36 (OMePMB), 55.31 (C-2) 47.30 (CHFmoc); IR (neat): 3487, 3340, 3050, 2880, 1674, 1250 cm-1; HRMS 
calculated for [C28H29NO5 +H]+: 460.2054, found 460.2059. 
 9H-fluoren-9-yl)methyl ((2S,3R,E)-1-(tert-butyldimethylsilyl)oxy)-3-hydroxy-octadec-4-en-2- yl)carbamate (21). 
To a solution of 18 (1.1 g, 2.45 mmol, 1 eq) in DCM (15 mL), 1-pentadecene 
(2.12 mL, 4.9 mmol, 2 eq) was added in a 500 mL RBF and stirred. Acetic acid 
(0.14 mL, 2 mmol, 1 eq) and Grubbs 2nd Generation (0.21 g, 0.25 mmol, 0.1 eq) 
were added and stirred for 2 days in a closed system at 40 °C. The resulting 
mixture was evaporated and separated using column chromatography on silica gel (10-40% EtOAc in pentane) 
giving a brownish solid (0.91 mg, 1.47 mmol 62%). Rf = 0.15 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3) δ  
7.76 (d, 2 H, J = 7.6 Hz, HFmoc), 7.60 (m, 2 H, HFmoc), 7.40 (t, 2 H, J = 7.2 Hz, HFmoc), 7.31 (t, 2 H, J = 7.6 Hz, HFmoc), 
5.78 (m, 1 H, H-5), 5.52 (m, 2 H, H-4 and NH), 4.38 (d, 2 H, J = 7.2 Hz, CH2-Fmoc), 4.24 (m, 2 H, H-3 and CHFmoc), 3.98 
(d, 1 H, J = 10.0 Hz, H-1b), 3.78 (d, 1 H, J = 10.0 Hz, H-1b), 3.67 (m, 1 H, H-2), 3.26 (d, 1 H, J = 8.0 Hz, OH), 2.05 (m, 2 
H, H-6), 1.43 (m, 2 H, H-7), 1.37-1.19 (m, 20 H, H-8 to H-17), 0.91 (s, 9 H, TBStBu), 0.87 (t, 3 H, J = 6.8 Hz, H-18), 
0.08 (s, 6 H, TBSMe); 13C NMR (101 MHz, CDCl3)  δ  156.31  (C=OFmoc), 144.11, 144.01, 141.44 (x2) (4x Cq-Fmoc), 133.57 
(C-5), 129.32 (C-4), 127.82, 127.17, 125.22, 124.90, 120.11 (CHFmoc), 74.64 (C-3), 67.16 (CH2-Fmoc), 63.53 (C-1), 
54.97 (C-2), 47.34 (CHFmoc), 32.44, 32.06, 29.83, 29.80, 29.77, 29.65, 29.50, 29.35, 29.33 (11x CH2 C-6 to C-17), 
25.95 (TBStBu), 22.83 (CH2 C-6 to C-17), 18.26 (TBStBu-q), -5.47 (TBSMe); IR (neat): 3441, 2924, 2852, 1716, 1463, 
1263, 1089 cm-1; HRMS calculated for [C39H61NO4Si +H]+: 636.4450, found 636.4452. 
 (9H-fluoren-9-yl)methyl ((2S,3R,E)-1-(tert-butyldimethylsilyl)oxy)-3-((4-methoxybenzyl)oxy)octadec-4-en-2- 
yl)carbamate (22). Fully protected sphingosine 19 (50 mg, 0.09 mmol, 1 eq) 
was dissolved in dry DCM (0.5 mL), followed by addition of 1-pentadecene (47 
µL, 0.17 mmol, 2 eq) . To the reaction was added acetic acid (5 µL, 0.09 mmol, 
1 eq) and catalytic amount of Grubbs 2nd catalyst (7 mg, 0.009 mmol, 0.1 eq). 
The reaction mixture was stirred at 40 oC in closed vessel for 2 days. The resulting mixture was concentrated and 
purified by silica column chromatography (5% EtOAc in pentane) giving a brownish solid 22 (12 mg, 0.016 mmol 
18%). Rf = 0.75 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ  7.75  (d, 2 H, J = 7.6 Hz, HFmoc), 7.57 (d, 2 H, J = 
7.2 Hz, HFmoc), 7.38 (t, 2 H, J = 7.2 Hz, HFmoc), 7.29 (t, 2 H, J = 7.6 Hz, HFmoc), 7.21 (d, 2 H, J = 7.2 Hz, HPMB), 6.88 (d, 2 
H, J = 6.8 Hz, HPMB), 5.71 (dt, 1 H, J = 12.4, 6.4 Hz, H-5), 5.44 (dd, 1 H, J = 15.6, 8.4 Hz, H-4), 5.06 (d, 1 H, J = 9.2 Hz, 
NH), 4.53 (d, 1 H, J = 11.2 Hz, CH2-PMB-a), 4.30 (m, 2 H, CH2-Fmoc), 4.24-4.19 (m, 2 H, CHFmoc and CH2-PMB-b), 3.92 (dd, 1 
H, J = 10.0, 3.2 Hz, H-1a), 3.86 (m, 1 H, H-3), 3.82-3.74 (m, 4 H, OMePMB and H-2), 3.67 (dd, 1 H, J = 10.0, 4.0 Hz, H-
1b), 2.05 (m, 2 H, H-6), 1.34 (m, 2 H, H-7), 1.30-1.20 (m, 20 H, H-7 to H-17), 0.90 (s, 9 H, TBStBu), 0.88 (t, 3 H, J = 6.8 
Hz, H-18), 0.06 (s, 3 H, TBSMe), 0.05 (s, 3 H, TBSMe); 13C NMR (101 MHz, CDCl3)  δ  156.04  (C=OFmoc), 144.21, 144.05, 
141.38, 141.36 (4x Cq-Fmoc), 136.98 (C-5), 130.63 (Cq-PMB), 129.84, 127.73 (2x CHFmoc), 127.57 (C-4) 127.08, 1250.26 
(2x CHFmoc), 120.05, 113.75 (2x CHPMB), 79.09 (C-3), 70.00 (CH2-PMB), 66.92 (CH2-Fmoc), 61.64 (C-1), 55.54 (C-2), 55.34 
(OMePMB), 47.31 (CHFmoc), 32.46 (C-6), 32.05, 30.40, 29.81, 29.78, 29.61, 29.49, 29.37, 29.34, 28.01, (10x CH2 C-7 
to C-17), 25.97 (TBStBu), 18.38 (TBStBu-q), 14.26 (C-18), -5.27 (TBSMe), -5.35 (TBSMe); IR (neat): 3444, 2924, 2852, 
1726, 1450, 1264, 1082, 1056, 1037 cm-1;  HRMS calculated for [C47H69NO5Si + H]+; 765.5025, found 765.5023. 
 (9H-fluoren-9-yl)methyl ((2S,3R,E)-1-hydroxy-3-((4-methoxybenzyl)oxy)octadec-4-en-2- yl)carbamate (7). 
Fmoc-protected sphingosine 20 (1.95 g, 4.25 mmol, 1 eq) was dissolved in 20 mL 
DCM under protected atmosphere. 1-Pentadecene (2.3 mL, 8.5 mmol, 2 eq) and 
acetic acid (0.24 mL, 4.25 mmol, 1 eq) were added before addition of Grubbs 2nd 
catalyst (370 mg, 0.4 mmol, 0.1 eq). The mixture was stirred for 2 days at 40 oC. 
The reaction mixture was concentrated in vacuo and the crude residue was purified with silica gel 
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in pentane); 1H NMR (400 MHz, CDCl3)  δ  7.76  (d, 2 H, J = 7.7 Hz, HFmoc), 7.63 – 7.55 (m, 2 H, HFmoc), 7.40 (t, 2 H, J = 
8.2 Hz, HFmoc), 7.31 (t, 2 H,  J  8.4 Hz, HFmoc), 7.20 (md, 2 H,  J  = 8.4 Hz, HPMB), 6.84 (d, 2 H, J = 8.4 Hz, HPMB), 5.78 (m, 
1 H, H-5), 5.55 (d, 1H, J = 8.3 Hz, N-H), 5.46 (d, 1 H, J 15.4, 6.5, Hz, H-4), 4.56 (d, 1 H, J = 11.4 Hz, CH2-PMB-a), 4.34 
(m, 2 H, CH2-Fmoc), 4.24-4.18 (m, 2 H, CHFmoc and CH2-PMB-b), 4.07-3.97 (m, 2 H, H-1a and H-3), 3.74 (s, 3 H, OMePMB), 
3.71 – 3.60 (m, 2 H, H-1b and H-2), 2.08 (m, 2H, H6), 1.26-1.14 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 6.7 Hz, H-
18); 13C NMR (101 MHz, CDCl3)  δ  159.5 (C=OFmoc), 144.08, 141.45 (4x Cq-Fmoc), 137.16 (C-5), 129.88 (CHPMB), 127.83, 
127.19 (2x CHFmoc), 125.23 (C-4), 125.29, 120.08 (2x CHFmoc) 114.03 (CHPMB), 81.61 (C-3), 70.44 (CH2-PMB), 66.95 
(CH2-Fmoc), 62.19 (C-1), 55.36 (OMePMB), 55.35 (C-2) 47.35 (CHFmoc), 32.46 (C-6), 32.05, 29.83, 29.81, 29.79, 29.76, 
29.70, 29.58, 29.49, 29.43, 29.32, 29.22, 22.82 (11x CH2, C-7 to C-17), 14.26 (C-18); IR (neat): 3464 and 3325, 
2924, 2854, 1689, 1249, 1233 cm-1; HRMS calculated for [C41H55NO5 + H]+: 642.4160, found 642.4157. 
Glucosylsphingosine (23a). See general procedure for the glycosylation of protected sphingosine 7 with 
trichloro-imidate donor 5a. Yield (0.1 mg 0.082 mmol, 82%). Rf = 0.4 
(20% EtOAc in pentane); 1 H NMR (400 MHz, CDCl3) δ  8.05   – 7.70 
(m, 10 H, Harom), 7.56 –7.16 (m, 20 H, Harom), 6.81 (d, 2 H, J = 8.6 Hz, 
HPMB), 5.93 (t, 1 H, J =, 10.0 Hz, H-3’),  5.71  (t,  1  H,  J = 10.0 Hz, H-4’),  
5.54 (t, 1 H, J = 8.0 Hz, H-2’),  5.45  (m,  1  H,  H-5sp), 5.29 (m, 1 H, H-4sp), 4.89 (d, 1 H, J = 8.8 Hz, NHsp), 4.78 (d, 1 H, J 
= 8.0 Hz, H-1’),  4.64  (dd,  1  H,  J = 8.4, 2.8 Hz, CH2-PMB-a), 4.52 (m, 1 H, CH2-PMB-b), 4.43 (d, 1 H, J = 11.2 Hz, CH2-Fmoc-a), 
4.36-4.24, (m, 3 H, H-1sp-a, CH2-Fmoc-b and H-6’a), 4.15-4.04 (m, 2 H, H-5’  and  H-6’b), 3.83 (m, 1 H, H-2sp) 3.75-3.72 
(m, 4 H, H-3sp and OMePMB),3.69 (m, 1 H, H-1sp-b ), 1.92 (m, 2 H, H-6sp), 1.35-1.19 (m, 22 H, H-7sp to H-17sp), 0.88 (t, 
3 H, J = 6.8 Hz, H-18sp); 13C NMR (101 MHz, CDCl3)   δ   166.3,   165.9,   165.4,   165,3   (4x   C=0Bz), 155.89 (C=OFmoc), 
144.15, 144.00 141.42, 141.36 (4x Cq-Fmoc), 137.36 (C-5sp), 133.61, 133.45, 133.40, 133.25 (4x CHarom), 130.47 (Cq-
arom), 129.96, 129.94, 129.88, 129.85, 129.64, 129.61, 129.50, 129.11, 128.88, 128.57, 128.57, 128.50, 128.45, 
127.81, 127.79, 127,16 (CHarom and Cq-arom), 125.23 (C-4sp), 120.09 (CHFmoc), 113.84 (CHPMB), 101.69 (C-1’),  79.08  (C-
3sp), 72.82 (C-3’),  72.37 (C-2’  and  C-5’),  70.32  (CH2-PMB), 69.81 (C-4’),  68.55  (C-1sp), 66.67 (C-6’),  63.28  (CH2-Fmoc), 
55.33 (OMePMB), 53.86 (C-2sp), 47.33 (CHFmoc), 32.05 (C-6sp), 29.84, 29.81, 29.79, 29.58, 29.49, 29.33, 29.28, 22.82, 
22.82 (11x CH2,  C-7sp to C-17sp),  14.27 (C-18sp); IR (neat): 2925, 2856, 1721, 1690, 1250, 1231, 1089, 1066, 1025 
cm-1; HRMS calculated for [C75H81NO14 + H]+: 1220.5665, found 1220.5669. 
 [1,2,3,4,5,6-13C6]-Glucosylsphingosine (23b). See general procedure for the glycosylation of protected 
sphingosine 7 with trichloro-imidate donor 5b. Yield (51 mg 0.041 
mmol, 82%).  Rf = 0.4 (20% EtOAc in pentane); 1H NMR (13C-
decoupled, 400 MHz, CDCl3) δ 8.05 – 7.80 (m, 10 H, Harom), 7.59 –
7.22 (m, 20 H, Harom), 6.84 (d, 2 H, J = 8.4 Hz, HPMB), 5.93 (m, 1 H, H-
3’),  5.71  (m,  1  H,  H-4’),  5.54  (m,  1  H,  H-2’),  5.45  (m,  1  H,  H-5sp), 5.29 (m, 1 H, H-4sp), 4.93 (d, 1 H, J = 8.8 Hz, NHsp), 
4.78 (m, 1 H, H-1’),  4.64  (m,  1  H,  CH2-PMB-a), 4.52 (m, 1 H, CH2-PMB-b), 4.48 (d, 1 H, J = 11.2 Hz, CH2-Fmoc-a), 4.36-4.28, 
(m, 3 H, H-1sp-a, CH2-Fmoc-b and H-6’a), 4.13-4.08 (m, 2 H, H-5’  and  H-6’b), 3.83 (m, 1 H, H-2sp) 3.75-3.72 (m, 4 H, H-
3sp and OMePMB),3.69 (m, 1 H, H-1sp-b ), 1.92 (m, 2 H, H-6sp), 1.35-1.19 (m, 22 H, H-7sp to H-17sp), 0.88 (t, 3 H, J = 6.8 
Hz, H-18sp); 13C NMR (101 MHz, CDCl3)  δ 166.12, 165.84, 165.36, 165.16 (4x C=0Bz), ), 155.87 (C=OFmoc), 144.03, 
143.86 141.34, 141.15 (4x Cq-Fmoc), 137.04 (C-5sp), 133.59, 133.44, 133.38, 133.23 (4x CHarom), 130.44, 129.93, 
129.86, 129.83, 129.58, 129.48, 128.90, 128.86, 128.64, 128.55, 128.48, 128.43, 127.80, 127.77, 127.14 (CHarom 
and Cq-arom), 125.21 (C-4sp), 120.07 (CHFmoc), 113.82 (CHPMB), 101.40 (d, J = 41.0 Hz, C-1), 78.94 (C-3Sp), 74.22-71.83 
(m, C-2’  and  C-5’),  70.82-68.38 (m, C-4’,  CH2-PMB, C-1sp), 63.4 (d, J = 45 Hz, C-6’),  60.51  (CH2-Fmoc), 55.31 (OMePMB), 
54.34 (C-2Sp), 47.30 (CH2-Fmoc), 32.03 (C-6sp), 29.79, 29.77, 29.57, 29.47, 29.31, 29.26, 22.80, 21.16 (C-7sp to C-17sp), 
14.30 (C-18sp); IR (neat): 2925, 2856, 1721, 1690, 1250, 1231, 1089, 1066, 1025 cm-1; HRMS calculated for 






















Glucosylsphingosine (25a). General procedure for deprotection of protected glycosylsphingosine. Yield (30 mg, 
0.06 mmol, 80%). [α]D22: -5.0 (c = 0.1 MeOH); 1H NMR (600 MHz, 
MeOD-d4) δ  5.87  (dtd,  1  H,  J = 15.0, 6.8, 1.2 Hz, H-5Sp), 5.48 (ddt, 1 H, 
J = 15.4, 6.9, 1.5 Hz, H-4Sp), 4.33-4.29 (m, 2 H, H-1 and H-3Sp), 3.97-
3.88 (m, 3 H, H-6 and H-1a-Sp), 3.66 (m, 1 H, H-1b-Sp), 3.40-3.32 (m, 2 H, H-5 and H-2sp), 3.29-2.21 (m 3 H, H-2, H-3 
and H-4), 2.1 (q, 2 H, J = 7.2 Hz, H-6sp), 1.42 (m, 2 H, H-7sp), 1.36-1.22 (m, 20 H, H-8sp to H-17sp), 0.9 (t, 3 H, J = 7.0 
Hz, H-18Sp); 13C NMR: (151 MHz, MeD-d4) δ 136.8 (C-5Sp), 128.4 (C-4Sp), 104.1 (C-1), 78.1 (C-4), 77.9 (C-5), 74.8 (C-
3), 71.5 (C-2), 70.9 (C-3sp), 67.3 (C-6), 62.5 (C-1sp), 56.8 (C-2sp), 33.4 (C-6sp), 33.1, 30.82, 30.81 (2x), 30.78, 30.77, 
30.66, 30.50, 30.41, 30.18, 23.6 (11x CH2-Sp), 14.2 (C-18Sp); IR (neat): 3300, 2918, 2850, 1668, 1435, 1202, 1134, 
1074, 1026, 800, 721 cm-1; HRMS calculated for [C24H47NO7 + H]+: 462.3431, found 462.3424. 
 [1,2,3,4,5,6-13C6]-Glucosylsphingosine (25b). General procedure for deprotection of protected 
glycosylsphingosine. Yield (15 mg, 0.03 mmol, 78%). [α]D22: -4.8 (c = 
0.1 MeOH); 1H NMR (13C-decoupled, 400 MHz, MeOD-d4) δ 5.87 (m, 1 
H, H-5sp), 5.52 (m, 1 H, H-4sp), 4.31 (m, 2 H, H-1 and H-3sp), 4.05-3.82 
(m, 3 H, H-6, H-1-a-Sp), 3.69 (m 1 H, H-1b-Sp), 3.56-3.39 –(m, 2 H, H-5 
and H-2sp), 3.31-3.10 (m, 3 H, H-2, H-3, H-4), 2.10 (m, 2 H, H-6sp), 1.42 (m, 2 H, H-7sp), 1.38-1.22 (m, 20 H, H-8sp to 
H-17sp), 0.88 (m, 3 H, H-18sp); 13C NMR (101 MHz, MeOD-d4) δ 131.4 (C-5Sp), 128.7 (C-4Sp), 104.1 (d, J = 46.0 Hz, C-
1), 78.4-76.04 (m, C-4 and C-5), 74.7 (dd, J = 52.0, 45.0 Hz, C-3), 71.5 (m, C-2 and C-3sp), 67.3 (d, J = 43.0 Hz, C-6), 
62.5 (C-1sp), 56.8 (C-2sp), 33.0 (C-6sp), 30.75, 30.72 (3x), 30.78, 30.77, 30.60, 30.50, 30.43, 30.36, 23.7 (11x CH2-Sp), 
14.4 (C-18Sp) IR (neat): 3300, 2918, 2850, 1668, 1435, 1202, 1134, 1074, 1026, 800, 721 cm-1; IR (neat): 3300, 
2918, 2850, 1668, 1435, 1202, 1134, 1074, 1026, 800, 721 cm-1: HRMS calculated for [C1813C6H47NO7 + H]+: 
468.3005, found 468.2996. 
 6-deoxy-6-Azido-Glucosesphingosine (27). See general procedure for the glycosylation of protected sphingosine 
7 with trichloro-imidate donor 26. Yield (0.18 g, 0.16 mmol, 79%) Rf 
= 0.55 (20% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ  7.95-
7.89 (m 4 H, Harom), 7.85-7.76 (m, 4 H, Harom), 7.55-7.50 (m, 2 H, 
Harom), 7.45 (m, 15 H, Harom), 6.87 (d, 2 H, J = 8.8 Hz, HPMB), 5.90 (t, 1 
H, J = 10.4 Hz, H-3’),  5.53-5.44 (m, 3 H, H-5sp, H-2’  and  H-4’),  5.29  (dd,  1  H,  J = 15.2, 7.6 Hz, H-4sp), 4.86 (d, 1 H, J = 
8.8 Hz, NHsp), 4.76 (d, 1 H, J = 8.0 Hz, H-1’),  4.47  (d,  1  H,  J = 11.2 Hz, CH2-PMB-a), 4.32-4.25 (m, 3 H, CH2-PMB-b, H-1sp-a, 
CH2-Fmoc-a), 4.10-4.05 (m, 2 H, CH2-Fmoc-b and CHFmoc), 3.94 (m, 1 H, H-5’),  3.85-3.70 (m, 6 H, OMePMB, H-1sp-b, H-2sp 
and H-3sp), 3.53 (dd, J = 13.6, 8.8 Hz, H-6a’),  3.38  (d,  1  H,  J = 12.0 Hz, H-6b’),  1.90  (m,  2  H,  H-6sp), 1.33-1.19 (m, 22 
H, H-7sp to H-17sp), 0.88 (t, 3 H, J = 6.8 Hz, H-18sp); 13C NMR (101 MHz, CDCl3)  δ  165.82,  165.43,  165.27  (3x  C=OOBz), 
159.19 (C=OFmoc), 144.16, 144.00, 141.42, 141.37 (4x Cq-Fmoc), 137.39 (C-5sp), 133.81, 133.44 (CHarom), 130.54 (Cq-
arom), 129.98, 129.86, 129.69, 129.51, 129.04, 128.85, 128.66, 128.55, 128.45, 127.80, 127.15 (CHarom and Cq-arom), 
125.30 (C-4sp), 120.11, 120.08 (2x CHFmoc), 113.90, 113.83 (2x CHPMB), 101.39 (C-1’),   79.10   (C-3sp), 74.12 (C-5’),  
72.59 (C-3’),  72.14   (C-2’),  70.14   (C-4’),  70.15   (CH2-PMB), 68.44 (C-1sp), 66.61 (CH2-Fmoc), 55.37 (OMePMB), 53.83 (C-
2sp), 51.34 (C-6’),  47.33  (CHFmoc), 32.34 (C-6sp), 29.83, 29.81, 29.78, 29.57, 29.49, 29.33, 29.26, 27.83, 22.82 (11x 
CH2 C-7sp to C-17sp), 14.27 (C-18sp); ); IR (neat): 2925, 2856, 2104, 1721, 1690, 1250, 1231, 1089, 1066, 1025 cm-1;  
HRMS calculated for [C68H76N4O12 + H]+: 1141.5468, found 1141.5464. 
6-deoxy-6-Azido-Glucosesphingosine (28). General procedure for deprotection of protected glycosylsphingosine. 
Yield (25 mg, 0.06 mmol, 77%). 1H NMR (400 MHz, MeOD-d4) δ 5.84 
(dt, 1 H, J = 15.2, 7.6 Hz, H-5sp), 5.48 (dd, 1 H, J = 15.2, 6.8 Hz, H-4sp), 
4.36 (d, 1 H, J = 8.0 Hz, H-1’),  4.28  (t,  1  H,  J = 5.6 Hz, H-3sp), 3.99 (m, 1 
H, H-1a-sp), 3.82 (d, 1 H, J = 10.8 Hz, H-1b-sp), 3.54-3.24 (m, 7 H, H-2sp, 
H-2’,  H-3’,  H-4’  and  H-5’,  H-6’),  3.08  (m,  2  H,  H-6sp), 1.41 (m, 2 H, H-7sp), 1.36-1.28 (m, 20 H, H-8sp to H-17sp), 0.90 
(t, 3 H, J = 6.4 Hz, H-18sp); 13C NMR (101 MHz, MeOD-d4) δ 136.56 (C-5sp), 128.57 (C-4sp), 103.86 (C-1’),  77.54,  
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30.79, 30.76, 30.63, 30.47, 30.39, 30.16, 23.73 (11x CH2 C-7sp to C-17sp), 14.45 (C-18sp); IR (neat): 3300, 2917, 
2850 , 2100, 1668, 1434, 1201, 800, 721 cm-1; HRMS calculated for [C24H46N4O6 +H]+: 487.3497, found 487.3506.  
 Galactosylsphingosine (30).  See general procedure for the glycosylation of protected sphingosine 7 with 
trichloro-imidate donor 29. Yield (91 mg 0.075 mmol, 75%). Rf = 0.4 
(20% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ  8.09  (d,  2  H,  J = 
7.6 Hz, Harom-OBz), 8.02 (d, 2 H, J = 7.2 Hz, Harom-OBz), 7.99 (d, 2 H, J = 8.0 
Hz, Harom-OBz), 7.81-7.75 (m, 4 H, Harom), 7.61 (t, 1 H, J = 7.6 Hz, Harom), 
7.55-7.18 (m, 19 H, Harom), 6.83 (d, 2 H, J = 8.8 Hz, HPMB), 6.01 (m, 1 H, H-4’),  5.77  (dd,  1  H,  J = 10.4, 10.0 Hz, H-2’),  
5.62 (dd, 1 H, J = 10.4, 3.2 Hz, H-3’),  5.44  (dt,  1  H,  J = 15.6, 6.4 Hz, H-5sp), 5.27 (dd, 1 H, J = 16.4, 8.0 Hz, H-4sp), 
4.90 (d, 1 H, J = 8.8 Hz, NHsp), 4.75 (d, 1 H, J = 7.6 Hz, H-1’),  4.65  (dd,  1  H,  J = 11.2, 6.4 Hz, CH2-PMB), 4.48-4.43 (m, 2 
H, CH2-PMB, CH2-Fmoc-a), 4.37-4.27 (m, 4 H, CH2-Fmoc-b, H-1sp-a, H-5’  and  H-6a), 4.12-4.05 (m, 2 H, H-6b’   and  CHFmoc), 
3.83-3.70 (m, 6 H, OMePMB, H-1sp-b, H-2sp, H-3sp), 1.90 (m, 2 H, H-6sp), 1.37-1.20 (m, 22 H, H-7sp to H-17sp), 0.87 (t, 3 
H, J = 7.2 Hz, H-18sp); 13C NMR (101 MHz, CDCl3)  δ  166.15, 2x 165.64, 165.47 (4x C=OBz), 159.21 (C=0Fmoc), 144.13, 
143.95, 141.42, 141.37 (Cq-Fmoc), 137.32 (C-5sp), 133.71, 133.43 (CHarom), 130.50 (Cq-arom), 130.12, 129.89, 129.86, 
129.42, 129.14, 128.88, 128.77, 128.61, 128.58, 128.42, 127.79, 127.15 (CHarom and Cq-arom), 125.16 (C-4sp), 120.08 
(CHFmoc), 113.85 (CHPMB), 102.04 (C-1’),  79.09  (C-3sp), 71.63 (C-3’),  71.48  (C-5’),  70.28  (CH2-PMB), 70.20 (C-2sp), 68.61 
(C-1sp), 68.20 (C-4’),   66.54   (C-6’),   62.14   (CH2-Fmoc), 55.31 (OMePMB), 53.97 (C-2sp), 47.36 (CHFmoc), 32.35 (C-6sp), 
29.82, 29.78, 29.58, 29.33, 29.28, 22.82 (11x CH2 C-7sp to C-17sp), 14.26 (C-18sp). IR (neat): 2924, 2854, 1722, 
1689, 1249, 1233, 1091, 1066, 1026 cm-1; HRMS calculated for [C75H81NO14 + H]+: 1220.5665, found 1220.5671. 
 Galactosylsphingosine (31). General procedure for deprotection of protected glycosylsphingosine. Yield (25 mg, 
0.55 mmol, 74%). 1H NMR (400 MHz, MeOD-d4)  δ  5.97   (dd,  1  H,   J = 
15.6, 6.6 Hz, H-5), 5.69 (dd, 1 H, J = 15.4, 6.9 Hz, H-4), 4.32 (d, 1 H, J = 
7.6 Hz, H-1’),  4.09  (m,  1  H,  H-3), 3.96 (t, 1 H, J = 6.4 Hz, H-5) 3.89-3.86 
(m, 2 H, H-6’),  3.84-3.81 (m, 1 H, H-1a), 3.77-3.70 (m, 2 H, H-1b and H-
2), 3.58- 3.48 (m, 3 H, H-2’,  H-3’  and  H-4’),  2.05  (m,  2  H,  H-6), 1.48 (m, 2 H, H-7), 1.33-1.23 (m, 20 H, H-8 to H-17), 
0.90 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, MeOD-d4)  δ  141.73  (C-5), 123.06 (C-4), 104.42 (C-1’),  77.00  (C-
4’),  74.72  (C-3’),  72.46  (C-2’),  70.67  (C-6’),  70.34  (C-3), 62.67 (C-1), 54.07 (C-2), 33.07 (C-6), 30.79, 30.76, 30.47, 
26.52, 23.73 (11x CH2 C-7 to C-17), 14.44 (C-18); IR (neat): 3300, 2918, 2850, 1668, 1435, 1202, 1134, 1074, 1026, 
800, 721 cm-1; HRMS calculated for [C24H47NO7 + H]+: 462.3431, found 461.3425. 
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4.1 Introduction 
Chapter 2 described the synthesis of carbon-13-labeled glycosphingolipids.[1] Another class 
of functionalized sphingolipids are the phospholipids, metabolites often encountered 
together with glycosphingolipids. As well, the metabolism of both sphingolipid families is 
often interconnected.[2,3] Some major phosphosphingolipids encountered in mammalian 
cells, and their biosynthetic pathways starting from ceramide (1) are shown in Figure 4.1. 
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Ceramide kinase (CERK) catalyzes phosphorylation of ceramide (1), using ATP as 
phosphate source, to form ceramide-1-phosphate (C1P, 3). The reverse reaction, 
dephosphorylation of C1P (3) to give ceramide is catalyzed by ceramide-1-phosphate 
phosphatase (C1PP). Alternatively, acid ceramidase (ACase) may take on C1P (3) as 
substrate to produce, by hydrolysis of the amide bond and concomitant release of the 
fatty acid, sphingosine-1-phosphate 4 (S1P). S1P, an important signaling lipid, is normally 
produced from sphingosine (2) by sphingosine kinase (SK) mediated phosphorylation of 
the primary alcohol. Sphingosine-1-phosphate phosphatase (S1PP) in turn produces 
sphingosine 2 from S1P (4). 
 
Scheme 4.1 Partial overview of phosphosphingolipid metabolism in man. ACase: acid ceramidase; aSMase: acid 
sphingomyelinase; C1PP: ceramide-1-phosphate phosphatase; CERK: ceramide kinase; S1PP: sphingosine-1-
phosphate phosphatase; SAT: sphingosine acyl transferase; SMS: sphingomyelin synthase. 
Another occurring phosphosphingolipid is sphingomyelin (5), a zwitterionic species 
composed of ceramide, the primary alcohol of which carries a choline phosphate group. 
Sphingomyelin synthase (SMS) converts ceramide to sphingomyelin using 
phosphatidylcholine as the choline phosphate donor in a transesterification process. Acid 
sphingomyelinase (aSMase) hydrolyzes sphingomyelin to ceramide and phosphocholine. 
Inherited, genetic deficiency in aSMase leads to accumulation of sphingomyelin in the 
lysosomes. This deficiency is caused by mutation of SMPD1 gene, leading to the lysosomal 
storage disorders, Niemann-Pick disease A and B.[5] Carbon-13-labeled sphingomyelin 
would be an excellent tool to determine sphingomyelin levels[6] and to identify potential 
alternative metabolic pathways in these disorders.[7] It has recently become clear that the 
primary storage material in Niemann-Pick patients, sphingomyelin (5) may be processed 
by ACase to produce sphingosine-1-cholinephosphate (6) as a secondary storage 
material.[8] This situation resembles earlier findings in relation to Gaucher disease 
(processing of glucosylceramide – the primary storage material – into glucosylsphingosine) 
and Fabry disease (globotriaosylceramide as the primary storage material is partially 
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alike, these secondary storage lysolipids may contribute to development of the diseases.[9] 
As well, very recently it has become clear that glucosylsphingosine, likely produced 
through the action of ceramidase (ACase), hardly present in healthy individuals and 
markedly increased in Gaucher patients, can give rise to plasma cells producing antibodies 
elicited against these lysolipids. Plasma cells that in turn may transform into malignant 
cells that eventually lead to multiple myeloma.[10] A panel of carbon-13-labeled 
phosphosphingolipids would be highly useful tools to study biosynthesis and degradation 
pathways of these molecules in health and disease. The synthesis of such a stable isotope 
metabolite panel is described in this Chapter and builds on the research described in 
Chapter 2, specifically the synthesis of 13C-labeled, protected sphingosine as a common 
building block. 
4.2 Results and discussion 
Partially protected sphingosine 9a/b (Chapter 2),[1] with the primary alcohol free for 
modification, bearing protective groups compatible with phosphoramidite chemistry,[12-14] 
and incorporating either zero carbon-13 isotopes (9a) or five carbon-13 isotopes (9b) 
served as the starting point of the synthesic efforts. The required phosphorylating agent, 
phosphoramidite (8), was synthesized from 2-cyanoethyl N,N-
diisopropylchlorophosphoramidate 7 using 4-methoxy benzyl alcohol and  
Scheme 4.1 Synthesis of (13C5-labeled)  sphingosine 1-phosphate 13a/b and ceramide 1-phosphate 
14a/b. 
 
Reagents and conditions: (a) PMBOH, DIPEA, DCM, r.t., 1 h, 82%; (b) 8, tetrazole, MeCN, r.t., 1 h; (c) tBuOOH, r.t., 
30 min; (d) (i) DBU, r.t., 1 h; (ii) AcOH:H2O (2:1), r.t., 2 days; (e) NaOMe, MeOH, r.t., 3 days; (vi) TFA:DCM (1:1), 
r.t., 1 h, 13a: 68%, 13b: 76% (over four steps); (f) (i) BSA, r.t., 20 h; (ii) palmitoyl chloride, DIPEA, DCM, 0 0C to r.t., 
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DIPEA in dry DCM in 82% yield. Phosphoramidite 8 and protected sphingosine 9a/b were 
coupled using tetrazole as the activator, giving the corresponding phosphite triester 
10a/b, which was subsequently oxidized (treatment with tBuOOH) without intermediate 
work-up and purification to give fully protected sphingosine 1-phosphate 11a/b. 
Treatment with DBU led to removal of the 2-cyanoethyl group in the phosphotriester, 
after which treatment with mild acid (acetic acid in water) gave phosphate 12a/b. Finally, 
treatment with sodium methoxide in methanol, followed by treatment with TFA led to 
methanolysis of the benzoyl ester and removal of the N-Boc group, respectively, to yield 
the target phosphosphingolipids 13a/b. Purification of crude sphingosine-1-phosphate 
13a/b proved complicated due to insolubility in solvent systems normally used in either 
silica gel chromatography or reverse-phase HPLC. Dissolving crude 13a/b in boiling acetic 
acid followed by addition of water led to precipitation of the product.[12,14] The precipitate 
was filtered successively and washed with water (to remove salts), followed by organic 
solvents (MeOH, DCM, acetone and diethyl ether to remove remaining organic impurities), 
giving analytically pure sphingosine-1-phosphate 13a/b in 68% (13a) and 76% (13b) yield, 
respectively (for the same reason – insolubility in most organic solvents – NMR spectra of 
13a/b were recorded in deuterated acetic acid[14]). Besides the utility as internal standards 
for metabolomics applications, sphingosine-1-phosphates 13a/b also served as starting 
point to produce the corresponding ceramide-1-phosphates 14a/b. In the first instance, 
subjecting 13a/b to Schotten-Bauman conditions (reaction of the free amine in 13a/b with 
palmitoyl chloride) appeared an unsuitable strategy, again because the starting material 
does not dissolve in suitable solvent systems. Treatment of 13a/b with N,O-
bis(trimethylsilyl)acetamide (BSA – a strong trimethylsilylation reagent) followed by 
treatment with palmitoyl chloride and aqueous work-up (at which stage the intermediate 
trimethylsilyl protective groups are removed) gave ceramide-1-phosphates 14a/b as the 
DIPEA salt in good yields.[16] 
The synthesis of sphingosine-1-cholinephosphates 19a/b and sphingomyelins 20a/b 
followed strategies (see Scheme 4.2) essentially the same as for compounds 13a/b and 
14a/b, but now starting from phosphoramidite 15.[17,18] It was decided to introduce the 
choline moiety already in the phosphoramidite stage and not following the 
phosphorylation event, to avoid unnecessarily harsh conditions in later stages of the 
synthesis. Known literature procedures on the synthesis of phosphocholine moieties are 
based on either tosylate[17] or hexafluorphosphate[18] as counter-ions for the quaternary 
ammonium ion. However, ammonium salts composed of these cations are often poorly 
soluble in DCM. For this reason, tetraphenylborate was selected as the counter-ion. For 
the coupling with sphingosine 9a/b and phosphoramidite 15, tetrazole activation (see 
Scheme 4.2) conditions were used, but the solvent was switched from DCM to MeCN. 
After confirming the formation of phosphite trimester 16a/b (31P NMR: 140 ppm), tBuOOH 
was added to oxidize the phosphite triester 16a/b forming 17a/b. 
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Scheme 4.2 Synthesis of (13C5-labeled) sphingosine 1-cholinephosphate 19a/b and sphingomyelins 20a/b. 
Reagents and conditions: (a) choline tetraphenylborane, diisopropylammonium tetrazolide DCM:MeCN (2:1), 
r.t., 2 h, quant; (b) 15, tetrazole, MeCN, r.t., 1 h; (c) tBuOOH, r.t., 30 min.; (d) DBU, r.t., 1 h; (e) (i) NaOMe, MeOH, 
r.t., 3 days; (ii) TFA:DCM (1:1), r.t., 1 h, 19a: 59%, 19b: 56% (four steps); (f) (i) BSA, r.t., 20 h; (ii) palmitoyl 
chloride, DIPEA, DCM, 0 oC to r.t., 2 h, 20a: 61%, 20b: 66%. 
The fully protected sphingosine-1-cholinephosphate 17a/b was deprotected, by first 
removing the protecting group on the choline phosphate (2-cyanoethyl) (DBU) giving the 
zwitter-ionic sphingosine 18a/b. Next, the sphingosine part was deprotected. To this end 
the benzoyl was removed using NaOMe in methanol, followed by acid treatment (TFA) to 
deprotect the amine giving crude sphingosine 1-choline phosphate 19a/b. Due to the 
better solubility compared to sphingosine 1-phosphate 13a/b, the crude mixture was 
purified by HPLC-MS giving the pure zwitter-ionic sphingosines 19a/b. Schotten-Bauman 
conditions were tried to get the corresponding ceramides 20a/b. Unfortunately, these 
conditions were not suitable to acylate the amine. Therefore the same conditions as 
described for the acylation of sphingosine-1-phosphate were applied giving after silica gel 
chromatography the corresponding sphingomyelin 20a/b in a yield of 61-66%.[13] 
4.3 Conclusion 
The synthesis of a comprehensive set of carbon-13-labeled phosphosphingolipids, 
together with their non-isotopically-enriched form, is described in this Chapter. The 
synthesic strategy is based on phosphoramidite chemistry to install either a phosphate (as 
in 11a/b) or a choline phosphate (13a/b). The strategy proved successful, but measures 
needed to be taken to deal with solubility issues in both syntheses. With these carbon-13-
labeled phosphosphingolipids in hand, improved mass spectrometric procedures can be 
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giving better understanding of the metabolism of phosphosphingolipids.[6] For the 
synthetic procedure that was developed, new phosphorylating agents were introduced. 
With the new phosphorylation reagents 8 and 15 it is possible to introduce 
(choline)phosphate diesters under mild conditions and in high yield.  
4.4 Experimental Section 
General Remarks: [13C2]-acetic acid (99.95% isotopically pure, product code CLM-105), potassium [13C]-cyanide 
(99% isotopically pure, product code CLM-297), and [1,2,3-13C3]-myristic acid (99% isotopically pure, product 
code CLM-3665) were purchased from Cambridge Isotope Laboratories, Inc., and were used as received. 
Commercially available reagents and solvents (Acros, Fluka, or Merck) were used as received, stated otherwise 
stated. CH2Cl2 and THF were freshly distilled before use, over P2O5 and Na/benzophenone, respectively. 
Triethylamine was distilled from calcium hydride and stored over potassium hydroxide. Traces of water were 
removed from starting compounds by coevaporation with toluene. All moisture-sensitive reactions were carried 
out under an argon atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column chromatography 
was carried out using airflow of the indicated solvent systems on Screening Devices Silica gel 60 (40–63   μm  
mesh). Size-exclusion chromatography was carried out on Sephadex LH20 (MeOH/CH2Cl2, 1:1). Analytical TLC 
 was carried out on aluminum sheets (Merck, silica gel 60, F254). Compounds were visualized by UV absorption 
(254 nm), or by spraying with ammonium molybdate/cerium sulphate solution [(NH4)6Mo7O24·4H2O (25 g/L), 
(NH4)4Ce(SO4)6·2H2O (10 g/L), 10 % sulphuric acid in ethanol] or phosphormolybdic acid in EtOH (150 g/L), 
followed by charring (ca. 150 °C). IR spectra were recorded with a Shimadzu FTIR-8300 instrument and are 
reported in cm–1. Optical rotations were measured with a Propol automatic polarimeter (sodium D-line, λ  = 589 
nm). 1H and 13C NMR spectra were recorded with a Bruker AV 400 MHz spectrometer at 400.2 (1H) and 100.6 
(13C) MHz, or with a Bruker AV 600 MHz spectrometer at 600.0 (1H) and 151.1 (13C) MHz. Chemical shifts are 
reported as δ  values (ppm), and were referenced to tetramethylsilane  (δ  =  0.00  ppm)  directly in CDCl3, or using 
the residual solvent peak (D2O). Coupling constants (J) are given in Hz, and all 13C spectra were proton decoupled. 
NMR assignments were made using COSY and HSQC, and in some cases TOCSY experiments. LC–MS analysis was 
carried out with an LCQ Advantage Max (Thermo Finnigan) instrument equipped with a Gemini C18 column 
(Phenomenex, 50, 4.6  mm,  3  μm),  using   the   following buffers: A: H2O, B: acetonitrile, and C: aq. TFA (1.0 %). 
HPLC–MS purifications were carried out with an Agilent Technologies 1200 Series automated HPLC system with a 
Quadrupole MS 6130, equipped with a semi-preparative Gemini C18 column (Phe-nomenex, 250 10.00, 5μm). 
Products were eluted using the following buffers: A: aq. TFA (0.2 %), B: acetonitrile (HPLC-grade), 5 mL/min. 
Purified products were lyophilized with a CHRIST ALPHA 2–4 LDPLUS apparatus to remove water and traces of 
buffer salts. 
4-methoxybenzyl-2-cyanoethyl N,N-diisopropylphosphoramidate (8). 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidate 7 (0.89 mL, 4.0 mmol, 1.0 eq) was dissolved in dry 
DCM (12 mL) under protected atmosphere and DIPEA (1.04 mL, 6.0 mmol, 1.5 eq) was 
added, followed by the addition of 4-methoxybenzyl alcohol (0.5 mL, 4.0 mmol, 1 eq). The 
reaction was stirred at room temperature for 1 hour. The reaction mixture was then 
transferred to an extraction funnel with EtOAc (100 mL) and washed twice with sat. aq. NaHCO3 (100 mL) and 
brine (100 mL). The aqueous layers were extracted with EtOAc (100 mL) and the combined organics dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography (10% DCM, 1% NEt3, in 
pentane to 10% DCM, 10% EtOAc, 1% NEt3, in pentane) giving titled compound 8 as a clear oil (1.11 g, 3.28 mmol, 
82%). Rf = 0.2 (10% DCM, 10% EtOAc, 1% NEt3, in pentane); 1H NMR (400 MHz, CDCl3) δ 7.27 (d, 2 H, J = 4.4 Hz, 2x 
HPMB), 6.87 (d, 2 H, J = 4.4 Hz, 2x HPMB), 4.69 (dd, 1 H, J  = 9.0, 8.4 Hz, CH2-PMB-a), 4.60 (dd, 1 H, J = 9.2, 9.0 Hz, CH2-
PMB-b), 3.83 (m, 2 H, -OCH2-, 3.81 (s, 3 H, OMePMB), 3.60 (m, 2 H, 2x CHdiisopropyl), 2.61 (t, 2 H, J = 6.4 Hz, -CH2-CN), 
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PMB), 117.7 (CN), 113.8 (CHarom-PMB), 65.2 (d, J = 1.8 Hz, CH2-PMB), 58.4 (d, J = 1.9 Hz, CH2-OCE), 55.3 (OMe-PMN), 43.2, 
43.1 (2x CHDiisopropyl), 24.72, 24.65, 24.62, 24.55 (4x CH3-Diisopropyl), 20.3 (CH2CN); 13P NMR (162 MHz, CDCl3) δ 148.5. 
 
1-Phosphate-Sphingosine (13a). Sphingosine acceptor (9a) (50 mg, 0.1 mmol, 1.0 eq) was co-evaporated twice in 
toluene (2.5 mL) and then dissolved in anhydrous MeCN (4 mL) under 
protected atmosphere. 2-Cyanoethoxy-diisopropylamino-4-methoxy-
benzyloxy-phosphine  8 (40 mg, 0.12 mmol, 1.2 eq) was added 
followed by the addition of 4,5-dicyanoimidazole (23.6 mg, 0.2 mmol, 
2.0 eq). The reaction was stirred until TLC showed complete conversion of the sphingosine acceptor 9a (~1 hour) 
and with 31P NMR (140 ppm). Anhydrous t-BuOOH (~5.5 M in nonane) (91 µL, 0.5 mmol, 5.0 eq) was added and 
the reaction was stirred (~30 minutes) at room temperature until 31P NMR (-1.7 ppm) showed full conversion. 
DBU (76 µL, 0.5 mmol, 5.0 eq) was added and stirred (~1 hour) at room temperature until HPLC-MS showed full 
removal of 2-Cyanoethoxy group. The reaction was concentrated in vacuo and coevaporated twice with toluene 
(20 mL). The crude reaction mixture was then dissolved in AcOH:H2O (95:5) (5 mL) and stirred (~2 days) at room 
temperature until LC-MS showed full removing of 4-methoxy-benzyloxy group. The crude reaction mixture was 
concentrated in vacuo and coevaporated twice with toluene (10 mL). The residu was dissolved in methanol (2.5 
mL) and sodium methoxide (30% in methanol) (0.26 mL, 2.0 mmol, 20 eq) was added. The reaction was stirred 
for 3 days at room temperature and the progression of the reaction was followed by HPLC-MS. The reaction was 
neutralized with Amberlite H+ resin and the reaction mixture was filtered and concentrated in vacuo. The crude 
reaction mixture was coevaporated in toluene (10 mL) and put on ice-bath before addition of DCM (1 mL) and 
TFA (1 mL). The reaction mixture was stirred for 5 minutes at 0°C. The solution was diluted with toluene (10 mL) 
and concentrated to about 2 mL in vacuo. The coevaporation was repeted two times with toluene (10 mL), 
before concentration to dryness. The residue was dissolved in hot galcial acetic acid followed by addition of 
water. The precipitate was filtered and washed with water, acetone and diethylether giving pure sphingosine-1-
phosphate 13a as white powder (29 mg, 0.07 mmol, 76% ). 1H NMR (600 MHz, Acetic acid-d3) δ 5.92 (dt, 1 H, J = 
14.3, 6.7 Hz, H-5), 5.55 (dd, 1 H, J = 15.5, 7.0 Hz, H-4), 4.50 (t, 1 H, J = 6.1 Hz, H-3), 4.25 (m, 2 H, H-1), 3.70 (m, 1 H, 
H-2), 2.09 (q, 2 H, J = 7.5 Hz, H-6), 1.41 (m, 2 H, H-7), 1.36-1.23 (m, 20 H, H-8 to H-17), 0.89 (t, 3 H, J = 7.2 Hz, H-
18); 13C NMR (151 MHz, Acetic acid-d3) δ 137.6 (C-5), 126.8 (C-4), 70.7 (C-3), 62.8 (C-1), 57.2 (C-2), 33.6 (C-6), 
32.7, 30.58, 30.56 x3, 30.52, 30.51, 30.42, 30.23, 30.16, 29.68, 23.47 (11x CH2 C-7 to C-17), 14.4 (C-18); 31P NMR 
(162 MHz, Acetic acid-d3) δ -0.51; IR (neat): 3427, 2950, 2847, 1634, 1543, 1460, 1246, 1066, 1029, 925 cm-1; 
HRMS calculated for [C18H38NO5P + H]+: 380.2568, found 380.2575. 
 
1-Phosphate-[5,6,7,8,9-13C5]-sphingosine (13b). Sphingosine acceptor (9b) (35 mg, 69 µmol, 1.0 eq) was co-
evaporated twice in toluene (2.5 mL) and then dissolved in anhydrous 
MeCN (3 mL) under protected atmosphere. 2-Cyanoethoxy-
diisopropylamino-4-methoxy-benzyloxy-phosphine 8 (28 mg, 83µmol, 
1.2 eq) was added followed by the addition of 4,5-dicyanoimidazole 
(16.2 mg, 0.14 mmol, 2.0 eq). The reaction was stirred until TLC showed complete conversion of the sphingosine 
acceptor (~1 hours) and with 31P NMR (140 ppm). Anhydrous t-BuOOH (~5.5 M in nonane) (63 µL, 0.35 mmol, 5.0 
eq) was added and the reaction was stirred (~30 minutes) at room temperature until 31P NMR (-1.7 ppm) showed 
full conversion. DBU (52 µL, 0.34 mmol, 5.0 eq) was added and stirred (~1 hour) at room temperature until HPLC-
MS showed full removing of 2-Cyanoethoxy group. The reaction was concentrated in vacuo and coevaporated 
twice with toluene (20 mL). The crude reaction mixture was then dissolved in AcOH:H2O (95:5) (4 mL) and stirred 
(~2 days) at room temperature until HPLCS-MS showed full removing of 4-methoxy-benzyloxy group. The crude 
reaction mixture was concentrated in vacuo and coevaporated twice with toluene (10 mL). The residu was 
dissolved in methanol (2.0 mL) and sodium methoxide (30% in methanol) (0.18 mL, 1.4 mmol, 20 eq) was added. 
The reaction was stirred for 3 days at room temperature and the progression of the reaction was followed by 
HPLC-MS. The reaction was neutralized with Amberlist H+ resin and the reaction mixture was filtered and 
concentrated in vacuo. The crude reaction mixture was coevaporated in toluene (10 mL) and put on ice-bath 















solution was diluted with toluene (10 mL) and concentrated to about 2 mL in vacuo. The coevaporation was 
repeted two times with toluene (10 mL), before concentration to dryness. The residue was dissolved in hot 
galcial acetic acid followed by addition of water. The precipitate was filtered and washed with water, acetone 
and diethylether giving pure sphingosine-1-phosphate as white powder (20 mg, 0.05 mmol, 76%). 1H NMR (600 
MHz, Acetic acid-d3) δ 5.91 (dm, 1 H, J = 152.9 Hz, H-5, 13C), 5.55 (m, 1 H, H-4), 4.49 (q, 1 H, J = 5.4 Hz, H-3), 4.25 
(m, 2 H, H-1), 3.70 (m, 1 H, H-2), 2.09 (dm, 2 H, J = 126.9 Hz, H-6, 13C), 1.56-1.13 (m, 22 H, H-7 to H-17, 3x 13C), 
0.89 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (150 MHz, Acetic acid-d3) δ 137.7 (d, J = 45.0 Hz, C-5, 13C), 128.5 (dd, J = 
72.4, 3.5 Hz C-4), 70.8 (d, J = 5.1 Hz, C-3), 62.8 (C-2), 57.2 (C-1), 33.1 (dd, J = 42.4, 32.3 Hz, C-6, 13C), 30.8-29.2 (m, 
10x CH2, 3x 13C), 23.5 (CH2), 14.3 (C-18); 31P NMR (Acetic acid-d3) δ - 0.51; IR (neat): 3428, 2949, 2847, 1634, 1542, 
1460, 1246, 1066, 1029, 925 cm-1. HRMS calculated for [C1313C5H38NO5P + H]+: 385.2213, found 385.2215.  
 
Ceramide-1-phosphate (DIPEA salt) (14a). Sphingosine 13a (9 mg, 0.025 mmol, 1 eq) was mixed with BSA (0.3 
mL) under protected atmosphere and stirred overnight at room 
temperature. The mixture was concentrated in high vacuum and the 
silylated phosphosphingosine was dissolved in dry DCM (0.3 mL) 
under a protected atmosphere and cooled to 0 oC. To the solution 
was added DIPEA (13 µL, 0.075 mmol, 3.0 eq) followed by palmitoyl 
chloride (9 µL ,0.03 mmol, 1.2 eq). The reaction was left stirring, 
reaching room temperatue over 2 h. The reaction mixture was then concentrated in vacuo and the residue was 
dissolved in a small amount of MeOH/DCM. Precipitated with acetone gaves ceramide-1-phosphate 14a (12 mg, 
0.02 mmol, 79%). 1H NMR (600 MHz, MeOD-d4) δ 5.70 (dt, 1 H, J = 15.6, 8.4 Hz, H-5),  5.45 (dd, 1 H, J = 15.0, 8.8 
Hz, H-4), 4.18 (m, 1 H, H-1a), 4.10 (t, 1 H, J = 7.2 Hz, H-3), 3.95-3.92 (m 2 H, H-1b and H-2), 3.68 (m, 1 H, DIPEA), 
3.17 (m, 2 H, DIPEA), 2.18 (m, 2 H, H-2*), 2.02 (m, 2 H, H-6), 1.58 (m, 2 H, H-7), 1.38-1.28 (m, 48 H, H-8 to H-17, 
H-3* to H-15* and DIPEA), 0.89 (t, 6 H, J = 7.2 Hz, H-18 and H-16*); 13C NMR (150 MHz, MeOD-d4) δ 175.9 (C=O), 
134.9 (C-5), 130.9 (C-4), 72.3 (C-3), 65.4 (C-1), 55.7 (C-2), 55.2 (CH, DIPEA), 37.3 (C-2*), 43.67 (CH2 DIPEA), 33.4, 
33.0, 30.76, 30.72 x7, 30.71, 30.69 x3, 30.68, 30.67, 30.65, 30.59, 30.52, 30.39, 30.37, 30.35, 30.35, 30.31, 27.03, 
(25x CH2 C-6 to C17 and C-3* to C-15*), 18.7, 17.2 (CH3 DIPEA), 14.4 (C-18 and C-16*); 31P NMR (162 MHz, MeOD-
d4) δ -0.53; IR (neat): IR (neat): 3429, 2916, 2847, 1738, 1633, 1543, 1460, 1247, 1065, 1029, 925 cm-1; HRMS 
Calculated for [C34H68NO6P + H]+: 618.4864, found 618.4865. 
 
1-Phosphate-2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (14b).  Sphingosine 13b (12 mg, 0.03 mmol, 1 eq) 
was mixted with BSA (0.4 mL) under protected atmosphere and 
stirred over night at room temperature. The mixture was 
concentrated under high vacuum and the silylated 
phosphosphingosine was dissolved in dry DCM (0.4 mL) under a 
protected atmosphere and cooled to 0 oC. To the solution was added 
DIPEA (16 µL, 0.1 mmol, 3.0 eq) followed by palmitoyl chloride (12 µL ,0.04 mmol, 1.2 eq). The reaction was left 
stirring, reaching room temperatue over 2 h. The reaction mixture was then concentrated in vacuo and the 
residue was dissolved in a small amount of MeOH/DCM and precipitated with acetone gaves 1-phosphate-
ceramide 14b (16 mg, 0.03 mmol, 81%); 1H NMR (600 MHz, MeOD-d4) δ 5.66 (dm, 1 H, J = 156 Hz, H-5), 5.44 (m, 1 
H, H-4), 4.18 (m, 1 H, H-1a), 4.09 (m, H-3), 3.94-3.91 (m, 2 H, H-1b and H-2), 3.68 (m, 1 H, DIPEA), 3.17 (m, 2 H, 
DIPEA), 2.17 (t, 2 H, J  = 7.2 Hz, H-2*), 2.01 (dm, 2 H, J = 126.0 Hz, H-6), 1.57-1.17 (m, 48 H, H-7 to H-17, H-3* to 
H-15* and DIPEA),), 0.88 (t, 6 H, J = 6.6 Hz, H-18 and H-16*); 13C NMR (150 MHz, MeOD-d4) δ 175.6 (C=O), 135.9 
(d, J = 42.0 Hz, C-5), 130. 4 (d, J = 72.0 Hz, C-4), 72.1 (d, J = 4.5 Hz, C-3), 65.3 (d, J = 4.5 Hz, H-1), 55.4 (C-2), 37.1 
(C-2*), 33.5-32.9 (m) 30.6-29.8 (m), 26.8 (25x CH2 C-6 to C-17 and C-3* to C15*), 18.7, 17.2 (CH3 DIPEA),  14.4 (C-
18 and C-16*); 13P NMR (162 MHz, MeOD-d4) δ -0.51; IR (neat): 3430, 2914, 2847, 1726, 1636, 1543, 1458, 1246, 
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Choline-2-cyanoethyl N,N-diisopropylphosporamidate tetraphenylborate (15). 2-cyanoethyl N,N,N,N’-
tetraisoproppylphosphordiamidite 7 (0.30 g, 1.0 mmol, 1.0 eq) was dissolved in 
DCM:MeCN (2:1, 3 mL) under protected atmosphere and diisopropyl ammonium 
tetrazolide (0.17 g, 0.5 mmol, 0.5 eq) was added. Choline tetraphenylborate (0.42 g, 
1.0 mmol, 1.0 eq)[19] was added and the reaction was stirred at room temperature for 
2 hours. The reaction mixture was diluted with DCM (10 mL) and was washed twice with sat. aq. NaHCO3 (10 mL). 
The aqoeous layers were extracted with DCM (10 mL) and the combined organics dried (Na2SO4), filtered and 
concentrated in vacuo giving a brownish solid which is used without further purification. 1H NMR (400 MHz, 
CDCl3) δ 7.54-7.45 (m, 8 H, Harom), 7.04 ( t, 8 H. J = 7.6 Hz, Harom), 6.88 (t, 4 H, J = 7.2 Hz, Harom), 3.70, (m, 1 H, -
OCH2-a-OCE), 3.56 (m, 1 H, -OCH2-b-OCE), 3.50 (m, 2 H, 2x CHdiisopropyl), 3.24 (m, 2 H, -OCH2-choline), 2.44 (t, 2 H, J = 6.0 
Hz, -CH2CN), 1.71 (m, 2 H, -CH2NMe3), 1.66 (s, 9 H, 3x Mecholine), 1.17, 1.15, 1.14, 1.13 (4x s, 3 H, CH3-diisopropyl); 13C 
NMR (100 MHz, CDCl3) δ 165.3, 164.8, 164.3, 163.8 (4x Cq-arom), 136.2 (CHarom), 126.1 (CHarom), 122.1 (CHarom), 
118.0 (CN), 65.5 (-CH2CN), 58.0 (-OCH2-OCE), 57.7 (-OCH2-choline), 53.2, (3x CH3-choline), 43.4, 43.4, (2x CHisopropyl), 24.8, 
2x 24.71, 24.64 (4x CH3-isopropyl), 20.4 (-CH2CN); 31P (162 MHz, CDCl3) δ 148.1.  
 
Sphingosine-1-cholinephosphate (19a) Sphingosine acceptor (9a) (0.213 g, 0.42 mmol, 1.0 eq) was co-
evaporated twice in toluene (10 mL) and then dissolved in 
anhydrous MeCN (17 mL) under protected atmosphere. 2- 
Choline-2-cyanoethyl N,N-diisopropylphosporamidate 
tetraphenylborate (15) (530 mg, 0.85 mmol, 2.0 eq) was added 
followed by the addition of tetrazole (0.45 M in MeCN) (0.93 mL, 0.42 mmol, 1.0 eq). The reaction was stirred 
until TLC showed complete conversion of the sphingosine acceptor (~2 hours). Anhydrous t-BuOOH (~5.5 M in 
nonane) (0.38 mL, 2.10 mmol, 5.0 eq) was added and the reaction was stirred (~ 30 minutes) at room 
temperature until 31P NMR showed full conversion. DBU (0.31 mL, 2.10 mmol, 5.0 eq) was added and stirred (~ 1 
hour) at room temperature until HPLC-MS showed full removal of 2-cyanoethoxy group. The reaction was 
concentrated in vacuo and coevaporated twice with toluene (20 mL). The crude reaction mixture was then 
dissolved in methanol (10 mL) and sodium methoxide (30% in methanol) (1.1 mL, 8.4 mmol, 20 eq) was added. 
The reaction was stirred for 3 days at room temperature and the progression of the reaction was followed by 
HPLC-MS. The reaction was neutralized with Amberlite H+ resin and the reaction mixture was filtered and 
concentrated in vacuo. The crude reaction mixture was coevaporated in toluene (10 mL) and put on ice-bath 
before addition of DCM (5 mL) and TFA (5 mL). The reaction mixture was stirred for 5 minutes at 0°C. The 
solution was diluted with toluene (50 mL) and concentrated to about 10 mL in vacuo. The coevaporation was 
repeted two times with toluene (40 mL), before concentration to dryness. The reaction progess was monitored 
by HPLC-MS and purified with HPLC-MS as well yielding 19a (0.11 g, 0.25 mmol, 59%). 1H NMR (600 MHz, MeOD-
d4)  δ  5.89  (dt,  1  H,  J = 15.2, 6.7 Hz, H-5), 5.49 (dd, 1 H, J = 15.2, 6.9 Hz, H-4), 4.29 (m, 3 H, H-3 and CH2-Choline), 4.12 
(m, 1 H, H-1a), 4.03 (m, 1 H, H-1b), 3.65 (m, 2 H, CH2-Choline), 3.37 (m, 1 H, H-2), 3.23 (s, 9 H, CH3-Choline), 2.11 (q, 2 H, 
J = 7.5 Hz, H-6), 1.43 (m, 2 H, H-7), 1.37-1.20 (m, 20 H, H-8 to H-17), 0.89 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR(151 
MHz, MeOD-d4)  δ  137.2  (C-5), 128.2 C-4), 70.7 (C-3), 67.4 (m, CH2-Choline), 63.6 (d, J = 5.1 Hz, C-1), 60.6 (d, J = 5.0 
Hz, CH2-Choline), 57.2 (d, J = 7.2 Hz, C-2), 55.2 (CH, DIPEA),  54.6 (CH3-Choline x3), 43.67 (CH2 DIPEA),  33.4 (C-6), 33.1, 
30.80 x4, 30.76, 30.74, 30.47, 30.44, 30.16, 23.7 (CH2 C-7 to C-17), 14.4 (C-18); 31P NMR (162 MHz, MeOD-d4) δ  -
0.37; IR (neat): 3429, 2948, 2846, 1635, 1541, 1461, 1248, 1067, 1030, 928 cm-1; HRMS calculated for 
[C23H49N2O5P +H]+: 465.3459, found 465.3475. 
 
 [5,6,7,8,9-13C5]-Sphingosine-1-cholinephosphate (19b). 13C5-Sphingosine acceptor (9b) (50 mg, 98 µmol, 1.0 eq) 
was co-evaporated twice in toluene (5 mL) and then dissolved 
in anhydrous MeCN (4 mL) under protected atmsophere. 2-
Cyanoethoxy-diisopropylamino-2-trimethylammonium-ethoxy-
phosphine 15 (125 mg, 0.2 mmol, 2.0 eq) was added followed 
by the addition of tetrazole (0.45 M in MeCN) (0.22 mL, 0.1 mmol, 1.0 eq). The reaction was stirred until TLC 























µL, 0.5 mmol, 5.0 eq) was added and the reaction was stirred (~ 30 minutes) at room temperature until 31P NMR 
showed full conversion. DBU (73 µL,  0.5 mmol, 5.0 eq) was added and stirred (~ 1 hour) at room temperature 
until HPLC-MS showed full removal of 2-cyanoethoxy group. The reaction was concentrated in vacuo and 
coevaporated twice with toluene (5 mL). The crude reaction mixture was then dissolved in methanol (2.5 mL) 
and sodium methoxide (30% in methanol) (0.26 mL, 2.0 mmol, 20 eq) was added. The reaction was stirred for 3 
days at room temperature and the progression of the reaction was followed by HPLC-MS. The reaction was 
neutralized with Amberlite H+ resin and the reaction mixture was filtered and concentrated in vacuo. The crude 
reaction mixture was coevaporated in toluene (2.5 mL) and put on ice-bath before addition of DCM (1 mL) and 
TFA (1 mL). The reaction mixture was stirred for 5 minutes at 0°C. The solution was diluted with toluene (10 mL) 
and concentrated to about 2 mL in vacuo. The coevaporation was repeted two times with toluene (10 mL), 
before concentration to dryness. The completion of the reaction was confirmed as well purified by HPLC-MS 
producing [5,6,7,8,9,-13C5]-sphingsine-1-cholinephosphate  19b (25 mg, 55 µmol, 56%). 1H NMR (600 MHz, 
MeOD-d4) δ  5.89  (dm,  1  H,  J = 151.0 Hz, H-5), 5.49 (m, 1 H, H-4), 4.30 (m, 3 H, H-3 and CH2-Choline), 4.13 (m, 1 H, H-
1a), 4.04 (m, 1 H, H-1b), 3.66 (m, 2 H, CH2-Choline), 3.37 (m, 1 H, H-2), 3.23 (s, 9 H, CH3-Choline x3), 2.11 (dm, 2 H, J = 
126.7 Hz, H-6), 1.57-1.15 (m, 22 H, H-7 to H-17), 0.90 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (151 MHz, MeOD-d4) 
137.1 (d, J = 42.6 Hz, C-5), 128.2 (d, J = 72.0 Hz, C-4), 70.7 (d, J = 5.3 Hz, C-3), 67.4 (m, CH2-Choline), 63.4 (d, J = 5.1 
Hz, C-1), 60.6 (d, J = 5.0 Hz, CH2-Choline), 57.2 (d, J = 7.2 Hz, C-2), 54.7 (CH3-Choline x3), 33.8 – 32.9 (m, C-6Sp and CH2-Sp), 
30.9 – 29.8 (m, CH2-Sp x10), 23.7 (CH2-Sp),  14.4 (C-18Sp); 31P NMR (162 MHz, MeOD-d4)  δ  -0.51; IR (neat): 3429, 
2948, 2846, 1635, 1541, 1461, 1248, 1067, 1030, 928 cm-1; HRMS Calculated for [C23H49N2O5P +H]+: 470.3104, 
found 465.3475 
 
Sphingomyelin (20a) . Sphingosine 19a (15 mg, 0.032 mmol, 1 eq) was mixed with BSA (0.4 mL) under protected 
atmospere and stirred overnight at room temperature. The 
mixture was concentrated in high vacuum and the silylated 
phosphosphingosine was dissolved in dry DCM (0.4 mL) under a 
protected atmosphere and cooled to 0 oC. To the solution was 
added DIPEA (17 µL, 0.096 mmol, 3.0 eq) followed by palmitoyl 
chloride (12 µL ,0.04 mmol, 1.2 eq). The reaction was left stirring, reaching room temperature over 2 h. The 
reaction mixture was then concentrated in vacuo and product was purified by silica column chromatography (9:1 
Chloroform/MeOH to 70:27:3 Chloroform:MeOH:H2O) giving  the titeld product 20a as white solid (14 mg, 0.02 
mmol, 61%). Rf = 0.18 (70:27:3 Chloroform:MeOH:H2O); 1H NMR (600 MHz, MeOD-d4) δ 5.70 (dt, 1 H, J = 15.2, 6.8 
Hz, H-5), 5.44 (dd, 1 H, J  =15.2, 7.6 Hz, H-4), 4.28 (m, 2 H, -OCH2-choline), 4.11 (m, 1 H, H-1a), 4.04 (t, 1 H, J = 8.0 Hz, 
H-3), 3.99-3.94 (m, 2 H, H-1b and H-2), 3.64 (m, 2 H, -CH2Ncholine), 3.30 (s, 9 H, 3x CH3-choline), 2.18 (t, 2 H, J = 7.2 Hz, 
H-2*), 2.04 (m, 2 H, H-6), 1.59 (m, 2 H, H-7), 1.42-1.20 (m, 48 H, H-8 to H-17 and H-3* to H-15*), 0.90 (t, 6 H, J = 
6.8 Hz, H-18 nd H-16*); 13C NMR (150 MHz, MeOD-d4) δ 175.8 (C=O), 135.0 (C-5), 130.8 (C-4), 76.3 (C-3), 70.7 (-
CH2Ncholine), 63.6 (d, J = 4.5 Hz, C-1), 60.6 (d, J = 4.5 Hz, -OCH2-choline), 57.2 (C-2), 54.7 (3x CH3-choline), 37.3, 33.9, 32.9, 
30.76, 30.72, 30.69, 30.68, 30.67, 30.65, 30.59, 30.52, 30.39, 30.37, 30.35, 30.31, ,27.03, 23.63 (25x CH2 C-6 to C-
17 and C-3* to C15*), 14.4 (C-18 and C-16*); 31P NMR (162 MHz, MeOD-d4)  δ  -0.51; IR (neat): 3429, 2915, 2846, 
1724, 1633, 1545, 1459, 1250, 1067, 1030, 928 cm-1; HRMS Calculated for [C39H79N2O6P +H]+: 702.5657, found 
702.5655. 
 
1-Cholinephosphate-2-N-(hexadecanoyl)-[5,6,7,8,9-13C5]-sphingosine (20b). Sphingosine 19b (10 mg, 0.021 
mmol, 1 eq) was mixed with BSA (0.3 mL) under protected 
atmosphere and stirred overnight at room temperature. The 
mixture was concentrated in high vacuum and the silylated 
phosphosphingosine was dissolved in dry DCM (0.3 mL) under a 
protected atmosphere and cooled to 0 oC. To the solution was 
added DIPEA (12 µL, 0.063 mmol, 3.0 eq) followed by palmitoyl chloride (9 µL ,0.032 mmol, 1.2 eq). The reaction 
was left stirring, reaching room temperatue over 2 h. The reaction mixture was then concentrated in vacuo and 
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Chloroform:MeOH:H2O) giving the titeld product 20b as white solid (10 mg, 0.014 mmol, 66%). Rf = 0.18 (70:27:3 
Chloroform:MeOH:H2O); 1H NMR (600 MHz, CDCl3) δ 5.68 (dm, 1 H, J = 151 MHz, H-5), 5.44 (m, 1 H, H-4), 4.28 
(m, 2 H, -OCH2-choline), 4.12 (m, 1 H, H-1a), 4.03 (m, 1 H, H-3), 3.98-3.94 (m, 2 H, H-1b and H-2), 3.65 (m, 2 H, -
CH2Ncholine), 3.29 (s, 9 H, 3x CH3-choline), 2.17 (t, 2 H, J = 7.2 Hz, H-2*), 2.03 (m, 2 H, H-6), 1.56-1.14 (m, 48 H, H-7 to 
H-17 and H-3* to H-15*), 0.88 (t, 6 H, J = 6.8 Hz, H-18 and H-16*); 13C NMR (151 MHz, MeOD-d4) δ  175.6 (C=O), 
135.6 (d, J = 42.4 Hz, C-5), 128.2 (d, J = 72 Hz, C-4), 76.2 (d, J = 4.5 Hz, C-3), 70.6 (-CH2Ncholine), 63.4 (d, J = 4.5 Hz, C-
1), 60.3 (d, J = 4.5 Hz, -OCH2-choline), 57.1 (C-2), 54.6 (3x CH3-choline), 37.1 (C-2*), 33.6-33.0 (m) 30.5-29.8 (m), 26.8 
(25x CH2 C-6 to C-17 and C-3* to C15*), 14.4 (C-18 and C-16*); 31P NMR (162 MHz, MeOD-d4)  δ  -0.51; IR (neat): 
3429, 2915, 2846, 1724, 1633, 1545, 1459, 1250, 1067, 1030, 928 cm-1;  HRMS Calculated for [C3413C5H79N2O6P 
+H]+: 707.5602, found 707.5599. 
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5.1 Introduction 
(Glyco)sphingolipids are a family of complex lipids found in all mammalian cells. Besides 
playing important structural roles as membrane components, they are involved in a 
multitude of intra- and intercellular signaling events and play a role in many 
(patho)physiological processes.[1] This structurally diverse class of lipids is composed of a 
sphingosine base, which can be acylated at the nitrogen with a variety of acyl chains.[2] 
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Further structural variation comes from differences in substitution at the primary alcohol 
group, at which position a large variety of glycans and phosphate groups can be attached. 
Structural modifications in the sphingosine base are also found. The most recently 
reported members of the human sphingolipid family, the 6-hydroxyceramides (e. g. 2, 
Figure 5.1) were discovered in 1989[3] and their structure, based on a 6-
hydroxysphingosine base (1, see Figure 5.1), was fully established in 1994.[4] These 
sphingolipids are important constituents of the human skin, especially the stratum 
corneum (SC), where they play a role in skin barrier pathologies.[5] Authentic samples of 
these sphingolipids are valuable to study their role in skin physiology processes. Because 
they are not commercially available and cannot be obtained from natural sources in pure 
form and sufficient quantity the development of synthetic routes to access these 
molecules is important.[6] To date three reports describing the synthesis of the 6-
hydroxysphingosine base have appeared.[7-9] These three syntheses all hinge on the 
diastereoselective nucleophilic attack of an appropriately protected alkyne lipid to (S)-
Garner aldehyde10 (3, See Figure 5.1), using strongly basic conditions and necessitating a 
subsequent reduction step. 
Figure 5.1 Literature strategy and this chapter. 
Chapter 2 describes the assembly of (glyco)sphingolipids using a cross-metathesis (CM) 
strategy as the key step.[11-14] In this approach an allylic sphingosine head is coupled with a 
long chain alkene (varying in length and carrying different functionalities[12] or 13C 
labels[13]) through the formation of the E-double bond. The mild conditions required for 
this transformation and the broad functional group tolerance make this an attractive 
strategy and therefore it could be an effective approach to access 6-hydroxysphingosines. 
To make this strategy successful, difficulties associated with the cross-metathesis of two 
similar allylic alcohols (Type II or III CM coupling partners)[15] had to be overcome. This 
Chapter describes that CM can be used as a key step in the synthesis of 6-


















































5.2  Results and discussion 
The synthesis of the required cross-metathesis partners 6 and 7, bearing different 
protecting group patterns is depicted in Scheme 5.1. The sphingosine head 6a was 
accessed in six steps from L-serine as previously described by Yamamoto et al.[14] The long 
chain allylic alcohol 7 was  assembled  using  a  “tellurium  transposition”  strategy,   in  which  
the primary allylic alcohol (12) is transformed into the regioisomeric secondary allylic 
alcohol (7a) following a Sharpless asymmetric epoxidation (SAE)-tellurium mediated 
reductive elimination sequence.[16] To this end, the first research objective was to 
generate the required primary allylic alcohol 12 from tridecanal 10. Since the 
commercially available tridecanal did not perform well in the ensuing olefination reaction,  
 
Scheme 5.1 Synthesis of cross-metathesis partners 6 and 7. 
Reagents and conditions: (a) N,N-disuccinimidyl carbonate, DMAP, THF, r.t., 20 h, 76%; (b) oxalyl chloride, DMF, 
DCM, 0 °C to r.t., 4 h; (ii) N,O-dimethylhydroxylamide, DCM, -78 °C to r.t, 20 h, 99% (over two steps); (iii) DIBAL-
H, THF, -60 °C, 3 h; (c) (i) diisopropyl (ethoxycarbonylmethyl) phosphonate, n-BuLi, r.t., 15 min; (ii) 10, THF, r.t., 
20 h, 77% (over two steps, ≥ 98%); (d) DIBAL-H, THF, -78 °C to -60 °C, 3 h, 94%; (e) Ti(OiPr)4, D-(-)-DET, tBuOOH. 
DCM, -19 °C, 5 h, 76% (e.e. 89%); (f) TsCl, Et3N, DMAP, DCM, 0 °C to r.t., 20 h, 96%; (g) Te, rongalite, 1 N NaOH, 
50 °C, 2 h; (ii) 14, THF, 0 °C to r.t., 20 h, 90%; (h) Bz2O, Et3N, DMAP, DCM, 40 °C, 20 h, 89%; (i) TBSCl, Et3N, DMAP, 
DCM, 0 °C to r.t., 20 h, 68%; (j) (i) NaH, DMF, 0 °C, 15 min.; (ii) PMBCl, 0 °C to r.t., 20 h, 87%; (k) MOMCl, DIPEA, 
DMAP DMF, 0 °C to r.t., 20 h, 94%. 
this aldehyde was prepared from tridecanoic acid. Thus, tridecanoic acid was transformed 
via the acid chloride into the Weinreb amide (99% over two steps), which was reduced to 
give tridecanal 10. The aldehyde was immediately used in the ensuing olefination event. 
The best E/Z-selectivity for trans-olefin 11 (≥98% E) was achieved using a Horner-
Wadsworth-Emmons (HWE) reaction with di-iso-propyl 
(ethoxycarbonylmethyl)phosphonate.[7] The Horner-Wittig reaction of tridecanal with 
(ethoxycarbonylmethyl) triphenylphosphonium bromide, as well as the HWE reaction with 



















7b R = Bz
7c R = TBS
7d R = PMB
7e R = MOM
9 R = COOH
10 R = (C=O)H
11 12
13 R = H








g h,i,j or k
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95:5). The α,β-unsaturated ester 10 was then reduced to the allylic alcohol 11 with di-iso-
butylaluminium hydride (DIBAL-H) to set the stage for Sharpless asymmetric epoxidation, 
which was used to introduce chirality in the molecule. After substantial optimization of 
this reaction, optimal conditions were found in the use of 13.5 mol% Ti(OiPr)4, 17.5 mol% 
D-(-)-di-ethyltartrate (D-(-)-DET), 2.2 equivalents of tert-butylhydroperoxide (tBuOOH), and 
molecular sieves 4Å (1 gram/mol) in dichloromethane at -19 oC. This delivered the chiral 
epoxide 13 in 79% yield and 89% ee (determined from tosylate 14). Installation of a 
tosylate function at the primary alcohol allowed for the tellurium mediated reductive 
elimination reaction. To this end an aqueous solution of Na2Te was generated from 
tellurium and rongalite (HOCH2SO2Na) in NaOH (aq).[16] Addition of 14 to this solution led 
to the nucleophilic displacement of the primary tosylate by tellurium ion, after which the 
ensuing epoxide ring opening generates an epitelluride ring that collapses upon exposure 
to   air   to   give   the   “transposed”   secondary   allylic   alcohol   7a. With both allylic alcohols in 
hand the stage was set for the crucial CM reaction. Generally for a productive CM event, 
two reaction partners of differing reactivity are required. Grubbs and co-workers[14] have 
divided alkenes in four categories based on their ability to form homodimers in CM 
reactions. Type I alkenes undergo rapid homodimerization and these can participate in an 
ensuing CM event. Type II alkenes undergo slow homodimerization leading to 
homodimers that can participate in CM to a limited extent. Type III alkenes do not form 
homodimers but they are able to react with type I and II homodimers in a CM. Type IV 
alkenes  are  essentially  “spectators  to  cross-metathesis”  as  they  do  not  display  any  activity 
towards the catalyst. For a selective CM, the reaction partners are preferably from 
different types. The two allylic alcohols at hand are classified as type II CM partners, 
making the desired CM reaction a challenging process. To discriminate between the 
reactivity of the alkenes the decision was made to protect the long chain alcohol 7a 
(generating a type III CM partner) and mask the hydroxyl group as a benzoyl ester (7b), a 
tert-butyldimethylsilyl ether (7c), a para-methoxybenzyl (PMB) ether (7d) or 
methoxylmethyl (MOM) ether (7e). The results of the CM reactions are summarized in 
Table 1. The first attempt, involving diol 6a and alcohol 7a, provided the desired CM 8a 
product in 23% yield (entry 1). Raising the temperature of this reaction did not lead to an 
improved reaction (entry 2). Next a CM was attempted with the more electron-poor 
benzoylated allylic alcohol 7b in combination with diol 6a, but this CM was unproductive 
(entry 3). Similarly the use of silylated CM partner 7c was to no avail (entry 4). Because 






aReaction conditions: Ratio 6:7 = 3:1; 20 mol % catalyst; 30 mol % (CuI). bYields denote isolated yields after 
column chromatography. cUnreacted cyclic carbonate  6b as well the protected allylic olefin (7b, 7c, 7d and 7e) 
could be recovered. 






1 6a/7a Grubbs II DCM 40 48 8a (23%) 2 E 8 -) 
3 6a/7b Grubbs II DCM 40 48 8b (-) 
4 6a/7c Grubbs II DCM 40 48 8c (-) 
5 6b/7a Grubbs II DCM 40 48 8d (48%) 
6 6b/7b Grubbs II DCM 40 48 8e (-)c 
7 6b/7c Grubbs II DCM 40 48 8f (-)c 
8 6b/7d Grubbs II DCM 40 48 8g (37%)c 
9 6b/7e Grubbs II DCM 40 66 8h (43%)c 
10 6b/7a Grubbs II DCE 80 48 8d (-) 
11 6b/7a Hoveyda-
Grubbs 
DCM 40 70 8d (48%) 
12 6b/7a Grubbs II + CuI Tol. 40 48 8d (78%) 
















6a R = H
6b R = -(C=O)-
8a R = H,  R1 = H
8b R = H,  R1 = Bz
8c R = H,  R1 = TBS
8d R = -(C=O)-,  R1 = H
8e R = -(C=O)-,  R1 = Bz
8f R = -(C=O)-,  R1 = TBS
8g R = -(C=O)-,  R1 = PMB
8h R = -(C=O)-,  R1 = MOM
7a R1 =H
7b R1 = Bz
7c R1 = TBS
7d R1 = PMB
7e R1 = MOM
Table 5.1 Cross-metathesis studies. 
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unsuccessful, it was decided to protect diol 6 as the cyclic carbonate and to investigate 
how the resulting 6b would behave in CM events. The cyclic carbonate group is both 
strongly electron withdrawing, changing the electronic properties of the alkene, and ties 
back the functionalities of the groups attached to the alkene, making it more accessible. 
When the allylic carbonate 6b and alcohol 7a were combined in a CM event the desired E-
alkene 8d was obtained in an increased yield (48%, entry 5). The use of benzoylated and 
silylated CM partners 7b and 7c again led to unproductive CM reactions (entries 6 and 7). 
The use of PMB and MOM protected allylic alcohols 7d and 7e did deliver the desired CM 
products 8g and 8h, respectively, but in a lower yield than obtained for 8e (entries 8 and 
9). Having established that the most productive CM reaction occurs between carbonate 6b 
and alcohol 7a, this reaction was further optimized. Raising the temperature led to 
decomposition of the cyclic carbonate and therefore no product was obtained (entry 10). 
Also different catalytic systems were explored. As the use of the Grubbs-Hoveyda catalyst 
led to an identical result as compared to the Grubbs II catalyzed CM reaction (entry 11), 
the next step was to explore the impact of additives on the reaction. As described by 
Voigtritter et al.[17], copper iodide (CuI) can be used to generate a more stable catalyst 
(due to the iodide), while making the system more reactive because the copper 
sequesters the phosphine ligands. As shown in entries 12 and 13, the use of this additive 
proved very successful and alkene 6b and allylic alcohol 7a could be fused to provide the 
desired E-alkene 8d in good yield. 
Scheme 5.2 Synthesis of 6-hydroxysphinhosine 1 and α-hydroxy ceramide 2. 
Reagents and conditions: (a) LiOH, THF/H2O (3:1), 0 °C, 3 h; (ii) TFA, DCM, 0 °C, 90 min, 80% over two steps; (b) 
HCl (g), MeOH, Et2O, 0 °C to -20 0 °C, 20 h, then H2O, 48%; (ii) 1-tetradecene, Grubbs 2nd generation catalyst, 
AcOH, DCM, 50 °C, 60 h, 73%; (iii) H2 (g), Pd/C, EtOAc, r.t., 20 h, 91%; (c) LiOH.H2O, THF:MeOH:H2O (2:2:1), r.t., 20 
h, 99%; (d) Ac2O, pyridine, DCM, r.t., 20 h, 97%; (e) EEDQ, EtOH, 50 °C, 20 h, 66%; (f) K2CO3, DCM/MeOH (4:1), 
r.t., 2 h, 88%. 
Having successfully constructed the 6-hydroxysphingosine backbone, the base was 
globally deprotected by saponification of the carbonate group and ensuing removal of the 
Boc protective group using dilute acid at low temperature (0 oC) to give α-hydroxy 
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1 = Me, R2 = H
16b R1 = H, R2 = H









complex reaction mixtures, presumably as a result of acid catalyzed allylic substitution 
reactions. The synthesis of the 6-hydroxysphingosine based ceramide 2, featuring an α-
hydroxyl side chain was finally accomplished as follows. First α-hydroxy fatty acid 16a was 
generated from optically pure cyanohydrin 15, obtained from crotonaldehyde by the 
action of almond hydroxynitrilase.[18] The cyanohydrin was transformed into the 
corresponding methyl ester using a Pinner reaction.[19] Next a CM reaction of the alkene 
with 1-tetradecene gave the unsaturated long chain lipid that was reduced and saponified 
to give the fatty acid 16b. To condense the α-hydroxy fatty acid with the 6-
hydroxysphingosine, the α-hydroxy group was first masked with an acetyl group. 
Activation of acid 16c with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ)[20] and 
ensuing condensation then gave acylated ceramide 17. Final saponification of the acetyl 
ester completed the synthesis of the target 6-hydroxyceramide 2. 
5.3 Conclusion  
In conclusion, this Chapter presents a new synthetic route for 6-hydroxysphingosine and 
its alpha-hydroxy-ceramide counterpart, employing a cross-metathesis (CM) strategy. The 
crucial CM reaction on which the synthesis hinges unites two similar allylic alcohol 
alkenes. The use of a cyclic carbonate group to protect the diol system, present in the 
sphingosine CM partner, with a cyclic carbonate functionality serves two purposes. Firstly, 
it makes the double bond less electron rich, discriminating it from its designated CM 
partner, the long chain allylic alcohol. Secondly, it ties back the functional groups on the 
olefin, making the alkene sterically most accessible for the catalyst and the CM event. In 
combination with an activated catalyst system (the Grubbs II – CuI reagent pair) this led to 
an efficient CM connection of the sphingosine head and tail alkenes. The mild conditions 
required for this connection in conjunction with the straightforward deprotection scheme 
(mild base followed by mild acid) make the approach versatile and amendable to the use 
of a variety of CM coupling partners to generate labeled and tagged 6-hydroxysphingosine 
derived probes for future biochemical studies.[13,21] 
5.4 Experimental section 
General Remarks. Commercially available reagents and solvents were used as received. DCM and THF were dried 
and distilled by standard procedures. All moisture-sensitive reactions were carried out under an argon 
atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column chromatography was carried out with 
Silica gel 60 (40–63   μm   mesh).      IR   spectra   are   reported   in   cm–1. Optical rotations were measured with an 
automatic polarimeter (sodium D-line, λ  = 589 nm). The enantiomeric purity was determined by HPLC analysis 
using an OD column (hexane/isopropyl alcohol (98:2), 1 mL/min, UV 254 nm). NMR spectra were recorded on a 
400 MHz or 850 MHz spectrometer. Chemical shifts are reported as δ  values (ppm), and were referenced to 
tetramethylsilane  (δ  =  0.00  ppm)  directly  in  CDCl3, or using the residual solvent peak (D2O). High-resolution mass 
spectra were recorded on a LTQ-Orbitrap  (Thermo Finnigan) mass spectrometer equipped with an electrospray 
ion source in positive mode or on a Synapt G2-Si MALDI-TOF mass spectrometer equipped with a 355-nm laser.  
Samples (1 mL, 100 mM in CHCl3) were spotted on the MALDI-plate, followed by aqueous silver benzoate (0.5 
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mL, 10 mM), drying and applying the matrix (2,5-dihydroxybenzoic acid, 0.5 mL, 0.5 M in methanol). A laser 
frequency of 1000 Hz (power set at 60%) was used. 
  
tert-Butyl ((4R,5S)-2-oxo-4-vinyl-1,3-dioxan-5-yl)carbamate (6b). Allylic alcohol 6a (3.03 g, 13.95 mmol, 1 eq) 
was dissolved in anhydrous THF (400 mL) under an argon atmosphere. N,N’-Disuccinimidyl 
carbonate (8.93 g, 34.88 mmol, 2.5 eq) and DMAP (4.26 g, 34.88 mmol, 2.5 eq) were added and 
then left stirring for 20 hours at room. The reaction mixture was concentrated in vacuo and 
purified with silica gel chromatography (30% EtOAc in pentane) giving Cyclic carbonate 6b (2.57 g, 
10.56 mmol, 76%) as a thick, colorless oil. Rf = 0.6 (50% EtOAc in pentane); [α]D = +46.0  (c = 1.0, 
CHCl3); 1H NMR (400 MHz, CDCl3)  δ 5.92 (ddd, 1 H, J = 16.8, 10.8, 4.4 Hz, H-4), 5.58 (d, 1 H, J = 7.2 Hz, -NH), 5.50 
(dd, 1 H, J = 16.8, 1.6 Hz, H-5a), 5.47 (dd, 1 H, J = 10.8, 1.6 Hz, H-5b), 5.02 (bs, 1 H, H-3), 4.54 (dd, 1 H, J = 11.2, 2.4 
Hz, H-1a), 4.31 (bd, 1 H, J = 11.2 Hz, H-1b), 3.97 (m, 1 H, H-2), 1.46 (s, 9 H, CH3-Boc); 13C NMR (101 MHz, CDCl3)  δ 
155.25 (C=OBoc), 147.67 (C=OCarbonate), 132.50 (C-4), 119.68 (C-5), 81.95 (C-3), 80.87 (Cq-Boc), 68.15 (C-1), 45.84 (C-
2), 28.34 (CH3-Boc); IR (neat): 2978, 2932, 1751, 1701, 1165 cm-1; HRMS for calculated [C11H18NO5 + H]+; 244.11795, 
found 244.11835. 
 
Tridecanal (10). Tridecanoic acid 9 (7.50 g, 35.0 mmol, 1 eq) was dissolved in anhydrous DCM (110 mL) under an 
argon atmosphere. The solution was cooled to 0oC before adding oxalyl chloride (2 M in DCM, 
35 mL, 70 mmol, 2 eq) and DMF (3 drops, cat.). The mixture was stirred for 4 to 5 hours at 
room temperature. Once gas formation subsided, the reaction mixture was concentrated in 
vacuo and the crude acyl chloride was immediately dissolved in anhydrous DCM (110 mL) under an argon 
atmosphere. The solution was cooled to -78oC before slowly addition of distilled N,O-dimethylhydroxylamine 
(6.42 mL, 87.5 mmol, 2.5 eq). After 30 minutes the reaction mixture was allowed to reach room temperature and 
stirred for 20 hours The reaction mixture was filtered, concentration in vacuo, and purified with silica gel 
chromatography (5% to 10% EtOAc in pentane) giving N-methoxy-N-methyltridecanamide (8.94 g, 34.74 mmol, 
99%) as an oil. Rf = 0.3 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ 3.68 (s, 3 H, -OCH3), 3.18 (s, 3 H, -
NCH3), 2.41 (t, 2 H, J = 7.6 Hz, H-1), 1.63 (p, 2 H, J = 7.6 Hz, H-2), 1.31 - 1.26 (m, 18 H, H-3 to H-11), 0.88 (t, 3 H, J = 
6.8 Hz, H-12); 13C NMR (101 MHz, CDCl3)  δ 175.03 (C=OWeinreb), 61.31 (-OCH3), 32.30 (-NCH3), 32.04 (C-1, CH2), 
29.79, 29.76 (x2), 29.64, 29.59, 29.56, 29.48 (CH2 x 7), 24.79 (C-2), 22.82 (CH2), 14.25 (C-12); IR (neat): 2922, 
2853, 1668 cm-1; HRMS calculated for [C15H32NO2 + H]; 258.24276; found 258.24257. 
N-methoxy-N-methyltridecanamide (2.59 g, 10.05 mmol, 1 eq) was dissolved in anhydrous THF (25 mL) under an 
argon atmosphere. The solution was cooled to -60 oC followed by addition of diisobutylaluminum hydride (1 M in 
THF, 12 mL, 12 mmol, 1.2 eq). The reaction mixture was stirred for 3 hours at -60 oC. The reaction was quenched 
by adding Rochelle salt solution (sat., 20 mL) at -60 oC. The mixture was then allowed to reach room temperature 
before extracting with EtOAc (2x 150 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtrated and concentrated in vacuo. The crude tridecanal 10 was collected as an oil, which was used for 
the next reaction without further purification. Rf = 0.7 (5% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ 9.76 (t, 
1 H, J = 1.6 Hz, -CHO), 2.42 (dt, 2 H, J = 7.2, 1.6 Hz, H-1), 1.63 (p, 2 H, J = 7.2 Hz, H-2), 1.30 – 1.26 (m, 18 H, H-3 to 
H-11), 0.88 (t, 3 H, J = 6.8 Hz, H-12); 13C NMR (101 MHz, CDCl3)  δ 202.96 (C=Oaldehyde), 44.03 (C-1), 32.03, 29.76, 
29.74, 29.70, 29.55, 29.48, 29.47, 29.28, 22.80, 22.19 (CH2 x 10), 14.22 (C-12); IR (neat): 3024, 2984, 2941, 1732, 
1236 cm-1. 
Ethyl (E)-pentadec-2-enoate (11). Diisopropyl (ethoxycarbonylmethyl) phosphonate (3.53 g, 14 mmol, 1.4 eq) 
was dissolved in anhydrous THF (40 mL) under an argon atmosphere. n-Butyllithium 
(2.5 M in hexanes, 5 mL, 12.5 mmol, 1.25 eq) was added and stirred for 15 minutes at 
room temperature followed by addition of a solution of crude tridecanal  10 in 
anhydrous THF (15 mL). The reaction mixture was stirred for 20 hours. The reaction mixture was diluted with H2O 











MgSO4, filtrated and concentrated in vacuo. The crude product was purified with silica gel chromatography (0-2% 
EtOAc in pentane).  The  α,β-unsaturated ester 11 (2.08  g,  7.73  mmol,  77%  over  2  steps,  ≥  98%  E)  was  collected  as  
a light yellow oil. Rf = 0.5 (2% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ 6.97 (dt, 1 H, J = 15.6, 6.8 Hz, H-4), 
5.81 (dt, 1 H, J = 15.6, 1.6 Hz, H-3), 4.18 (q, 2 H, J = 7.2 Hz, H-2), 2.19 (dq, 2 H, J = 7.2, 1.2 Hz, H- 5), 1.45 (m, 2 H, 
H-6), 1.32 – 1.26 (m, 21 H, H-1 and H-7 to H-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C NMR (101 MHz, CDCl3)  δ 166.89 
(C=O), 149.60 (C-4), 121.30 (C-3), 60.21 (C-2), 32.32 (C-5), 32.04, 29.78, 29.76 (x2), 29.65, 29.52, 29.48, 29.28 
(CH2 x 8), 28.14 (C-6), 22.81 (CH2), 14.39 (C-1), 14.23 (C-16); IR (neat): 2922, 2853, 1722, 1655, 1179 cm-1; HRMS 
calculated for [C17H33O2 + H]+: 269.2475, found 269.2475. Spectroscopic data was identical to literature.[7]  
 (E)-Pentadec-2-en-1-ol (12). Ethyl (E)-pentadec-2-enoate 11 (2.39 g, 8.89 mmol, 1 eq) was dissolved in 
anhydrous THF (45 mL) under an argon atmosphere. The solution was cooled to -78oC 
followed by addition of diisobutylaluminum hydride (1M in THF, 26.7 mL, 26.7 mmol, 3 eq). 
The reaction mixture was stirred for 3 hours, slowly warming up to -60oC. The reaction was 
quenched with NH4Cl solution (sat.) at -60oC. The mixture was then allowed to warm to room temperature 
before adding HCl (5%, 100 mL). The mixture was extracted with Et2O (3x 100 mL). The combined organic layers 
were washed with brine, dried over MgSO4, filtrated and concentrated in vacuo. The crude product was purified 
with silica gel chromatography (2.5-5% EtOAc in pentane). Allylic alcohol 12 (1.89 g, 8.34 mmol, 94%) was 
collected as a colorless oil that slowly crystallized into a white solid. Rf = 0.3 (5% EtOAc in pentane): 1H NMR (400 
MHz, CDCl3)  δ 5.73 – 5.59 (m, 2 H, H-2 & H-3), 4.08 (d, 2 H, J = 6.0 Hz, H-1), 2.04 (m, 2 H, H-4), 1.50 (bs, 1 H, -OH), 
1.37 (m, 2 H, H-5), 1.32 – 1.26 (m, 18 H, H-6 to H- 14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C NMR (101 MHz, CDCl3)  δ 
133.75, 128.90 (C-2, C-3), 63.98 (C-1), 32.36 (C-4), 32.06, 29.83, 29.81, 29.79, 29.76, 29.65, 29.50, 29.34, 29.28, 
22.83 (CH2 x 10), 14.26 (C- 15); IR (neat): 3292, 2955, 2918, 2849, 1672, 1462 cm-1. Spectroscopic data was 
identical to literature.[7] 
 ((2R,3R)-3-dodecyloxiran-2-yl)methanol (13). Activated, powdered molecular sieves (~5 g, 4Å) were added to a 
flame dried flask with freshly distilled, anhydrous DCM (15 mL) under an argon 
atmosphere. The suspension was stirred for 10 minutes at room temperature, 
completely drying DCM in the process. (-)-Diethyl D tartrate (0.15 mL, 0.86 mmol, 0.17 
eq) and titanium (IV) isopropoxide (0.2 mL, 0.69 mmol, 0.14 eq) were added to this solution at -19oC. Allylic 
alcohol 12 (1.13 g, 5.00 mmol, 1 eq) was co-evaporated with toluene (2x) and dissolved in freshly distilled, 
anhydrous DCM (10 mL). After stirring the titanium-tartrate solution for 30 minutes, the solution of allylic alcohol 
12 was added followed by addition of tert-butyl hydroperoxide (~5.5 M in decane, 2 mL, 11.0 mmol, 2.2 eq). The 
reaction mixture was stirred for 5 hours at -19 oC. The reaction was quenched by adding H2O (20 mL) at -19 oC. 
After warming up to room temperature, NaOH (30% in brine, 2.5 mL) was added to hydrolysis of (-)-Diethyl D 
tartrate. The mixture was stirred for 15 minutes, followed by extraction with DCM (3x 30 mL). The combined 
organic layers were dried over MgSO4, filtrated and concentrated in vacuo. Remaining tert-butyl hydroperoxide 
was removed by co-evaporation with toluene. The crude product was purified with silica gel chromatography 
(10-15% EtOAc in pentane). Epoxide 13 (0.92 g, 3.80 mmol, 76%, e.e. = 89% (determined from tosylate 14) was 
collected as a white solid. The analytical sample was recrystallized from petroleum ether (40-60%). Rf = 0.3 (20% 
EtOAc in pentane); [α]D = +23.4 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)  δ 3.92 (ddd, 1 H, J = 12.4, 5.2, 2.4 Hz, H-
1a), 3.63 (ddd, 1 H, J = 12.0, 7.2, 4.4 Hz, H-1b), 2.96 (m, 1 H, H-2), 2.92 (m, 1 H, H-3), 1.66 (m, 1 H, -OH), 1.56 (m, 2 
H, H-4), 1.44 (m, 2 H, H-5), 1.35 – 1.26 (m, 18 H, H-6 to H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C NMR (101 MHz, 
CDCl3)   δ 61.82 (C-1), 58.51 (C-3), 56.13 (C-2), 32.07 (CH2), 31.71 (C-4), 29.81, 29.78 (x2), 29.70, 29.68, 29.55, 
29.50 (CH2 x 7), 26.10 (C-5), 22.84 (CH2), 14.28 (C-15); IR (neat): 3252, 2953, 2916, 2870, 2847, 1458, 1248, 868 
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 ((2R,3R)-3-dodecyloxiran-2-yl)methyl 4-methylbenzenesulfonate (14). Epoxide 13 (716 mg, 2.95 mmol, 1 eq) 
was dissolved in anhydrous DCM (30 mL) under an argon atmosphere. The solution was 
cooled to 0 oC followed by addition of p-toluenesulfonyl chloride (1.13 g, 5.91 mmol, 2 
eq), DMAP (25 mg, 0.2 mmol, cat.) and triethylamine (1.24 mL, 8.86 mmol, 3 eq). The reaction mixture was 
stirred for 20 hours at room temperature. The reaction was quenched with H2O (30 mL). The aqueous layer was 
extracted with DCM (3x 30 mL). The combined organic layers were washed with H2O (2x), dried over MgSO4, 
filtrated and concentrated in vacuo. The crude product was purified with silica gel chromatography (2-5% EtOAc 
in pentane). Tosylate 14 (1.12 g, 2.82 mmol, 96%) was collected as colorless oil that slowly crystallized into a 
white solid. Rf = 0.3 (5% EtOAc in pentane);  [α]D = +24.0o (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)  δ 8.00 (ad, 2 
H, J = 8.4 Hz, H-17), 7.35 (d, 2 H, J = 8.0 Hz, H-18), 4.18 (dd, 1 H, J = 11.2, 4.0 Hz, H-1a), 3.97 (dd, 1 H, J = 11.2, 6.0 
Hz, H-1b), 2.95 (ddd, 1 H, J = 6.0, 4.0, 2.0 Hz, H-2), 2.78 (td, 1 H, J = 5.6, 2.0 Hz, H-3), 2.45 (s, 3 H, H-20), 1.51 (m, 2 
H, H-4), 1.36 (m, 2 H, H-5), 1.32 – 1.25 (m, 18 H, H-6 to H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C NMR (101 MHz, 
CDCl3)  δ 145.18 (C-16), 132.86 (C-19), 130.04 (C-18), 128.10 (C-17), 70.34 (C-1), 56.95 (C-3), 54.66 (C-2), 32.05 
(CH2), 31.43 (C-4), 29.79, 29.77, 29.76, 29.65, 29.61, 29.49, 29.43 (CH2 x 7), 25.87 (C-5), 22.83 (CH2), 21.81 (C-20), 
14.27 (C-15); IR (neat): 2953, 2916, 2870, 2849, 1599, 1364, 1177, 829, 808 cm-1; HRMS calculated for [C22H37O4S 
+ H]+: 397.2407, found 397.2404.   
 (R)-pentadec-1-en-3-ol (7a). Sodium hydroxymethanesulfinate hydrate (6.50 g, 55.0 mmol, 7.3 eq) was dissolved 
in NaOH (1M, 150 mL). Argon was purged through the solution before addition of tellurium 
(powder, -200 mesh, 1.92 g, 15.1 mmol, 2 eq). The reaction mixture was stirred for 2 hours 
at 50 oC. The purple solution of tellurides was cooled to 0oC followed by slowly addition of a 
solution of Tosylate 14 (2.99 g, 7.53 mmol, 1 eq) in THF (75 mL). The reaction was stirred for 20 hours at room 
temperature. The reaction was quenched by bubbling air through the solution. The crude reaction mixture was 
then filtrated over a pad of Celite and concentrated in vacuo. The aqueous layer was extracted with Et2O (2x 150 
mL). The combined organic layers were washed with H2O2 (3%, 75 mL), sodium thiosulfate (10%) and brine 
before being dried over MgSO4, filtrated and concentrated in vacuo. The crude product was purified with silica 
gel chromatography (5-10% Et2O in pentane). Allylic alcohol 7a (1.54 g, 6.78 mmol, 90%) was collected as a white 
solid. Rf = 0.4 (20% Et2O in pentane);  [α]D = -7.0o (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)  δ 5.87 (ddd, 1 H, J = 
16.8, 10.4, 6.4 Hz, H-2), 5.22 (dt, 1 H, J = 17.2, 1.2 Hz, H- 1a), 5.10 (dt, 1 H, J = 10.4, 1.2 Hz, H-1b), 4.10 (m, 1 H, H-
3), 1.69 (bs, 1 H, -OH), 1.52 (m, 2 H, H-4), 1.43 – 1.26 (m, 20 H, H-5 to H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C 
NMR (101 MHz, CDCl3)  δ 141.45 (C-2), 114.67 (C-1), 73.45 (C-3), 37.19 (C-4), 32.07, 29.82, 29.80, 29.74, 29.70, 
29.51, 25.48, 22.84 (CH2 x 8), 14.28 (C-15); IR (neat): 3348, 2918, 2853, 1643, 1466 cm-1. Spectroscopic data was 
identical to literature.[22]  
 
 (R)-pentadec-1-en-3-yl benzoate (7b). Allylic alcohol 7a (325 mg, 1.44 mmol, 1 eq) was dissolved in anhydrous 
DCM (17 mL) under an argon atmosphere. Benzoic anhydride (974 mg, 4.31 mmol, 3 eq), 
triethylamine (0.80 mL, 5.74 mmol, 4 eq) and DMAP (17 mg, 0.14 mmol, cat.) were added 
and the reaction mixture was stirred under reflux for 20 hours. The reaction was quenched 
by adding NH4Cl (sat., 25 mL). The aqueous layer was extracted with Et2O (3x 30 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtrated and concentrated in vacuo. The crude product was 
purified with silica gel chromatography (0-2% EtOAc in pentane). The benzoylated product 7b (424 mg, 1.28 
mmol, 89%) was collected as an oil. Rf = 0.8 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3)  δ 8.07 (m, 2 H, H-
17), 7.55 (m, 1 H, H-19), 7.44 (m, 2 H, H-18), 5.89 (ddd, 1 H, J = 17.2, 10.4, 6.4 Hz, H-2), 5.49 (m, 1 H, H-3), 5.32 
(dt, 1 H, J = 17.2, 1.2 Hz, H-1a), 5.20 (dt, 1 H, J = 10.4, 1.2 Hz, H-1b), 1.75 (m, 2 H, H-4), 1.46 – 1.25 (m, 20 H, H-5 to 
H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C NMR (101 MHz, CDCl3)   δ 165.97 (C=O), 136.75 (C-2), 132.95 (C-19), 
130.72 (C-16), 129.70 (C-17), 128.44 (C-18), 166.66 (C-1), 75.50 (C- 3), 34.47 (C-4), 32.05, 29.80, 29.77 (x2), 29.70, 
29.64, 29.54, 29.49, 25.23, 22.83 (CH2 x 10), 14.27 (C-15); IR (neat): 3088, 3030, 2922, 2853, 1719, 1267 cm-1; 









 (R)-tert-butyldimethyl(pentadec-1-en-3-yloxy)silane (7c). Allylic alcohol 7a (259 mg, 1.14 mmol, 1 eq) was 
dissolved in anhydrous DMF (5 mL) under an argon atmosphere. DMAP (6 mg, 0.05 mmol, 
cat.) was added and the solution was cooled to 0 oC followed by addition of tert-
Butyldimethylsilyl chloride (175 mg, 1.16 mmol, 1.02 eq) and triethylamine (0.18 mL, 1.29 
mmol, 1.1 eq). The reaction mixture was stirred for 20 hours at room temperature. The reaction was quenched 
with H2O (>50 mL) and extracted with Et2O (3x 50 mL). The combined organic layers were washed with brine, 
dried over MgSO4, filtrated and concentrated in vacuo. The crude product was purified with silica gel 
chromatography (0% to 2% EtOAc in pentane). The silylated product 7c was collected as a colorless oil (265 mg, 
0.78 mmol, 68%). Rf = 0.4 (pentane); 1H NMR (400 MHz, CDCl3) δ 5.79 (ddd, 1 H, J = 16.8, 10.4, 6.0 Hz, H-2), 5.12 
(dt, 1 H, J = 17.2, 1.6 Hz, H-1a), 5.01 (dt, 1 H, J = 10.4, 1.6 Hz, H-1b), 4.07 (m, 1 H, H-3), 1.45 (m, 2 H, H-4), 1.37 – 
1.26 (m, 20 H, H-5 to H-14), 0.90 (s, 9 H, CH3-Si-tBu), 0.88 (t, 3 H, J = 6.8 Hz, H-15), 0.05 (s, 3 H, CH3-Si), 0.03 (s, 3 H, 
CH3-Si); 13C MR (101 MHz, CDCl3)  δ 142.12 (C-2), 113.48 (C-1), 74.06 (C-3), 38.29 (C-4), 32.10, 29.85, 29.83, 29.82, 
29.80, 29.79 (x2), 29.53 (CH2 x 8), 26.06 (CH3-Si-tBu), 25.37, 22.86 (CH2 x 2), 18.44 (Cq-Si), 14.29 (C-15), -4.21 (CH3-Si), 
-4.66 (CH3-Si); IR (neat): 2955, 2924, 2853, 1252, 1080, 814 cm-1; HRMS (MALDI-TOF) calculated for  [for C21H44OSi  
+Ag]+: 447.2212, found 447.2229.  
 (R)-1-methoxy-4-((pentadec-1-en-3-yloxy)methyl)benzene (7d). Allylic alcohol 7a (232 mg, 1.02 mmol, 1 eq) 
was dissolved in anhydrous DMF (5 mL) under an argon atmosphere. The solution was 
cooled to 0oC, followed by addition of sodium hydride (60% in mineral oil, 48 mg, 2.0 mmol, 
2 eq). After stirring for 15 minutes, 4-methoxybenzyl chloride (0.27 mL, 2.0 mmol, 2 eq) was 
slowly added to the reaction mixture. The solution was stirred for 20 hours at room temperature. The reaction 
was quenched by adding NH4Cl (sat., 20 mL) drop wise. After quenching, H2O (>50 mL) was added and extracted 
with Et2O (2x 100 mL). The combined organic layers were washed with brine, dried over MgSO4, filtrated and 
concentrated in vacuo. The crude product was purified with silica gel chromatography (0% to 1% Et2O in 
pentane). The PMB-protected product 7d (309 mg, 0.89 mmol, 87%) was collected as a light yellow oil. Rf = 0.2 
(1% Et2O in pentane);  [α]D = +19.0o (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.25 (ad, 2 H, J = 8.8 Hz, H-18), 
6.87 (ad, 2 H, J = 8.8 Hz, H-19), 5.72 (ddd, 1 H, J = 18.4, 10.4, 8.0 Hz, H-2), 5.21 (dm, 1 H, H-1a), 5.18 (dm, 1 H, H-
1b), 4.52 (d, 1 H, J = 11.6 Hz, H-16a), 4.28 (d, 1 H, J = 11.6 Hz, H-16b), 3.80 (s, 3 H, H-21), 3.69 (m, 1 H, H-3), 1.63 
(m, 1 H, H-4a), 1.46 (m, 1 H, H-4b), 1.40 – 1.25 (m, 20 H, H-5 to H- 14), 0.88 (t, 3 H, J = 6.8 Hz, H-15); 13C NMR (101 
MHz, CDCl3)  δ 159.14 (Cq-PMB), 139.50 (C-2), 131.09 (Cq-PMB), 129.46 (C-18), 117.00 (C-1), 113.85 (C-19), 80.44 (C-3), 
69.80 (C-16), 55.42 (C-21), 35.67 (C- 4), 32.08, 29.83, 29.81 (x2), 29.78, 29.75, 29.70, 29.52, 25.54, 22.85 (CH2 x 
10), 14.28 (C-15); IR (neat): 2922, 2853, 1612, 1246, 1038 cm-1; HRMS (MALDI-TOF) calculated for [C17H34O2 + 
Ag]+: 377.1610, found 377.1598.  
 (R)-3-(methoxymethoxy)pentadec-1-ene (7e). Allylic alcohol 7a (229 mg, 1.01 mmol, 1 eq) was dissolved in  
anhydrous DCM (6 mL) under an argon atmosphere. DMAP (16 mg, 0.13 mmol, cat.) was 
added and the solution was cooled to 0 oC.  DIPEA (0.87 mL, 5.0 mmol, 5 eq) and 
chloromethyl methyl ether (0.34 mL, 4.5 mmol, 4.5 eq) were added. The reaction was stirred 
for 20 hours at room temperature. The reaction was quenched by adding NH4Cl (sat., 20 mL). The reaction 
mixture was diluted with H2O and extracted with DCM (3 x 50 mL). The combined organic layers were dried over 
MgSO4, filtrated and concentrated in vacuo. The crude product was purified with silica gel chromatography (1-
20% Toluene in pentane). The MOM-protected product 7e (256 mg, 0.95 mmol, 94%) was collected as a light 
yellow oil. Rf = 0.2 (20% Toluene in pentane);  [α]D = +50.0 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.66 (ddd, 
1 H, J = 17.6, 10.4, 7.6 Hz, H-2), 5.19 (dm, 1 H, H-1a), 5.16 (dm, 1 H, H-1b), 4.70 (d, 1 H, J = 6.8 Hz, H-16a), 4.53 (d, 1 
H, J = 6.8 Hz, H-16b), 3.97 (m, 1 H, H-3), 3.37 (s, 3 H, H-17), 1.61 (m, 1 H, H-4a), 1.49 (m, 1 H, H-4b), 1.45 – 1.26 (m, 
20 H, H-5 to H-14), 0.88 (t, 3 H, J = 6.8 Hz, H-15);  13C NMR (101 MHz, CDCl3)  δ 138.69 (C-2), 117.09 (C-1), 93.83 
(C-16), 77.52 (C-3), 55.49 (C-17), 35.58 (C-4), 32.07, 29.82, 29.80 (x2), 29.76, 29.75, 29.70, 29.51, 25.53, 22.83 
(CH2 x 10), 14.25 (C-15); IR (neat): 2924, 2853, 1036 cm-1; HRMS (MALDI-TOF) calculated for [C22H34O2 +Ag]+: 
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tert-Butyl ((4R,5S)-4-((R,E)-3-hydroxypentadec-1-en-1-yl)-2-oxo-1,3-dioxan-5-yl)carbamate (8d). Allylic alcohol 
7a (24 mg, 0.11 mmol, 1 eq) and cyclic carbonate 6b (73 mg, 0.30 mmol, 3 eq) were 
combined and co-evaporated with toluene in a 50 mL round bottom flask. The 
mixture was dissolved in anhydrous Et2O (0.5 mL) under an argon atmosphere. The 
solution was stirred briefly before addition of second generation Grubbs Catalyst (17 
mg, 0.02 mmol, 0.2 eq) and copper (I) iodide (6 mg, 0.03 mmol, 0.3 eq). The reaction 
mixture was stirred at room temperature for 48 hours. The reaction mixture was concentrated in vacuo. The 
crude product was purified with silica gel chromatography (20-30% EtOAc in pentane). The metathesized product 
8d was collected as a brown oil that slowly crystallized (39 mg, 0.088 mmol, 83%). Rf = 0.4 (40% EtOAc in 
pentane);  [α]D = +24.4o (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.96 (dd, 1 H, J = 15.6, 4.8 Hz, H-5), 5.78 (dd, 1 
H, J = 15.2, 4.8 Hz, H-4), 5.53 (d, 1 H, J = 7.2 Hz, -NH), 5.00 (m, 1 H, H-3), 4.55 (bd, 1 H, J = 9.6 Hz, H-1a), 4.30 (bd, 1 
H, J = 10.4 Hz, H-1b), 4.19 (m, 1 H, H-6), 3.94 (bs, 1 H, H-2), 2.41 (bs, 1 H, -OH), 1.51 (m, 2 H, H-7), 1.46 (s, 9 H, CH3-
Boc), 1.32 – 1.26 (m, 20 H, H-8 to H-17), 0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, CDCl3)  δ 155.25 (C=OBoc), 
147.83 (C=OCarbonate), 139.19 (C-5), 123.77 (C-4), 81.73 (C-3), 80.93 (Cq-Boc), 71.32 (C-6), 68.36 (C-1), 46.20 (C-2), 
37.16 (C-7), 32.00, 29.76, 29.74 (x2), 29.71, 29.66, 29.61, 29.44 (CH2 x 8), 28.37 (CH3-Boc), 25.44, 22.77 (CH2 x 2), 
14.21 (C-18); IR (neat): 3464, 3352, 2951, 2917, 2850, 1759, 1695, 1190, 1165 cm-1; HRMS calculated for 
[C19H36NO4 (M-Boc) +H]+: 342.2639, found 342.2641.   
6-Hydroxy sphingosine (1). Protected 6-hydroxysphingosine 8d (35 mg, 0.080 mmol) was dissolved in THF/H2O  
(3:1, 1.5 mL) at room temperature. The solution was cooled to 0oC before 
addition of lithium hydroxide monohydrate (9 mg, 0.21 mmol, 2.7 eq). The 
reaction mixture was stirred for 3 hours at 0oC. The reaction mixture was 
acidified by addition of Amberlyst. The reaction mixture was filtrated, washed with MeOH/EtOAc and 
concentrated in vacuo. The crude tert-Butyl ((2S,3R,6R,E)-1,3,6-trihydroxyoctadec-4-en-2-yl)carbamate was 
collected as a solid, which was used for the next reaction without further purification. Rf = 0.4 (80% EtOAc in 
pentane); 1H NMR (400 MHz, CDCl3)  δ 5.82 (dd, 1 H, J = 15.6, 5.2 Hz, H-5), 5.74 (dd, 1 H, J = 15.6, 5.2 Hz, H-4), 5.46 
(d, 1 H, J = 8.4 Hz, -NH), 4.33 (t, 1 H, J = 4.6 Hz, H-3), 4.11 (m, 1 H, H-6), 3.88 (dd, 1 H, J = 11.2, 3.6 Hz, H- 1a), 3.67 
(dd, 1 H, J = 11.2, 3.6 Hz, H-1b), 3.60 (m, 1 H, H-2), 1.50 (m, 2 H, H-7), 1.44 (s, 9 H, CH3-Boc), 1.28 – 1.26 (m, 20 H, H-
8 to H-17), 0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, CDCl3)  δ 156.55 (C=OBoc), 135.66 (C-5), 129.57 (C-4), 
80.09 (Cq-Boc), 73.64 (C-3), 72.03 (C-6), 62.29 (C-1), 55.44 (C-2), 37.35 (C-7), 32.06, 29.83 (x3), 29.80 (x2), 29.76, 
29.50 (CH2 x 8), 28.55 (CH3-Boc), 25.70, 22.82 (CH2 x 2), 14.25 (C-18); HRMS calculated for [C23H45NO5+Na]+: 
438.3190, found 438.3187.  
The crude tert-Butyl ((2S,3R,6R,E)-1,3,6-trihydroxyoctadec-4-en-2-yl)carbamate previously described was 
dissolved in DCM (2.7 mL). The solution was cooled to 0oC before slowly adding TFA (0.3 mL). The solution was 
stirred for 90 minutes at 0oC. The reaction mixture was diluted with toluene (~20 mL) followed by concentration 
in vacuo. Before complete evaporation of all solvents, the reaction mixture was diluted with toluene 2 more 
times (2x 20 mL). The crude product was purified with silica gel chromatography (neutralized silica, 5-7.5% MeOH 
in CHCl3). 6-Hydroxy sphingosine 1 was collected as a waxy solid (20 mg, 0.063 mmol, 80% over 2 steps). Rf = 0.3 
(30% MeOH in CHCl3); [α]D = -9.6o (c = 0.5, MeOH); 1H NMR (400 MHz, MeOD-d4) δ 5.86 (dd, 1 H, J = 15.6, 6.0 Hz, 
H-5), 5.67 (dd, 1 H, J = 15.6, 6.4 Hz, H-4), 4.37 (t, 1 H, J = 5.2 Hz, H-3), 4.09 (q, 1 H, J = 6.0 Hz, H-6), 3.80 (dd, 1 H, J 
= 11.6, 4.0 Hz, H-1a), 3.70 (dd, 1 H, J = 11.6, 8.0 Hz, H-1b), 3.24 (m, 1 H, H-2), 1.51 (m, 2 H, H-7), 1.46 – 1.29 (m, 20 
H, H-8 to H-17), 0.90 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, MeOD-d4)  δ 138.26 (C-5), 128.69 (C-4), 72.52 
(C-6), 70.43 (C-3), 59.28 (C- 1), 58.30 (C-2), 38.27 (C-7), 33.05, 30.77 (x2), 30.74 (x3), 30.45, 26.53, 23.71 (CH2 x 
9), 14.44 (C-18); IR (neat): 3329, 3096, 2953, 2922, 2853, 1668, 1464, 1456, 1435, 1200, 1186, 1136 cm-1; HRMS 
calculated [C18H37NO3 +H+]: C18H37NO3 316.2846, found 316.2847.  Spectroscopic data was identical to 
literature.[8]  














Methyl (R)-2-hydroxyhexadecanoate (16a). (R,E)-2-hydroxypent-3-enenitrile 15 (1.95 g, 20.10 mmol, 1 eq, ee > 
99%) was dissolved in anhydrous Et2O (25.0 mL) in a flame-dried three necked round 
bottom flask under an argon atmosphere. Anhydrous MeOH (1.66 mL, 20.98 mmol, 2.0 
eq) was added. This solution was purged with dry HCl gas (1.47 g, 40.19 mmol, 2 eq). 
The acidified reaction mixture was stored at -20oC for 20 hours under an argon 
atmosphere. H2O (10 mL)  was added and stirring for 40 minutes. The aqueous layer was extracted with EtOAc 
(3x 40 mL). The combined organic layers were washed with NaHCO3 (sat., 40 mL) and brine, dried over MgSO4, 
filtrated and concentrated in vacuo. The crude product was purified with silica gel chromatography (10% DCM, 
10% Et2O in pentane, isocratic) giving Methyl (R,E)-2-hydroxypent-3-enoate as a yellow oil (1.26 g, 9.66 mmol, 
48%). Rf = 0.2 (10% DCM, 10% Et2O in pentane); 1H NMR (400 MHz, CDCl3) δ 5.90 (m, 1 H, H-4), 5.53 (m, 1 H, H-3), 
4.61 (d, 1 H, J = 6.4 Hz, H-2), 3.80 (s, 3 H, -OMe), 3.20 (bs, 1 H, -OH), 1.74 (d, 3 H, J = 6.8 Hz, H-5); 13C NMR (101 
MHz, CDCl3)  δ 174.26 (C-1), 129.92 (C-4), 127.26 (C-3), 71.48 (C-2), 52.80 (-OMe), 17.74 (C-5); IR (neat): 3439, 
2922, 2855, 1732, 1445, 1198 cm-1. Spectroscopic data was identical to literature.[18] 
Methyl (R,E)-2-hydroxypent-3-enoate (1.42 g, 10.94 mmol, 1 eq) was dissolved in anhydrous DCM (6 mL) under 
an argon atmosphere in a 250 mL round bottom flask. 1-Tetradecene (5.55 mL, 21.88 mmol, 2 eq), acetic acid (63 
µL, 1.09 mmol, 0.5 eq) and second generation Grubbs Catalyst (93 mg, 0.11 mmol, 0.05 eq) were added to the 
reaction mixture. The reaction mixture was stirred for 60 hours at 50 oC. Afterwards, the reaction mixture was 
concentrated in vacuo. The crude product was purified with silica gel chromatography (5% Et2O, 10% DCM to 7.5 
% Et2O, 10% DCM to 10% Et2O, 10% DCM in pentane). The metathesized product Methyl (R,E)-2-hydroxyhexadec-
3-enoate was collected as a brown oil (2.27 g, 7.99 mmol, 73%). Rf = 0.2 (10% Et2O, 10% DCM in pentane); 1H 
NMR (400 MHz, CDCl3) δ 5.88 (dt, 1 H, J = 14.4, 6.8 Hz, H-4), 5.50 (dd, 1 H, J = 15.2, 6.0 Hz, H-3), 4.61 (d, 1 H, J = 
6.0 Hz, H-2), 3.80 (s, 3 H, -OMe), 2.80 (s, 1 H, -OH), 2.06 (q, 2 H, J = 7.2 Hz, H-5), 1.39 (m, 2 H, H-6), 1.35 – 1.26 (m, 
18 H, H-7 to H-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C NMR (101 MHz, CDCl3)  δ 174.44 (C-1), 135.27 (C-4), 125.95 
(C-3), 71.58 (C-2), 52.92 (-OMe), 32.29, 32.06, 29.82, 29.80, 29.79, 29.75, 29.60, 29.50, 29.29, 28.96, 22.83 (CH2 x 
11), 14.27 (C-16); IR (neat): 3458, 2922, 2853, 1713, 1466 cm-1.   
Methyl (R,E)-2-hydroxyhexadec-3-enoate (1.16 g, 4.08 mmol, 1 eq) was dissolved in EtOAc (40 mL) under an 
argon atmosphere. The solution was purged with argon followed by addition of palladium on carbon (10% 
loading, 22 mg, 0.2 mmol, 0.05 eq). The mixture was then stirred for 30 minutes under a flow of hydrogen gas 
and was then left for 60 hours under a hydrogen  atmosphere.  The mixture was filtered over a pad of Celite and 
concentration in vacuo giving the crude product 16a as a solid (1.07 g, 3.72 mmol, 91%). Rf = 0.2 (10% Et2O, 10% 
DCM in pentane); 1H NMR (400 MHz, CDCl3)  δ 4.19 (dd, 1 H, J = 7.2, 4.4 Hz, H-2), 3.79 (s, 3 H, -OMe), 2.69 (bs, 1 H, 
-OH), 1.78 (m, 1 H, H-3a), 1.63 (m, 1 H, H-3b), 1.54 – 1.25 (m, 24 H, H-4 to H-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C 
NMR (101 MHz, CDCl3)  δ 176.02 (C-1), 70.62 (C-2), 52.63 (-OMe), 34.57 (C-3), 32.08, 29.84, 29.83, 29.81 (x2), 
29.78, 29.70, 29.61, 29.51, 29.45, 24.88, 22.85 (CH2 x 12), 14.28 (C-16); IR (neat): 3462, 2920, 2853, 1736, 1460, 
1215 cm-1. HRMS (MALDI-TOF) calculated [C17H34O3 + Ag]+: 393.1559, found 393.1572.  
α-Hydroxy fatty acid (16b). Methyl ester 16a (926 mg, 3.23 mmol, 1 eq) was dissolved in THF/MeOH/H2O (2:2:1, 
30 mL) at room temperature. Lithium hydroxide monohydrate (420 mg, 10.0 mmol, 3.1 
eq) was added and the reaction mixture was stirred for 20 hours at room temperature. 
The reaction mixture was quenched by HCl (1M, 15 mL). The aqueous mixture was 
extracted with EtOAc (3x 75 mL). The combined organic layers were washed with H2O 
(100 mL) and brine, dried over MgSO4, filtrated and concentrated in vacuo.  The  crude  α-hydroxy fatty acid 16b 
was collected as a solid (873 mg, 3.20 mmol, 99%) and was used for the next step without further purification. Rf 
= 0.1 (30% EtOAc in pentane); 1H NMR (400 MHz, CDCl3) δ 4.28 (dd, 1 H, J = 7.6, 4.4 Hz, H-2), 1.86 (m, 1 H, H-3a), 
1.71 (m, 1 H, H-3b), 1.46 (m, 2 H, H-4), 1.38 – 1.26 (m, 22 H, H-5 to H-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C NMR 
(101 MHz, CDCl3)  δ 179.41 (C-1), 70.38 (C-2), 34.36 (C-3), 32.08, 29.84 (x2), 29.81 (x2), 29.79, 29.71, 29.60, 29.52, 
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Spectroscopic data was identical to literature.[23]    
 (R)-2-Acetoxyhexadecanoic acid (16c). The   crude   α-hydroxy fatty acid 16b (808 mg, 2.97 mmol, 1 eq) was 
dissolved in anhydrous DCM (30 mL) under an argon atmosphere at room temperature. 
Acetic anhydride (4.49 mL, 47.45 mmol, 16 eq) and pyridine (7.45 mL, 92.15 mmol, 31 
eq) were added and the reaction mixture was stirred for 20 hours. The reaction was 
quenched by adding NaHCO3 (sat. aq., 50 mL). The aqueous layer was extracted with CHCl3 (2x 50 mL). The 
combined organic layers were washed with KHSO4 (0.5 M, 75 mL), dried over MgSO4, filtrated and concentrated 
in vacuo. The acetylated product 16c was collected as a yellow solid (905 mg, 2.88 mmol, 97%), which was used 
for the next step without further purification. Rf = 0.2 (30% EtOAc in pentane);   [α]D = + 9.0 (c = 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 10.61 (bs, 1 H, -COOH), 5.00 (t, 1 H, J = 6.4 Hz, H-2), 2.14 (s, 3 H, CH3-Acetyl), 1.86 (m, 2 H, 
H-3), 1.42 (m, 2 H, H-4), 1.37 – 1.26 (m, 22 H, H-5 to H-15), 0.88 (t, 3 H, J = 6.8 Hz, H-16); 13C NMR (101 MHz, 
CDCl3)  δ 175.96 (C-1), 170.79 (C=OAcetyl), 72.00 (C-2), 32.08 (CH2), 31.09 (C-3), 29.83 (x2), 29.80 (x2), 29.76, 29.68, 
29.51, 29.49, 29.26 (CH2 x 9), 25.26 (C-4), 22.85 (CH2), 20.73 (CH3-acetyl), 14.28 (C-16); IR (neat): 2955, 2916, 2849, 
1742, 1722, 1228 cm-1. HRMS (MALDI-TOF) calculated [C18H34O4 + Ag]+: 421.1508, found 421.1516. Spectroscopic 
data was identical to literature.[23]  
 (R)-1-Oxo-1-(((2S,3R,6R,E)-1,3,6-trihydroxyoctadec-4-en-2-yl)amino)hexadecan-2-yl acetate (17). 6-Hydroxy 
sphingosine 1 (11 mg, 0.035 mmol, 1 eq) and carboxylic acid 16c (14 mg, 0.045 
mmol, 1.3 eq) were dissolved in anhydrous EtOH (1.5 mL) under an argon 
atmosphere. 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (17 mg, 0.069 
mmol, 2 eq) was added and the reaction mixture was stirred for 20 hours at 
50oC. The reaction mixture was concentrated in vacuo and purified with silica gel 
chromatography (0-3% MeOH in CHCl3). Acetylated ceramide 17 was collected as a waxy white solid (14 mg, 
0.023 mmol, 66%). Rf = 0.3 (5% MeOH in CHCl3); 1H NMR (400 MHz, CDCl3)  δ 6.76 (d, 1 H, J = 8.0 Hz, -NH), 5.84 
(dd, 1 H, J = 15.6, 6.4 Hz, H-5), 5.73 (dd, 1 H, J = 15.6, 5.6 Hz, H-4), 4.99 (t, 1 H, J = 6.4 Hz, H-2’),  4.37  (t,  1  H,  J = 4.8 
Hz, H-3), 4.13 (q, 1 H, J = 6.4 Hz, H-6), 3.97 (dd, 1 H, J = 11.2, 3.2 Hz, H-1a), 3.89 (m, 1 H, H-2), 3.69 (dd, 1 H, J = 
11.2, 3.6 Hz, H-1b), 3.24 (bs, 1 H, -OH), 2.86 (bs, 1 H, -OH), 2.16 (s, 3 H, CH3-Acetyl), 1.83 (m, 2 H, H-3’),  1.52  (m,  2  H,  
H-7), 1.37 – 1.26 (m, 44 H, H-8 to H-17 and H-4’  to  H-15’),  0.88  (t,  6  H,  J = 6.8 Hz, H-18 and H- 16’);  13C NMR (101 
MHz, CDCl3)  δ 170.85, 170.75 (C-1’  and  C=OAcetyl), 136.27 (C-5), 129.50 (C-4), 74.76 (C-2’),  73.55  (C-3), 72.21 (C-6), 
61.94 (C-1), 54.20 (C-2), 37.34 (C-7), 32.08 (CH2), 31.97 (C-3’),  29.85  (x4),  29.83  (x3),  29.81  (x3),  29.73  (x2), 29.59, 
29.51 (x2), 29.41, 25.63, 25.16, 22.84 (CH2 x 19), 21.10 (CH3-Acetyl), 14.27 (C-18 and C-16’); HRMS calculated 
[C36H69NO6 +Na]+: 634.5017, found 634.5011.  
Ceramide (2). Acetylated ceramide 17 (11 mg, 0.018 mmol, 1 eq) was dissolved in DCM/MeOH (4:1, 0.2 mL) 
under an argon atmosphere. Potassium carbonate (catalytic amount) was added 
and the reaction mixture was stirred for 2 hours at room temperature. The 
reaction mixture was acidified by adding Amberlyst 1, followed by filtration and 
concentration in vacuo. The crude product was purified with silica gel 
chromatography (0- 5% MeOH in CHCl3) giving Ceramide 2 as a white solid (9 mg, 
0.016 mmol, 88%). Rf = 0.5 (10% MeOH in CHCl3); 1H NMR (850 MHz, CDCl3/MeOD-d4, 9:1) δ 7.42 (d, 1 H, J = 8.5 
Hz, -NH), 5.77 (dd, 1 H, J = 15.3, 6.0 Hz, H-5), 5.66 (dd, 1 H, J = 15.3, 6.0 Hz, H-4), 4.23 (at, 1 H, J = 5.1 Hz, H-3), 
4.07 (m, 1 H, H- 6), 4.03 (dd, 1 H, J = 8.5, 3.4 Hz, H-2’),  3.85  (m,  1  H,  H-2), 3.81 (dd, 1 H, J = 12.0, 4.3 Hz, H-1a), 3.69 
(dd, 1 H, J = 11.9, 2.6 Hz, H-1b), 1.58 – 1.44 (m, 4 H, H-7 and H-3’),  1.41  – 1.26 (m, 44 H, H-8 to H-17 and H-4’  to  H-
15’),  0.88  (t,  6  H,  J = 6.8 Hz, H-18 and H-16’);  13C NMR (214 MHz, CDCl3/MeOD-d4,  9:1)  δ 176.21 (C-1’),  135.79  (C-
5), 129.16 (C-4), 72.59 (C-3), 72.18 (C-2’),  71.79  (C-6), 61.45 (C-1), 54.59 (C- 2), 37.12 (C-7), 34.37 (C-3’),  31.96,  
29.75, 29.73 (x2), 29.72 (x2), 29.71 (x2), 29.70 (x2), 29.68 (x2), 29.66, 29.63, 29.48, 29.40 (x2), 25.60, 22.72 (CH2 x 
19), 14.11 (C-18 and C-16’); IR (neat): 3377, 3264, 2953, 2916, 2849, 1738, 1715, 1651, 1620, 1470, 1074, 1043 
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Synthesis of Ceramide-Mimetic Aziridines as 
Potential Mechanism-Based Enzyme 
Inhibitors  
6.1 Introduction 
Glucosylceramide (1) is the substrate of at least three hydrolases.[1] In healthy tissues, 
glucosylceramide is predominantly processed by lysosomal acid glucosylceramidase (GBA, 
Figure 6.1) to form glucose (2) and ceramide (3). Gaucher disease is characterized by 
genetic impairment of GBA, resulting in glucosylceramide accumulation. Within the 
lysosomes, elevated glucosylceramide levels can be taken on by acid ceramidase (ACase), 
which in healthy individuals is responsible for hydrolysis of the amide bond in ceramide to 
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produce sphingosine (4) and a fatty acid (5).[2] In case of increased glucosylceramide 
levels, acid ceramidase is found to be capable of producing the corresponding 
glucosylsphingosine (6), which is normally not (or only in low quantities) observed, and 
thus serves as a marker for GBA deficiency. Glucosylceramide (1) may also escape from 
lysosomes to the cytosol, where it can be processed by neutral glucosylceramidase 
(GBA2).[3] Also GBA2 produces glucose (2) and ceramide (3), but does so (in comparison 
with GBA) in a different subcellular environment: the cytoplasm. 
Figure 6.1 Partial overview of metabolism of glucosylceramide 1. ACase: acid ceramidase; GBA: 
glucosylceramidase; GBA2: neutral glucosylceramidase. 
 
In recent years, activity-based probes (ABPs) for each of the three glucosylceramide-
processing enzymes, GBA, GBA2[4,5] and acid ceramidase,[6] have been developed. In 
general, the design of an ABP starts with the identification of a covalent, irreversible 
inhibitor of the enzyme, or enzyme family, at hand. Cyclophellitol (7)[7] is a naturally 
occurring -glucopyranose analogue that, upon binding to the enzyme active site, reacts 
with retaining -glucosidases to form a covalent, irreversible enzyme-inhibitor adduct 
(Figure 6.2). Both GBA and GBA2 are retaining -glucosidases and indeed effective ABPs 
for both enzymes have been developed based on the cyclophellitol scaffold. Substitution 
of the primary alcohol in 7 with an azide gave azido-cyclophellitol (8)[8,9] that served as a 
starting point for the construction (through copper(I)-catalyzed azide-alkyne [2+3] 
cycloaddition   ‘click’   conjugation)   of ABPs specific for GBA in the presence of GBA2 and 
other retaining -glucosidases. Substitution of the epoxide oxygen for nitrogen and 
alkylation of the resulting aziridine yielded cyclophellitol aziridine (9),[10] also featuring an 




















































targeting amongst others both GBA and GBA2. An acid ceramidase-recognizing ABP[6] has 
been developed based on the covalent and irreversible inhibitor, carmofur (10).[11] Again, 
installment of an azide (as in 11) allowed for click ligation of a reporter fluorophore to 
yield a selective acid ceramidase probe. 
 
 
Figure 6.2 A) Mechanism of inhibition of GBA by cyclophellitol 7 and ABP-cyclophellitols 8 and 9. B) Mechanism 
of inhibition of acid ceramidase by carmofur 10 and carmofur-azide 11. C) Possible mechanism of inhibition of 
GBA/GBA2 and synthetic ceramide aziridine targets 12 and 13 described in this chapter. 
 
The mode of action of the cyclophellitol-based probes 7[8,9] and 8 and their derivatives is 
based on several features. Cyclophellitols are configurational analogues of -
glucopyranose that adopt a 4H3 conformation within the enzyme active site.[12] Once 
bound, a good leaving group (epoxide-oxygen or aziridine-nitrogen) is positioned 
optimally for nucleophilic attack by the active-site nucleophilic residue and the 
electrophilic nature of the epoxide/aziridine is likely enhanced by protonation by the 
active site acid-base catalyst. Once reacted, an ester bond is formed which is more stable 
than the acylacetal linkage that emerges during GBA/GBA2-mediated glucosylceramide 
processing. Looking at this mechanism, one could argue that cyclophellitol emulates only 
half of the GBA/GBA2 substrate, namely the glucopyranose portion of glucosylceramide 
(1). This in turn invites the question whether an electrophile featuring characteristics of 
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this idea in mind, ceramide-derived aziridines 12 and 13 (Figure 6.2C), both featuring an 
azide for bioconjugation or two-step activity-based protein profiling (ABPP) were 
designed. The synthesis of aziridines 12 and 13 is described in this chapter. 
 
6.2 Results and discussion 
The construction of aziridine-ceramides 12 and 13 started from the easily accessible 
azidosphingosine 14.[13] In the first step, selective mesylation of the primary hydroxyl 
group in 15 was accomplished by reacting methanesulfonyl chloride and 2,4,6-collidine to 
in situ form a mesylcollidinium species,[14] which due to its steric bulk reacts exclusively 
with the primarily hydroxyl, yielding compound 15. The allylic hydroxyl in 15 was masked 
as the TBS-ether (TBSOTf, 2,4,6-collidine).[15,16] Treatment of the resulting 16 with PPh3 
and water allowed Staudinger reduction of the azide.[17] The in situ formed free amine 
displaced the primary mesyl group in an intramolecular SN2 nucleophilic substitution to 
give partially protected aziridine 17 ready for either N-alkylation or N-acylation towards 
the two target compounds 12 and 13. 
 
Scheme 6.1 Synthesis of aziridine 16 and azides 22 and 25. 
 
Reagents and conditions: (a) MsCl, 2,4,6-collidine, DCM, 0 oC to 4 oC, 20 h; (b) TBSOTf, 2,4,6-collidine, DCM, 0 
oC to 4 oC, 20 h, 65% (over two steps); (c) PPh3, DIPEA, THF/H2O (10:1), r.t., 4 h, 59%; (d) NaOMe, MeOH, 60 oC, 3 
h, 91%; (e) NCS, PPh3, THF, r.t., 20 h, 61%; (f) NaN3, NaI, DMF, 55 oC, 20 h, 94%; (g) LiOH.H2O, THF/MeOH/H2O 
(2:2:1), r.t., 20 h, 61%; (h) oxalyl chloride, DMF, DCM, 0 oC to r.t., 2 h, quant.; (i) LiAlH4 (1 M in THF), THF, 0 oC, 2 
h, 86%: (j) NaN3, NaI, DMF, 55 oC, 20 h, 93%; (k) Tf2O, pyridine, DCM, 0 oC, 1 h, quant. 
 
The required 16-azido palmitoyl chloride 23 and 16-azido hexadecanoyl triflate 26 for the 
construction of these target compounds from aziridine 17 were prepared as follows 
(Scheme 6.1.B). Trans-esterification of cyclohexadecanolide 18 (NaOMe, methanol) 
provided methyl ester 19 in 91% yield.[18] The primarily hydroxyl group in 19 was 
transformed into chloride 20 using Appel conditions (N-chlorosuccinimide, 






















































yielding azide 21 in 55% yield over the three steps based on 18. Next, the methyl ester in 
21 was saponified (LiOH in wet THF/MeOH), giving 16-azido-palmitoic acid 22.[19] Reaction 
of 22 with oxalyl chloride gave 16-azido-palmitoyl chloride 23, which was used for 
aziridine-N-acylation without further purification. In order to enable N-alkylation with an 
azide-functionalized C16-alkane, the methyl ester in 20 was treated with excess LiAlH4 to 
yield alcohol 24. Next, the chloride in 24 was substituted for an azide (NaN3, catalytic NaI), 
giving 16-azido hexadecan-1-al 25 in 94% yield. The primary hydroxyl in 25 was reacted 
with triflic anhydride and pyridine yielding triflate 26, which was directly used for N-
alkylation of aziridine 17. 
 
Scheme 6.2 Synthesis of aziridine-ceramides 12 and 13. 
 
Reagents and conditions: (a) 23, Et3N, DCM, -10 oC to r.t., 3 h, 61%; (b) 26, DIPEA, DCM, -20 oC, 3 h; ii) MeOH, 
62%; (c) TBAF, THF, r.t., 1 h, 62% 12, 55% 13. 
 
With aziridine-sphingosine 17, acyl azide 23 and alkyl azide 26 in hand, the construction of 
target compounds 12 and 13 was undertaken. Treatment of aziridine 17 with crude 16-
azidopalmitoyl chloride 23 and triethylamine gave compound 27.[17] The TBS protecting 
group in 27 was removed using TBAF in dry THF to afford N-acyl-aziridine 12 in 61% yield. 
N-alkylation of aziridine 17 was accomplished by treatment with crude triflate 26 in 
methanol, providing 28 in 62% yield. Removal of the TBS protecting group in 28 (TBAF, dry 
THF) gave N-alkyl-aziridine 13 in 55% yield. 
 
6.3 Conclusion 
In conclusion, this Chapter describes the synthesis of aziridines 12 and 13 as potential 
GBA/GBA2 ABPs that are distinguished from the existing ABPs 8 and 9 by emulating the 
ceramide fragment of the natural substrate (glucosylceramide), rather than the glucose 
portion. Future research is required to establish whether compounds 12 and 13 are 
indeed capable of reacting with GBA/GBA2 and to do so in cell extracts or live cells. To this 
end, compounds 12 and 13 can be conjugated (through click ligation) either prior to or 
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also been done in the past with azido cyclophellitol 8.[9] By performing the ABPP 
experiments in an unbiased fashion enzymes other than GBA/GBA2 may be identified, 
enzymes that may be involved in the processing of ceramide derivatives as well and that 
are characterized by an active site nucleophile that plays a role in enzyme catalysis. 
 
6.4 Experimental section 
General Remarks. Commercially available reagents and solvents were used as received. DCM and THF were 
dried and distilled by standard procedures. All moisture-sensitive reactions were carried out under an argon 
atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column chromatography was carried out with 
Silica gel 60 (40–63   μm   mesh).   IR   spectra   are   reported   in   cm–1. Optical rotations were measured with an 
automatic polarimeter (sodium D-line, λ = 589 nm). The enantiomeric purity was determined by HPLC analysis 
using an OD column (hexane/isopropyl alcohol (98:2), 1 mL/min, UV 254 nm). NMR spectra were recorded on a 
400 MHz or 850 MHz spectrometer. Chemical shifts are reported as δ  values (ppm), and were referenced to 
tetramethylsilane  (δ  =  0.00  ppm)  directly  in  CDCl3, or using the residual solvent peak (D2O). High resolution mass 
spectra were recorded on a LTQ-Orbitrap (Thermo Finnigan) mass spectrometer equipped with an electrospray 
ion source in positive mode 
 (2S,3R,E)-2-azido-3-((tert-butyldimethylsilyl)oxy)octadec-4-en-1-yl methanesulfonate (16). Azidosphingosine 
14 (1.11 g, 3.39 mmol, 1 eq.) was dissolved in DCM (38 mL) under an atmosphere of 
argon and 2,4,6-collidine (4.5 mL, 33.9 mmol, 10 eq.) was added. The mixture was left 
to stir for 15 minutes at 0 °C. MsCl (0.29 mL, 3.73 mmol, 1.1 eq.) was added and the 
reaction was left to stir for 21 h at 4  °C, after which the reaction was quenched with water. The mixture was 
diluted with DCM and washed with 1 M HCl (aq.), sat. aq. NaHCO3 and water. The water layers were extracted 
with DCM and combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The crude 
mesylated product 15 was used in the next step without any further purification. The mesylated sphingosine was 
then dissolved in DCM (35 mL) and 2,4,6-collidine (4.15 mL, 33.9 mmol, 10 eq.) was added. The mixture was left 
to stir for 15 minutes at 0 °C. TBSOTf (1.46 mL, 6.8 mmol, 2 eq.) was added and the mixture was left to stir over 
night at 4 °C. The mixture was diluted with DCM and washed with 1 M HCl (aq.), sat. aq. NaHCO3 and water. The 
water layers were extracted with DCM and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified by column chromatography (5% acetone in pentane) giving a 
colorless oil (1.12 g, 2.17 mmol, 65%). Rf =  0.35  (5%  acetone  in  pentane);  [α]20D: -32.8 (C= 1.0, CHCl3); 1H NMR 
(400 MHz, CDCl3)  δ 5.71(m, 1 H, H-5), 5.41 (dd, 1 H, J = 15.8, 7.6 Hz, H-4), 4.31 (dd, 1 H, J = 10.8, 3.6 Hz, H-3), 4.19 
(dd, 1 H, J = 8.0, 5.3 Hz, H-1), 4.10 (dd, 1 H, J = 11.0, 8.0 Hz, H-1b), 3.63 (m, 1 H, H-2), 3.04 (s, 3 H, MeMs), 2.04 (q, 2 
H, J = 6.8 Hz, H-6), 1.36-1.22 (m, 22 H, H-7 to H-17), 0.89-0.81 (m, 12 H, H-18 and SitBu) 0.07 (s, 3 H, SiMe) 0.03 (s, 3 
H, SiMe); 13C NMR (101 MHz, CDCl3)  δ 135.8 (C-5), 128.2 (C-4), 74.2 (C-3), 68.3 (C-1), 65.3 (C-2), 37.7 (CH3, MeMs), 
32.36, 32.06, 29.83, 29.80, 29.79 x2, 29.59, 29.50, 29.32, 29.02 (11x CH2, C-6 to C-17), 25.9 (SitBu), 22.8 (CH2, C-6 
to C-17), 14.22 (C-18),-2.85 (SiMe), -4.0 (SiMe); IR (neat): 2924, 2855, 2102, 1360, 1252, 1179, 964, 835, 777 cm-1; 
HRMS calculated for [C25H51N3O4SSi + H]+ : 518.3450, found 518.3464. 
 
 (S)-2-((R,E)-1-((tert-butyldimethylsilyl)oxy)hexadec-2-en-1-yl)aziridine (17). Compound 16 (279 mg, 0.54 mmol, 
1 eq.) was dissolved in a mixture of THF/H2O (10:1, 4 ml). Triphenylphosphine (230 mg, 
0.88   mmol,   1.63   eq.)   and   DIPEA   (190   μL,   1.09   mmol,   2   eq.)   were   added   at   room  
temperature and the reaction mixture was stirred for 4 hours. The mixture was diluted 
with EtOAc and washed with brine. The water layer was extracted with EtOAc and the combined organic layers 
were dried (MgSO4), filtered and concentrated in vacuo. The product was purified by column chromatography 
(silica gel, 4-8% acetone/pentane) giving a colorless oil (116 mg, 0.3 mmol, 59%). Rf = 0.5 (10% 










15.6, 7.0 Hz, H-4), 4.06 (dd, 1 H, J = 7.2, 4.0 Hz, H-3), 2.03 (q, 2 H, J = 7.0 Hz, H-6), 1.07 (m, 1 H, H-2), 1.62 (d, 1 H, 
J = 3.6, H-1a), 1.52 (d, 1 H, J = 5.5 Hz, H-1b), 1.43-1.15 (m, 22 H, H-7 to H-17), 0.87-0.84 (m, 12 H, H-18 and SitBu), 
0.04 (s, 3 H, SiMe), 0.02 (s, 3 H, SiMe); 13C NMR (101 MHz, CDCl3)  δ 132.7 (C-5), 131.0 (C-4), 72.2 (C-3), 35.0 (C-2), 
32.3, 32.1, 29.85, 29.83 x2, 29.81 x2, 29.77, 29.63, 29.51, 29.32, 29.27, (12x CH2, C-1 and C-6 to C-17), 26.0 (SitBu), 
22.8, (CH2, C-6 to C-17), 14.3 (C-18), -3.9 (SiMe), -4.7 (SiMe); IR (neat): 2924, 2853, 1462, 1252, 1060, 906, 835, 731 
cm-1. HRMS calculated for [C24H49NOSi +H]+: 396.3663, found 396.3653. 
 
methyl 16-hydroxyhexadecanoate (19). Cyclohexadecanolide 18 (2.6 g, 10.2 mmol, 1 eq.) was dissolved in dry 
MeOH (60 mL) under an atmosphere of argon. To the solution was added NaOMe (30% in 
methanol, 9.3 mL, 50 mmol, 5 eq.) was added. The reaction mixture was refluxed for 3 
hours at 65 °C after which it was cooled to room temperature. The reaction was 
quenched with 1 M HCl (aq.) to a pH of 11. The mixture was diluted with EtOAc, washed with sat. aq. NaHCO3. 
The water layer was extracted with EtOAc and combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified by column chromatography (Silica gel, 1:2 EtOAc/pentane) 
giving a white solid (2.62 g, 9.11 mmol, 91 %). Rf = 0.75 (1:2 EtOAc/pentane). 1H NMR (400 MHz, CDCl3)  δ 3.66 (s, 
3 H, OMe), 3.64 (t, 2 H, J= 7.2 Hz, H-16), 2.30 (t, 2 H, J= 7.8 Hz, H-2) 1.65-1.51 (m, 4 H, H-3 and H-15), 1.28-1.25 
(m, 22 H, H-4 to H-14). 13C NMR (101 MHz, CDCl3)  δ 174.5 (C-1), 63.2 (C-16), 51.6 (C-OMe), 34.3 (C-2), 33.0 (C-15), 
29.77 x2, 29.76, 29.74, 29.72, 29.58, 29.39, 29.29, 25.88, 25.10 (12x CH2, C-3 to C-14); IR (neat): 2918, 2849, 
1738, 1161 cm-1. 
 
methyl 16-chlorohexadecanoate (20). Compound 19 (2.62 g, 9.1 mmol, 1 eq.) was dissolved in dry THF (60 mL) 
under an atmosphere of argon. To the solution was added PPh3 (2.64 g, 10.02 mmol, 1.1 
eq.) and NCS (1.39 g, 10.02 mmol, 1.1 eq.). The reaction stirred over night at room 
temperature. The mixture was diluted with EtOAc and washed with water and brine. The 
water layers were extracted with EtOAc and combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo.  The crude product was purified by column chromatography in (Silica gel, 0% to 4% 
EtOAc/pentane) giving a colorless oil (1.69 g, 5.53 mmol, 61%). Rf = 0.8 (2 % EtOAc in pentane); 1H NMR (400 
MHz, CDCl3)  δ 3.66 (s, 3 H, -OMe), 3.53 (t, 2 H, J= 7.0 Hz, H-16), 2.30 (t, 2 H, J = 7.6 Hz, H-2) 1.76 (p, 2 H, J = 7.2 
Hz, H-15), 1.62 (m, 2 H, H-3), 1.42 (m, 2 H, H-14), 1.28-1.26 (m, 18 H, H-4 to H-13); 13C NMR (101 MHz, CDCl3)  δ 
174.4 (C-1), 51.5 (-OMe), 45.2 (C-16), 34.2 (C-2), 32.8, 29.7 x3, 29.68, 29.65, 29.57, 29.55, 29.36, 29.26, 29.00, 
27.0, 25.1 (13x CH2, C-3 to C15); IR (Neat): 2922, 2853, 1740, 1435, 1169, 721 cm-1.  
 
methyl 16-azidohexadecanoate (21). Chloride 20 (856 mg, 2.8 mmol, 1 eq.) was dissolved in DMF (13 mL) and 
NaN3 (580 mg, 8.9 mmol, 3 eq.) and a catalytic amount of NaI were added. The reaction 
was stirred over night at 55  ℃. The mixture was diluted with ether, washed with water 
and brine and extracted. The water layers were extracted with Ether and the combined 
organic layers were dried (MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (silica gel, 1-2% acetone in pentane) giving a white solid (791 mg, 2.54 mmol, 94%). Rf = 
0.8 (2% acetone/pentane); 1H NMR (400 MHz, CDCl3)  δ:  3.65  (s,  3  H,  OMe),  3.24  (t,  2  H,  J= 7.0 Hz, H-16), 2.29 (t, 2 
H, J = 7.4 Hz, H-2), 1.63-1.55 (m, 4 H, H-3 and H-15), 1.38-1.26 (m, 22H, H-4 to H-14); 13C NMR (101 MHz, CDCl3) 
δ:   173.9 (C-1), 51.3 (C-16), 51.2 (CH3, C-OMe), 33.9 (C-2), 29.56 x3, 29.52, 29.48, 29.43, 29.39, 29.02, 29.09, 
29.08, 29.87, 26.66, 24.87 (13x CH2, C-3 to C-15); IR (neat): 2922, 2853, 2093, 1740, 1252, 1169 cm-1. HRMS 
calculated for [C16H31N3O2 + H]+: 298.2496, found 298.2509. 
 
16-azidohexadecanoic acid (22).  Compound 21 (791 mg, 2.54 mmol, 1 eq.) was dissolved in a mixture of 
THF/MeOH/H2O (2:2:1, 25 mL) and LiOH.H2O (337 mg, 7.88 mmol, 3.1 eq.) was added. The 
reaction stirred over night at room temperature, after which it was acidified with 1 M HCl 
(aq) to a pH of 1-2. The mixture was diluted with EtOAc and extracted with water and brine. 
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concentrated in vacuo giving a white solid (446 mg, 1.5 mmol, 59%), which was used without any further 
purification. Rf = 0.2  (1:1:8 ether/DCM/pentane); 1H NMR (400 MHz, CDCl3)  δ 3.26 (t, 2 H, J= 7.0 Hz, H-16), 2.35 
(t, 2 H, J= 7.4 Hz, H-2), 1.67-1.56 (m, 4 H, H-3 and H-15), 1.36-1.22 (m, 22 H, H-4 to H-14). 13C NMR (101 MHz, 
CDCl3)  δ 180.2 (C-1), 51.6 (C-16), 34.0 (C-2), 29.7, 29.6, 29.5, 29.3, 29.2, 29.0, 26.7, 24.9 (13x CH2, C-3 to C-15); IR 
(neat): 2913, 2847, 2112, 1699, 1290 cm-1. HRMS calculated for [C15H29N3O2 + H]+: 284.2340, found 284.2335. 
 
16-azidohexadecanoyl chloride (23). Compound 22 (151 mg, 0.5 mmol, 1 eq.) was dissolved in dry DCM (1.6 mL) 
and the mixture was cooled to 0  °C.   Oxalyl   chloride   (85   μL,   1   mmol,   2   eq.)   was   added,  
followed by 1 drop of DMF, which released gas. The reaction was allowed to warm to room 
temperature. After no more gas was released, another drop of DMF was added. This 
process was repeated until no more gas was formed as DMF was added. The solvent was removed in vacuo and 
not purified any further, as the crude was immediately used in the production of compound 27. Quantitate yield 
was assumed. Rf = 0.85 (10% acetone/pentane); 1H NMR (400 MHz, CDCl3)  δ 3.25 (t, 2 H, J= 7.0 Hz, H-16), 2.88 (t, 
2 H, J= 7.2 Hz, H-2), 1.74-1.66 (m, 2 H, H-3), 1.63-1.56 (m, 2 H, H-15), 1.32-1.26 (m, 22 H, H-4 to H-14); 13C NMR 
(101 MHz, CDCl3)  δ 173.8 (C-1), 51.5 (C-16), 47.2 (C-2), 29.7, 29.6, 29.5, 29.4, 29.2, 29.1, 28.9, 28.5, 26.8, 25.10 
(13C, C-3 to C-15). IR (near): 2914, 2849, 2097, 1800, 1701 cm-1. 
 
16-Chloro-hexadecan-1-al (24). Methyl ester 20 (0.6 g, 2 mmol, 1 eq) was dissolved in dry diethyl ether (10 mL) 
under protected atmosphere and cooled to 0 0C. LiAlH4 (1 M in THF, 2.5 mL, 2.5 mmol, 1.25 
eq) was added drop wise and the reaction mixture was stirred for 2 hours at 0 0C. The 
reaction was then quenched with 1 M HCl, followed by filtration to remove inorganic salts. 
The diethyl ether was separated from the water layer, dried (MgSO4), filtered and concentrated in vacuo. The 
product was purified by silica column chromatography (10% EtOAc in Pentane) giving a white solid (0.47 g, 1.72 
mmol, 86%). Rf = 0.60 (20% EtOAc in Pentane); 1H NMR (400 MHz, CDCl3) δ 3.64 (t, 2 H, J = 6.8 Hz, H-1), 3.53 (t, 2 
H, J = 6.8 Hz, H-16), 1.77 (p, 2 H, J = 6.8 Hz, H-15), 1.57 (p, 2 H,  J = 6.8, H-2), 1.42 (m, 2 H, H-14), 1.35-1.22 (m, 14 
H, H-3 to H-13); 13C NMR (101 MHz, CDCl3) δ 63.2 (C-1), 45.4 (C-16), 32.94 (C-2), 32.79 (C-15), 29.78, 29.75, 29.73, 
29.68, 29.60, 29.57, 29.03, 27.03, 25.87 (12 x CH2 C-3 to C-14). IR (neat) 3279, 2922, 2853, 1464, 1055, 721 cm-1. 
 
16-Azido-hexadecan-1-al (25). 16-chloro-pentanol 24 (0.4 g, 1.45 mmol, 1 eq) was dissolved in dry DMF (10 mL) 
followed by addition of NaN3 (0.19 g, 2.9 mmol, 2 eq) and catalytic amount of NaI. The 
mixture was heated to 60 oC and left stirring over night. The reaction mixture was diluted 
with diethyl ether and washed with water and brine. The water layers were extracted with 
diethyl ether and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The 
product was purified with silica column chromatography (10% EtOAc in Pentane) giving a white solid (0.37 g, 
1.31 mmol, 94%). Rf = 0.60 (20% EtOAc in Pentane); 1H NMR (101 MHz, CDCl3)  δ 3.64 (t, 2 H, J = 6.8 Hz, H-1), 3.25 
(t, 2 H, J = 7.2 Hz, H-16), 1.63-1.53 (m, 4 H, H-2 and H-15), 1.40-1.26 (m, 24 H, H-3 to H-14); 13C NMR (101 MHz, 
CDCl3)  δ 63.2 (C-1), 51.2 (C-16), 33.01 (C-2), 29.55, 29.51, 29.47, 29.41, 29.37, 29.19, 29.08, 29.07, 28.77, 26.64, 
24.85 (13x CH2 C-3 to C-15); IR (neat) 3294, 2922, 2853, 2098, 1464, 1055 cm-1. 
 
16-Azido-hexadecan-1-O-triflate (26). 16-Azido-hexadecan-1-al 25 (57 mg, 0.2 mmol, 1.0 eq) was dissolved in 
dry DCM (2 mL) under protected atmosphere and cooled to 0 oC. Pyridine (19 μL, 0.24 
mmol, 1.2 eq) was added followed by addition of Tf2O (41 μL, 0.24 mmol, 1.2 eq). The 
mixture was stirred for 1 hour followed by dilution with DCM (10 mL). The reaction was washed with water and 
brine. The water layers were extracted with DCM and the combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo giving the crude triflate, which was directly used without any further purification in 


















1-((S)-2-((R,E)-1-((tert-butyldimethylsilyl)oxy)hexadec-2-en-1-yl)aziridin-1-yl)hexadecan-1-one (27). Aziridine 
sphingosine 17 (101 mg, 0.26 mmol, 1 eq.) was dissolved in DCM (5 mL) and triethylamine 
(62   μL,   0.44   mmol,   1.73   eq.)   was   added.   The   mixture   was   cooled   to   -10  °C. 16-azido-
palmitoyl chloride 23 (0.5 mmol, 1.9 eq.) was added drop-wise and the mixture stirred and 
was allowed to warm to room temperature over 3 h. The solvent was removed in vacuo to 
give a crude product. The crude was purified by column chromatography giving a colorless oil. (silica gel, 0% to 
2% acetone/pentane). Yield (155 mg, 0.23 mmol, 90%), Rf = 0.65 (5% acetone/pentane); [α]20D: -27.0 (C= 0.2, 
CHCl3); 1H NMR (400 MHz, CDCl3)  δ 5.81-5.78 (m, 1 H, H-5), 5.58 (dd, 1 H, J = 15.6, 8.0 Hz, H-4), 4.20-4.18 (m, 2 H, 
H-3), 3.37 (t, 2 H, J = 7.0 Hz, H-16*) 2.58-2.54 (m, 1 H, H-2), 2.45-2.41 (m, 1 H, H-1a), 2.20 (d, 1 H, J = 3.2 Hz, H-1b), 
2.17-2.13 (m, 2 H, H-6), 1.76-1.69 (m, 4 H, H-2* and H-15*), 1.48-1.37 (m, 46 H, H-7 to H-17 and H-3* to H-14*), 
1.00-0.98 (m, 12 H, H-18 and SitBu), 0.16 (s, 3 H, SiMe), 0.15 (s, 3 H, SiMe); 13C NMR (101 MHz, CDCl3)  δ 133.5 (C-5), 
129.5 (C-4), 73.2 (C-3), 51.6 (C-16*), 41.1 (C-2), 36.8 (C-6), 32.3, 32.9, 29.7, 29.6, 29.4, 29.3, 29.2, 28.9, 27.8 (C-1, 
C-7 to C-17 and C-2* to C-15*), 26.8 (3x CH3, SitBu), 25.9, 25.3, 22.8 ( C-1, C-7 to C-17 and C-2* to C-15*), 14.2 (C-
18), -4.0 (2x CH3, SiMe); IR (neat): 2922, 2853, 2093, 1703, 1464, 1250, 970, 835 cm-1. HRMS calculated for 
[C39H74N4O2Si + H]+: 675.5974, found 675.5998. 
 
1-((S)-2-((R,E)-1-hydroxyhexadec-2-en-1-yl)aziridin-1-yl)hexadecan-1-one (12). Aziridine-ceramide 27 (0.23 
mmol,  1  eq.)  was  dissolved  in  THF  (1.5  mL)  and  TBAF  (1M  in  THF,  275  μL,  0.28  mmol,  1.2  
eq.) was added. The reaction stirred for 1 h. at room temperature. The mixture was diluted 
with EtOAc/H2O and washed with brine and extracted. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. The yielded product was purified by column 
chromatography giving a colorless oil. (Silica gel, 10% to 20% acetone/pentane) Yield (81 
mg, 0.14 mmol, 61%), Rf = 0.5  (10%  acetone/pentane),  [α]20D: -16.2 (C= 1.0, CHCl3); 1H NMR (400 MHz, CDCl3)  δ 
5.84-5.75 (m, 1 H, H-5), 5.44 (dd, 1 H, J = 15.6, 8.0 Hz, H-4), 5.08 (t, 1 H, J = 10.4 Hz, H-3), 3.26 (t, 2 H, J = 9.2 Hz, 
H-34), 2.32 (t, 2 H, J = 10 Hz, H-20), 2.24-2.18 (m, 1 H, H-2), 2.05-2.03 (m, 2 H, H-6), 1.78 (d, 1 H, J = 7.6 Hz, H-1), 
1.62-1.55 (m, 5 H, H-1, H-21 and H-33), 1.26 (s, 44 H, H-7 to H-17 and H-22 to H-32), 0.88 (t, 3 H, J = 8.8 Hz, H-18); 
13C NMR (101 MHz, CDCl3)  δ 173.1 (C-19), 136.6 (C-5), 124.9 (C-4), 75.6 (C-3), 51.7 (C-34), 34.7 (C-20), 32.5, 32.2 
(25C, C-1, C-21 to C-33), 32.1 (C-2), 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 29.0, 26.9, 25.2, 23.1, 22.9 (25C, C-1, C-21 to 
C-33), 14.3 (C-18). IR (Neat): 2914, 2849, 2095, 1726, 1468, 1177, 968 cm-1; HRMS calculated for [C34H64N4O2 + 
H]+: 561.5109, found 561.5138. 
 
Alkylaziridine sphingosine (28). Aziridine 17 (58 mg, 0.15 mmol, 1.0 eq) was dissolved in dry DCM (1.5 mL) under 
protected atmosphere and cooled -20 0C. DIPEA (29 μL, 0.16 mmol, 1.1 eq) was added 
followed by addition of triflate 26 (1 M in DCM, 1.6 mL, 0.16 mmol, 1.1 eq) and was left 
stirring for 3 hours. The reaction mixture was quenched with MeOH (0.1 mL) and washed 
with water and brine. The water layers were extracted with DCM and combined organic 
layers were dried (MgSO4) filtered and concentrated in vacuo. The product was purified by silica column 
chromatography (pentane to 2% acetone in pentane) giving a colorless oil (63 mg, 0.09 mmol 62%). [α]20D: 44 (C= 
0.5, CHCl3);  Rf = 0.72 (5% acetone in pentane); 1H NMR (400 MHz, CDCl3) δ  5.61 (m, 1 H, H-5), 5.53 (dd, 1 H, J 
=12.4  6.0 Hz, H-4), 3.55 (t, 1 H, J = 6.8 Hz, H-3), 3.25 (t, 2 H, J = 7.2 Hz, H-16*), 2.43 (m, 1 H, H-1a*),  2.01 (q, 1 H, J 
= 7.2 Hz, H-6), 1.93 (m, 1 H, H-1b*), 1.66 (d, 1 H, J = 3.2 Hz, H-1a), 1.61 (m, 1 H, H-2*), 1.41-1.25 (m, 48 H, H-1b, H-
2, H-7 to H-17 and H-3* to H-15*), 0.88 (m, 12 H, H-18 and SitBu), 0.02 (s, 3 H, SiMe), 0.01 (s, 3 H, SiMe); 13C NMR 
(101 MHz, CDCl3) δ 134.96 (C-5), 127.79 (C-4), 76.13 (C-3), 61.39 (C-1*), 51.62 (C-16*), 44.80 (C-2), 33.48, 32.33, 
32.08, 29.97, 29.70, 29.64, 29.41, 29.36, 29.31, 28.98, 27.57, 26.86, 26.71, 26.86, 26.71 (C-1, C-6 to C-17 and C-
2* to C-15*), 22.84 (SitBu), 18.38 (Cq-Si-tBu), 14.27 (C-18), -4.29, -4.39 (2x CSi-Me); IR (neat); 2922, 2852, 2094, 1463, 




















Synthesis of Ceramide-Mimetic Aziridine as Potential Mechanism-Based Enzyme Inhibitors 
 101 
Alkylaziridine sphingosine (13). The alkylated aziridine 28 (52 mg, 0.08 mmol, 1.0 eq) was dissolved in dry THF  
(0.8 mL) under an atmosphere of Argon. TBAF (1 M in THF, 0.1 mL, 0.1 mmol, 1.25 eq) was 
added and the reaction was stirred for 2 hours at room temperature. The reaction was 
diluted with EtOAc and washed with water and Brine. The water layers were extracted with 
EtOAc and combined organic layers were dried (MgSO4), filtered and concentrated in 
vacuo. The product was purified by silica column chromatography (5 % Acetone in Pentane) giving waxy white 
solid (24 mg, 0.044 mmol, 55%). [α]20D: 25 (C= 0.25, CHCl3);  Rf = 0.56 (10% Acetone in Pentane); 1H NMR (400 
MHz, CDCl3): 5.73 (dt, 1 H, J = 15.6, 8.0 Hz, H-5), 5.38 (dd, 1 H, J = 15.6, 7.6 Hz, H-4), 4.15 (m, 1 H, H-3), 3.25 (t, 2 
H, J = 6.8 Hz, H-16*), 2.41 (m, 1 H, H-1a*), 2.19 (m, 1 H, H-1b*), 2.03 (m, 2 H, H-6), 1.81 (d, 1 H, J = 3.2 Hz, H-1a), 
1.62-1.53 (m, 5 H, H-1b, H-2* and H-15*), )1.35-1.25 (m, 45 H, H-2, H-7 to H-17 and H-3* to H-14*), 0.88 (t, 3 H, J 
= 7.2 Hz, H-18); 13C NMR (101 MHz, CDCl3) : 134.00 (C-5), 129.39 (C-4), 70.05 (C-3), 60.28 (C-1*), 51.63 (C-16*), 
42.71 (C-2),  32.47, 32.07, 29.81, 29.77, 29.69, 29.65, 29.54, 29.51, 29.35, 29.30, 29.24, 28.98, 28.77, 27.47, 
26.86, 25.66, 22.84 (C-1, C-6 to C-17 and C-2* to C-15*), 14.27 (C-18); IR (neat) 2921, 2850, 2094, 1467, 1177, 
968 cm-1. HRMS calculated for [C34H66N3O +H]+:  547.5317, found 547.5339. 
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2 Summary and Future Prospects 
 
Sphingolipids constitute a broad class of biomolecules that play key roles in numerous 
physiological processes in various organisms. The availability of synthetic sphingolipid 
derivatives, both the natural products themselves (which may be stable-isotope-enriched) 
and synthetic analogues, is key to unravel sphingolipids biology. The work described in this 
Thesis focused on the development of synthetic methodology towards modified 
sphingolipids. Specifically, methodology has been developed for the synthesis of both 
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in natural abundance and stable-isotope-enriched forms. As well, methodology has been 
developed that allowed the synthesis of a rare hydroxylated sphingosine base, as well as 
unnatural, azide-modified sphingoid bases. Although not discussed in depth in this Thesis, 
the compounds prepared during this PhD work are highly useful in chemical biology and 
metabolomics studies on biological systems and processes in which sphingolipid 
metabolism plays a key role. These include human inherited disorders in which a specific 
enzyme involved in sphingolipid metabolism is impaired, such as the lysosomal storage 
disorders, Gaucher disease and Fabry disease. Chapter 1 introduces sphingolipid biology 
with a focus on the current status in the literature on chemically prepared, sphingolipid-
derived reporter molecules by reviewing the literature of existing sphingolipid analogues 
including those that are isotopically labeled, equipped with a fluorophore, or outfitted 
with a bioorthogonal ligation handle. Chapter 2 describes the synthesis of a panel of 
carbon-13-labeled (glyco-)sphingolipids based on a cross-metathesis event as the key step. 
The linear, terminal 13C5-1-pentadecene for this purpose was assembled from 13C2-acetic 
acid and potassium 13C-cyanide using, amongst other transformations, Horner-
Wadsworth-Emmons chemistry. After assembling the partially protected sphingosine base 
(which was prepared both in 13C5-enriched and natural abundance-carbon form), different 
donor glycosides (glucosyl and GB3) were condensed with the free primary alcohol to 
yield, after further chemical manipulations, the corresponding glycosylsphingosines. N-
acylation of the free amine of these with palmitoyl chloride (13C0 or 13C3) produced the 
corresponding glycosylceramides. Although all target compounds could be obtained in 
good quantity and purity, a caveat of the procedure described in Chapter 2 is the low yield 
in the glycosylation steps, which can be correlated to the acid-sensitivity of the N-Boc 
protective group chosen. With the aim to improve on the methodology, Chapter 3 
introduces the use of the Fmoc group, instead of the Boc group, as a means to protect the 
secondary amine in the sphingoid base. This change of N-protective group necessitated 
also changing the nature of the protective group for the secondary alcohol in the 
sphingoid base, as is outlined in Chapter 3. The net result of the studies described in 
Chapter 3 is an improvement in yield in the glycosylation step, and 13C6-
glucosylsphingosine, 6-azido-6-deoxy-glucosylsphingosine as well as galactosylsphingosine 





Scheme 7.1 Automated solid-phase oligosaccharide synthesis using light[2]- or base[5] sensitive linkers.  
 
An alternative strategy to the solution synthesis of carbohydrates that has received 
considerable attention in recent years comprises (automated) solid phase oligosaccharide 
synthesis (see for examples Scheme 7.1).[1] Key in solid phase carbohydrate synthesis 
campaigns are full control over stereochemical outcome in the formation of glycosidic 
linkages, as well as the availability of appropriate linker systems that allow assembly of the 
oligosaccharides on a solid support, and that can be cleaved at the end of synthesis 
campaign. With respect to the latter, the Seeberger group has reported two linker systems 
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glycosphingolipids: a photo-cleavable[2,3] linker (sensitive to 305 nm light) and a base-labile 
linker.[4,5] Both linker systems are on paper suitable for the construction of 
glycosphingolipids on solid support, as is outlined in Schemes 7.2 and 7.3. Protective 
group manipulations on azidosphingosine 1 affords in three steps and good yield partially 
protected sphingosine 4, with the amine free for coupling to with the base-sensitive linker 
(4 to 5). After coupling to a solid support (6 to 8) and selective unmasking of the primary 
alcohol (removal of the acid-labile DMT group, 8 to 9) an immobilized sphingosine 
derivative was obtained and that is ready for study on its suitability as an acceptor in 
ensuing glycosylation events. 
Scheme 7.2 Synthesis of immobilized sphingosine featuring a base-labile linker system. 
Reagents and conditions: (a) DMTCl, 2,4,6-collidine, DCM, 0 oC, 2 h, 92%; (b) (i) NaH, DMF, 0 oC, 15 min; (ii) BnBr, 
TBAI, 0 oC to r.t., 20 h, 88%; (c) (i) PMe3, wet THF, r.t., 20 h; (d) DIPEA, DMF, 0 oC to r.t., 20 h, 75%; (e) TBAF (1 M 
in THF), THF, r.t., 2 h, 98%; (f) DIC, DMAP, DCM, 20 h; (g) TCA, DCM, 5 min. 
 
In a related strategy amine 10[6] (obtained from 2 in one step) can be transformed into 
carbamate 12, with the carbamate nitrogen functionalized with a photosensitive 2-nitro-4-
hydroxytoluyl moiety (Scheme 7.3). Further elaboration of 12 may yield an immobilized 
sphingoid acceptor ready for glycosylation, featuring a photosensitive linker for cleavage 
of the fully assembled glycosphingolipid. Both 9 and 12 will, after a successful solid phase 
oligosaccharide synthesis scheme, cleavage from the resin and global deprotection, yield 
glycosylsphingosines. Acylation of the free amine will then yield the corresponding 
glycosylceramides. Obviously, the feasibility of 9 and 12 as building blocks for solid phase 
synthesis schemes requires considerable synthetic studies, as the stereospecific 
introduction of glycosidic linkages is not guaranteed and stereoselective outcome may 























































Scheme 7.3 Synthesis light-cleavable sphingosine solid-support. 
Reagents and conditions: (a) H2 (g), Lindlar cat., EtOH, r.t., 20 h, 54%; (b) (i) 5-hydroxy-2-nitrobenzaldehyde, 
MeOH, r.t., 1 h; (ii) NaBH3CN, r.t., 20 h, 65%; (c) CDI, DCM, r.t., 20 h, 90%  
Chapter 4 describes the synthesis of a panel of carbon-13-labeled phosphosphingolipids. 
Key in these studies, apart from identifying the optimal order of transformations, was the 
identification of suitable solvent systems to dissolve the sphingosine-1-phosphate 
derivatives, both for purification and acylation of the sphingosine-amine. Chapter 5 
presents an efficient synthesis of 6-hydroxysphingosine and alpha-hydroxy palmitoic acid 
in which cross-metathesis features as a key step. The main synthetic challenge proved to 
be the Grubbs cross-metathesis between two different allylic alcohols, to avoid cross 
metathesis between two copies of the same alkene. To discriminate between the allylic 
hydroxyls, the amino-alcohol system of the sphingosine head group (involving the 
secondary, allylic alcohol) was protected as a cyclic carbamate, while the allylic hydroxyl of 
the hydroxyalkene was left free. Furthermore, addition of CuI to form a Grubbs 2nd-
catalyst CuI complex proved essential to obtain an efficient cross-metathesis between the 
two alkenes. Extention of the strategy may involve the introduction of 13C isotopes, 
fluorophores or a ligation handle (Scheme 7.4). Such modified 6-hydroxysphingosines may 
be useful for visualization of, for instance, 6-hydroxysphingosine trafficking in mammalian 
cells. 
Scheme 7.4 Example of possible modifications of 6-hydroxysphingosines and alpha-hydroxy fatty acids. 
Chapter 6 describes the synthesis of two ceramide-mimetic aziridines which were 
designed as covalent inhibitors for enzymes involved in glycosphingolipid processing, 
including the glucosylceramidases, GBA and GBA2. In case successful, the azide in both 
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aziridines into potential two-step activity-based probes. Another interesting ceramide-
mimetic aziridine is compound 18, in which the primarily hydroxyl has been substituted by 
an aziridine (Scheme 7.5). The synthesis of 18 started from DMT-protected sphingosine 2, 
which was silylated with TBSOTf and 2,4,6-collidine resulting in sphingosine 13. DMT 
removal (TFA, addition of dodecanethiol as scavenger)[9], subsequent triflation (Tf2O, 
pyridine) followed by N-alkylation with ethyleneimine[10] yielded aziridine 15. Azide 
reduction, N-acylation and TBS removal should yield aziridine 18 as a potential alternative 
sphingosine-derived ABP. 
Scheme 7.5 Synthesis towards 1-aziridine ceramide 18. 
Reagents and conditions: (a) TBSOTf, 2,4,6-collidine, DCM 0 oC, 20 h, 65%; (b) dodecanethiol, TFA, DCM, 0 oC, 
80%; (c) (i) Tf2O, pyridine, DCM, 0 oC, 1 h; (ii) ethyleneimine, DCM, r.t., 20 h, 45%. 
APBs have been proven to be excellent tools to study sphingolipid metabolic enzymes, but 
in order to get insight in sphingolipid pools as a function of these enzymes another 
chemical biology approach may be more suited. In a recent article by Delgado and co-
workers[11], the sphingolipidome was studied by exposing cells to azide-modified 
sphinganine 22a (Scheme 7.6). All sphingolipids are derived from sphinganine and 
therefore treatment of cells with azido-sphinganine should result in azide tagging of the 
complete sphingolipidome. The azide can, following lysis of the tissue culture and isolation 
of the lipid fraction, be addressed as a ligation handle for introduction of, for instance, a 
fluorophore. Combining the strategy of Delgado and co-workers with the stable-isotope-
encoding strategy presented in this Thesis would lead to 13C5-labeled azidosphinganine 
22b that, together with its non-isotopically enriched counterpart 22a may be used for 
quantitative, chemical metabolomics studies.[12] Cross metathesis of either aminodiol 19a 
or 19b with halogenated alkene 20a/b yielded sphingosine derivatives 21 and 21b, 
respectively. Palladium-catalyzed hydrogenation of the double bond, followed by 
substitution of the halogen for azide and final global deprotection yielded the isotope-





































Scheme 7.6 Overview  of  Delgado’s  (22a) work and this work (22b).  
The synthesis of 13C5-azido-sphingosine 22b was accomplished following the strategy as 
detailed in Chapter 2[12] and is outlined in Scheme 7.7. 
Scheme 7.7 Synthesis of carbon-13-labeled azidosphinganine 22b.  
 
Reagents and conditions: (a) K13CN, EtOH/H2O, 80 oC, 20 h, 99%; (b) NCS, PPh3, THF, 20 h, 96%; (c) (i) DIBAL-H, 
THF, -78 oC, 1.5 h; (ii) 1 M HCl (aq), -78 oC, 30 min, 84%; (d) (i) 13C2-HWE reagent, n-BuLi, 0 oC, 10 min; (ii) 26, THF, 
0 oC to r.t., 20 h, 89%; (e) Pt/C, H2(g), EtOAc, r.t., 20 h, 93%; (f) (i) DIBAL-H, THF, -78 oC, 1.5 h; (ii) sat. Rochelle salt 
(aq), -78 oC to r.t.; (iii) 13C2-HWE reagent, BuLi, 0 oC, 10 min; (iv) 13C3-aldehyde, THF, 0 oC to r.t., 20 h, 94%; (g) (i) 
DIBAL-H, THF, -78 oC, 1.5 h.; (ii) sat. Rochelle salt (aq), -78 oC to r.t.; (iii) PPh3MeBr, NaH, THF, 80 oC, 3 h; (iv) 13C5-
aldehyde, THF, 0 oC to r.t., 20 h, 82%; (h) Grubbs 2nd cat., AcOH, DCM, 40 oC, 2 days, 86%; (i) PtO2, H2 (g), EtOAc, 
20 h, 86%; (j) NaN3, NaI, DMF, 55 oC, 20 h, 99%; (k) TFA, H2O, 0 oC, 30 min, 71%. 
The isotope-encoded sphingolipids described in this thesis have been used for studying 
the metabolism of sphingolipids in tissue from healthy individuals as well as from patients 
suffering from various sphingolipidoses.[14-19] Amongst others, the characteristically high 
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levels of lyso-GB3[14] and glucosylsphingosine[15] as secondary storage lipids in Fabry and 
Gaucher patients, respectively, can be quantified using the corresponding 13C5-enriched 
sphingolipids as internal standard. By creating a comprehensive panel of stable isotope-
enriched sphingolipids, and by developing the chemistry that allows expansion to 
sphingolipids not yet synthesized in the context of this Thesis, it is expected that the 
chemical toolset developed will find broader use in metabolomics studies, in relation to 
lysosomal storage disorders and perhaps as well in other human pathologies. 
7.1 Experimental section 
General Remarks: [13C2]-acetic acid (99.95% isotopically pure, product code CLM-105), potassium [13C]-cyanide 
(99% isotopically pure, product code CLM-297), and [1,2,3-13C3]-myristic acid (99% isotopically pure, product 
code CLM-3665) was purchased from Cambridge Isotope Laboratories, Inc., and was used as received. 
Commercially available reagents and solvents (Acros, Fluka, or Merck) were used as received, unless otherwise 
stated. CH2Cl2 and THF were freshly distilled before use, over P2O5 and Na/benzophenone, respectively. 
Triethylamine was distilled from calcium hydride and stored over potassium hydroxide. Traces of water were 
removed from starting compounds by coevaporation with toluene. All moisture-sensitive reactions were carried 
out under an argon atmosphere. Molecular sieves (3 Å) were flame-dried before use. Column chromatography 
was carried out using forced flow of the indicated solvent systems on Screening Devices silica gel 60 (40–63  μm  
mesh). Size-exclusion chromatography was carried out on Sephadex LH20 (MeOH/CH2Cl2, 1:1). Analytical TLC 
 was carried out on aluminum sheets (Merck, silica gel 60, F254). Compounds were visualized by UV absorption 
(254 nm), or by spraying with ammonium molybdate/cerium sulphate solution [(NH4)6Mo7O24· 4 H2O (25 g/L), 
(NH4)4Ce(SO4)6· 2 H2O (10 g/L), 10 % sulphuric acid in ethanol] or phosphormolybdic acid in EtOH (150 g/L), 
followed by charring (ca. 150 °C). IR spectra were recorded with a Shimadzu FTIR-8300 instrument and are 
reported in cm–1. Optical rotations were measured with a Propol automatic polarimeter (sodium D-line, λ  = 589 
nm). 1H and 13C NMR spectra were recorded with a Bruker AV 400 MHz spectrometer at 400.2 (1H) and 100.6 
(13C) MHz, or with a Bruker AV 600 MHz spectrometer at 600.0 (1H) and 151.1 (13C) MHz. Chemical shifts are 
reported as δ  values (ppm), and were referenced to tetramethylsilane  (δ  =  0.00  ppm)  directly in CDCl3, or using 
the residual solvent peak (D2O). Coupling constants (J) are given in Hz, and all 13C spectra were proton decoupled. 
NMR assignments were made using COSY and HSQC, and in some cases TOCSY experiments. LC–MS analysis was 
carried out with an LCQ Advantage Max (Thermo Finnigan) instrument equipped with a Gemini C18 column 
(Phenomenex, 50  4.6 mm, 3 μm), using the following buffers: A: H2O, B: acetonitrile, and C: aq. TFA (1.0 %). 
HPLC–MS purifications were carried out with an Agilent Technologies 1200 Series automated HPLC system with a 
Quadrupole MS 6130, equipped with a semi-preparative Gemini C18 column (Phe-nomenex, 250 10.00, 5μm). 
Products were eluted using the following buffers: A: aq. TFA (0.2 %), B: acetonitrile (HPLC-grade), 5 mL/min. 
Purified products were lyophilized with a CHRIST ALPHA 2–4 LDPLUS apparatus to remove water and traces of 
buffer salts. 
 (2S, 3S, 4E)-2-Azido-1-(DMT)octadec-4-ene-3-ol (2). Azidosphingosine 1 (5.2 g, 16.0 mmol, 1.0 eq) was dissolved 
in dry DCM (80 mL). The solution was cooled to 0 oC followed by addition of 2,4,6-
collidine (4.7 mL, 35.2 mmol, 2.2. eq) and DMT-Cl (5.9 g, 17.6 mmol, 1.1 eq) and the 
reaction was stirred for 2 hours allowing to reach room temperature. The reaction 
was washed with sat. NaHCO3 (50 mL) and brine (50 mL). The aqueous layers were extracted with DCM (50 mL) 
and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography (5% acetone, 1% Et3N in pentane) giving 2 as a colorless oil (9.3 g, 
14.7 mmol, 92%). Rf = 0.23 (5% Acetone in Pentane); 1H NMR (400 MHz, CDCl3) δ 7.44 (d, 2 H, J = 7.6 Hz, Harom), 
7.32-7.19 (m, 7 H, Harom), 6.84 (d, 1 H, J = 8.8 Hz, Harom), 5.66 (dt, 1 H, J = 15.2, 6.8 Hz, H-5), 5.33 (dd, 1 H, J = 15.2, 






H, OH), 1.96 (q, 2 H, J = 6.4 Hz, H-6), 1.30-1.12 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (101 
MHz, CDCl3) δ 158.66, 144.55, 135.76, 135.73 (4x Cq-DMT), 135.45 (C-5), 130.11, 130.01, 128.57, 128.17, 128.05, 
127.78 (CHarom), 127.03 (C-4), 113.31 (CHarom-DMT), 86.97 (Cq-DMT), 73.25 (C-3), 65.89 (C-4), 63.38 (C-1), 55.33 
(OMeDMT), 32.38 (C-6), 32.06, 29.82, 29.79, 29.74, 29.59, 29.50, 29.31, 29.04, 22.83 (11x CH2 C-7 to C-17), 14.27 
(C-18); IR (neat) 3415, 2924, 2853, 2101, 1732, 1453, 1270, 1069 cm-1; HRMS calculated for [C39H53N3O4 + H]+: 
628.4116, found 628.4119. 
 
 (2S, 3S, 4E)-2-Azido-1-(DMT)octadec-4-ene-3-O-benzyl-ol (3). DMT-protected sphingosine 2 (4.7 g, 7.5 mmol, 
1.0 eq) was dissolved in dry DMF (40 mL) under an atmosphere of argon. The 
solution was cooled to 0 oC and NaH (0.45 g, 11.3 mmol, 1.5 eq) was added and 
stirred for 30 minutes. To the reaction mixture was added benzyl bromide (1.4 mmol, 
12.0 mmol, 1.6 eq) and was left to stir overnight. The reaction mixture was quenched 
with MeOH (1 mL) and diluted with diethyl ether. The mixture was washed with water and brine. The water 
layers were extracted with diethyl ether and the combined organic layers were extracted with diethyl ether, 
dried (MgSO4),filtered and concentrated in vacuo. The crude product was purified by silica column 
chromatography (pentane to 2% EtOAc in Pentane) giving a colorless oil giving a colorless oil (4.2 g, 6.3 mmol, 
88%). Rf = 0.4 (2% EtOAc in Pentane); 1H NMR (400 MHz, CDCl3) δ 7.44 (d, 2 H, J = 7.6 Hz, Harom-DMT), 7.31-7.24 (m, 
12H, Harom), 6.80 (d, 4 H, J = 8.8 Hz, Harom), 5.65 (dt, 1 H, J = 15.6, 8.8 Hz, H-5), 5.33 (dd, 1 H, J = 15.6, 8.8 Hz, H-4), 
4.55 (d, 1 H, J = 12.0 Hz, CH2a-Bn), 4.27 (d, 1 H, J = 12.0 Hz, CH2b-Bn), 3.88 (m, 1 H, H-3), 3.77 (s, 6 H, OMeDMT), 3.57 
(m, 1 H, H-2), 3.25 (m, 2 H, H-1), 2.03 (q, 2 H, J = 6.8 Hz, H-6), 1.34-1.25 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H J = 7.2 
Hz, H-18); 13C NMR (101 MHz, CDCl3) δ 158.59, 144.85 (2x Cq-DMT), 138.29 (Cq-Bn), 137.95 (C-5), 136.05, 136.02 (Cq-
DMT), 130.19, 130.16, 128.40, 128.27, 127.94, 127.65, 127.56, 126.89 (CHarom), 126.15 (C-4), 113.23 (CHarom-DMT), 
86.57 (Cq-DMT), 79.53 (C-3), 69.98 (CH2-Bn), 65.17 (C-2), 63.14 (C-1), 55.31 (OMeDMT), 32.47 (C-6), 32.06, 29.83, 
29.80, 29.78, 29.60, 29.50, 29.31, 29.16, 22.83 (11x CH2 C-7 to C-17), 14.26 (C-18); HRMS calculated for 
[C46H59N3O4 + H]+: 718.4586, found 718.4591. 
 
 (2S, 3S, 4E)-2-amino-1-(DMT)octadec-4-ene-3-O-benzyl-ol (4).  The DMT-Bn-protected sphingosine 3 (4.6 g, 6.4 
mmol, 1.0 eq) was dissolved in THF:H2O (95:5, 40 mL). To the solution was added 
PMe3 (1 M in THF, 13 mL, 13 mmol, 2.0 eq) and left to stir overnight. The reaction 
mixture was concentrated in vacuo giving crude sphingosine 4 as a colorless oil (4.29 
g, 6.2 mmol, 97%); 1H NMR (400 MHz, CDCl3) δ 7.43-7.16 (m, 14 H, Harom), 6.79 (m, 4 H, Harom-DMT), 5.67 (dt, 1 H, J = 
15.6, 8.8 Hz, H-5), 5.31 (dd, 1 H, J = 15.2, 8.8 Hz, H-4), 4.54 (d, 1 H, J = 12.0 Hz, CH2a-Bn), 4.26 (d, 1 H, J = 12.0 Hz, 
CH2b-Bn), 3.78 (m, 1 H, H-3), 3.75 (s, 6 H, OMeDMT), 3.20 (m, 2 H, H-1), 3.09 (m, 1 H, H-2), 2.03 (m, 2 H, H-6), 1.37-
1.26 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (101 MHz, CDCl3) δ 158.47, 145.29 (2x Cq-DMT), 
138.83 (Cq-Bn), 137.29 (C-5), 136.43 (Cq-DMT) 130.22, 130.18, 129.25, 128.54, 128.50, 128.42, 128.31, 128.05, 
127.87, 127.82, 127.73, 127.38, 127.21, 127.10, 127.03, 126.73 (CHarom), 126.00 (C-4)m 113.11 (CHarom-DMT), 85.92 
(Cq-DMT), 81.87 (C-3), 69.97 (CH2-Bn), 64.94 (C-1), 55.24 (OMeDMT), 54.97 (C-2), 32.52 (C-6), 32.04, 30.43, 29.81, 
29.77, 29.59, 29.47, 29.35, 22.81 (CH2 C-7 to C-17), 14.24 (C-18); HMRS calculated for [C46H61NO4 + H]+: 692.4681, 
found 692.4679. 
 
 (2S, 3S, 4E)-2-N-(4-(OTBS)methyl)benzylcarbamate-1-(ODMT)-octadec-4-ene-3-O-benzyl-ol (6). Sphingosine 4 
(4.1 g, 6.0 mmol, 1.0 eq) was dissolved in dry DMF (30 mL) under protected 
atmosphere. To the solution was DIPEA (1.35 mL, 7.8 mmol, 1.3 eq) added followed 
by addition of nitrophenol linker 5[4] (2.6 g, 6.3 mmol, 1.05 eq) at 0 oC. The reaction 
was stirred overnight allowing to reach room temperature. The reaction was diluted 
with diethyl ether and washed with water, twice with sat. aq. NaHCO3 and brine. The 
water layers were extracted with diethyl ether and the combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo. The product was purified by silica 
column chromatography (5% EtOAc in pentane) giving a colorless oil (4.3 g, 4.5 
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7.15 (m, 16 H, Harom), 6.77-6.73 (m, 4 H, Harom-DMT), 5.69 (dt, 1 H, J = 15.2, 8.0 Hz, H-5), 5.32 (dd, 1 H, J = 15.2, 8.0 
Hz, H-4), 5.05 (s, 2 H, CH2-Linker), 5.02 (d, 1 H, J = 8.0 Hz, NH), 4.73 (s, 2 H, CH2-Linker), 4.56 (d, 1 H, J = 12.0 Hz, CH2a-
Bn), 4.28 (d, 1 H, J = 12.0 Hz, CH2b-Bn), 4.03-3.94 (m, 2 H, H-2 and H-3), 3.73 (s, 6 H, OMeDMT), 3.47 (m, 1 H, H-1a), 
3.19 (dd, 1 H, J = 9.2, 3.6 Hz, H-1b), 2.02 (m, 2 H, H-6), 1.36-1.23 (m, 22 H, H-7 to H-17), 0.94 (s, 9 H, tBuTBS), 0.88 
(t, 3 H, J = 7.2 Hz, H-18), 0.10 (s, 6 H, MeTBS); 13C NMR (101 MHz, CDCl3) δ 158.53 (Cq-DMT), 156.06 (C=Olinker), 
145.02, 141.48, 138.55 (3x Cq-arom), 137.32 (C-5), 136.10, 135.31 (2x Cq-arom), 130.23, 130.12, 129.24, 128.35, 
128.26, 128.09, 127.87, 127.69, 127.46, 127.32, 127.05, 126.81 (CHarom), 126.23(C-4), 126.10 (CHarom), 133.10 
(CHarom-DMT), 86.08 (Cq-DMT), 80.17 (C-3), 70.29 (CH2-Bn), 66.59 (CH2-Linker), 64.79 (CH2-Linker), 61.87 (C-1), 55.24 
(OMeDMT), 54.43 (C-2), 32.42 (C-6), 32.04, 29.83, 29.78, 29.64, 29.48, 29.37, 29.30 (CH2 C-7 to C-17), 26.06 (CH3-tBu-
TBS), 22.81 (CH2 C-7 to C-17), 18.51 (Cq-tBu-TBS), 14.25 (C-18), -5.15 (MeTBS); HRMS calculated for [C61H83NO7Si + H]+: 
970.6019, found 970.6023. 
 
 (2S, 3S, 4E)-2-N-(4-(hydroxy)methyl)benzylcarbamate-1-ol-octadec-4-ene-3-O-benzyl-ol (7). Protected 
sphingosine-linker 6  (1.94 g, 2.0 mmol, 1.0 eq) was dissolved in THF (10 mL) and 
cooled to 0 oC. To the solution was added TBAF (1 M in THF, 3.0 mL, 3.0 mmol, 1.5 
eq) and the reaction was stirred for 2 hours allowing to reach room temperature. 
The mixture was diluted with EtOAc and washed with water and brine. The water 
layers were extracted with EtOAc and combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo. The product was purified by silica column 
chromatography (5-10% EtOAc in pentane) giving a colorless oil (1.68 g, 1.96 mmol, 
98 %). Rf = 0.30 (10% EtOAc in pentane); 1H NMR (400 MHz, CDCl3) δ 7.40-7.17 (m, 18 H, Harom), 6.72 (d, J = 8.8 Hz, 
Harom-DMT), 5.69 (dt, 1 H, J = 11.6, 8.4 Hz, H-5), 5.26 (dd, 1 H, J = 11.6, 8.4 Hz, H-4), 5.12-4.97 (m, 3 H, CH2-Linker and 
NH), 4.66 (s, 2 H, CH2-linker), 4.56 (d, 1 H, J = 11.6 Hz, CH2a-Bn), 4.27 (d, 1 H, J = 11.6 Hz, CH2-Bn), 4.01-3.95 (m, 2 H, H-
2 and H-3), 3.74 (d, 6 H, J = 3.6 Hz, OMeDMT), 3.45 (m, 1 H, H-1a), 3.20 (m, 1 H, H-1b), 2.02 (m, 2 H, H-6), 1.42-1.26 
(m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (101 MHz, CDCl3) δ 158.44 (Cq-DMT), 156.00 
(C=Olinker), 145.01, 140.97, 138.49 (Cq-arom), 137.06 (C-5), 136.15 (Cq-arom), 130.16, 129.24, 128.82, 128.62, 128.41, 
128.35, 128.26, 127.93, 127.86, 127.70, 127.48, 127.27, 127.21, 127.18 (CHarom and C-4), 113.14 (CHarom-DMT), 
86.06 (Cq-DMT), 80.10 (C-3), 70.30 (CH2-Bn), 66.39 (CH2-linker), 65.04 (CH2-linker),  61.87 (C-1), 55.26 (OMeDMT), 54.46 (C-
2), 32.43, 32.06, 29.82, 29.78, 29.63, 29.57, 29.47, 29.36, 29.29, 29.17, 22.80 (C-6 to C-17), 14.25 (C-18); HRMS 
calculated for [C55H69NO7 + H]+: 856.5154, found 856.5149. 
 
Down tuning of loading resin. Carboxylpolysteryl resin (~2.2 mmol, 1 g) was swelled with DCM (5 mL) and 
purged with argon for 15 minutes. The solvent was released and the resin washed with 3x with DCM, followed by 
three times swelling and shrinking with DCM/Hexane. After this the resin was washed again three times with 
DMC and then left to dry. The resin was swollen by THF (5 mL) for 15 minutes before addition of MeOH (0.15 mL, 
3.8 mmol, 2.25 eq). This suspension was shacken for 15 minutes before trimethylsilyl diazomethane (2 M in 
hexane, 0.84 mL, 1.7 mmol, 0.75 eq) was added. The suspension was shacken overnight. It was faninally washed 
with 3x DCM, 3x swelling/shrinking with DCM/hexane and 3x washed with THF. 
 
Coupling basic cleavable sphingosine linker to resin (8). The resin was swollen with DCM (5 mL) for 15 minutes, 
followed by filtration. To the swollen resin DCM (9 mL) was added followed by 
addition of a solution existing of sphingosine linker 7 (1.4 g, 1.65 mmol, 3.0 eq) and 
DIC (0.26 mL, 1.65 mmol, 3.0 eq) in DCM (4 mL). Next, DMAP (10 mg, 0.05 mmol, 
0.1 eq) was added and the reaction was left to shake overnight. The reaction was 
quenched by addition of MeOH (0.15 mL) and left to shake for 1 hour. The resin 
was filtered and washed three times with DCM, followed by swelling/shrinking 
DCM/hexane procedure. Finally, the resin was washed with three times with DCM 

















Removal of DMT-group and determination of resin loading (9). This procedure was performed in triple to get 
accurate numbers. DMT-Linker (10 mg) was suspended in 3% TCA in DCM (3 mL) and shaken for 5 minutes (the 
mixture turned instantly to orange/red). The suspension was filtered and diluted with DCM to 10 mL. From this 
10 mL DMT solution, 0.1 mL was taken and diluted to 10 mL with DCM. Absorption of the dilution was measured 
and the resin loading derived from the obtained values using the following formula: Loading ([A504]/76) x 100 = 
loading  in mmol/g. 
 
 (2S, 3S, 4E)-2-Amino-1-(DMT)octadec-4-ene-3-ol (10).  Protected azidosphingosine 2 (1.0 g, 1.6 mmol, 1 eq) was 
dissolved in EtOH (8 mL). The solution was purged with argon before the addition of 
Lindlar catalyst (5% wt. Pd on CaCO3, poisoned with lead). The reaction mixture was 
purged with H2 (g) for 15 minutes. The reaction was stirred overnight under an 
atmosphere of hydrogen gas. The mixture was filtered over Celite and concentrated in vacuo. The crude product 
was purified by silica column chromatography (2% MeOH, 1% Et3N in DCM) giving a colorless oil (0.54 g, 0.90 
mmol, 54%). Rf = 0.5 (5% MeOH in DCM);  1H NMR (400 MHz, CDCl3) δ 7.41 (d, 2 H, J = 7.6 Hz, Harom-DMT), 7.31-7.18 
(m, 7 H, Harom-DMT), 6.82 (d, 4 H, J = 7.2 Hz, Harom-DMT), 5.64 (dt, 1 H, J = 15.2, 7.6 Hz, H-5), 5.26 (dd, 1 H, J = 15.2, 6.8 
Hz, H-4), 4.12 (t, 1 H, J = 6.0 Hz, H-3), 3.78 (s, 6 H, OMeDMT), 3.18 (d, 2 H, J = 5.6 Hz, H-1), 3.02 (m, 1 H, H-2), 2.42 
(bs, 2 H, NH2), 1.94 (m, 2 H, H-6), 1.34-1.23 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (101 
MHz, CDCl3) δ 158.58, 144.90, 136.13, 136.09 (Cq-DMT),  134.16 (C-5), 130.11, 129.24, 128.79, 128.20, 128.17, 
127.88, 127.74 (CHarom-DMT), 126.91 (C-4), 113.26 (CHarom-DMT), 86.43 (Cq-DMT), 74.84 (C-3), 65.81 (C-1), 55.30 
(OMeDMT), 46.29 (C-2), 32.04 (C-6), 29.82, 29.78, 29.65, 29.61, 29.48, 29.37, 29.27, 22.81 (CH2 C-7 to C-17), 14.24 
(C-18); IR (neat) 3330, 2914, 2849, 1661, 1469, 1198 cm-1; HRMS calculated for [C39H55NO4 +H]+: 602.4211, found 
602.4223. 
 
 (2S, 3S, 4E)-2-N-(5-hydroxy-2-nitrobenzyl)-1-(DMT)octadec-4-ene-3-ol (11). The DMT protected sphingosine 10 
(0.5 g, 0.83 mmol, 1 eq) was dissolved in wet THF (3 mL). 5-hydroxy-2-
nitrobenzaldehyde (0.13 g, 0.83 mmol, 1.0 eq) was added and stirred for one hour. 
To the reaction was added NaBH3CN (52 mg, 0.83 mmol, 1.0 eq) was added and 
mixture was stirred overnight at room temperature. The reaction was quenched 
with NaHCO3 (10 mL) and EtOAc (10 mL). The two layers were separated and the 
water layer was extracted with EtOAc. The combined organic layers were washed 
with brine, dried with MgSO4, filtered and concentrated in vacuo. Purification by 
column chromatography (20% EtOAc in Pentane) giving a yellow oil (0.38 g, 0.5 mmol, 62%) NMR will depend on 
acidity of the chloroform. Rf = 0.27 (30% EtOAc in Pentane); 1H NMR (400 MHz, CDCl3) δ 7.93 (d, 1 H, J = 9.2 Hz, 
Harom-nitro phenol), 7.38 (d, 2 H, J = 7.2 Hz, Harom-DMT), 7.29-7.14 (m, 7 H, Harom-DMT), 6.82-6.79 (m, 5 H, 4x Harom-DMT and 
Harom-nitro phenol), 6.58 (dd, 1 H, J = 9.2, 2.0 Hz, Harom-nitro phenol), 5.65 (dt, 1 H, J = 15.6, 7.6 Hz, H-5), 5.20 (dd, 1 H, J = 
15.2, 6.0 Hz, H-4), 4.35 (m, 1 H, H-3), 4.06 (d, 1 H, J = 14.0 Hz, CH2a-nitrophenol), 3.94 (d, 1 H, J = 14.0 Hz, CH2-nitrophenol), 
3.73 (s, 6 H, OMeDMT), 3.41 (m, 2 H, H-1), 2.91 (m, 1 H, H-2), 1.91 (m, 2 H, H-6), 1.33-1.22 (m, 22 H, H-7 to H-17), 
0.88 (t, 3 H, J = 6.8 Hz, H-18); 13C NMR (101 MHz, CDCl3) δ 165.43 (Cq-nitro phenol), 158.78, 144.35 (Cq-arom-DMT), 139.38 
(C-5), 139.09 (Cq-nitro phenol), 135.41, 135.26 (Cq-DMT), 130.15,130.13, 129.26, 128.80, 128.20, 127.24, (CHarom-DMT and 
CHnitrophenol), 125.34 (C-4), 115.50, 114.38 (CHnitrophenol), 133.48 (CHarom-DMT), 78.52 (C-3), 62.48 (C-2), 59.59 (C-1), 
55.34 (OMeDMT), 46.21 (CH2-nitrophenol), 32.48, 32.05, 29.83, 29.80, 29.62, 29.50, 29.41, 29.09, 22.82 (C-6 to C-17), 
14.29 (C-18); HRMS calculated for [C46H60N2O7 + H]+: 753.4481, found 753.4494. 
  
 (2S, 3S, 4E)-2,3-O,N-carbamate-2-N-(5-hydroxy-2-nitrobenzyl)-1-(DMT)octadec-4-ene (12). The nitro phenol 
sphingosine 11 (0.18 g, 0.4 mmol, 1.0 eq) was dissolved in dry DCM. To the solution 
was added carbonyl-diimidazole (1.23 g, 7.6 mmol, 2 eq) and was stirred overnight 
at room temperature. The mixture was concentrated and purified by silica column 
chromatography (10% EtOAc in Pentane) giving a yellow oil (0.17g 0.36 mmol, 90%). 
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Harom-nitro phenol), 7.40-7.21 (m, 9 H, Harom-DMT), 6.88-6.81 (m, 5 H, 4x Harom-DMT and Harom-nitro phenol), 6.70 (dd, 1 H, J = 
8.8, 2.4 Hz, Harom-nitro phenol), 5.81 (dt, 1 H, J = 15.6, 8.4 Hz, H-5), 5.52 (dd, 1 H, J = 15.2, 8.4 Hz, H-4), 5.21 (t, 1 H, J = 
8.4 Hz, H-3), 5.02 (d, 1 H, J = 18.4 Hz, CH2a-nitrophenol), 4.57 (d, 1 H, J = 17.6 Hz, CH2-nitrophenol), 3.81-3.74 (m, 7 H, 
OMeDMT and H-2), 3.55 (dd, 1 H, J = 10.8, 3.2 Hz, H-1a), 3.13 (dd, 1 H, J = 10.8, 2.4 Hz, H-1b), 1.88 (m, 2 H, H-6), 
1.34-1.19 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H, J = 7.2 Hz, H-18); 13C NMR (101 MHz, CDCl3) δ 163.09 (Cq-nitrophenol), 
158.80, 144.00 (Cq-nitrophenol), 140.67 (C-5), 135.21, 135.06 (Cq-DMT), 130.15, 130.03, 129.75, 129.34, 128.80, 128.20, 
127.24 (CHarom-DMT and CHarom-nitro phenol), 122.25 (C-4), 115.56 114.31 (CHarom-nirophenol), 113.48, 113.42 (CHarom-DMT), 
79.78 (C-3), 60.88 (C-2), 59.69 (C-1), 55.37 (OMeDMT), 43.96 (CH2-nitrophenol), 32.46, 32.09, 29.89, 29.70, 29.53, 
29.47, 29.03, 22.85 (C-6 to C-17), 14.29 (C-18); IR (neat);  HRMS calculated for [C47H58N2O8 + H]+: 779.4273, found 
779.4278. 
(2S, 3S, 4E)-2-Azido-1-(DMT)octadec-4-ene-3-O-TBS. (13).  1-DMT-sphingosine 2 (1.25g, 2 mmol, 1.0 eq) was 
dissolved in dry DCM (10 mL) under protected atmosphere and cooled to 0 oC. 2,4,6-
Collidine (0.65 mL, 5 mmol, 2.5 eq) was added to the solution followed by addition of 
TBSOTf (0.57 mL, 2.5 mmol, 1.25 eq). The reaction was stirred overnight at 4 0C.  The 
reaction was diluted with DCM and washed with sat. aq. NaHCO3 and brine. The 
water layers were extracted with DCM and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified by silica column chromatography (1% to 5% Acetone in 
Pentane) giving a colorless oil (0.93 g, 1.3 mmol, 65%). Rf = 0.6 (5% Aceton in pentane); 1H NMR  (400 MHz, 
CDCl3)  δ  7.43 (d, 2 H, J = 7.6 Hz, Harom-DMT), 7.33-7.29 (m, 12 H, Harom), 6.81 (dd, 4 H, J = 8.8, 1.6 Hz, Harom), 5.52 (dt, 
1 H, J = 15.2, 8.8 Hz, H-5), 5.32 (dd, 1 H, J = 15.2, 7.2 Hz, H-4), 4.07 (m, 1 H, H-3), 3.78 (s, 6 H, OMeDMT), 3.54 (m, 1 
H, H-2), 3.15 (m, 2 H, H-1), 2.03 (m, 2 H, H-6), 1.34-1.24 (m, 22 H, H-7 to H-17), 0.88 (t, 3 H J = 7.2 Hz, H-18), 0.78 
(s, 9 H, TBStBu), -0.05 (s, 3 H, TBSMe), -0.07 (s, 3 H, TBSMe); 13C NMR (101 MHz, CDCl3) δ 158.60, 144.89, 136.19, 
136.06 (2x Cq-DMT), 134.34 (C-5), 130.16, 130.10, 129.00, 128.26, 127.93 127.73 (CHarom-DMT), 126.80 (C-4), 113.23 
(CHarom-DMT), 86.57 (Cq-DMT), 74.52 (C-3), 67.44 (C-2), 63.45 (C-1), 55.31 (OMeDMT), 32.31, 32.06, 29.83, 29.81, 29.76, 
29.60, 29.49, 29.31, 29.15, (11x CH2 C-6 to C-17), 25.83 (TBStBu), 22.82 (CH2 C-6 to C17), 18.09 (TBScq-tBu) 14.25 (C-
18), -3.98, -4.89 (2x TBSMe). 
 
 (2S, 3S, 4E)-2-Azido-1-octadec-4-ene-3-O-TBS. (14). Silylated sphingosine 13 (0.9 g, 1.22 mmol, 1.0 eq) was 
dissolved in dry DCM (12 mL) under protected atmosphere and dodecanethiol (0.6 mL, 
2.5 mmol, 2.0 eq) was added to solution. The solution was cooled to 0 oC, followed by 
addition of trifluoracetic acid (72 μL, 0.96 mmol, 0.8 eq) and the reaction was left to stir 
for 2 hours. The reaction was diluted with DCM and was washed with sat. aq. NaHCO3 
and brine. The water layers were extracted with DCM and the combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo. The product was purified by silica column chromatography giving a colorless 
oil (0.42 g, 0.96 mmol, 80%). Rf = 0.15 (5% Aceton in pentane); 1H NMR (400 MHz, CDCl3) δ 5.61 (dt, 1 H, J = 15.6, 
7.2 Hz, H-5), 5.40 (dd, 1 H, J = 15.6, 7.2 Hz, H-4), 4.17 (m, 1 H, H-3), 3.66-3.62 (m, 2 H, H-1), 3.36 (m, 1 H, H-2), 
2.20 (bs, 1 H, OH), 2.00 (m, 2 H, H-6), 1.34 (m, 2 H, H-7), 1.30-1.20 (m, 20 H, H-8 to H-17), 0.89-0.81 (m, 12 H, H-
18 and TBStBu), 0.04 (s, 3 H, TBSMe), -0.01 (s, 3 H, TBSMe); 13C NMR (101 MHz, CDCl3) δ 134.92 (C-5), 129.14 (C-4), 
75.39 (C-3), 67.83 (C-2), 62.37 (C-1), 32.38, 32.27, 32.07, 29.84, 29.82, 29.75, 29.60, 29.33, 29.10, 28.80 (11x CH2 
C-6 to C-17), 25.87 (TBStBu),  22.82 (CH2 C-6 to C17), 18.16 (TBScq-tBu) 14.25 (C-18), -3.96, -4.88 (2x TBSMe). 
 
 (2S, 3S, 4E)-2-Azido-1-(ethyleenime)-octadec-4-ene-3-O-TBS. (15). Sphingosine 14 (0.4 g, 0.91 mmol, 1.0 eq) 
was dissolved in dry DCM (5 mL) under protected atmosphere and cooled to 0 oC. 
Pyridine (88 μL, 1.1 mmol, 1.2 eq) was added followed by addition of Tf2O (0.18 mL, 1.1 
mmol, 1.2 eq). The mixture was stirred for 1 hour following dilution with DCM (10 mL). 
The reaction was washed with water and brine. The water layers were extracted with 
DCM and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo giving the crude 
triflate, which directly used without any further purification in the next step. The crude triflated sphingosine was 












eq) was added followed by addition of dry ethyleneimine (1 mL 20 mmol, 20 eq), and was left stirring for 3 hours. 
The reaction mixture was quenched with MeOH (0.1 mL) and washed with water and brine. The water layers 
were extracted with DCM and combined organic layers were dried (MgSO4) filtered and concentrated in vacuo. 
The product was purified by silica column chromatography (pentane to 2% acetone in pentane) giving a colorless 
oil (0.18 g, 0.40 mmol 45%). [α]20D: -26 (C= 0.5, CHCl3); Rf = 0.72 (5% acetone in pentane); 1H NMR (400 MHz, 
CDCl3) δ  5.64  (dt,  1  H,  J = 15.2, 7.6 Hz, H-5), 5.42 (dd, 1 H, J = 15.6, 7.2 Hz, H-4), 4.19 (m, 1 H, H-3), 3.54 (m, 1 H, 
H2), 2.36 (dd, 1 H, J = 12.8, 4.0 Hz, H-1a), 2.10 (dd, 1 H, J = 12.4, 8.4 Hz, H-1b), 2.03 (q, 2 H, J = 7.2 Hz, H-6), 1.84 
(dd, 1 H, J = 6.0, 4.0 Hz, Haziridine), 1.75 (dd, 1 H, J = 6.0, 4.0 Hz, Haziridine), 1.40-1.24 (m, 23 H, H-7 to H-17 and 
Haziridine), 1.10 (dd, 1 H, J = 6.0, 4.0 Hz, Haziridine), 0.91-0.86 (m, 12 H, H-18 and TBStBu), 0.06 (s, 3 H, TBSMe), 0.03 (s, 3 
H, TBSMe); 13C NMR (101 MHz, CDCl3)  δ  134.56   (C-5), 128.86 (C-4), 75.53 (C-3), 67.92 (C-2), 61.23 (C-1), 32.36, 
32.05, 29.81, 29.78, 29.76, 29.68, 29.60, 29.49, 29.15, 28.98, 28.23, 27.03, 26.01 (11x CH2 C-6 to C-17 and 2x CH2-
aziridine), 25.90 (TBStBu), 18.21 (TBSCq-tBu), 14.25 (C-18), -3.98, -4.80 (2x TBSMe). 
 
 [1-13C1]-10-Hydroxydecanitrile (24). 9-Bromo-1-nonanol 23 (8.87 g, 39.8 mmol, 1.05 eq) was dissolved in 
EtOH/H2O (9:1, 17 mL), and K13CN (2.5 g, 37.9 mmol) was added. The reaction mixture was 
heated at 80 °C overnight.  The reaction was then diluted with ether and was washed 2x with 
water and 1x with brine. The water layers were extracted with ether and the combined organic layer were dried 
(Na2SO4) and concentrated in vacuo. The product was purified by column chromatography (20% EtOAc in 
petroleum ether) giving colorless oil (6.43 g, 37.8 mmol, 99%).  Rf = 0.51 (1:1 EtOAc: petroleum ether). 1H NMR 
(400 MHz, CDCl3) δ 3.63 (t, 2 H, J = 6.8 Hz, H-10), 2.34 (dt, 2 H, J = 9.6, 7.2 Hz, H-2), 1.69-1.62 (m, 3 H, H-9 and 
OH), 1.55 (m, 2 H, H-3), 1.44 (m, 2 H, H-8), 1.39-1.28 (m, 8 H, H-4 to H-7). 13C NMR (101 MHz, CDCl3) δ 119.9 (CN), 
63.8 (C-OH), 32.7, 29.3 (d, J =1.5 Hz), 28.71, 28.65 (d, J = 3.3 Hz) 25.7, 25.35 (d, J = 2.7 Hz), 17.1 (d, J = 56.6 Hz, C-
2). IR (neat): 3294, 2926, 2854, 2193, 1463, 1425, 1055 cm-1. HRMS calculated for [C913CH19NO + H]+: 171.1466, 
found 171.1470. 
 
 [1-13C1]-10-Chloro-decanitrile (25).  [1-13C1]-10-Hydroxydecanitrile 24 (6.21 g, 36.5 mmol) was dissolved in THF 
(240 mL) to which PPh3 (10.5 g, 40.2 mmol, 1.1 eq) and NCS (5.36 g, 40.2 mmol, 1.1 eq) were 
added.  The mixture was stirred overnight at room temperature. After the reaction was finished 
on TLC the mixture was diluted with EtOAc and 2x washed with water and 1x with brine. The water layers were 
extracted with EtOAc and the combined organic layers were dried (Na2SO4) and concentrated. Petroleum ether 
was added to residue and the remaining solids were filtered off and the organic solution was concentrated in 
vacuo. The product was purified by column chromatography (3% EtOAc in petroleum ether) giving a colorless oil 
(6.60 g, 35.0 mmol, 96%). Rf = 0.24 (3% EtOAc in petroleum ether). 1H NMR (400 MHz, CDCl3) δ 3.53 (t, 2 H, J = 6.8 
Hz, H-10), 2.34 (dt, 2 H, J = 9.6, 7.2 Hz, H-2), 1.77 (p, 2 H, J = 6.9 Hz, H-9), 1.65 (m, 2 H, H-3), 1.48-1.37 (m, 4 H, H-4 
and H-8), 1.34-1.25 (m, 6 H, H-5 to H-7). 13C NMR (101 MHz, CDCl3) δ 119.7 (CN), 45.0 (C-10), 32.4 (C-9), 29.00, 
28.59, 28.52, 28.46 ( d, J = 3.3 Hz), 26.66 (5x -CH2-, C-4 to C-8), 25.2 (d, J = 2.7 Hz, C-3), 17.0 (d, J =55.5 Hz, C-2).  




[1-13C1]- 10-chlorodecanal (26).  [1-13C1]-10-Chloro-decanitrile 25 (2.09 g, 10.66 mmol) was dissolved in dry DCM 
(40 mL) and was cooled to -78 °C under protected atmosphere. DIBAL-H (1.5 M in toluene, 10.67 
mL, 16.0 mmol, 1.5 eq) was slowly added, and stirred for 1.5 h at -78 °C. The reaction mixture was 
quenched with 1 M HCl (aq) (15 mL) and was stirred for 30 minutes at -78 °C. Then the reaction 
mixture was warmed to room temperature and was diluted with ether. The mixture was washed 
2x with water and 1x with brine. The water layers were extracted with ether and the combined organic layers 
were dried (Na2SO4) and concentrated in vacuo. The product was purified by column chromatography (3% EtOAc 
in petroleum ether) giving a colorless oil (1.71 g, 8.95 mmol, 84 %). Rf = 0.25 (3%  EtOAc in petroleum ether). 1H 
NMR (400 MHz, CDCl3) δ 9.76 (dt, 1 H, J = 169.6, 1.6 Hz, H-1), 3.52 (t, 2 H, J = 6.8 Hz, H-10), 2.43 (dq, 2 H, J = 7.2, 
1.6 Hz, H-2), 1.78 (p, 2 H, J = 6.8 Hz, H-9), 1.63 (m, 2 H, H-3), 1.42(m, 2 H, H-8), 1.41-1.27 (m, 8 H, H-4 to H-7). 13C 
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NMR (101 MHz, CDCl3) δ 202.8 (t, J = 19.2 Hz, C-1), 45.1 (C-10), 43.9 (d, J = 39.4 Hz, C-2), 32.64 (C-9), 2x 29.27 
(CH2 C-4 to C-8), 29.12 (d, J = 3.4 Hz, C-3), 28.83, 26.86, 21.8 (3x CH2 C-4 to C-8). IR (neat); 2926, 2855, 2710, 
1664, 1464.  
 
 [1,2,3-13C3]-(E)-12-Chloro-N-methoxy-N-methyl-dodec-2-enamide and [1,2,3-13C3]-(Z)-12-Chloro-N-methoxy-N-
methyl-dodec-2-enamide (27). Diethyl ([1,2-13C2]-N-methoxy-N-
methylacetamide)phosphonate (2.46 g, 10.2 mmol, 1.05) was dissolved in dry THF (47 mL) 
under protected atmosphere. n-BuLi (1.6 M in hexane, 6.37 mL, 10.2 mmol, 1.05 eq) was 
added at 0 °C and stirred for 10 min at this temperature. [1-13C1]- 10-chlorodecanal 26 (1.86 g, 9.71 mmol) was 
dissolved in dry THF (10.0 mL) was added to the phosphonate carbanion and the mixture was stirred overnight at 
room temperature. The reaction mixture was diluted with ether and was washed 2x with water and 1x brine. The 
water layers were extracted with ether and the combined organic layers were dried (Na2SO4) and concentrated in 
vacuo. The product was purified by column chromatography (10% EtOAc in petroleum ether) giving a colorless oil 
(2.41 g, 8.64 mmol, 89%, E:Z = 11:1). Rf (E) = 0.12 and Rf (Z) = 0.20 (10% EtOAc in petroleum ether).  (E-isomer) 1H 
NMR (400 MHz, CDCl3) δ 6.97 (dm, 1 H, J = 154.0 Hz, H-3), 6.41 (ddd, 1 H, J = 160.4, 15.2, 3.6 Hz, H-2), 3.70 (s, 3 H, 
CH3-OMe), 3.53 (t, 2 H, J = 6.4 Hz, H-12), 3.24 (s, 3 H, CH3-NMe), 2.24 (m, 2 H, H-4), 1.76 (p, 2 H, J = 6.8 Hz, H-11), 
1.52-1.38 (m, 4 H, H-5 and H-10), 1.37-1.20 (m, 8 H, H-6 to H-9). 13C NMR (101 MHz, CDCl3) δ 167.1 (d, J = 67.7 Hz, 
C-1), 148.0 (d, J = 71.7 Hz, C-3), 118.6 (dd, J = 71.7, 67.7 Hz, C-2), 61.7 (CH3-OMe), 45.2 (C-12), 32.7 (C-11), 32.6 (m, 
C-4), 31.8 (m, CH3-NMe), 29.41, 29.35, 29.3 (d, J = 3.6 Hz), 28.9, 28.35 (m), 26.9 (6x CH2 C-5 to C-10). IR (neat) 2926, 
2854, 1616, 1581, 1462, 1367, 1177, 983 cm-1. (Z-isomer) 1H NMR (400 MHz, CDCl3) δ 6.24 (dd, 1 H, J = 162.0, 
10.4 Hz, H-2), 6.11 (dm, 1 H, J = 152.4 Hz, H-3), 3.68 (s, 3 H, CH3-OMe), 3.53 (t, 2 H, J = 6.8 Hz, H-12), 3.21 (s, 3 H, 
CH3-NMe), 2.61 (m, 2 H, H-4), 1.76 (p, 2 H, J = 7.0 Hz, H-11), 1.49-1.37 (m, 4 H, H-5 and H-10), 1.36-1.22 (m, 8 H, H-6 
to H-9). 13C NMR (101 MHz, CDCl3) δ 167.6 (d, J = 66.7 Hz, C-1), 147.7 (d, J = 71.7 Hz, C-3), 117.9 (t, J = 69.7 Hz, C-
2), 61.5 (CH3-OMe), 45.2 (C-12), 32.63 (C-11), 32.2-31.8 (m, CH3-NMe and C-4), 29.45, 29.31, 2x 29.4-29.2 (m), 28.9, 
26.94 (6x CH2 C-5 to C-10). IR (neat); 2926, 2855, 1612, 1460, 1332, 1177, 997 cm-1. HRMS calculated for 
[C1113C3H26NO2Cl + H]+: 279.1652, found 279.1651. 
 
 [1,2,3-13C3]-12-Chloro-N-methoxy-N-methyl-dodecanamide (28). [1,2,3-13C3]-(E/Z)-12-Chloro-N-methoxy-N-
methyl-dodec-2-enamide 27 (5.76 g, 20.68 mmol) was dissolved in EtOAc (240 mL).  The 
solution was purged with argon under stirring and a catalytic amount of palladium 10% on 
charcoal (1.0 g, 1.0 mmol, 0.05 eq) was added. The reaction was stirred under a flow of 
hydrogen gas for 30 minutes and was then left under a hydrogen atmosphere overnight. 
The palladium was removed by filtration over a plug of Celite and then rinsed with EtOAc followed by removal of 
the solvent under reduced pressure giving the desired product, a colorless oil (5.40 g, 19.3 mmol, 93%). Rf = 0.15 
(10% EtOAc in petroleum ether). 1H NMR (400 MHz, CDCl3) δ 3.68 (s, 3 H, CH3-OMe), 3.53 (t, 2 H, J = 6.8 Hz, H-12), 
3.18 (s, 3 H, CH3-NMe), 2.41 (dm, 2 H, J = 127.6 Hz, H-2), 1.82-1.72 (m, 2 H, H-11), 1.64 (dm, 2 H, J = 127.6 Hz, H-3), 
1.54-1.38 (m, 2 H, H-10), 1.37-1.22 (m, 12 H-4 to H-9). 13C NMR (101 MHz, CDCl3) δ 174.9 (d, J = 51.5 Hz, C-1), 
61.3 (CH3-OMe), 45.3 (C-12), 32.64 (C-11), 32.2 (dd, J = 51.5, 37.2 Hz, C-2 and CH3-NMe), 29.48 (m, C-4), 28.87, 26.85, 
24.64 (d, J = 35.1 Hz, C-3), 24.7 (7x CH2 C-4 to C-10). IR (neat); 2924, 2852, 1626, 1464, 1371 1175, 1001 cm-1. 
HRMS calculated for [C1113C3H28NO2Cl + H]+: 281.1808, found 281.1805. 
 
 [1,2,3,4,5-13C5]-(E)-14-Chloro-N-methoxy-N-methyl-dodec-2-enamide and [1,2,3,4,5-13C5]-(Z)-14-Chloro-N-
methoxy-N-methyl-dodec-2-enamide (29).  [1,2,3-13C3]-12-Chloro-N-Methoxy-N-
methyl-dodecanamide 28 (5.29 g, 18.6 mmol) was dissolved in dry THF (75 mL) and 
was cooled to -78°C under protected atmosphere.  DIBAL-H (1.5 M in toluene, 14.9 mL, 
22.4 mmol, 1.2 eq) was added and the mixture was stirred for 1 hour at -78°C. The 
mixture was quenched with sat. Rochelle salt (aq) (75 mL) at -78°C and was roughly stirred to room temperature. 
The mixture was diluted with ether and was washed 2x with water and 1 x with brine. The water layers were 
extracted with ether and the combined organic layers was dried (Na2SO4) and concentrated in vacuo giving  
crude [1,2,3- 13C3]-12-Chloro-dodecanal as a clear oil which was used without further purification. [1,2-13C2]-
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Diethyl (N-Methoxy-N-methylacetamide)phosphonate (4.33 g, 18.0 mmol, 1.05) was dissolved in dry THF (90 mL) 
under protected atmosphere. n-BuLi (1.6 M in hexane, 11.2 mL, 18.0 mmol, 1.05 eq) was added at 0 °C and 
stirred for 10 min at this temperature. 12-Chloro-dodecanal (3.80 g, 17.1 mmol) was dissolved in dry THF (18 mL) 
was added to the phosphonate carbanion and the mixture was stirred overnight at room temperature. The 
reaction mixture was diluted with ether and was washed 2x with water and 1x with brine. The water layers were 
extracted with ether and the combined organic layers were dried (Na2SO4) and concentrated in vacuo. The 
product was purified by column chromatography (10% EtOAc in petroleum ether) giving a colorless oil (5.41 g, 
17.5 mmol, 94%, E:Z = 10.5: 1). Rf (E) = 0.2 and Rf (Z) =0.31 (10 % EtOAc in petroleum ether). (E-isomer) 1H NMR 
(400 MHz, CDCl3) δ 6.96 (dm, 1 H, J = 156.0 Hz, H-3), 6.38 (ddm, 1 H, J = 160.4, 15.6 Hz, H-2), 3.70 (s, 3 H, CH3-OMe), 
3.53 (t, 2 H, J = 6.8 Hz, H-14), 3.24 (s, 3 H, CH3-NMe), 2.21 (dm, 2 H, J = 127.2 Hz, H-4), 1.76 (p, 2 H J = 7.0 Hz, H-13), 
1.68-1.20 (m, H 16, H-5 to H-12). 13C NMR (101 MHz, CDCl3) δ 167.2 (dd, J = 67.1, 5.7 Hz, C-1), 148.1 (dd, J = 71.7, 
41.2 Hz, C-3), 118.7 (ddd, J = 71.7, 67.1, 4.6 Hz, C-2), 61.8 (CH3-OMe), 45.3 (C-14), 32.5 (C-13), 32.4 (dddd, J = 41.2, 
33.8, 5.7, 1.3 Hz, C-4), 32.2 (CH3-NMe), 29.6-29.0 (6x CH2 C-6 to C-11), 28.6 (dd, J = 36.6, 33.8 Hz, C-5), 27.0 (C-12). 
IR (neat); 2922, 2852, 1616, 1581, 1462, 1368, 1177, 988 cm-1. (Z-isomer) 1H NMR (400 MHz, CDCl3) δ 6.22 (dm, 1 
H, J =161.2 Hz, H-2), 6.11 (dm, 1 H, J = 152.8 Hz, H-3), 3.68 (s, 3 H, CH3-NMe), 3.53 (t, 2 H, J = 6.8 Hz, H-14), 3.21 (s, 3 
H, CH3-NMe), 2.62 (dm, 2 H, J = 123.6 Hz, H-4), 1.76 (p, 2 H, J = 7.6 Hz, H-13), 1.67-1.20 (m, 16 H, H-5 to H-12). 13C 
NMR (101 MHz, CDCl3) δ 167.7 (d, J = 67.7 Hz, C-1), 147.9 (dd, J = 67.5, 34.4 Hz, C-3), 118.0 (t, J = 67.2 Hz, C-2), 
61.5 (CH3-OMe), 45.8 (C-14), 32.7 (C-13), 32.2 (CH3-NMe), 29.7-28.7 (m, 8x CH2 C-4 to C-13), 27.0 (C-12). IR (neat); 
2922, 2853, 1614, 1462, 1331, 1177, 1086, 997 cm-1. HRMS calculated for [C1113C5H30NO2Cl + H]+: 309.1965, found 
309.1966. 
 
[1,2,3,4,5-13C5]-14-Chloro-N-methoxy-N-methyl-tetradecanamide (30).  [1,2,3,4,5-13C5]-(E/Z)-12-Chloro-N-
methoxy-N-methyl-dodec-2-enamide 29 (5.18 g, 16.8 mmol) was dissolved in EtOAc 
(200 mL).  The solution was purged with argon under stirring and a catalytic amount 
of palladium 10% on charcoal was added. The reaction was stirred under a flow of 
hydrogen gas for 30 minutes and was then left under a hydrogen atmosphere 
overnight. The palladium was removal by filtration over a plug of Celite and the rinsed with EtOAc followed by 
removal of the solvent under reduced pressure giving the desired product, a colorless oil (5.00 g, 16.1 mmol, 
95%). Rf = 0.15 (10% EtOAc in petroleum ether). 1H NMR (400 MHz, CDCl3) δ 3.68 (s, 3 H, CH3-OMe), 3.53 (t, 2 H, J = 
6.4 Hz, H-14), 3.18 (s, 3 H, CH3-NMe), 2.40 (dm, 2 H, J = 128.0 Hz, H-2), 1.81-1.73 (m 2 H, H-13), 1.60 (dm, 2 H, J = 
130.4 Hz, H-3), 1.55-1.05 (m, H 18, H-4 to H-12).  13C NMR (101 MHz, CDCl3) δ 174.9 (d, J = 53.5 Hz, C-1), 61.3 
(CH3-OMe), 45.3 (C-14), 32.8-31.6 (m, C-2, C-13 and CH3-NMe), 30.0-29.0 (m, 7x CH2 C-3 to C-12), 27.0 (CH2 C-3 to C-
12), 25.4-24.1 (m, 2x CH2 C-3 to C-12). IR (neat) 2922, 2852, 1624, 1462, 1369, 1175, 997 cm-1. HRMS calculated 
for [C1113C5H32NO2Cl + H]+: 311.2121, found 311.2123. 
 
 [2,3,4,5,6-13C5]-15-Chloro-pentadec-1-ene (31).  [1,2,3,4,5-13C5]-14-Chloro-N-methoxy-N-methyl-
tetradecanamide 30 (3.76 g, 12.11 mmol) was dissolved in dry THF (50 mL) and was 
cooled to -78°C under protected atmosphere.  DIBAL-H (1.5 M in toluene, 9.7 mL, 14.5 
mmol, 1.2 eq) was added and the mixture was stirred for 1 hour at -78°C. The mixture was quenched with 1 M 
HCl aq (50 mL) at -78°C and was vigoursly stirred to room temperature. The mixture was diluted with ether and 
was washed 2x with water and 1 x with brine. The water layers were extracted with ether and the combined 
organic layers was dried (Na2SO4) and concentrated in vacuo giving  crude [1,2,3,4,5 - 13C5]-14-Chloro-
tetradecanal, which was used without further purification. Methyltriphenylphosphonium bromide (8.65 g, 24.2 
mmol, 2 eq) was suspended in dry THF (120 mL) and NaH (60% in mineral oil, 0.74 mg, 18.2 mmol, 1.5 eq) was 
added. The reaction mixture was refluxed for 3 h to form the ylide. (mixture turned to yellow) Then the crude 
[1,2,3,4,5-13C5]-14-Chloro-tetradecanal dissolved in THF (12 mL) was then added to the ylide at 0 °C. The reaction 
mixture was stirred at room temperature over night. The reaction was diluted with Et2O and then washed 2x 
with water and 1x with brine. The water layers were extracted with Et2O and the organic layers were dried 
(Na2SO4) and concentrated in vacuo. The product was purified by column chromatography (hexane) giving a 
colorless oil (2.48 g, 9.9 mmol, 82%). Rf = 0.95 (pentane). 1H NMR (400 MHz, CDCl3) δ 5.81 (dm, 1 H, J = 150.4 Hz), 
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5.01 (ddd, 1 H, J = 17.7 6.4, 1.6 Hz, H-1z), 4.92 (t, 1 H, J = 10.8 Hz, H-1E), 3.53 (t, 2 H, J =6.4 Hz, H-15), 2.03 (dm, J = 
126.4 Hz, H-3), 1.76 (p, 2 H, J = 7.0 Hz, H-14), 1.56-1.05 (m, 20 H, H-4 to H-13). 13C NMR (101 MHz, CDCl3) δ 139.4 
(d, J = 42.4 Hz, C-2), 114.5 (d, J = 69.2 Hz, C-1), 45.4 (C-15), 34.0 (m, C-3), 32.8 (C-14), 30.2-28.0 (m, 9x CH2 C-4 to 
C-13), 26.9 (C-13). IR (neat); 2920, 2851, 1612, 1464, 990, 908 cm-1.  
 
 [5,6,7,8,9-13C5]-[E]-18-Chloro-N-(tert-butyloxycarbonyl)-D-erytro-sphingosine (32). (2S,3R)-2-amino-N-(tert-
butyloxycarbonyl)-1,3-dihydroxy-4-pentene (1.5 g, 6.9 mmol, 3 eq) and  
[2,3,4,5,6-13C5]-15-chloro-pentadec-1-ene 31 (0.57 g, 2.3 mmol) were 
dissolved in dry DCM (5 mL) and AcOH (26 μL,   0.46  mmol,   0.2   eq).   The  
mixture was flushed with argon before addition of 2nd generation Grubbs 
catalyst (58 mg, 0.069 mmol, 0.03 eq). The reaction was refluxed for 2 days. The reaction mixture was 
concentrated in vacuo and purified by column chromatography (20% EtOAc in petroleum ether) giving pale 
brown viscuous oil (882 mg, 2.01 mmol, 86%). Rf = 0.44 (1:1 EtOAc: petroleum ether). Mp 59-60°C.  [α]  : + 8.6 (C 
= 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 5.80 (dm, J = 148.0 Hz, H-5), 5.55 (m, 1 H, H-4), 4.28 (m, 1 H, H-3), 3.80 
(ddd, 2 H, J = 92.8, 11.6, 3.6 Hz, H-1), 3.59 (bs, 1 H, H-2), 3.53 (t, 2 H, J = 6.8 Hz, H-18), 3.30-3.00 (m, 2 H, 2x OH), 
2.04 (dm, 2 H, J = 125.2 Hz, H-6), 1.80-1.72 (m, 2 H, H-17), 1.58-1.05 (m, 27 H,  3x CH3-tBu and H-7 to H-16). 13C 
NMR (101 MHz, CDCl3) δ 156.2  (C=O Boc), 134.1 (d, J = 43.4, C-5), 125.1 (d, J = 71.7 Hz, H-4), 74.8 (C-3), 62.8 (C-
1), 55.6 (C-2), 45.2 (C-18), 32.9-31.7 (m, C-6 and C-17), 29.9-28.4 (m, 10x CH2 C-7 to C-16 and 3x CH3-tBu), 27.0 (CH2 
C-7 to C-16), 14.1 (Cq-tBu). IR (neat) 3390, 2920, 2851, 1688, 1506, 1365 1169, 1053, cm-1. HRMS calculated for 
[C1813C5H44NO4Cl + H]+: 439.2958, found 439.2970. 
 
[5,6,7,8,9-13C5] -18-Azido-N-(tert-butyloxycarbonyl)-sphinganine (33). Chloro-D-erythro-sphingosine 32 (0.8 g, 
1.82 mmol, 1.0 eq) was dissolved in EtOAc (10 mL).  The solution was 
purged with argon under stirring and a catalytic amount of (PtO2) was 
added. The reaction was stirred under a flow of hydrogen gas for 30 
minutes and was then left under a hydrogen atmosphere overnight. The 
palladium was removed by filtration over a plug of Celite and then rinsed with EtOAc followed by concentration 
in vacuo. The product was purified by column chromatography (30% EtOAc in petroleum ether) giving a white 
solid (0.44 g, 1.0 mmol, 86%). Rf = 0.44 (1:1 EtOAc: petroleum ether). Mp 74-75°C. [α] : + 7.4 (C = 1.0, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 5.38 (m, 1 H, NH), 3.84 (ddd, 2 H, J =97.2, 11.2, 2.8 Hz, H-1), 3.85-3.60 (m, 1 H, H-3), 
3.50-3.46 (t, 3 H, J = 6.8 Hz, 1 H of H-2 and 2 H of H-18), 2.50 (bs, 1 H, OH), 2.40 (bs, 1 H, OH),1.74-1.68 (m, 2 H, 
H-17), 1.60-1.05 (m, 35 H, 3x CH3-tBu and 13x CH2 H-4 to H-16). 13C NMR (101 MHz, CDCl3) δ 156.2 (Boc), 74.6 (C-
3), 62.8 (C-1), 54.9 (C-2), 45.3 (C-18), 34.6 (C-4), 32.8 (C-17), 29.9-25.7 (12x CH2 C-5 to C-16 and 3x CH3-tBu), 14.2 
(Cq-tBu). IR (neat); 3341, 2913, 2847, 1684, 1530, 1171 cm-1. HRMS calculated for [C1813C5H46NO4Cl + H]+: 441.3115, 
found 441.3119. 
Chloro-N-(tert-butyloxycarbonyl)-sphinganine (0.4 g, 0.9 mmol, 1.0 eq) was dissolved in dry DMF (4 mL). To the 
solution was  added NaN3 (0.16 g, 2.7 mmol, 3 eq) and a catalytic amount of NaI and the mixture was heated to 
55 °C overnight. The mixture was diluted with ether and 2x washed with water and 1x with brine. The water 
layers were extracted with ether and the organic layers were combined, dried (Na2SO4) and concentrated in 
vacuo. The product was purified by column chromatography (30% EtOAc in petroleum ether) giving a white solid 
(0.44 mg, 0.9 mmol, 99%). Rf = 0.40 (1:1 EtOAc: petroleum ether). Mp 62-63 °C. [α] :   + 8.8 (C = 1.0, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 5.38 (m, 1 H, NH), 3.87 (ddd, 2 H, J = 94.8, 11.6, 3.6 Hz, H-1), 3.85-3.60 (m, 1 H, H-2), 
3.55-3.48 (m, 1 H, H-3), 3.25 (t, 2 H, J = 7.2 Hz, H-18), 2.75 (bs, 1 H, OH), 2.65 (m, 1 H, OH), 1.80-1.00 (m, 37 H, 3x 
CH3-tBu and 13x CH2 H-4 to H-17). 13C NMR (101 MHz, CDCl3) δ 156.2 (C=O), 74.6 (C-3), 62.8 (C-1), 54.9 (C-2), 51.6 
(C-18), 34,4 (C-4), 29.9-25.7 (12x CH2 C-5 to C-16 and 3x CH3-tBu), 14.2 (Cq-tBu). IR (neat) 3341, 2914, 2849, 2097, 




 [5,6,7,8,9-13C5]  - 18-Azido-sphinganine (22b). To azido-N-(tert-butyloxycarbonyl)-sphinganine (0.36 g, 0.8 mmol, 
1 eq) was added  a mixture of TFA:water (3:1, 8 mL) at 0 °C and stirred for 
30 minutes. The mixture was diluted with toluene and concentrated in 
vacuo. The product was purified by column chromatography (9:1 
CHCl3:MeOH to 70:27:3 CHCl3:MeOH:H2O) giving a white TFA-solid (197 
mg, 0.56 mmol, 71%). Rf = 0.34 (CHCl3:MeOH:H2O 70:27:3).  [α] − 3.4  (C = 1.0,MeOH). Mp 82-83 °C. 1H NMR 
(400 MHz, MeOD); 3.83 (dd, 1 H, J = 11.5, 4.0 Hz, H-1a), 3.78 (m, 1 H, H-3), 3.70 (dd, 1 H, J = 11.5, 8.8 Hz, H-1), 
3.27 (t, 2 H, J = 6.8 Hz, H-18), 3.19 (dt, 1 H, J = 8.4, 4.0 Hz, H-2), 1.58 (p, 2 H, J = 7.2 Hz, H-17), 1.53-1.05 (m, 26 H, 
H-4 to H-5). 13C NMR (101 MHz, MeOD); 70.34 (C-3), 58.97 (C-1), 58.37 (d, J = 3.0 Hz, C-2), 52.45 (C-18), 34.16 (d, 
J = 34.3 Hz, C-4), 30.8-30.0, 29.9, 27.8, 27.4-26.7 (13x CH2 C-5 to C-17). IR (neat); 3340, 2916, 2849, 2099, 1645, 
1215, 1161, 1049, 725 cm-1. HRMS calculated for [C1313C5H38N4O2 + H]+: 348.2994, found 348.2785. 
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Sphingolipiden zijn samen met sterolen en glycerophospholipiden hoofdbestanddelen van 
celmembranen. Deze lipiden zijn ondersteunende structuurelementen, die niet alleen 
belangrijk zijn voor het functioneren van het membraan als barrière voor het transport 
van moleculen, maar bijvoorbeeld ook voor cel-cel herkenning en intercellulaire 
communicatie. Sphingolipiden bestaan uit een apolair deel, ceramide genaamd en een 
polair deel, dat zich buiten de cel bevindt. Het apolaire ceramide is weer opgebouwd uit 
sphingosine en een daaraan gekoppeld vetzuur. Het polaire gedeelte van sphingolipiden 
bestaat uit verschillende koolhydraten en fosfaten esters, die belangrijk zijn voor de 
verschillende functies van sphingolipiden.  
In menselijke cellen zijn verschillende enzymen betrokken bij de opbouw en afbraak (het 
metabolisme) van sphingolipiden. Verstoring van het sphingolipide metabolisme door een 
defect enzym of zelfs het ontbreken van een betrokken enzym kan verschillende medische 
aandoeningen tot gevolg hebben. Om het inzicht in het sphingolipide metabolisme en de 
daaraan gekoppelde medische aandoeningen te vergroten is het beschikbaar hebben van 
gedefinieerde sphingolipiden alsmede analoga of derivaten daarvan van groot belang. 
Dergelijke verbindingen kunnen toegankelijk worden gemaakt door organische synthese. 
In dit kader beschrijft dit proefschrift het ontwerp en de synthese van verschillende 
gemodificeerde sphingolipiden. 
Hoofdstuk 1 geeft een overzicht van verschillende synthetische gemodificeerde 
sphingolipiden, die gebruikt worden om het metabolisme van sphingolipiden te 
bestuderen. Het soort modificatie in sphingolipiden en de bijbehorende synthetische 
strategieën zijn daarbij als leidraad gebruikt. 
Hoofdstuk 2 beschrijft de synthese van een kleine bibliotheek van verschillende koolstof-
13-verrijkte (glyco)sphingolipiden. Deze koolstof-13 verrijkte sphingolipiden worden 
gebruikt als interne standaard voor bepalen en vergelijken van de concentratie van 
sphingolipiden in het plasma en urine van verschillende individuen. Uitgezonderd het 
molecuulgewicht, zijn de fysische-chemische eigenschappen van koolstof-13-verrijkte 
sphingolipiden identiek aan de overeenkomstige natuurlijk voorkomende sphingolipiden. 
Hierdoor zijn deze verbindingen ideaal om de concentratie van sphingolipiden in plasma 
en urine te bepalen en kunnen de verkregen waarden van gezonde individuen vergeleken 
worden met die van patiënten met een lysosomale sphingolipide stapelingsziekte. Tevens 
kan met deze bepalingen het ziekteverloop van patiënten gevolgd worden, waardoor de 
behandelingsmethode per patiënt geoptimaliseerd kan worden. Tenslotte kunnen de 
gesynthetiseerde koolstof-13-gelabeled sphingolipiden worden gebruikt voor het vinden 
van alternatieve metabole routes. De in dit hoofdstuk beschreven synthese van koolstof-





13-gelabeled sphingolipiden maakt gebruikt een nieuwe synthetische strategie met 13C2-
azijnzuur als uitgangsstof.  
Hoofdstuk 3 is een vervolg op hoofdstuk 2 en is gericht op het optimaliseren van de 
koppeling van suikermoleculen aan beschermde sphingosine bouwstenen. Voor deze 
zogenoemde glycosyleringsreactie werd in hoofdstuk 2 een methode beschreven met de 
Boc-groep voor de bescherming van de amino functie in de sphingosine bouwsteen. 
Echter de Boc-groep bleek onvoldoende stabiel onder de zure condities van verschillende 
glycosyleringsreacties. Hierdoor waren de opbrengsten van sommige suikerkoppelingen 
laag terwijl glycosyleringen met andere suikermoleculen en N-Boc beschermde 
sphingolipiden zelfs onmogelijk waren. In hoofdstuk 3 wordt aangetoond dat het 
vervangen van de N-Boc door de baselabiele N-Fmoc beschermende groep in 
sphingolipiden bouwstenen een uitstekende manier is om glycosyleringen met goede 
opbrengsten te bewerkstelligen. 
Hoofdstuk 4 behandelt de synthese van fosfaat monoesters van koolstof-13-gelabelde 
sphingolipiden. Evenals de koolstof-13-gelabelde (glyco)sphingolipiden van hoofdstuk 2 
kunnen deze verbindingen worden gebruikt als interne standaard bij de analyse van 
patiënten met een lysosomale stapelingsziekte. Ook hier werd gebruik gemaakt van het 
met koolstof-13-gelabeled N-Boc beschermde sphingosine. Voor de synthese van de doel 
fosfaat monoesters werden twee fosfor amidaat reagentia, geschikt voor de introductie 
van fosfaat monoesters ontwikkeld. Ook wordt aandacht besteed aan een eenvoudige  
zuiveringsmethode voor het moeilijk op te lossen sphingosine-1-fosfaat. Daarnaast wordt 
een nieuwe methode voor de N-acylering van gefosforyleerd sphingosine besproken. 
Het onderwerp van Hoofdstuk 5 is de ontwikkeling van nieuwe syntheseroutes voor zowel 
6-hydroxyl-sphingosine als voor een alpha-hydroxy-vetzuur met behulp van een cross-
metathese strategie. Het hoofdzakelijk in de huid voorkomende 6-hydroxy-sphingosine is 
het meest recente ontdekte sphingosine in de mens. De enige gepubliceerde synthetische 
strategie voor 6-hydroxyl-sphingosines maakt gebruik van een nucleophilic aanval van een 
beschermd alkyn op Garner aldehyde. Deze sterk basische condities beperken de 
modificatie mogelijkheden van 6-hydroxylsphingosine, die met een strategie, zoals die is 
beschreven in hoofdstuk 5 wordt omzeild. Door gebruik te maken van kruis-metathese 
werd een robuuste, milde en eenvoudige syntheseroute naar 6-hydroxy-sphingosine 
alsmede een bekende modificatie (zie hoofdstuk 1) mogelijk. Alpha-hydroxy ceramides zijn 
voorzien van een N-acyl alpha-hydroxy vetzuur. Ook dit vetzuur kon gesynthetiseerd 
worden met een vergelijkbare kruis-metathese strategie waarbij, een chiraal cyanohydrin 
als startmateriaal werd gebruikt.  
Hoofdstuk 6 beschrijft het ontwerp en de synthese van gemodificeerde ceramides, die 
voorzien zijn van een aziridine functie. Twee aziridine-ceramide verbindingen werden 
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gesynthetiseerd vanuit azido-sphingosine. Deze aziridines kunnen worden getest als 
“activity-based   probes”   (ABPs)   voor   de   glycosidase   enzymen   van   het   sphingolipide  
metabolisme en kunnen worden geëvalueerd naast de bekende ABPs als de van 





Curriculum Vitae  
Nederlands 
Patrick Wisse werd geboren op 20 april 1989 te Kapelle. In 2007 behaalde hij het VWO 
diploma met de profielen Natuur en Techniek en Natuur en Gezondheid aan het Goese 
Lyceum te Goes. Na de middelbare school volgde hij eerst de bacheloropleiding Molecular 
Science & Technology aan de Universiteit Leiden en de Technische Universiteit Delft, en 
vervolgens aan de Universiteit Leiden de masteropleiding Chemistry met als studierichting 
Design & Synthesis.  
In 2010 voltooide hij zijn bachelor scriptie in de vakgroep Medicinal Chemistry van Prof. dr 
A. P. IJzerman, onder dagelijkse begeleiding van dr J. Brussee. In 2011-2012 werd de 
masterstage uitgevoerd in de groep Bio-Organic Synthesis van Prof. dr H. S. Overkleeft en 
Prof. dr G. A. van der Marel, onder dagelijkse begeleiding van dr H. Gold en dr G. Lutteke. 
De   titel   van   zijn   master   thesis   was      ‘The   Synthesis   of   Tools   to   Study   Sphinganine  
Metabolism’.  In Oktober 2012 werd de masteropleiding succesvol afgesloten. 
Onmiddellijk na het behalen van masterdiploma werd in Oktober 2012 begonnen met het 
hier beschreven promotieonderzoek onder begeleiding van Prof. dr H. S. Overkleeft en dr 
J. D. C. Codée. Delen van dit onderzoek zijn gepresenteerd in de vorm van posters op de 
NWO-CW sectie bijeenkomst Design and Synthesis in Lunteren (2013) en de Nederlandse 
chemie ‘Chains’ congressen in Veldhoven (2014, 2015). Daarnaast heeft hij een 
mondelinge presentatie gegeven op het KNCV Organische Chemie symposium  in 
Wageningen (2015). Tijdens zijn promotietraject heeft hij deelgenomen aan het HRMS 










Curriculum Vitea  
English 
Patrick Wisse was born in Kapelle on April 20 1989. In 2007, he finished his VWO 
education with the majors Life Science & Technology and Life Science & Health at the 
Goese Lyceum in Goes. After his secondary education he completed the bachelor study 
Molecular Science & Technology at Leiden University and Delft University of Technology 
and subsequently he completed the master study Chemistry with the research track 
Design & Synthesis at Leiden University. 
In 2010, he did his bachelor internship in the group of Medicinal Chemistry of Prof. dr A. P. 
IJzerman, under supervision of dr J. Brussee. Between 2011-2012 he did his master 
internship in the Bio-Organic Synthesis group of Prof. dr H. S. Overkleeft and Prof. dr G. A. 
van der Marel, under the daily supervision of dr H. Gold and dr G. Lutteke. His master 
thesis  was  entitled  ‘The  Synthesis  of  Tools  to  Study  Sphinganine  Metabolism’.  In  October  
2012, he completed his master study. 
In October 2012 he commenced the Ph.D. studies, that are described in this thesis, under 
supervision of Prof. dr H. S. Overkleeft and dr J. D. C. Codée. During his Ph.D. studies, parts 
of the research described in this thesis were presented on posters at the NWO-CW 
Synthetic and Design section meeting in Lunteren (2013) and the Chains conferences in 
Veldhoven (2014 and 2015). An oral presentation was given at the KNCV Organic 
Chemistry Symposium in Wageningen (2015). During his PhD. he participated in HRMS 
Summer school in Maastricht (2013). 
 
129 
 
